Vaccine Studies List

Description: This is a list of 1,700+ studies on vaccines and autism as well as vaccine efficacy/effectiveness, safety, and immunogenicity. I apologize for any mistakes, broken links, or potential duplicates. **Thank you.**

Content:

Vaccines & Autism

1.) Taylor, L. E., Swerdfeger, A. L., & Eslick, G. D. (2014). Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. *Vaccine*, *32*(29), 3623-3629. https://pubmed.ncbi.nlm.nih.gov/24814559/ & https://vaccines.org.il/images/4/4e/Vaccines-are-not-associated-with-autism.pdf

2.) Hviid, A., Hansen, J. V., Frisch, M., & Melbye, M. (2019). Measles, mumps, rubella vaccination and autism: a nationwide cohort study. *Annals of internal medicine*, *170*(8), 513-520. https://pubmed.ncbi.nlm.nih.gov/30831578/ & https://www.acpjournals.org/doi/full/10.7326/M18-2101

3.) Madsen, K. M., Hviid, A., Vestergaard, M., Schendel, D., Wohlfahrt, J., Thorsen, P., ... & Melbye, M. (2002). A population-based study of measles, mumps, and rubella vaccination and autism. *New England Journal of Medicine*, *347*(19), 1477-1482. https://www.nejm.org/doi/full/10.1056/nejmoa021134 & https://web.math.princeton.edu/~sswang/autism/madsen_melbye02_nejm_MMR-autism-risk.pdf

4.) Taylor, B., Miller, E., Farrington, C., Petropoulos, M. C., Favot-Mayaud, I., Li, J., & Waight, P. A. (1999). Autism and measles, mumps, and rubella vaccine: no

epidemiological evidence for a causal association. *The Lancet*, *353*(9169), 2026-2029. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)01239-8/fulltext & https://antiantivax.info/wp-content/uploads/2019/05/MMR-Autism-norelation_1999.pdf

5.) Hviid, A., Stellfeld, M., Wohlfahrt, J., & Melbye, M. (2003). Association between thimerosal-containing vaccine and autism. *Jama*, *290*(13), 1763-1766. https://jamanetwork.com/journals/jama/fullarticle/197365 & https://pubmed.ncbi.nlm.nih.gov/14519711/

6.) Farrington, C. P., Miller, E., & Taylor, B. (2001). MMR and autism: further evidence against a causal association. *Vaccine*, *19*(27), 3632-3635. https://sci-hub.scihubtw.tw/https://doi.org/10.1016/S0264-410X(01)00097-4 & https://www.sciencedirect.com/science/article/pii/S0264410X01000974

7.) Smeeth, L., Cook, C., Fombonne, E., Heavey, L., Rodrigues, L. C., Smith, P. G., & Hall, A. J. (2004). MMR vaccination and pervasive developmental disorders: a case-control study. *The Lancet*, *364*(9438), 963-969. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17020-7/fulltext & http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.424.5341&rep=rep1&type=pdf

8.) Uchiyama, T., Kurosawa, M., & Inaba, Y. (2007). MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. *Journal of autism and developmental disorders*, *37*(2), 210-217. https://link.springer.com/article/10.1007%2Fs10803-006-0157-3 & https://sci-hub.scihubtw.tw/https://doi.org/10.1007/s10803-006-0157-3

9.) Kaye, J. A., del Mar Melero-Montes, M., & Jick, H. (2001). Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. *Bmj*, *322*(7284), 460-463. https://www.bmj.com/content/322/7284/460.short & https://www.ncbi.nlm.nih.gov/pmc/articles/PMC26561/

10.) Mäkelä, A., Nuorti, J. P., & Peltola, H. (2002). Neurologic disorders after measles-mumps-rubella vaccination. *Pediatrics*, *110*(5), 957-963. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.582.2068&rep=rep1&type=pdf

11.) Wilson, K., Mills, E., Ross, C., McGowan, J., & Jadad, A. (2003). Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. *Archives of Pediatrics & Adolescent Medicine*, *157*(7), 628-634. https://jamanetwork.com/journals/jamapediatrics/article-abstract/481371 & http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.561.2652&rep=rep1&type=pdf

12.) Uno, Y., Uchiyama, T., Kurosawa, M., Aleksic, B., & Ozaki, N. (2012). The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case–control study in Asia. *Vaccine*, *30*(28), 4292-4298. https://www.sciencedirect.com/science/article/pii/S0264410X12005828 & https://sci-hub.scihubtw.tw/https://doi.org/10.1016/j.vaccine.2012.01.093

13.) Madsen, K. M., Lauritsen, M. B., Pedersen, C. B., Thorsen, P., Plesner, A. M., Andersen, P. H., & Mortensen, P. B. (2003). Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. *Pediatrics*, *112*(3), 604-606. https://pediatrics.aappublications.org/content/112/3/604.short & http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.524.6880&rep=rep1&type=pdf

14.) Stehr-Green, P., Tull, P., Stellfeld, M., Mortenson, P. B., & Simpson, D. (2003). Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. *American journal of preventive medicine*, *25*(2), 101-106. https://www.ajpmonline.org/article/S0749-3797(03)00113-2/fulltext & https://pubmed.ncbi.nlm.nih.gov/12880876/

15.) Heron, J., & Golding, J. (2004). Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. *Pediatrics*, *114*(3), 577-583. https://pubmed.ncbi.nlm.nih.gov/15342824/ & https://sci-hub.scihubtw.tw/https://doi.org/10.1542/peds.2003-1176-L

16.) Price, C. S., Thompson, W. W., Goodson, B., Weintraub, E. S., Croen, L. A., Hinrichsen, V. L., ... & Bernal, P. (2010). Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. *Pediatrics*, *126*(4), 656-664. https://pediatrics.aappublications.org/content/126/4/656.short & https://sci-hub.scihubtw.tw/10.1542/peds.2010-0309

17.) Gerber, J., Offit, P., & Plotkin, S. (2009). Vaccines and Autism: A Tale of Shifting Hypotheses. *Clinical Infectious Diseases*, *48*(4), 456-461. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908388/ & http://drgreenmom.com/wp-content/uploads/2014/04/Vaccines-and-Autism-A-Tale-of-Shifting-Hypotheses.pdf

18.) Croen, L. A., Matevia, M., Yoshida, C. K., & Grether, J. K. (2008). Maternal Rh D status, anti-D immune globulin exposure during pregnancy, and risk of autism spectrum disorders. *American journal of obstetrics and gynecology*, *199*(3), 234-e1. https://www.ajog.org/article/S0002-9378(08)00494-8/fulltext

19.) DeStefano, F., Price, C. S., & Weintraub, E. S. (2013). Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism. *The Journal of pediatrics*, *163*(2), 561-567. https://www.jpeds.com/article/S0022-3476(13)00144-3/fulltext & https://vaccines.org.il/images/3/37/PIIS0022347613001443.pdf

20.) Schechter, R., & Grether, J. K. (2008). Continuing increases in autism reported to California's developmental services system: mercury in retrograde. *Archives of general psychiatry*, *65*(1), 19-24. https://europepmc.org/article/med/18180424 & https://jamanetwork.com/journals/jamapsychiatry/fullarticle/482546

21.) Parker, S. K., Schwartz, B., Todd, J., & Pickering, L. K. (2004). Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. *Pediatrics*, *114*(3), 793-804. https://pediatrics.aappublications.org/content/114/3/793.short & http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.327.363&rep=rep1&type=pdf

22.) Jain, A., Marshall, J., Buikema, A., Bancroft, T., Kelly, J. P., & Newschaffer, C. J. (2015). Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. *Jama*, *313*(15), 1534-1540. https://jamanetwork.com/journals/jama/article-abstract/2275444 & https://vaccines.org.il/images/e/ed/Joi150033.pdf

23.) Hornig, M., Briese, T., Buie, T., Bauman, M. L., Lauwers, G., Siemetzki, U., ... & Sheils, O. (2008). Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. *PloS one*, *3*(9), e3140. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0003140

24.) Uno, Y., Uchiyama, T., Kurosawa, M., Aleksic, B., & Ozaki, N. (2015). Early exposure to the combined measles–mumps–rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. *Vaccine*, *33*(21), 2511-2516. https://www.sciencedirect.com/science/article/pii/S0264410X14016892 & https://sci-hub.scihubtw.tw/https://doi.org/10.1016/j.vaccine.2014.12.036

25.) Yoshimasu, K., Kiyohara, C., Takemura, S., & Nakai, K. (2014). A meta-analysis of the

evidence on the impact of prenatal and early infancy exposures to mercury on autism and attention deficit/hyperactivity disorder in the childhood. *Neurotoxicology*, *44*, 121-131. https://www.sciencedirect.com/science/article/abs/pii/S0161813X14000989 & https://sci-hub.scihubtw.tw/https://doi.org/10.1016/j.neuro.2014.06.007

26.) Schultz, S. T. (2010). Does thimerosal or other mercury exposure increase the risk for autism. *Acta Neurobiol Exp*, *70*, 187-195. https://pubmed.ncbi.nlm.nih.gov/20628442/ & http://images.shoutwiki.com/farmaciakarmel/c/cb/Ane_7023.pdf

27.) Ball, L. K., Ball, R., & Pratt, R. D. (2001). An assessment of thimerosal use in childhood vaccines. *Pediatrics*, *107*(5), 1147-1154. https://pediatrics.aappublications.org/content/107/5/1147.short & https://sci-hub.scihubtw.tw/10.1542/peds.107.5.1147

28.) Fombonne, E., Zakarian, R., Bennett, A., Meng, L., & McLean-Heywood, D. (2006). Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. *Pediatrics*, *118*(1), e139-e150. https://pediatrics.aappublications.org/content/118/1/e139.short & https://sci-hub.scihubtw.tw/10.1542/peds.2005-2993

29.) Gentile, I., Bravaccio, C., Bonavolta, R., Zappulo, E., Scarica, S., Riccio, M. P., ... & Borgia, G. (2013). Response to measles-mumps-rubella vaccine in children with autism spectrum disorders. *in vivo*, *27*(3), 377-382. https://iv.iiarjournals.org/content/27/3/377.long

30.) Gadad, B. S., Li, W., Yazdani, U., Grady, S., Johnson, T., Hammond, J., ... & Ferrier, C. (2015). Administration of thimerosal-containing vaccines to infant rhesus macaques does not result in autism-like behavior or neuropathology. *Proceedings of the National Academy of Sciences*, *112*(40), 12498-12503. https://www.pnas.org/content/112/40/12498

31.) D'Souza, Y., Fombonne, E., & Ward, B. J. (2006). No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. *Pediatrics*, *118*(4), 1664-1675. https://pediatrics.aappublications.org/content/118/4/1664.short & https://sci-hub.scihubtw.tw/https://doi.org/10.1542/peds.2006-1262

32.) Zerbo, O., Qian, Y., Yoshida, C., Fireman, B. H., Klein, N. P., & Croen, L. A. (2017). Association between influenza infection and vaccination during pregnancy and risk of autism spectrum disorder. *JAMA pediatrics*, *171*(1), e163609-e163609. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2587559 & https://pubmed.ncbi.nlm.nih.gov/27893896/

33.) Ludvigsson, J. F., Winell, H., Sandin, S., Cnattingius, S., Stephansson, O., & Pasternak, B. Maternal Influenza A (H1N1) Immunization During Pregnancy and Risk for Autism Spectrum Disorder in Offspring: A Cohort Study. *Annals of internal medicine*. https://pubmed.ncbi.nlm.nih.gov/32866418/ & https://www.acpjournals.org/doi/10.7326/M20-0167

34.) Richler, J., Luyster, R., Risi, S., Hsu, W. L., Dawson, G., Bernier, R., ... & Goudie-Nice, J. (2006). Is there a 'regressive phenotype'of autism spectrum disorder associated with the measles-mumps-rubella vaccine? A CPEA study. *Journal of autism and developmental disorders*, *36*(3), 299-316. https://link.springer.com/article/10.1007%252Fs10803-005-0070-1 & http://www.bu.edu/autism/files/2010/03/2006-Richler-et-al-MMR-Vaccine1.pdf

35.) Mrozek-Budzyn, D., Kieltyka, A., & Majewska, R. (2010). Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. *The Pediatric infectious disease journal*, *29*(5), 397-400. https://pubmed.ncbi.nlm.nih.gov/19952979/ & https://sci-hub.scihubtw.tw/10.1097/INF.0b013e3181c40a8a

36.) Hensley, E., & Briars, L. (2010). Closer look at autism and the measles-mumps-rubella vaccine. *Journal of the American Pharmacists Association*, *50*(6), 736-741. https://www.sciencedirect.com/science/article/abs/pii/S1544319115309134 & https://pubmed.ncbi.nlm.nih.gov/21071320/

37.) Halsey, N. A., & Hyman, S. L. (2001). Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12–13, 2000. *Pediatrics*, *107*(5), e84-e84. https://pediatrics.aappublications.org/content/107/5/e84.long

38.) Klein, K. C., & Diehl, E. B. (2004). Relationship between MMR vaccine and autism. *Annals of pharmacotherapy*, *38*(7-8), 1297-1300. https://pubmed.ncbi.nlm.nih.gov/15173555/ & http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.872.5313&rep=rep1&type=pdf

39.) Taylor, B., Miller, E., Lingam, R., Andrews, N., Simmons, A., & Stowe, J. (2002). Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. *Bmj*, *324*(7334), 393-396. https://www.bmj.com/content/bmj/324/7334/393.full.pdf & http://www.morrisonlucas.com/GL/vaccines/British_medical_journal_324_393_MMR_autism.pdf

40.) Berger, B. E., Navar-Boggan, A. M., & Omer, S. B. (2011). Congenital rubella syndrome and autism spectrum disorder prevented by rubella vaccination-United States, 2001-2010. *BMC Public Health*, *11*(1), 1-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123590/ & https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-340

41.) Baird, G., Pickles, A., Simonoff, E., Charman, T., Sullivan, P., Chandler, S., ... & Jin, L. (2008). Measles vaccination and antibody response in autism spectrum disorders. *Archives of disease in childhood*, *93*(10), 832-837. https://immunize.ca/sites/default/files/resources/1017e.pdf & http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.979.8965&rep=rep1&type=pdf

42.) Chen, W., Landau, S., Sham, P., & Fombonne, E. (2004). No evidence for links between autism, MMR and measles virus. *Psychological medicine*, *34*(3), 543-553. https://pubmed.ncbi.nlm.nih.gov/15259839/ & https://sci-hub.scihubtw.tw/10.1017/s0033291703001259

43.) Dales, L., Hammer, S. J., & Smith, N. J. (2001). Time trends in autism and in MMR immunization coverage in California. *Jama*, *285*(9), 1183-1185. https://pubmed.ncbi.nlm.nih.gov/11231748/ & https://jamanetwork.com/journals/jama/fullarticle/193604

44.) Hurley, A. M., Tadrous, M., & Miller, E. S. (2010). Thimerosal-Containing Vaccines and Autism: A Review of Recent Epidemiologic Studies. *The Journal of Pediatric Pharmacology and Therapeutics*, *15*(3), 173-181.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018252/

45.) Modabbernia, A., Velthorst, E., & Reichenberg, A. (2017). Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. *Molecular autism*, *8*(1), 13. https://molecularautism.biomedcentral.com/articles/10.1186/s13229-017-0121-4?dom=prime&src=syn & https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356236/

46.) Jefferson, T., Price, D., Demicheli, V., Bianco, E., & European Research program for Improved Vaccine Safety Surveillance (EUSAFEVAC) Project. (2003). Unintended events following immunization with MMR: a systematic review. *Vaccine*, *21*(25-26), 3954-3960. http://skepdic.com/skeptimedia/Jefferson.pdf & https://www.sciencedirect.com/science/article/pii/S0264410X03002718

47.) Maglione, M. A., Das, L., Raaen, L., Smith, A., Chari, R., Newberry, S., ... & Gidengil, C. (2014). Safety of vaccines used for routine immunization of US children: a systematic review. *Pediatrics*, *134*(2), 325-337. https://pediatrics.aappublications.org/content/134/2/325?source=post_page-----6df1b46c14cc---------- & https://escholarship.org/content/qt2f93s53t/qt2f93s53t.pdf

48.) Ng, M., de Montigny, J. G., Ofner, M., & Do, M. T. (2017). Environmental factors associated with autism spectrum disorder: a scoping review for the years 2003-2013. *Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice*, *37*(1), 1-23. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480297/

49.) Sealey, L. A., Hughes, B. W., Sriskanda, A. N., Guest, J. R., Gibson, A. D., Johnson-Williams, L., ... & Bagasra, O. (2016). Environmental factors in the development of autism spectrum disorders. *Environment international*, *88*, 288-298. https://knowthecause.com/wp-content/uploads/2019/02/Sealey2016EnvironmentAutism.pdf & https://pubmed.ncbi.nlm.nih.gov/26826339/

50.) Singh, V. K., & Rivas, W. H. (2004). Detection of antinuclear and antilaminin antibodies in autistic children who received thimerosal-containing vaccines. *Journal of biomedical science*, *11*(5), 607-610. https://pubmed.ncbi.nlm.nih.gov/15316135/ & https://www.vacinfo.org/uploads/7/9/8/5/79856028/produkte.pdf

51.) Taylor, B. (2006). Vaccines and the changing epidemiology of autism. *Child: care, health and development*, *32*(5), 511-519. & https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2214.2006.00655.x &

https://ecee.colorado.edu/~ecen5009/Resources/Vaccination/Taylor2006.pdf

52.) Miller, L., & Reynolds, J. (2009). Autism and vaccination—the current evidence. *Journal for Specialists in Pediatric Nursing*, *14*(3), 166-172. https://people.wou.edu/~bersanh/autism/current%20evidence.pdf

53.) Whitehouse, A. J., Maybery, M., Wray, J. A., & Hickey, M. (2011). No association between early gastrointestinal problems and autistic‐like traits in the general population. *Developmental Medicine & Child Neurology*, *53*(5), 457-462. https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1469-8749.2011.03915.x & https://onlinelibrary.wiley.com/doi/full/10.1111/j.1469-8749.2011.03915.x

54.) Kalkbrenner, A. E., Schmidt, R. J., & Penlesky, A. C. (2014). Environmental chemical exposures and autism spectrum disorders: a review of the epidemiological evidence. *Current problems in pediatric and adolescent health care*, *44*(10), 277-318. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855851/

55.) Verstraeten, T., Davis, R. L., DeStefano, F., Lieu, T. A., Rhodes, P. H., Black, S. B., ... & Chen, R. T. (2003). Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. *Pediatrics*, *112*(5), 1039-1048. https://childrenshealthdefense.org/wp-content/uploads/5.5-Safety-of-Thimerosal-Containing-Vaccines.pdf
&
http://healing-arts.org/children/mercury_in_vaccines_autism_research/Verstraeten_IOM_Vaccines_Thimerosal_Study.pdf

56.) Doja, A., & Roberts, W. (2006). Immunizations and autism: a review of the literature. *Canadian Journal of Neurological Sciences*, *33*(4), 341-346. https://pubmed.ncbi.nlm.nih.gov/17168158/ & https://pdfs.semanticscholar.org/08ce/a4987e8d64e519936fb883b3208de92fe482.pdf

57.) Afzal, M. A., Ozoemena, L. C., O'hare, A., Kidger, K. A., Bentley, M. L., & Minor, P. D. (2006). Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK. *Journal of medical virology*, *78*(5), 623-630. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20585 & https://sci-hub.scihubtw.tw/https://doi.org/10.1002/jmv.20585

58.) Honda, H., Shimizu, Y., & Rutter, M. (2005). No effect of MMR withdrawal on the incidence of autism: a total population study. *Journal of Child Psychology and Psychiatry*, *46*(6), 572-579. https://acamh.onlinelibrary.wiley.com/doi/full/10.1111/j.1469-7610.2005.01425.x

59.) Becerra-Culqui, T. A., Getahun, D., Chiu, V., Sy, L. S., & Tseng, H. F. (2018). Prenatal tetanus, diphtheria, acellular pertussis vaccination and autism spectrum disorder. *Pediatrics*, *142*(3). https://pediatrics.aappublications.org/content/142/3/e20180120

60.) Patja, A., Davidkin, I., Kurki, T., Kallio, M. J., Valle, M., & Peltola, H. (2000). Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. *The Pediatric infectious disease journal*, *19*(12), 1127-1134. http://www.wellwithin1.com/MMR.pdf

61.) Becerra-Culqui, T. A., Getahun, D., Chiu, V., Sy, L. S., & Tseng, H. F. (2022). Prenatal influenza vaccination or influenza infection and autism spectrum disorder in offspring. *Clinical Infectious Diseases*. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac101/6528744?login=true & https://t.co/GnYN4JBbnv

61.) Institute of Medicine (US) Immunization Safety Review Committee. (2004). Immunization safety review: vaccines and autism. In *Immunization Safety Review: Vaccines and Autism*. National Academies Press (US). https://www.ncbi.nlm.nih.gov/books/NBK25349/

62.) Demicheli, V., Rivetti, A., Debalini, M. G., & Di Pietrantonj, C. (2012). Vaccines for measles, mumps and rubella in children. *Evidence‐Based Child Health: A Cochrane Review Journal*, *8*(6), 2076-2238. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004407.pub3/full
Update: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004407.pub4/full

Vaccine Safety, Efficacy/Effectiveness, & Immunogenicity

1.) Vennemann, M. M. T., Butterfass-Bahloul, T., Jorch, G., Brinkmann, B., Findeisen, M., Sauerland, C., ... & Mitchell, E. A. (2007). Sudden infant death syndrome: no increased risk after immunisation. *Vaccine*, *25*(2), 336-340. https://www.sciencedirect.com/science/article/pii/S0264410X06008978 & https://pubmed.ncbi.nlm.nih.gov/16945457/

2.) Castellsague, X., Munoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., ... & Bryan, J. (2011). End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. *British journal of cancer*, *105*(1), 28-37. https://www.nature.com/articles/bjc2011185

3.) Huh, W. K., Joura, E. A., Giuliano, A. R., Iversen, O. E., de Andrade, R. P., Ault, K. A., ... & Mayrand, M. H. (2017). Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. *The Lancet*, *390*(10108), 2143-2159. https://www.sciencedirect.com/science/article/abs/pii/S0140673617318214 & https://cdn.mednet.co.il/2018/10/Efficacy-immunogenicity-safety-Gardasil-9-Lancet-102017.pdf

4.) Naud, P. S., Roteli-Martins, C. M., De Carvalho, N. S., Teixeira, J. C., de Borba, P. C., Sanchez, N., ... & Descamps, D. (2014). Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up

study up to 9.4 years post-vaccination. *Human vaccines & immunotherapeutics*, *10*(8), 2147-2162. https://www.tandfonline.com/doi/pdf/10.4161/hv.29532

5.) Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., ... & Draguez, B. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). *The Lancet*, *389*(10068), 505-518. https://www.sciencedirect.com/science/article/pii/S0140673616326216

6.) Staat, M. A., Payne, D. C., Donauer, S., Weinberg, G. A., Edwards, K. M., Szilagyi, P. G., ... & Salisbury, S. (2011). Effectiveness of pentavalent rotavirus vaccine against severe disease. *Pediatrics*, *128*(2), e267-e275. https://pediatrics.aappublications.org/content/128/2/e267.short & https://sci-hub.scihubtw.tw/https://doi.org/10.1542/peds.2010-3722

7.) Zhu, F. C., Meng, F. Y., Li, J. X., Li, X. L., Mao, Q. Y., Tao, H., ... & Hu, Y. M. (2013). Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*, *381*(9882), 2024-2032. https://www.sciencedirect.com/science/article/abs/pii/S0140673613610491 & https://edisciplinas.usp.br/pluginfile.php/2520337/mod_resource/content/2/Kay-Zhu_efficaccy%20enterovirus%20vaccine.pdf

8.) RTS, S Clinical Trials Partnership. (2011). First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. *New England Journal of Medicine*, *365*(20), 1863-1875. https://www.nejm.org/doi/full/10.1056/Nejmoa1102287

9.) Schmader, K. E., Levin, M. J., Gnann Jr, J. W., McNeil, S. A., Vesikari, T., Betts, R. F., ... & Zhao, Y. (2012). Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. *Clinical infectious diseases*, *54*(7), 922-928. https://academic.oup.com/cid/article/54/7/922/299086

10.) Asante, K. P., Abdulla, S., Agnandji, S., Lyimo, J., Vekemans, J., Soulanoudjingar, S., ... & Salim, N. (2011). Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. *The Lancet infectious diseases*, *11*(10), 741-749. https://www.sciencedirect.com/science/article/abs/pii/S1473309911701001 & https://core.ac.uk/download/pdf/11306701.pdf

11.) DiazGranados, C. A., Denis, M., & Plotkin, S. (2012). Seasonal influenza vaccine

efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. *Vaccine*, *31*(1), 49-57. https://www.sciencedirect.com/science/article/pii/S0264410X12015575 & https://sci-hub.scihubtw.tw/https://doi.org/10.1016/j.vaccine.2012.10.084

12.) Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., ... & Pitisuttithum, P. (2014). Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. *The Lancet*, *384*(9951), 1358-1365. https://www.sciencedirect.com/science/article/abs/pii/S0140673614610606 & https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61060-6/fulltext?rss=yes

13.) Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S. J., ... & Vesikari, T. (2015). Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. *New England Journal of Medicine*, *372*(22), 2087-2096. https://www.nejm.org/doi/full/10.1056/NEJMoa1501184

14.) Zhu, F. C., Zhang, J., Zhang, X. F., Zhou, C., Wang, Z. Z., Huang, S. J., ... & Wang, Y. J. (2010). Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. *The Lancet*, *376*(9744), 895-902. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61030-6/fulltext & https://www.natap.org/2010/newsUpdates/hepvaccine.pdf

15.) Lehtinen, M., & Dillner, J. (2013). Clinical trials of human papillomavirus vaccines and beyond. *Nature reviews Clinical oncology*, *10*(7), 400-410. https://www.nature.com/articles/nrclinonc.2013.84

16.) Lehtinen, M., Paavonen, J., Wheeler, C. M., Jaisamrarn, U., Garland, S. M., Castellsagué, X., ... & Chow, S. N. (2012). Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *The lancet oncology*, *13*(1), 89-99. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70286-8/fulltext?utm_medium=twitter&utm_source=twitterfeed&rss=yes & http://www.hsu.is/wp-content/uploads/2011/11/Wheeler.pdf

17.) Zaman, K., Anh, D. D., Victor, J. C., Shin, S., Yunus, M., Dallas, M. J., ... & Lewis, K. (2010). Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. *The Lancet*, *376*(9741), 615-623. https://www.sciencedirect.com/science/article/abs/pii/S0140673610607556 & https://sci-hub.scihubtw.tw/10.1016/S0140-6736(10)60755-6

18.) Tricco, A. C., Chit, A., Soobiah, C., Hallett, D., Meier, G., Chen, M. H., ... & Loeb, M. (2013). Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. *BMC medicine*, *11*(1), 153. https://link.springer.com/article/10.1186/1741-7015-11-153 \

19.) Treanor, J. J., Talbot, H. K., Ohmit, S. E., Coleman, L. A., Thompson, M. G., Cheng, P. Y., ... & Berman, L. (2012). Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. *Clinical infectious diseases*, *55*(7), 951-959. https://academic.oup.com/cid/article/55/7/951/427559

20.) Treanor, J. J., El Sahly, H., King, J., Graham, I., Izikson, R., Kohberger, R., ... & Cox, M. (2011). Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. *Vaccine*, *29*(44), 7733-7739. https://www.sciencedirect.com/science/article/pii/S0264410X11011789 & https://sci-hub.scihubtw.tw/https://doi.org/10.1016/j.vaccine.2011.07.128

21.) Skowronski, D. M., Janjua, N. Z., De Serres, G., Hottes, T. S., Dickinson, J. A., Crowcroft, N., ... & Gubbay, J. B. (2011). Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. *Bmj*, *342*. https://www.bmj.com/content/342/bmj.c7297.long

22.) Barrett, P. N., Berezuk, G., Fritsch, S., Aichinger, G., Hart, M. K., El-Amin, W., ... & Ehrlich, H. J. (2011). Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. *The Lancet*, *377*(9767), 751-759. https://www.sciencedirect.com/science/article/abs/pii/S0140673610622283 & https://pubmed.ncbi.nlm.nih.gov/21329971/

23.) Manzoli, L., Ioannidis, J. P., Flacco, M. E., De Vito, C., & Villari, P. (2012). Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. *Human vaccines & immunotherapeutics*, *8*(7), 851-862. https://www.tandfonline.com/doi/pdf/10.4161/hv.19917

24.) Mateen, F. J., Shinohara, R. T., & Sutter, R. W. (2013). Oral and inactivated poliovirus \ vaccines in the newborn: a review. *Vaccine*, *31*(21), 2517-2524. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979583/

25.) Lochlainn, L. M. N., de Gier, B., van der Maas, N., van Binnendijk, R., Strebel, P. M., Goodman, T., ... & Hahné, S. J. (2019). Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis. *The Lancet Infectious Diseases*, *19*(11), 1246-1254. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30396-2/fulltext#seccestitle130

26.) El-Sayed, N., El-Gamal, Y., Abbassy, A. A., Seoud, I., Salama, M., Kandeel, A., ... & van der Avoort, H. G. (2008). Monovalent type 1 oral poliovirus vaccine in newborns. *New England Journal of Medicine*, *359*(16), 1655-1665. https://www.nejm.org/doi/full/10.1056/nejmoa0800390

27.) He, H., Chen, E., Chen, H., Wang, Z., Li, Q., Yan, R., ... & Xie, S. (2014). Similar immunogenicity of measles–mumps–rubella (MMR) vaccine administrated at 8 months versus 12 months age in children. *Vaccine*, *32*(31), 4001-4005. https://www.sciencedirect.com/science/article/pii/S0264410X14005829 & https://sci-hub.scihubtw.tw/https://doi.org/10.1016/j.vaccine.2014.04.044

28.) Jenkins, H. E., Aylward, R. B., Gasasira, A., Donnelly, C. A., Abanida, E. A., Koleosho-Adelekan, T., & Grassly, N. C. (2008). Effectiveness of immunization against paralytic poliomyelitis in Nigeria. *New England Journal of Medicine*, *359*(16), 1666-1674. https://www.nejm.org/doi/full/10.1056/nejmoa0803259

29.) Oosterhuis-Kafeja, F., Beutels, P., & Van Damme, P. (2007). Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998–2006). *Vaccine*, *25*(12), 2194-2212. https://www.sciencedirect.com/science/article/pii/S0264410X0601245X &

https://sci-hub.scihubtw.tw/https://doi.org/10.1016/j.vaccine.2006.11.032

30.) Hieu, N. T., Kim, K. H., Janowicz, Z., & Timmermans, I. (2002). Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. *Vaccine*, *20*(13-14), 1803-1808. https://www.sciencedirect.com/science/article/pii/S0264410X01005187 & https://pubmed.ncbi.nlm.nih.gov/11906768/

31.) Jain, V. K., Rivera, L., Zaman, K., Espos Jr, R. A., Sirivichayakul, C., Quiambao, B. P., ... & Cravioto, A. (2013). Vaccine for prevention of mild and moderate-to-severe influenza in children. *New England Journal of Medicine*, *369*(26), 2481-2491. https://www.nejm.org/doi/full/10.1056/NEJMoa1215817

32.) Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., ... & Diacon, A. (2018). Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. *New England Journal of Medicine*, *379*(17), 1621-1634. https://www.nejm.org/doi/full/10.1056/NEJMoa1803484

33.) Flannery, B., Chung, J. R., Monto, A. S., Martin, E. T., Belongia, E. A., McLean, H. Q., ... & Jackson, M. L. (2019). Influenza vaccine effectiveness in the United States during the 2016–2017 season. *Clinical Infectious Diseases*, *68*(11), 1798-1806. https://academic.oup.com/cid/article/68/11/1798/5094815

34.) Liang, X. F., Li, L., Liu, D. W., Li, K. L., Wu, W. D., Zhu, B. P., ... & Yin, D. P. (2011). Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. *New England Journal of Medicine*, *364*(7), 638-647. https://www.nejm.org/doi/full/10.1056/NEJMoa1008553

35.) Madhi, S. A., Cutland, C. L., Kuwanda, L., Weinberg, A., Hugo, A., Jones, S., ... & Venter, M. (2014). Influenza vaccination of pregnant women and protection of their infants. *New England Journal of Medicine*, *371*(10), 918-931. https://www.nejm.org/doi/full/10.1056/NEJMoa1401480

36.) Agnandji, S. T., Huttner, A., Zinser, M. E., Njuguna, P., Dahlke, C., Fernandes, J. F., ... & Adegnika, A. A. (2016). Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. *New England Journal of Medicine*, *374*(17), 1647-1660. https://www.nejm.org/doi/full/10.1056/NEJMoa1502924

37.) Bonten, M. J., Huijts, S. M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., ... & Patton, M. (2015). Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

New England Journal of Medicine, *372*(12), 1114-1125. https://www.nejm.org/doi/full/10.1056/NEJMoa1408544

38.) Wu, J., Xu, F., Lu, L., Lu, M., Miao, L., Gao, T., ... & Yu, R. (2010). Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. *New England Journal of Medicine*, *363*(25), 2416-2423. https://www.nejm.org/doi/full/10.1056/NEJMoa1006736

39.) Pleguezuelos, O., James, E., Fernandez, A., Lopes, V., Rosas, L. A., Cervantes-Medina, A., ... & Hunsberger, S. (2020). Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. *NPJ vaccines*, *5*(1), 1-9. https://www.nature.com/articles/s41541-020-0174-9

40.) Claeys, C., Zaman, K., Dbaibo, G., Li, P., Izu, A., Kosalaraksa, P., ... & Cabanero, M. A. (2018). Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. *The Lancet Child & Adolescent Health*, *2*(5), 338-349. https://www.sciencedirect.com/science/article/abs/pii/S2352464218300622

41.) Tinoco, J. C., Pavia-Ruz, N., Cruz-Valdez, A., Doniz, C. A., Chandrasekaran, V., Dewé, W., ... & Jain, V. K. (2014). Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged≥ 18 years: a phase III, randomized trial. *Vaccine*, *32*(13), 1480-1487. https://www.sciencedirect.com/science/article/pii/S0264410X14000541

42.) Flannery, B., Reynolds, S. B., Blanton, L., Santibanez, T. A., O'Halloran, A., Lu, P. J., ... & Singleton, J. A. (2017). Influenza vaccine effectiveness against pediatric deaths: 2010–2014. *Pediatrics*, *139*(5), e20164244. https://pediatrics.aappublications.org/content/139/5/e20164244 & https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728382/

43.) Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012). Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *The Lancet infectious diseases*, *12*(1), 36-44. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2811%2970295-X/fulltext

44.) Grijalva, C. G., Zhu, Y., Williams, D. J., Self, W. H., Ampofo, K., Pavia, A. T., ... & Anderson, E. J. (2015). Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination. *Jama*, *314*(14), 1488-1497. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688454/

45.) Arriola, C., Garg, S., Anderson, E. J., Ryan, P. A., George, A., Zansky, S. M., ... & Yousey-Hindes, K. (2017). Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. *Clinical Infectious Diseases*, *65*(8), 1289-1297. https://academic.oup.com/cid/article/65/8/1289/3836421

46.) Restivo, V., Costantino, C., Bono, S., Maniglia, M., Marchese, V., Ventura, G., ... & Vitale, F. (2018). Influenza vaccine effectiveness among high-risk groups: a systematic literature review and meta-analysis of case-control and cohort studies. *Human vaccines & immunotherapeutics*, *14*(3), 724-735. https://www.tandfonline.com/doi/pdf/10.1080/21645515.2017.1321722

47.) Rondy, M., El Omeiri, N., Thompson, M. G., Levêque, A., Moren, A., & Sullivan, S. G. (2017). Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. *Journal of Infection*, *75*(5), 381-394. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912669/

48.) Nichol, K. L., Nordin, J. D., Nelson, D. B., Mullooly, J. P., & Hak, E. (2007). Effectiveness of influenza vaccine in the community-dwelling elderly. *New England Journal of Medicine*, *357*(14), 1373-1381. https://www.nejm.org/doi/full/10.1056/NEJMoa070844

49.) Villar, L., Dayan, G. H., Arredondo-García, J. L., Rivera, D. M., Cunha, R., Deseda, C., ... & Rey, L. C. (2015). Efficacy of a tetravalent dengue vaccine in children in Latin America. *New England Journal of Medicine*, *372*(2), 113-123. https://www.nejm.org/doi/full/10.1056/nejmoa1411037

50.) Munoz, F. M., Bond, N. H., Maccato, M., Pinell, P., Hammill, H. A., Swamy, G. K., ... & Healy, C. M. (2014). Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. *Jama*, *311*(17), 1760-1769. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333147/

51.) Weston, W. M., Friedland, L. R., Wu, X., & Howe, B. (2012). Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): results of two randomized trials. *Vaccine*, *30*(9), 1721-1728. https://www.sciencedirect.com/science/article/pii/S0264410X11019906

52.) Dabrera, G., Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S., Kara, E., ... & Ramsay, M. (2015). A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. *Clinical Infectious Diseases*, *60*(3), 333-337. https://academic.oup.com/cid/article/60/3/333/312015

53.) Hoang, H. T. T., Leuridan, E., Maertens, K., Nguyen, T. D., Hens, N., Vu, N. H., ... & Dang, A. D. (2016). Pertussis vaccination during pregnancy in Vietnam: results of a randomized controlled trial pertussis vaccination during pregnancy. *Vaccine*, *34*(1), 151-159. https://pubmed.ncbi.nlm.nih.gov/26529073/

54.) Gkentzi, D., Katsakiori, P., Marangos, M., Hsia, Y., Amirthalingam, G., Heath, P. T., & Ladhani, S. (2017). Maternal vaccination against pertussis: a systematic review of the recent literature. *Archives of Disease in Childhood-Fetal and Neonatal Edition*, *102*(5), F456-F463. http://www.dottorvincenzomazza.it/allegaticlasse/593.pdf

55.) Skoff, T. H., Blain, A. E., Watt, J., Scherzinger, K., McMahon, M., Zansky, S. M., Kudish, K., Cieslak, P. R., Lewis, M., Shang, N., & Martin, S. W. (2017). Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 65(12), 1977–1983. https://academic.oup.com/cid/article/65/12/1977/4237166

56.) Furuta, M., Sin, J., Ng, E. S., & Wang, K. (2017). Efficacy and safety of pertussis vaccination for pregnant women–a systematic review of randomised controlled trials and observational studies. *BMC pregnancy and childbirth*, *17*(1), 390. https://link.springer.com/article/10.1186/s12884-017-1559-2

57.) Hall, C., Abramovitz, L. M., Bukowinski, A. T., Ricker, A. A., Khodr, Z. G., Gumbs, G. R., Wells, N. Y., & Conlin, A. (2020). Safety of tetanus, diphtheria, and acellular pertussis vaccination among pregnant active duty U.S. military women. Vaccine, 38(8), 1982–1988. https://pubmed.ncbi.nlm.nih.gov/31952872/

58.) Panozzo, C. A., Becker-Dreps, S., Pate, V., Weber, D. J., Jonsson Funk, M., Stürmer, T., & Brookhart, M. A. (2014). Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007–2010. *American journal of epidemiology*, *179*(7), 895-909. https://academic.oup.com/aje/article/179/7/895/87148

59.) Khodr, Z. G., Bukowinski, A. T., Gumbs, G. R., & Conlin, A. (2017). Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections. Vaccine, 35(42), 5603–5610. https://sci-hub.se/https://doi.org/10.1016/j.vaccine.2017.08.041

60.) Petousis-Harris, H., Walls, T., Watson, D., Paynter, J., Graham, P., & Turner, N. (2016). Safety of Tdap vaccine in pregnant women: an observational study. *BMJ open*, *6*(4). https://bmjopen.bmj.com/content/6/4/e010911.long

61.) Stojanov, S., Liese, J. G., Belohradsky, B. H., Vandermeulen, C., Hoppenbrouwers, K., Van der Wielen, M., ... & Watson, M. (2007). Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP–IPV–PRP~ T–HBs) combination vaccine. *Vaccine*, *25*(43), 7549-7558. https://www.sciencedirect.com/science/article/pii/S0264410X07009632 & https://pubmed.ncbi.nlm.nih.gov/17905486/

62.) Ciarlet, M., He, S., Lai, S., Petrecz, M., Yuan, G., Liu, G. F., ... & Koller, D. Y. (2009). Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. *The Pediatric infectious disease journal*, *28*(3), 177-181. https://journals.lww.com/pidj/Abstract/2009/03000/Concomitant_Use_of_the_3_Dose_Oral_Pentavalent.3.aspx

63.)Behrouzi, B., Bhatt, D. L., Cannon, C. P., Vardeny, O., Lee, D. S., Solomon, S. D., & Udell, J. A. (2022). Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. *JAMA network open*, *5*(4), e228873. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055450/?report=classic

64.) Yeh, S. H., Gurtman, A., Hurley, D. C., Block, S. L., Schwartz, R. H., Patterson, S., ... & Scott, D. A. (2010). Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. *Pediatrics*, *126*(3), e493-e505. https://pediatrics.aappublications.org/content/126/3/e493

65.) Esposito, S., Tansey, S., Thompson, A., Razmpour, A., Liang, J., Jones, T. R., ... & Pugni, L. (2010). Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. *Clinical and vaccine immunology*, *17*(6), 1017-1026. https://cvi.asm.org/content/17/6/1017

66.) Ruiz-Aragon, J., Peláez, S. M., Molina-Linde, J. M., & Grande-Tejada, A. M. (2013). Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis. *Vaccine*, *31*(46), 5349-5358. https://www.sciencedirect.com/science/article/pii/S0264410X13012358

67.) Müller-Nordhorn, J., Hettler-Chen, C. M., Keil, T., & Muckelbauer, R. (2015). Association between sudden infant death syndrome and diphtheria-tetanus-pertussis immunisation: an ecological study. *BMC pediatrics*, *15*(1), 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326294/

68.) Gillet, Y., Habermehl, P., Thomas, S., Eymin, C., & Fiquet, A. (2009). Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (MM-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. *BMC medicine*, *7*(1), 1-11. https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-7-16

69.) Black, S. B., Cimino, C. O., Hansen, J., Lewis, E., Ray, P., Corsaro, B., ... & Laufer, D. (2006). Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. *The Pediatric infectious disease journal*, *25*(4), 306-311. https://pubmed.ncbi.nlm.nih.gov/16567981/

70.) Schmitt, H. J., Knuf, M., Ortiz, E., Sänger, R., Uwamwezi, M. C., & Kaufhold, A. (2000). Primary vaccination of infants with diphtheria-tetanus-acellular pertussis–hepatitis B virus–inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. *The Journal of pediatrics*, *137*(3), 304-312. https://pubmed.ncbi.nlm.nih.gov/10969252/

71.) Vesikari, T., Karvonen, A., Lindblad, N., Korhonen, T., Lommel, P., Willems, P., ... & Schuerman, L. (2010). Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. *The Pediatric infectious disease journal*, *29*(6), e47-e56. https://pubmed.ncbi.nlm.nih.gov/20508478/

72.) Watson, B. M., Laufer, D. S., Kuter, B. J., Staehle, B., & White, C. J. (1996). Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMRIIV) in healthy children. *Journal of Infectious Diseases*, *173*(3), 731-734. https://academic.oup.com/jid/article/173/3/731/880923

73.) Shinefield, H., Black, S., Thear, M., Coury, D., Reisinger, K., Rothstein, E., ... & Schödel, F. (2006). Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. *The Pediatric infectious disease journal*, *25*(4),

287-292.
https://journals.lww.com/pidj/Abstract/2006/04000/Safety_and_Immunogenicity_of_a_Measles,_Mumps,.2.aspx

74.) Halperin, S. A., McDonald, J., Samson, L., & Danzig, L. (2002). Simultaneous administration of meningococcal C conjugate vaccine and diptheria-teatanus-acellular pertusis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: A randomized double-blind study. *Clinical and investigative medicine*, *25*(6), 243. https://pubmed.ncbi.nlm.nih.gov/12516995/

75.) Schmitt, H. J., Faber, J., Lorenz, I., Schmöle-Thoma, B., & Ahlers, N. (2003). The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. *Vaccine*, *21*(25-26), 3653-3662. https://www.sciencedirect.com/science/article/pii/S0264410X0300389X

76.) Rodriguez, Z. M., Goveia, M. G., Stek, J. E., Dallas, M. J., Boslego, J. W., DiNubile, M. J., & Heaton, P. M. (2007). Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. *The Pediatric infectious disease journal*, *26*(3), 221-227. https://pubmed.ncbi.nlm.nih.gov/17484218/

77.) Vesikari, T., Esposito, S., Prymula, R., Ypma, E., Kohl, I., Toneatto, D., ... & EU Meningococcal B Infant Vaccine Study group. (2013). Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. *The Lancet*, *381*(9869), 825-835. https://www.unav.edu/documents/16089811/16216616/menB_phaseIII.pdf

78.) Ferrera, G., Cuccia, M., Mereu, G., Icardi, G., Bona, G., Esposito, S., ... & Hardt, K. (2012). Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2+ 1 schedule in infancy. *Human vaccines & immunotherapeutics*, *8*(3), 355-362. https://www.tandfonline.com/doi/pdf/10.4161/hv.18650

79.) DeStefano, F., Gu, D., Kramarz, P., Truman, B. I., Iademarco, M. F., Mullooly, J. P., ... & Marcy, S. M. (2002). Childhood vaccinations and risk of asthma. *The Pediatric infectious disease journal*, *21*(6), 498-504. http://www.smartvax.com/images/PDF/cdc%20-%20childhood%20vaccinations%20and%20risk%20of%20asthma.pdf

80.) Rieckmann, A., Hærskjold, A., Benn, C. S., Aaby, P., Lange, T., & Sørup, S. (2019). Measles, mumps and rubella vs diphtheria–tetanus–acellular-pertussis–inactivated-polio–Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'. *International Journal of Epidemiology*, *48*(6), 2026-2038. https://academic.oup.com/ije/article-abstract/48/6/2026/5443284

81.) Snape, M. D., Dawson, T., Oster, P., Evans, A., John, T. M., Ohene-Kena, B., ... & Toneatto, D. (2010). Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. *The Pediatric infectious disease journal*, *29*(11), e71-e79. https://journals.lww.com/pidj/Abstract/2010/11000/Immunogenicity_of_Two_Investigational_Serogroup_B.28.aspx

82.) Findlow, J., Borrow, R., Snape, M. D., Dawson, T., Holland, A., John, T. M., ... & Oster, P. (2010). Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. *Clinical Infectious Diseases*, *51*(10), 1127-1137. https://academic.oup.com/cid/article/51/10/1127/391958

83.) Maruyama, T., Taguchi, O., Niederman, M. S., Morser, J., Kobayashi, H., Kobayashi, T., ... & Takei, Y. (2010). Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. *Bmj*, *340*, c1004. https://www.bmj.com/content/340/bmj.c1004.long

84.) Giuliano, A. R., Palefsky, J. M., Goldstone, S., Moreira Jr, E. D., Penny, M. E., Aranda, C., ... & Chang, Y. H. (2011). Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. *New England Journal of Medicine*, *364*(5), 401-411. https://www.nejm.org/doi/full/10.1056/nejmoa0909537

85.) Schmitz, R., Poethko-Müller, C., Reiter, S., & Schlaud, M. (2011). Vaccination status and health in children and adolescents: findings of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). *Deutsches Aerzteblatt International*, *108*(7), 99. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057555/

86.) Iqbal, S., Barile, J. P., Thompson, W. W., & DeStefano, F. (2013). Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7–10 years. *pharmacoepidemiology and drug safety*, *22*(12), 1263-1270. https://circleofmamas.com/wp-content/uploads/2019/07/AntigenNeuropsych_PharmacoEpidemiology2013.pdf

87.) Thompson, W. W., Price, C., Goodson, B., Shay, D. K., Benson, P., Hinrichsen, V. L., ... & Dunn, J. (2007). Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. *New England Journal of Medicine*, *357*(13), 1281-1292. https://www.nejm.org/doi/full/10.1056/NEJMoa071434

88.) Stillo, M., Carrillo Santisteve, P., & Lopalco, P. L. (2015). Safety of human papillomavirus vaccines: a review. *Expert opinion on drug safety*, *14*(5), 697-712. https://www.tandfonline.com/doi/pdf/10.1517/14740338.2015.1013532

89.) Lu, B., Kumar, A., Castellsagué, X., & Giuliano, A. R. (2011). Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. *BMC infectious diseases*, *11*(1), 13. https://link.springer.com/article/10.1186/1471-2334-11-13

90.) Keller-Stanislawski, B., Englund, J. A., Kang, G., Mangtani, P., Neuzil, K., Nohynek, H., ... & Zuber, P. (2014). Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. *Vaccine*, *32*(52), 7057-7064. https://www.sciencedirect.com/science/article/pii/S0264410X14013206

91.) Zhu, F. C., Wurie, A. H., Hou, L. H., Liang, Q., Li, Y. H., Russell, J. B., ... & Xu, W. B. (2017). Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet*, *389*(10069), 621-628. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32617-4/fulltext?rss=yes&code=lancet-site

92.) Cohet, C., van der Most, R., Bauchau, V., Bekkat-Berkani, R., Doherty, T. M., Schuind, A., ... & Innis, B. L. (2019). Safety of AS03-adjuvanted influenza vaccines: a review of the evidence. *Vaccine*, *37*(23), 3006-3021. https://www.sciencedirect.com/science/article/pii/S0264410X19305225

93.) Huang, W. T., Huang, Y. S., Hsu, C. Y., Chen, H. C., Lee, H. C., Lin, H. C., ... & Yang, C. H. (2020). Narcolepsy and 2009 H1N1 pandemic vaccination in Taiwan. *Sleep medicine*, *66*, 276-281. https://www.sciencedirect.com/science/article/abs/pii/S1389945718305677

94.) Weibel, D., Sturkenboom, M., Black, S., de Ridder, M., Dodd, C., Bonhoeffer, J., ... & Gentile, A. (2018). Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines–Multi-country assessment. *Vaccine*, *36*(41), 6202-6211. https://www.sciencedirect.com/science/article/pii/S0264410X18311150

95.) Lee, G. M., Greene, S. K., Weintraub, E. S., Baggs, J., Kulldorff, M., Fireman, B. H., ... & Yin, R. (2011). H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. *American journal of preventive medicine*, *41*(2), 121-128. https://www.ajpmonline.org/article/S0749-3797(11)00260-1/fulltext

96.) Stokley, S., Curtis, C. R., Jeyarajah, J., Harrington, T., Gee, J., & Markowitz, L. (2013). Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2013—United States. *MMWR. Morbidity and mortality weekly report*, *62*(29), 591. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604972/

97.) White, C. J., Stinson, D., Staehle, B., Cho, I., Matthews, H., Ngai, A., ... & Kuter, B. (1997). Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. *Clinical infectious diseases*, *24*(5), 925-931. https://academic.oup.com/cid/article/24/5/925/478684

98.) Lieberman, J. M., Williams, W. R., Miller, J. M., Black, S., Shinefield, H., Henderson, F., ... & Klopfer, S. (2006). The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. *The Pediatric infectious disease journal*, *25*(7), 615-622. https://journals.lww.com/pidj/Abstract/2006/07000/The_Safety_and_Immunogenicity_of_a_Quadrivalent.10.aspx

99.) Nolan, T., Bernstein, D. I., Block, S. L., Hilty, M., Keyserling, H. L., Marchant, C., ... & Cho, I. (2008). Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. *Pediatrics*, *121*(3), 508-516. https://pediatrics.aappublications.org/content/121/3/508.short

100.) Shinefield, H. R., Black, S., Ray, P., Chang, I. H., Lewis, N. E. D., Fireman, B., ... & Madore, D. V. (1999). Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. *The Pediatric infectious disease journal*, *18*(9), 757-763. https://journals.lww.com/pidj/Abstract/1999/09000/Safety_and_immunogenicity_of_heptavalent.4.aspx

101.) Hoke, C. H., Nisalak, A., Sangawhipa, N., Jatanasen, S., Laorakapongse, T., Innis, B. L., ... & Burke, D. S. (1988). Protection against Japanese encephalitis by inactivated vaccines. *New England Journal of Medicine*, *319*(10), 608-614. https://www.nejm.org/doi/full/10.1056/NEJM198809083191004

102.) Weibel, R. E., Neff, B. J., Kuter, B. J., Guess, H. A., Rothenberger, C. A., Fitzgerald, A. J., ... & Scolnick, E. M. (1984). Live attenuated varicella virus vaccine: efficacy trial in healthy children. *New England Journal of Medicine*, *310*(22), 1409-1415. https://www.nejm.org/doi/full/10.1056/NEJM198405313102201

103.) Maupas, P., Barin, F., Chiron, J. P., Coursaget, P., Goudeau, A., Perrin, J., ... & Mar, I. D. (1981). Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children: controlled trial in an endemic area (Senegal). *The Lancet*, *317*(8215), 289-292. https://www.sciencedirect.com/science/article/abs/pii/S0140673681919085

104.) Fritzell, B., & Plotkin, S. (1992). Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. *The Journal of pediatrics*, *121*(3), 355-362. https://www.sciencedirect.com/science/article/abs/pii/S002234760581786X

105.) Szmuness, W., Stevens, C. E., Harley, E. J., Zang, E. A., Oleszko, W. R., William, D. C., ... & Kellner, A. (1980). Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. *New England Journal of Medicine*, *303*(15), 833-841. https://www.nejm.org/doi/full/10.1056/NEJM198010093031501

106.) Trollfors, B., Taranger, J., Lagergård, T., Lind, L., Sundh, V., Zackrisson, G., ... & Robbins, J. B. (1995). A placebo-controlled trial of a pertussis-toxoid vaccine. *New England Journal of Medicine*, *333*(16), 1045-1050. https://www.nejm.org/doi/full/10.1056/NEJM199510193331604

107.) Dienstag, J. L., Werner, B. G., Polk, B. F., Snydman, D. R., Craven, D. E., Platt, R., ... & Grady, G. F. (1984). Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. *Annals of internal medicine*, *101*(1), 34. https://www.acpjournals.org/doi/abs/10.7326/0003-4819-101-1-34

108.) Francis, D. P., Hadler, S. C., Thompson, S. E., Maynard, J. E., Ostrow, D. G., Altman, N., ... & Penley, K. (1982). The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. *Annals of internal medicine*, *97*(3), 362. https://www.acpjournals.org/doi/abs/10.7326/0003-4819-97-3-362

109.) Sierra, G. V., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P. L., Sotolongo, P. F., ... & Terry, M. H. (1991). Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. *NIPH annals*, *14*(2), 195-207. https://europepmc.org/article/med/1812432

110.) Langenberg, A. G., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L., & Corey, L. (1995). A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. *Annals of internal medicine*, *122*(12), 889-898. https://www.acpjournals.org/doi/abs/10.7326/0003-4819-122-12-199506150-00001

111.) Edwards, K. M., Dupont, W. D., Westrich, M. K., Plummer Jr, W. D., Palmer, P. S., & Wright, P. F. (1994). A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. *Journal of Infectious Diseases*, *169*(1), 68-76. https://academic.oup.com/jid/article-abstract/169/1/68/896278

112.) Innis, B. L., Snitbhan, R., Kunasol, P., Laorakpongse, T., Poopatanakool, W., Kozik, C. A., ... & Boslego, J. W. (1994). Protection against hepatitis A by an inactivated vaccine. *Jama*, *271*(17), 1328-1334. https://jamanetwork.com/journals/jama/article-abstract/371192

113.) Hall, C. B., Douglas, R. G., & Fralonardo, S. A. (1975). Live attenuated influenza virus vaccine trial in children. *Pediatrics*, *56*(6), 991-998. https://pediatrics.aappublications.org/content/56/6/991

114.) Van Damme, P., Matheï, C., Thoelen, S., Meheus, A., Safary, A., & Andre, F. E. (1994). Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. *Journal of medical virology*, *44*(4), 435-441. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.1890440422

115.) Sanchez, J. L., Vasquez, B., Begue, R. E., Meza, R., Castellares, G., Cabezas, C., ... & Taylor, D. N. (1994). Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. *The Lancet*, *344*(8932), 1273-1276. https://www.sciencedirect.com/science/article/abs/pii/S0140673694907552

116.) Simanjuntak, C., Totosudirjo, H., Witham, N., Punjabi, N., Burr, D., Sorenson, K., ... & Wasserman, S. S. (1992). Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. *The Lancet*, *340*(8821), 689-694. https://www.sciencedirect.com/science/article/abs/pii/0140673692922314

117.) Jones, W. R., Judd, S. J., Ing, R. M. Y., Powell, J., Bradley, J., Denholm, E. H., ... & Stevens, V. C. (1988). Phase I clinical trial of a World Health Organisation birth control vaccine. *The Lancet*, *331*(8598), 1295-1298. https://www.sciencedirect.com/science/article/abs/pii/S0140673688921174

118.) Clemens, J., Harris, J., Khan, M. R., Kay, B., Yunus, M. D., Svennerholm, A. M., ... & Atkinson, W. (1986). Field trial of oral cholera vaccines in Bangladesh. *The Lancet*, *328*(8499), 124-127. https://www.sciencedirect.com/science/article/abs/pii/S0140673686919446

119.) Levine, M., Herrington, D., Losonsky, G., Tall, B., Kaper, J., Ketley, J., ... & Cryz, S. (1988). Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. *The Lancet*, *332*(8609), 467-470. https://www.sciencedirect.com/science/article/abs/pii/S0140673688901201

120.) Ferreccio, C., Levine, M. M., Rodriguez, H., Contreras, R., & Chilean Typhoid Committee. (1989). Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. *The Journal of infectious diseases*, 766-769. https://www.jstor.org/stable/30137110?seq=1 & https://sci-hub.do/https://doi.org/10.1093/infdis/159.4.766

121.) Schwartz, J. S. (1982). Pneumococcal vaccine: clinical efficacy and effectiveness. *Annals of internal medicine*, *96*(2), 208-220. https://www.acpjournals.org/doi/abs/10.7326/0003-4819-96-2-208

122.) Francis Jr, T., & Tillett, W. S. (1930). Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. *The Journal of experimental medicine*, *52*(4), 573-585. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.273.9224&rep=rep1&type=pdf

123.) Decker, M. D., Edwards, K. M., Bradley, R., & Palmer, P. (1992). Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. *The Journal of pediatrics*, *120*(2), 184-189. https://www.sciencedirect.com/science/article/abs/pii/S002234760580424X

124.) Santosham, M., Wolff, M., Reid, R., Hohenboken, M., Bateman, M., Goepp, J., ... & Capriotti, L. (1991). The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. *New England Journal of Medicine*, *324*(25), 1767-1772. https://www.nejm.org/doi/full/10.1056/nejm199106203242503

125.) Cryz Jr, S. J., Levine, M. M., Kaper, J. B., Fürer, E., & Althaus, B. (1990). Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. *Vaccine*, *8*(6), 577-580.

126.) Bernstein, D. I., Glass, R. I., Rodgers, G., Davidson, B. L., Sack, D. A., Anderson, E., ... & Blumberg, D. (1995). Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. *Jama*, *273*(15), 1191-1196. https://jamanetwork.com/journals/jama/article-abstract/387979

127.) Roy, M. J., Wu, M. S., Barr, L. J., Fuller, J. T., Tussey, L. G., Speller, S., ... & Widera, G. (2000). Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. *Vaccine*, *19*(7-8), 764-778. https://www.sciencedirect.com/science/article/pii/S0264410X00003029

128.) Van Damme, P., Thoelen, S., Cramm, M., De Groote, K., Safary, A., & Meheus, A. (1994). Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long‐term antibody persistence. *Journal of medical virology*, *44*(4), 446-451. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.1890440425

129.) Gordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., ... & Hauser, P. (1995). Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. *Journal of Infectious Diseases*, *171*(6), 1576-1585. https://academic.oup.com/jid/article-abstract/171/6/1576/803986

130.) Werzberger, A., Mensch, B., Kuter, B., Brown, L., Lewis, J., Sitrin, R., ... & Ryan, J. (1992). A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. *New England journal of medicine*, *327*(7), 453-457. https://www.nejm.org/doi/full/10.1056/NEJM199208133270702

131.) Madore, H. P., Christy, C., Pichichero, M., Long, C., Pincus, P., Vosefsky, D., ... & Elmwood, Panorama, and Westfall Pediatric Groups. (1992). Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. *Journal of infectious diseases*, *166*(2), 235-243. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.825.5815&rep=rep1&type=pdf

132.) Redfield, R. R., Innis, B. L., Scott, R. M., Cannon, H. G., & Bancroft, W. H. (1985). Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost reduction strategy. *Jama*, *254*(22), 3203-3206. https://jamanetwork.com/journals/jama/article-abstract/402051

133.) Brown, A. E., Singharaj, P., Webster, H. K., Pipithkul, J., Gordon, D. M., Boslego, J. W., ... & Permpanich, B. (1994). Safety, immunogenicity and limited efficacy study of a recombinant

Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. *Vaccine*, *12*(2), 102-108. https://www.sciencedirect.com/science/article/pii/0264410X94900469

134.) Tacket, C. O., Losonsky, G., Nataro, J. P., Comstock, L., Michalski, J., Edelman, R., ... & Levine, M. M. (1995). Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. *Journal of Infectious Diseases*, *172*(3), 883-886. https://academic.oup.com/jid/article-abstract/172/3/883/885281

135.) Tilzey, A. J., Palmer, S. J., Barrow, S., Perry, K. R., Tyrrell, H., Safary, A., & Banatvala, J. E. (1992). Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. *British Medical Journal*, *304*(6837), 1272-1276. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1881873/pdf/bmj00073-0022.pdf

136.) Gold, R., & Artenstein, M. S. (1971). Meningococcal infections: 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. *Bulletin of the World Health Organization*, *45*(3), 279. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427931/pdf/bullwho00196-0007.pdf

137.) Szmuness, W., Stevens, C. E., Harley, E. J., Zang, E. A., Alter, H. J., Taylor, P. E., ... & Kellner, A. (1982). Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. *The New England journal of medicine*, *307*(24), 1481. https://pubmed.ncbi.nlm.nih.gov/6755247/

138.) Desmyter, J., De Groote, G., Colaert, J., Reynders, M., Reerink-Brongers, E. E., Dees, P. J., ... & Group, T. L. R. T. C. (1983). Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff: double-blind placebo-controlled trial. *The Lancet*, *322*(8363), 1323-1328. https://www.sciencedirect.com/science/article/abs/pii/S0140673683910899

139.) Wahdan, M. H., Rizk, F., El-Akkad, A. M., El Ghoroury, A. A., Hablas, R., Girgis, N. I., ... & Triau, R. (1973). A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. *Bulletin of the World Health Organization*, *48*(6), 667. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483073/pdf/bullwho00179-0030.pdf

140.) Watson, B., Rothstein, E., Bernstein, H., Arbeter, A., Arvin, A., Chartrand, S., ... & Starr, S. E. (1995). Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. *Journal of Infectious Diseases*, *172*(1), 217-219. https://academic.oup.com/jid/article-abstract/172/1/217/853335

141.) Kuter, B. J., Ngai, A., Patterson, C. M., Staehle, B. O., Cho, I., Matthews, H., ... & Oka/Merck Varicella Vaccine Study Group. (1995). Safety, tolerability, and immunogenicity of

two regimens of Oka/Merck varicella vaccine (Varivax®) in healthy adolescents and adults. *Vaccine*, *13*(11), 967-972. https://www.sciencedirect.com/science/article/pii/0264410X95000464

142.) Gothefors, L., Wadell, G., Juto, P., Taniguchi, K., Kapikian, A. Z., & Glass, R. I. (1989). Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. *The Journal of infectious diseases*, *159*(4), 753-757. https://pubmed.ncbi.nlm.nih.gov/2538521/ & https://sci-hub.do/https://www.jstor.org/stable/30137107?seq=1

143.) Kotloff, K. L., Wasserman, S. S., O'Donnell, S., Losonsky, G. A., Cryz, S. J., & Levine, M. M. (1992). Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. *Infection and immunity*, *60*(10), 4430-4432. https://iai.asm.org/content/iai/60/10/4430.full.pdf

144.) Fine, M. J., Smith, M. A., Carson, C. A., Meffe, F., Sankey, S. S., Weissfeld, L. A., ... & Kapoor, W. N. (1994). Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. *Archives of Internal Medicine*, *154*(23), 2666-2677. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/619742

145.) Shang, M., Chung, J. R., Jackson, M. L., Jackson, L. A., Monto, A. S., Martin, E. T., ... & Zimmerman, R. K. (2018). Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012–2016. *Vaccine*, *36*(52), 8047-8053. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282182/

146.) Alexandrova, G. I., Budilovsky, G. N., Koval, T. A., Polezhaev, F. I., Garmashova, L. M., Ghendon, Y. Z., ... & Smorodintsev, A. A. (1986). Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. *Vaccine*, *4*(2), 114-118. https://www.sciencedirect.com/science/article/pii/0264410X86900496

147.) Avila, R. (1978). Results of a clinical trial with a Dermatophagoides pteronyssinus tyrosine adsorbed vaccine. *Allergologia et Immunopathologia*, *6*(3), 231-235. https://europepmc.org/article/med/362875

148.) Maiztegui, J. I., McKee Jr, K. T., Oro, J. G. B., Harrison, L. H., Gibbs, P. H., Feuillade, M. R., ... & Halsey, N. A. (1998). Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. *Journal of Infectious Diseases*, *177*(2), 277-283. https://academic.oup.com/jid/article/177/2/277/925328

149.) Takala, A. K., Peltola, H., & Eskola, J. (1994). Disappearance of epiglottitis during large‐scale vaccination with Haemophilus influenzae type B conjugate vaccine among children

in Finland. *The Laryngoscope*, *104*(6), 731-735. https://onlinelibrary.wiley.com/doi/pdf/10.1288/00005537-199406000-00013

150.) Lai, C. L., Wong, B. C. Y., Yeoh, E. K., Lim, W. L., Chang, W. K., & Lin, H. J. (1993). Five‐year follow‐up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma‐derived vaccine in children: immunogenicity and anamnestic responses. *Hepatology*, *18*(4), 763-767. https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840180403

151.) Tudor-Williams, G., Frankland, J., Isaacs, D., Mayon-White, R. T., MacFarlane, J. A., Rees, D. G., & Moxon, E. R. (1989). Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom. *Archives of disease in childhood*, *64*(4), 520-524. https://adc.bmj.com/content/archdischild/64/4/520.full.pdf

152.) Wahdan, M. H., Serie, C. H., Cerisier, Y., Sallam, S., & Germanier, R. (1982). A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. *Journal of Infectious Diseases*, *145*(3), 292-295. https://academic.oup.com/jid/article-abstract/145/3/292/2189941

153.) Plotkin, S. A., & Bouveret-Le Cam, N. (1995). A new typhoid vaccine composed of the Vi capsular polysaccharide. *Archives of internal medicine*, *155*(21), 2293-2299. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/621271

154.) Dandolos, E., Roumeliotou‐Karayannis, A., Richardson, S. C., & Papaevangelou, G. (1985). Safety and immunogenicity of a recombinant hepatitis B vaccine. *Journal of medical virology*, 17(1), 57-62. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.1890170109

155.) de Moraes, J. C., Camargo, M. C. C., Hidalgo, N. R., Barbosa, H. A., Gattas, V. L., Vasconcelos, H. D. G., ... & Plikaytis, B. D. (1992). Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. *The Lancet*, *340*(8827), 1074-1078. https://www.sciencedirect.com/science/article/abs/pii/0140673692930863

156.) Vesikari, T., Rautanen, T., Varis, T., Beards, G. M., & Kapikian, A. Z. (1990). Rhesus rotavirus candidate vaccine: clinical trial in children vaccinated between 2 and 5 months of age. *American journal of diseases of children*, *144*(3), 285-289. https://jamanetwork.com/journals/jamapediatrics/article-abstract/515050

157.) Klugman, K., Koornhof, H., Schneerson, R., Cadoz, M., Gilbertson, I., Robbins, J., ... & Committee, V. A. (1987). Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. *The Lancet*, *330*(8569), 1165-1169.

https://www.sciencedirect.com/science/article/abs/pii/S014067368791316X

158.) Crosnier, J., Jungers, P., Couroucé, A. M., Laplanche, A., Benhamou, E., Degos, F., ... & Guesry, P. (1981). Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. *The Lancet*, *317*(8218), 455-459. https://www.sciencedirect.com/science/article/abs/pii/S014067368191847X

159.) Ferreccio, C., Ortiz, E., Cryz, S., & Levine, M. M. (1990). Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. *The Lancet*, *336*(8720), 891-894. https://www.sciencedirect.com/science/article/abs/pii/014067369092266K

160.) Tacket, C. O., Losonsky, G., Nataro, J. P., Cryz, S. J., Edelman, R., Kaper, J. B., & Levine, M. M. (1992). Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD l03-HgR. *Journal of infectious diseases*, *166*(4), 837-841. https://doc.rero.ch/record/299866/files/166-4-837.pdf

161.) Wahdan, M. H., Serie, C., Germanier, R., Lackany, A., Cerisier, Y., Guerin, N., ... & Guesry, P. (1980). A controlled field trial of live oral typhoid vaccine Ty21a. *Bulletin of the World Health Organization*, *58*(3), 469. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395909/pdf/bullwho00426-0126.pdf

162.) Furesz, J., Scheifele, D. W., & Palkonyay, L. (1995). Safety and effectiveness of the new inactivated hepatitis A virus vaccine. *CMAJ: Canadian Medical Association Journal*, *152*(3), 343. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1337532/pdf/cmaj00063-0033.pdf

163.) Simanjuntak, C. H., O'Hanley, P., Punjabi, N. H., Noriega, F., Pazzaglia, G., Dykstra, P., ... & Losonsky, G. (1993). Safety, Immunogenicity, and Transmissibility of Single-Dose Live Oral Cholera Vaccine Strain CVD l03-HgR in 24-to 59-Month-Old Indonesian Children. *Journal of infectious diseases*, *168*(5), 1169-1176. https://doc.rero.ch/record/297081/files/168-5-1169.pdf

164.) Talwar, G. P., Hingorani, V., Kumar, S., Roy, S., Banerjee, A., Shahani, S. M., ... & Singh, O. (1990). Phase I clinical trials with three formulations of anti-human chorionic gonadotropin vaccine. *Contraception*, *41*(3), 301-316. https://www.sciencedirect.com/science/article/abs/pii/0010782490900713

165.) Watson, B., Boardman, C., Laufer, D., Piercy, S., Tustin, N., Olaleye, D., ... & Starr, S. E. (1995). Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. *Clinical infectious diseases*, *20*(2), 316-319.

http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.915.8040&rep=rep1&type=pdf

166.) Collier, A. C., Corey, L., Murphy, V. L., & Handsfield, H. H. (1988). Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. *Annals of internal medicine*, *109*(2), 101-105.
https://academic.oup.com/jid/article/158/3/570/2190338

167.) Edees, S., Pullan, C. R., & Hull, D. (1991). A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. *Public health*, *105*(2), 91-97.
https://www.sciencedirect.com/science/article/abs/pii/S0033350605802823

168.) Booy, R., Taylor, S. A., Dobson, S. R., Isaacs, D., Sleight, G., Aitken, S., ... & Macfarlane, J. A. (1992). Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule. *Archives of disease in childhood*, *67*(4), 475-478.
https://adc.bmj.com/content/archdischild/67/4/475.full.pdf

169.) Zamora, I., Simon, J. M., Da Silva, M. E., & Piqueras, A. I. (1994). Attenuated varicella virus vaccine in children with renal transplants. *Pediatric nephrology*, *8*(2), 190-192.
https://link.springer.com/article/10.1007/BF00865476

170.) Colditz, G. A., Berkey, C. S., Mosteller, F., Brewer, T. F., Wilson, M. E., Burdick, E., & Fineberg, H. V. (1995). The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. *Pediatrics*, *96*(1), 29-35.
https://www.ncbi.nlm.nih.gov/books/NBK66429/

171.) Weitberg, A. B., Weitzman, S. A., Watkins, E., Hinkle, C., O'Rourke, S., & Dienstag, J. L. (1985). Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy. *Journal of Clinical Oncology*, *3*(5), 718-722.
https://pubmed.ncbi.nlm.nih.gov/3158725/

172.) Wainwright, R. B., McMahon, B. J., Bulkow, L. R., Hall, D. B., Fitzgerald, M. A., Harpster, A. P., ... & Heyward, W. L. (1989). Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. *Jama*, *261*(16), 2362-2366.
https://jamanetwork.com/journals/jama/article-abstract/377108

173.) Halliday, M. L., Rankin, J. G., Bristow, N. J., Coates, R. A., Corey, P. N., & Strickler, A. C. (1990). A randomized double-blind clinical trial of a mammalian cell-derived recombinant DNA

hepatitis B vaccine compared with a plasma-derived vaccine. *Archives of Internal Medicine*, *150*(6), 1195-1200. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/613457

174.) Vadheim, C. M., Greenberg, D. P., Partridge, S., Jing, J., & Ward, J. I. (1993). Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. *Pediatrics*, *92*(2), 272-279. https://pediatrics.aappublications.org/content/92/2/272

175.) Payne, D. C., Baggs, J., Zerr, D. M., Klein, N. P., Yih, K., Glanz, J., ... & Parashar, U. D. (2014). Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. *Clinical infectious diseases*, *58*(2), 173-177. https://academic.oup.com/cid/article/58/2/173/334292?numero_etudiant=/revue.presse.responsabilite.php?numero_etudiant=

176.) Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J. R., ... & Malinoski, F. (2000). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. *The Pediatric infectious disease journal*, *19*(3), 187-195. https://journals.lww.com/pidj/Abstract/2000/03000/Efficacy,_safety_and_immunogenicity_of_heptavalent.3.aspx

177.) Clark, H. F., Bernstein, D. I., Dennehy, P. H., Offit, P., Pichichero, M., Treanor, J., ... & Laura, D. (2004). Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. *The Journal of pediatrics*, *144*(2), 184-190. https://www.sciencedirect.com/science/article/abs/pii/S0022347603007741

178.) Chien, Y. C., Jan, C. F., Chiang, C. J., Kuo, H. S., You, S. L., & Chen, C. J. (2014). Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: A 20‐year cohort study of 3.8 million vaccinees. *Hepatology*, *60*(1), 125-132. https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.27048

179.) Elkayam, O., Paran, D., Caspi, D., Litinsky, I., Yaron, M., Charboneau, D., & Rubins, J. B. (2002). Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. *Clinical Infectious Diseases*, *34*(2), 147-153. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1032.2263&rep=rep1&type=pdf

180.) Jackson, L. A., Gaglani, M. J., Keyserling, H. L., Balser, J., Bouveret, N., Fries, L., & Treanor, J. J. (2010). Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in

healthy adults: a randomized, placebo-controlled trial over two influenza seasons. *BMC infectious diseases*, *10*(1), 71. https://link.springer.com/article/10.1186/1471-2334-10-71

181.) Trimble, C. L., Morrow, M. P., Kraynyak, K. A., Shen, X., Dallas, M., Yan, J., ... & Brown, A. S. (2015). Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. *The Lancet*, *386*(10008), 2078-2088. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888059/

182.) Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., O'Hagan, D. T., & Podda, A. (2009). Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. *The Pediatric infectious disease journal*, *28*(7), 563-571. https://journals.lww.com/pidj/Abstract/2009/07000/Enhanced_Immunogenicity_of_Seasonal_Influenza.1.aspx

183.) Andre, F., Van Damme, P., Safary, A., & Banatvala, J. (2002). Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. *Expert review of vaccines*, *1*(1), 9-23. https://sci-hub.do/https://doi.org/10.1586/14760584.1.1.9 & https://www.tandfonline.com/doi/abs/10.1586/14760584.1.1.9

184.) Leroux-Roels, I., Vets, E., Freese, R., Seiberling, M., Weber, F., Salamand, C., & Leroux-Roels, G. (2008). Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. *Vaccine*, *26*(51), 6614-6619. https://www.sciencedirect.com/science/article/pii/S0264410X08012802

185.) Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., ... & Bachmann, M. F. (2005). A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. *European journal of immunology*, *35*(7), 2031-2040. https://onlinelibrary.wiley.com/doi/full/10.1002/eji.200526285

186.) Zeng, M., Mao, X. H., Li, J. X., Tong, W. D., Wang, B., Zhang, Y. J., ... & Lu, D. S. (2015). Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*, *386*(10002), 1457-1464. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60310-5/fulltext

187.) Wardenburg, J. B., & Schneewind, O. (2008). Vaccine protection against Staphylococcus aureus pneumonia. *The Journal of experimental medicine*, *205*(2), 287-294.

https://rupress.org/jem/article/205/2/287/40288/Vaccine-protection-against-Staphylococcus-aureus

188.) Bhandari, N., Sharma, P., Taneja, S., Kumar, T., Rongsen-Chandola, T., Appaiahgari, M. B., ... & Rotavirus Vaccine Development Group. (2009). A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. *Journal of Infectious Diseases*, *200*(3), 421-429. https://academic.oup.com/jid/article/200/3/421/901173

189.) Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J. (2009). Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. *The Journal of infectious diseases*, *200*(2), 172-180. https://pubmed.ncbi.nlm.nih.gov/19508159/

190.) Salinas, B., Schael, I. P., Linhares, A. C., Palacios, G. M. R., Guerrero, M. L., Yarzábal, J. P., ... & De Vos, B. (2005). Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. *The Pediatric infectious disease journal*, *24*(9), 807-816. https://journals.lww.com/pidj/Abstract/2005/09000/Evaluation_of_Safety,_Immunogenicity_and_Efficacy.14.aspx

191.) Madhi, S. A., Maskew, M., Koen, A., Kuwanda, L., Besselaar, T. G., Naidoo, D., ... & Sanne, I. (2011). Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. *Clinical infectious diseases*, *52*(1), 128-137. https://academic.oup.com/cid/article/52/1/128/402208

192.) Nolan, T., McVernon, J., Skeljo, M., Richmond, P., Wadia, U., Lambert, S., ... & Hartel, G. (2010). Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial. *Jama*, *303*(1), 37-46. https://jamanetwork.com/journals/jama/article-abstract/185153

193.) Vesikari, T., Clark, H. F., Offit, P. A., Dallas, M. J., DiStefano, D. J., Goveia, M. G., ... & DiNubile, M. J. (2006). Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. *Vaccine*, *24*(22), 4821-4829. https://www.sciencedirect.com/science/article/pii/S0264410X0600288X

194.) Perez, G., Lazcano‐Ponce, E., Hernandez‐Avila, M., García, P. J., Munoz, N., Villa, L. L., ... & Vuocolo, S. (2008). Safety, immunogenicity, and efficacy of quadrivalent human

papillomavirus (types 6, 11, 16, 18) L1 virus‐like‐particle vaccine in Latin American women. *International Journal of Cancer*, *122*(6), 1311-1318. https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.23260

195.) Rudenko, L. G., Arden, N. H., Grigorieva, E., Naychin, A., Rekstin, A., Klimov, A. I., ... & Cox, N. J. (2000). Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. *Vaccine*, *19*(2-3), 308-318. https://www.sciencedirect.com/science/article/pii/S0264410X00001535

196.) Huygen, K., Content, J., Denis, O., Montgomery, D. L., Yawman, A. M., Deck, R. R., ... & Drowart, A. (1996). Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. *Nature medicine*, *2*(8), 893-898. https://www.nature.com/articles/nm0896-893

197.) Moa, A. M., Chughtai, A. A., Muscatello, D. J., Turner, R. M., & MacIntyre, C. R. (2016). Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. *Vaccine*, *34*(35), 4092-4102. https://www.sciencedirect.com/science/article/pii/S0264410X16305151

198.) Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., ... & De Rosa, S. C. (2016). Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial. *Jama*, *315*(15), 1610-1623. https://jamanetwork.com/journals/jama/article-abstract/2514196

199.) Squarcione, S., Sgricia, S., Biasio, L. R., & Perinetti, E. (2003). Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. *Vaccine*, *21*(11-12), 1268-1274. https://pubmed.ncbi.nlm.nih.gov/12559808/

200.) Vesikari, T., Groth, N., Karvonen, A., Borkowski, A., & Pellegrini, M. (2009). MF59®-adjuvanted influenza vaccine (FLUAD®) in children: safety and immunogenicity following a second year seasonal vaccination. *Vaccine*, *27*(45), 6291-6295. https://www.sciencedirect.com/science/article/pii/S0264410X09002138

201.) Orr, N. A. D. A. V., Robin, G., Cohen, D., Arnon, R., & Lowell, G. H. (1993). Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. *Infection and immunity*, *61*(6), 2390-2395. https://iai.asm.org/content/iai/61/6/2390.full.pdf

202.) Ndiaye, B. P., Thienemann, F., Ota, M., Landry, B. S., Camara, M., Dièye, S., ... & January, V. (2015). Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. *The Lancet Respiratory Medicine*, *3*(3), 190-200. https://www.sciencedirect.com/science/article/pii/S2213260015000375

203.) Neuzil, K. M., Dupont, W. D., Wright, P. F., & Edwards, K. M. (2001). Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. *The Pediatric infectious disease journal*, *20*(8), 733-740. https://journals.lww.com/pidj/Abstract/2001/08000/Efficacy_of_inactivated_and_cold_adapted_vaccines.4.aspx

204.) Wheeler, C. M., Skinner, S. R., Del Rosario-Raymundo, M. R., Garland, S. M., Chatterjee, A., Lazcano-Ponce, E., ... & Martens, M. G. (2016). Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. *The Lancet Infectious Diseases*, *16*(10), 1154-1168. https://www.sciencedirect.com/science/article/abs/pii/S1473309916301207

205.) Block, S. L., Vesikari, T., Goveia, M. G., Rivers, S. B., Adeyi, B. A., Dallas, M. J., ... & Heaton, P. M. (2007). Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. *Pediatrics*, *119*(1), 11-18. https://pediatrics.aappublications.org/content/119/1/11.short

206.) Jackson, L. A., Gurtman, A., van Cleeff, M., Jansen, K. U., Jayawardene, D., Devlin, C., ... & Schmoele-Thoma, B. (2013). Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. *Vaccine*, *31*(35), 3577-3584. https://www.sciencedirect.com/science/article/pii/S0264410X13005872

207.) Baxter, R., Patriarca, P. A., Ensor, K., Izikson, R., Goldenthal, K. L., & Cox, M. M. (2011). Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. *Vaccine*, *29*(12), 2272-2278. https://www.sciencedirect.com/science/article/pii/S0264410X11000788

208.) Zhu, F., Xu, W., Xia, J., Liang, Z., Liu, Y., Zhang, X., ... & Hu, Y. (2014). Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. *New England Journal of Medicine*, *370*(9), 818-828. https://www.nejm.org/doi/full/10.1056/NEJMoa1304923

209.) Antrobus, R. D., Lillie, P. J., Berthoud, T. K., Spencer, A. J., McLaren, J. E., Ladell, K., ... & Gilbert, S. C. (2012). AT cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+ M1 in adults aged over 50 years. *PloS one*, *7*(10), e48322. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0048322

210.) Roteli-Martins, C. M., Naud, P., De Borba, P., Teixeira, J. C., De Carvalho, N. S., Zahaf, T., ... & Descamps, D. (2012). Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. *Human vaccines & immunotherapeutics*, *8*(3), 390-397. https://www.tandfonline.com/doi/pdf/10.4161/hv.18865

211.) Kosten, T. R., Rosen, M., Bond, J., Settles, M., Roberts, J. S. C., Shields, J., ... & Fox, B. (2002). Human therapeutic cocaine vaccine: safety and immunogenicity. *Vaccine*, *20*(7-8), 1196-1204. https://www.sciencedirect.com/science/article/pii/S0264410X0100425X

212.) De Donato, S., Granoff, D., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., ... & Podda, A. (1999). Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. *Vaccine*, *17*(23-24), 3094-3101. https://www.sciencedirect.com/science/article/pii/S0264410X99001383

213.) Armijos, R. X., Weigel, M. M., Aviles, H., Maldonado, R., & Racines, J. (1998). Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. *The Journal of infectious diseases*, *177*(5), 1352-1357. https://academic.oup.com/jid/article/177/5/1352/803754

214.) Cohen, M. B., Giannella, R. A., Bean, J., Taylor, D. N., Parker, S., Hoeper, A., ... & Killeen, K. P. (2002). Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. *Infection and immunity*, *70*(4), 1965-1970. https://iai.asm.org/content/70/4/1965.short

215.) Esen, M., Kremsner, P. G., Schleucher, R., Gässler, M., Imoukhuede, E. B., Imbault, N., ... & Knobloch, J. (2009). Safety and immunogenicity of GMZ2—a MSP3–GLURP fusion protein malaria vaccine candidate. *Vaccine*, *27*(49), 6862-6868. https://www.ufjf.br/pgcbio/files/2009/10/Artigo-Nicolli.pdf

216.) Tacket, C. O., Forrest, B., Morona, R., Attridge, S. R., LaBrooy, J., Tall, B. D., ... & Levine, M. M. (1990). Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. *Infection and immunity*, *58*(6), 1620-1627. https://iai.asm.org/content/iai/58/6/1620.full.pdf

217.) Rennels, M. B., Edwards, K. M., Keyserling, H. L., Reisinger, K. S., Hogerman, D. A., Madore, D. V., ... & Kimura, A. (1998). Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. *Pediatrics*, *101*(4), 604-611. https://pediatrics.aappublications.org/content/101/4/604.short

218.) Reisinger, K. S., Block, S. L., Lazcano-Ponce, E., Samakoses, R., Esser, M. T., Erick, J., ... & Alvarez, F. B. (2007). Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. *The Pediatric infectious disease journal*, *26*(3), 201-209. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.616.7814&rep=rep1&type=pdf

219.) De Santis, O., Audran, R., Pothin, E., Warpelin-Decrausaz, L., Vallotton, L., Wuerzner, G., ... & Thierry, A. C. (2016). Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. *The Lancet infectious diseases*, *16*(3), 311-320. https://www.sciencedirect.com/science/article/pii/S1473309915004867

220.) Vesikari, T., Wysocki, J., Chevallier, B., Karvonen, A., Czajka, H., Arsène, J. P., ... & Schuerman, L. (2009). Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. *The Pediatric infectious disease journal*, *28*(4), S66-S76. https://journals.lww.com/pidj/fulltext/2009/04001/immunogenicity_of_the_10_valent_pneumococcal.2.aspx

221.) Kjaer, S. K., Nygård, M., Sundström, K., Dillner, J., Tryggvadottir, L., Munk, C., ... & Bjelkenkrantz, K. (2020). Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. *EClinicalMedicine*, *23*, 100401. https://www.sciencedirect.com/science/article/pii/S2589537020301450

222.) Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006). Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. *New England Journal of Medicine*, *354*(13), 1343-1351.

https://www.nejm.org/doi/full/10.1056/NEJMoa055778

223.) López-Macías, C., Ferat-Osorio, E., Tenorio-Calvo, A., Isibasi, A., Talavera, J., Arteaga-Ruiz, O., ... & Pincus, S. (2011). Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. *Vaccine*, *29*(44), 7826-7834. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126971/

224.) Mok, C. C., Ho, L. Y., Fong, L. S., & To, C. H. (2013). Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case–control study. *Annals of the rheumatic diseases*, *72*(5), 659-664. https://ard.bmj.com/content/72/5/659.short

225.) Hsu, H. Y., Chang, M. H., Ni, Y. H., Chiang, C. L., Chen, H. L., Wu, J. F., & Chen, P. J. (2010). No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. *The Journal of infectious diseases*, *201*(8), 1192-1200. https://academic.oup.com/jid/article/201/8/1192/864057

226.) Slobod, K. S., Shenep, J. L., Luján-Zilbermann, J., Allison, K., Brown, B., Scroggs, R. A., ... & Hurwitz, J. L. (2004). Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. *Vaccine*, *22*(23-24), 3182-3186. https://www.sciencedirect.com/science/article/pii/S0264410X04001392

227.) Harro, C. D., Pang, Y. Y. S., Roden, R. B., Hildesheim, A., Wang, Z., Reynolds, M. J., ... & Dillner, J. (2001). Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. *Journal of the National Cancer Institute*, *93*(4), 284-292. https://academic.oup.com/jnci/article/93/4/284/2906462

228.) Ray, P., Hayward, J., Michelson, D., Lewis, E., Schwalbe, J., Black, S., ... & Mullooly, J. (2006). Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case–control study. *The Pediatric infectious disease journal*, *25*(9), 768-773. https://www.rima.org/web/medline_pdf/EncephalopathyAfterVaccination.pdf

229.) Golden, G. S. (1990). Pertussis vaccine and injury to the brain. *The Journal of pediatrics*, *116*(6), 854-861. https://www.sciencedirect.com/science/article/abs/pii/S0022347605806407 & https://sci-hub.st/https://doi.org/10.1016/S0022-3476(05)80640-7

230.) Griffin, M. R., Ray, W. A., Mortimer, E. A., Fenichel, G. M., & Schaffner, W. (1990). Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. *Jama*, *263*(12), 1641-1645. https://jamanetwork.com/journals/jama/article-abstract/381150 & https://sci-hub.st/10.1001/jama.1990.03440120063038

231.) Schwarz, T. F., Flamaing, J., Rümke, H. C., Penzes, J., Juergens, C., Wenz, A., ... & Schmoele-Thoma, B. (2011). A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged≥ 65 years. *Vaccine*, *29*(32), 5195-5202. https://www.sciencedirect.com/science/article/pii/S0264410X11007420

232.) Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A. B., Romanowski, B., Roteli-Martins, C. M., ... & HPV Vaccine Study group. (2006). Sustained efficacy up to 4· 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *The Lancet*, *367*(9518), 1247-1255. https://www.sciencedirect.com/science/article/pii/S0140673606684390

233.) DeStefano, F., Pfeifer, D., & Nohynek, H. (2008). Safety profile of pneumococcal conjugate vaccines: systematic review of pre-and post-licensure data. *Bulletin of the World Health Organization*, *86*, 373-380A. https://www.scielosp.org/article/bwho/2008.v86n5/373-380A/en/

234.) Caspard, H., Heikkinen, T., Belshe, R. B., & Ambrose, C. S. (2016). A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children. *Human vaccines & immunotherapeutics*, *12*(7), 1721-1727. https://www.tandfonline.com/doi/pdf/10.1080/21645515.2015.1115164

235.) Rouphael, N. G., Paine, M., Mosley, R., Henry, S., McAllister, D. V., Kalluri, H., ... & Kabbani, S. (2017). The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. *The Lancet*, *390*(10095), 649-658. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30575-5/fulltext

236.) Gorse, G. J., Keitel, W., Keyserling, H., Taylor, D. N., Lock, M., Alves, K., ... & Gurwith, M. (2006). Immunogenicity and tolerance of ascending doses of a recombinant protective

antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. *Vaccine*, *24*(33-34), 5950-5959. https://www.sciencedirect.com/science/article/pii/S0264410X06005883

237.) Genton, B., Al-Yaman, F., Betuela, I., Anders, R. F., Saul, A., Baea, K., ... & Irving, D. O. (2003). Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. *Vaccine*, *22*(1), 30-41. https://www.sciencedirect.com/science/article/pii/S0264410X0300536X

238.) Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Dramé, M., Clement, F., Hons, E., ... & Leroux-Roels, G. (2007). Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. *The Lancet*, *370*(9587), 580-589. https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.524.5403&rep=rep1&type=pdf

239.) Wu, J., Fang, H. H., Chen, J. T., Zhou, J. C., Feng, Z. J., Li, C. G., ... & Dong, S. S. (2009). Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. *Clinical infectious diseases*, *48*(8), 1087-1095. https://academic.oup.com/cid/article/48/8/1087/335899

240.) Dagan, R., Patterson, S., Juergens, C., Greenberg, D., Givon-Lavi, N., Porat, N., ... & Scott, D. A. (2013). Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. *Clinical infectious diseases*, *57*(7), 952-962. https://academic.oup.com/cid/article/57/7/952/337783

241.) Lell, B., Agnandji, S., Von Glasenapp, I., Haertle, S., Oyakhiromen, S., Issifou, S., ... & Demoitie, M. A. (2009). A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS, S malaria vaccine candidates in children in Gabon. *PLoS one*, *4*(10), e7611. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007611

242.) Greenberg, D. P. (1993). Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. *The Pediatric infectious disease journal*, *12*(5), 438-445. https://europepmc.org/article/med/8327313

243.) Greenberg, D. P., Vadheim, C. M., Wong, V. K., MARCY, S. M., Partridge, S., Greene, T., ... & Ward, J. I. (1996). Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. *The Pediatric infectious disease journal*, *15*(7), 590-596. https://journals.lww.com/pidj/Abstract/1996/07000/Comparative_safety_and_immunogenicity_of_two.6.aspx

244.) Clemens, J. D., Stanton, B. F., Chakraborty, J., Chowdhury, S., Rao, M. R., Mohammed, A., ... & Wojtyniak, B. (1988). Measles vaccination and childhood mortality in rural Bangladesh. *American journal of epidemiology*, *128*(6), 1330-1339. https://academic.oup.com/aje/article-abstract/128/6/1330/70098

245.) Hammarlund, E., Lewis, M. W., Hansen, S. G., Strelow, L. I., Nelson, J. A., Sexton, G. J., ... & Slifka, M. K. (2003). Duration of antiviral immunity after smallpox vaccination. *Nature medicine*, *9*(9), 1131-1137. https://www.nature.com/articles/nm917

246.) Jokinen, S., Österlund, P., Julkunen, I., & Davidkin, I. (2007). Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. *Journal of Infectious Diseases*, *196*(6), 861-867. https://academic.oup.com/jid/article/196/6/861/2191978

247.) Ferris, D., Samakoses, R., Block, S. L., Lazcano-Ponce, E., Restrepo, J. A., Reisinger, K. S., ... & Shou, Q. (2014). Long-term study of a quadrivalent human papillomavirus vaccine. *Pediatrics*, *134*(3), e657-e665. https://pediatrics.aappublications.org/content/134/3/e657

248.) De Vincenzo, R., Conte, C., Ricci, C., Scambia, G., & Capelli, G. (2014). Long-term efficacy and safety of human papillomavirus vaccination. *International journal of women's health*, *6*, 999. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262378/

249.) Kramarz, P., DeStefano, F., Gargiullo, P. M., Chen, R. T., Lieu, T. A., Davis, R. L., ... & Ward, J. I. (2001). Does influenza vaccination prevent asthma exacerbations in children?. *The Journal of pediatrics*, *138*(3), 306-310. https://www.sciencedirect.com/science/article/abs/pii/S0022347601571504

250.) Grabenhenrich, L. B., Gough, H., Reich, A., Eckers, N., Zepp, F., Nitsche, O., ... & Hoffmann, U. (2014). Early-life determinants of asthma from birth to age 20 years: a German birth cohort study. *Journal of Allergy and Clinical Immunology*, *133*(4), 979-988. https://pubmedinfo.org/wp-content/uploads/2019/03/Early-life-determinants-of-asthma-from-birth-to-age-20-years-german.pdf

251.) Adegbola, R. A., Secka, O., Lahai, G., Lloyd-Evans, N., Njie, A., Usen, S., ... & Mulholland, K. (2005). Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. *The Lancet*, *366*(9480), 144-150. https://www.sciencedirect.com/science/article/abs/pii/S0140673605667888

252.) Richardson, V., Hernandez-Pichardo, J., Quintanar-Solares, M., Esparza-Aguilar, M., Johnson, B., Gomez-Altamirano, C. M., ... & Patel, M. (2010). Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. *New England Journal of Medicine*, *362*(4), 299-305. https://evidenciasenpediatria.es/files/41-35-RUTA/19%20Rotavirusvaccine_Richardson_NEJM_PAG.pdf

253.) Monto, A. S., Davenport, F. M., Napier, J. A., & Francis Jr, T. (1970). Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. *Journal of Infectious Diseases*, *122*(1-2), 16-25. https://academic.oup.com/jid/article-abstract/122/1-2/16/855940 & https://sci-hub.st/https://www.jstor.org/stable/30108280?seq=1

254.) Rudenko, L. G., Slepushkin, A. N., Monto, A. S., Kendal, A. P., Grigorieva, E. P., Burtseva, E. P., ... & Ghendon, Y. Z. (1993). Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. *Journal of infectious diseases*, *168*(4), 881-887. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.841.8324&rep=rep1&type=pdf

255.) Hurwitz, E. S., Haber, M., Chang, A., Shope, T., Teo, S., Ginsberg, M., ... & Cox, N. J. (2000). Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. *Jama*, *284*(13), 1677-1682. https://jamanetwork.com/journals/jama/fullarticle/193137

256.) Reichert, T. A., Sugaya, N., Fedson, D. S., Glezen, W. P., Simonsen, L., & Tashiro, M. (2001). The Japanese experience with vaccinating schoolchildren against influenza. *New England Journal of Medicine*, *344*(12), 889-896. https://www.nejm.org/doi/full/10.1056/NEJM200103223441204

257.) Ramsay, M. E., Andrews, N. J., Trotter, C. L., Kaczmarski, E. B., & Miller, E. (2003). Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. *Bmj*, *326*(7385), 365-366. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC148893/

258.) Gangarosa, E. J., Galazka, A. M., Wolfe, C. R., Phillips, L. M., Miller, E., Chen, R. T., & Gangarosa, R. E. (1998). Impact of anti-vaccine movements on pertussis control: the untold story. *The Lancet*, *351*(9099), 356-361. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.574.1566&rep=rep1&type=pdf

259.) Bernstein, D. I., Smith, V. E., Sherwood, J. R., Schiff, G. M., Sander, D. S., DeFeudis, D., ... & Ward, R. L. (1998). Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. *Vaccine*, *16*(4), 381-387. https://www.sciencedirect.com/science/article/pii/S0264410X97002107

260.) Salmon, D. A., Haber, M., Gangarosa, E. J., Phillips, L., Smith, N. J., & Chen, R. T. (1999). Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. *Jama*, *282*(1), 47-53. https://jamanetwork.com/journals/jama/article-abstract/190649

261.) Hahné, S., Macey, J., van Binnendijk, R., Kohl, R., Dolman, S., van der Veen, Y., ... & van Loon, A. (2009). Rubella outbreak in the Netherlands, 2004–2005: high burden of congenital infection and spread to Canada. *The Pediatric infectious disease journal*, *28*(9), 795-800. https://journals.lww.com/pidj/Abstract/2009/09000/Rubella_Outbreak_in_the_Netherlands,_2004_2005_.8.aspx

262.) Hoffman, H. J., Hunter, J. C., Damus, K., Pakter, J., Peterson, D. R., van Belle, G., & Hasselmeyer, E. G. (1987). Diphtheria-tetanus-pertussis immunization and sudden infant death: results of the National Institute of Child Health and Human Development Cooperative Epidemiological Study of Sudden Infant Death Syndrome risk factors. *Pediatrics*, *79*(4), 598-611. https://pediatrics.aappublications.org/content/79/4/598.short

263.) Griffin, M. R., Ray, W. A., Livengood, J. R., & Schaffner, W. (1988). Risk of sudden infant death syndrome after immunization with the diphtheria–tetanus–pertussis vaccine. *New England Journal of Medicine*, *319*(10), 618-623. https://www.nejm.org/doi/full/10.1056/nejm198809083191006

264.) Kuhnert, R., Schlaud, M., Poethko-Müller, C., Vennemann, M., Fleming, P., Blair, P. S., ... & Hecker, H. (2012). Reanalyses of case-control studies examining the temporal association between sudden infant death syndrome and vaccination. *Vaccine*, *30*(13), 2349-2356. https://circleofmamas.com/wp-content/uploads/2019/01/Reanalysis-of-case-control-studies-examining.pdf & https://www.sciencedirect.com/science/article/pii/S0264410X12000692

265.) Zepp, F., Schmitt, H. J., Cleerbout, J., Verstraeten, T., Schuerman, L., & Jacquet, J. M. (2009). Review of 8 years of experience with Infanrix hexa™(DTPa–HBV–IPV/Hib hexavalent vaccine). *Expert review of vaccines*, *8*(6), 663-678. https://pubmed.ncbi.nlm.nih.gov/19485747/ & https://sci-hub.st/https://doi.org/10.1586/erv.09.32

266.) Fleming, P. J., Blair, P. S., Platt, M. W., Tripp, J., Smith, I. J., Golding, J., & CESDI SUDI research group. (2001). The UK accelerated immunisation programme and sudden unexpected death in infancy: case-control study. *Bmj*, *322*(7290), 822. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC30557/

267.) Mak, T. K., Mangtani, P., Leese, J., Watson, J. M., & Pfeifer, D. (2008). Influenza vaccination in pregnancy: current evidence and selected national policies. *The Lancet infectious diseases*, *8*(1), 44-52. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.519.1630&rep=rep1&type=pdf

268.) Pasternak, B., Svanström, H., Mølgaard-Nielsen, D., Krause, T. G., Emborg, H. D., Melbye, M., & Hviid, A. (2012). Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. *Bmj*, *344*. https://www.bmj.com/content/344/bmj.e2794.short

269.) Fell, D. B., Sprague, A. E., Liu, N., Yasseen III, A. S., Wen, S. W., Smith, G., ... & Better Outcomes Registry & Network (BORN) Ontario. (2012). H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. *American journal of public health*, *102*(6), e33-e40. https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2011.300606

270.) Håberg, S. E., Trogstad, L., Gunnes, N., Wilcox, A. J., Gjessing, H. K., Samuelsen, S. O., ... & Madsen, S. (2013). Risk of fetal death after pandemic influenza virus infection or vaccination. *New England Journal of Medicine*, *368*(4), 333-340. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602844/

271.) Pasternak, B., Svanström, H., Mølgaard-Nielsen, D., Krause, T. G., Emborg, H. D., Melbye, M., & Hviid, A. (2012). Risk of adverse fetal outcomes following administration of a pandemic influenza A (H1N1) vaccine during pregnancy. *Jama*, *308*(2), 165-174. https://jamanetwork.com/journals/jama/fullarticle/1216475

272.) Donahue, J. G., Kieke, B. A., King, J. P., Mascola, M. A., Shimabukuro, T. T., DeStefano, F., ... & Hechter, R. C. (2019). Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15. *Vaccine*, *37*(44), 6673-6681. https://www.sciencedirect.com/science/article/pii/S0264410X19312447

273.) Bednarczyk, R. A., Adjaye-Gbewonyo, D., & Omer, S. B. (2012). Safety of influenza immunization during pregnancy for the fetus and the neonate. *American journal of obstetrics and gynecology*, *207*(3), S38-S46.
https://www.ajog.org/action/showPdf?pii=S0002-9378%2812%2900739-9

274.) Naleway, A. L., Irving, S. A., Henninger, M. L., Li, D. K., Shifflett, P., Ball, S., ... & Thompson, M. G. (2014). Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. *Vaccine*, *32*(26), 3122-3127.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898611/

275.) Bratton, K. N., Wardle, M. T., Orenstein, W. A., & Omer, S. B. (2015). Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. *Clinical Infectious Diseases*, *60*(5), e11-e19.
https://academic.oup.com/cid/article/60/5/e11/291123

276.) Siston, A. M., Rasmussen, S. A., Honein, M. A., Fry, A. M., Seib, K., Callaghan, W. M., ... & Moore, Z. (2010). Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. *Jama*, *303*(15), 1517-1525.
https://jamanetwork.com/journals/jama/fullarticle/185713

277.) Rubinstein, F., Micone, P., Bonotti, A., Wainer, V., Schwarcz, A., Augustovski, F., ... & Karolinski, A. (2013). Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. *Bmj*, *346*.
https://www.bmj.com/content/346/bmj.f393

278.) Chambers, C. D., Johnson, D. L., Xu, R., Luo, Y. J., Louik, C., Mitchell, A. A., ... & OTIS Collaborative Research Group. (2016). Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. *Vaccine*, *34*(37), 4443-4449.
https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/About/Chambers-Safety-of-the-2010-11-2013-14-seasonal-flu-vaccines-Vaccine2016.pdf

279.) Irving, S. A., Kieke, B. A., Donahue, J. G., Mascola, M. A., Baggs, J., DeStefano, F., ... & Nordin, J. D. (2013). Trivalent inactivated influenza vaccine and spontaneous abortion. *Obstetrics & Gynecology*, *121*(1), 159-165.
https://journals.lww.com/greenjournal/Fulltext/2013/01000/Trivalent_Inactivated_Influenza_Vaccine_and.24.aspx

280.) Gasparini, R., Panatto, D., Lai, P. L., & Amicizia, D. (2015). The" urban myth" of the association between neurological disorders and vaccinations. *Journal of preventive medicine and hygiene*, *56*(1), E1.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718347/

281.) Nguyen, H. Q., Jumaan, A. O., & Seward, J. F. (2005). Decline in mortality due to varicella after implementation of varicella vaccination in the United States. *New England Journal of Medicine*, *352*(5), 450-458.
https://www.nejm.org/doi/full/10.1056/NEJMoa042271

282.) Ahmed, A. H., Nicholson, K. G., & Nguyen-Van-Tam, J. S. (1995). Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. *The Lancet*, *346*(8975), 591-595.
https://www.sciencedirect.com/science/article/abs/pii/S014067369591434X

283.) Nordin, J., Mullooly, J., Poblete, S., Strikas, R., Petrucci, R., Wei, F., ... & Nichol, K. L. (2001). Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. *The Journal of infectious diseases*, *184*(6), 665-670.
https://academic.oup.com/jid/article/184/6/665/841892

284.) Nichol, K. L., Nordin, J., Mullooly, J., Lask, R., Fillbrandt, K., & Iwane, M. (2003). Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. *New England Journal of Medicine*, *348*(14), 1322-1332.
https://www.nejm.org/doi/full/10.1056/NEJMoa025028

285.) Arnheim-Dahlström, L., Pasternak, B., Svanström, H., Sparén, P., & Hviid, A. (2013). Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. *Bmj*, *347*, f5906.
https://www.bmj.com/content/bmj/347/bmj.f5906.full.pdf

286.) Jefferson, T., & Demicheli, V. (1998). No evidence that vaccines cause insulin dependent diabetes mellitus. *Journal of epidemiology and community health*, *52*(10), 674.
https://jech.bmj.com/content/jech/52/10/674.full.pdf

287.) DeStefano, F., Mullooly, J. P., Okoro, C. A., Chen, R. T., Marcy, S. M., Ward, J. I., ... & Bohlke, K. (2001). Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. *Pediatrics*, *108*(6), e112-e112.
https://pediatrics.aappublications.org/content/108/6/e112.short

288.) Obonyo, C. O., & Lau, J. (2006). Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. *European Journal of Clinical Microbiology and Infectious Diseases*, *25*(2), 90-97. https://www.ncbi.nlm.nih.gov/books/NBK72323/

289.) Stanley, F. J., Sim, M., Wilson, G., & Worthington, S. (1986). The decline in congenital rubella syndrome in Western Australia: an impact of the school girl vaccination program?. *American journal of public health*, *76*(1), 35-37. https://ajph.aphapublications.org/doi/pdfplus/10.2105/AJPH.76.1.35

290.) Rambout, L., Hopkins, L., Hutton, B., & Fergusson, D. (2007). Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. *Cmaj*, *177*(5), 469-479. https://www.cmaj.ca/content/cmaj/177/5/469.full.pdf

291.) Pollock, T. M., & Morris, J. (1983). A 7-year survey of disorders attributed to vaccination in North West Thames region. *The Lancet*, *321*(8327), 753-757. https://www.sciencedirect.com/science/article/abs/pii/S0140673683920378

292.) Donahue, J. G., Kieke, B. A., Yih, W. K., Berger, N. R., McCauley, J. S., Baggs, J., ... & Hambidge, S. J. (2009). Varicella vaccination and ischemic stroke in children: is there an association?. *Pediatrics*, *123*(2), e228-e234. https://pediatrics.aappublications.org/content/123/2/e228.short

293.) Klugman, K. P., Madhi, S. A., Huebner, R. E., Kohberger, R., Mbelle, N., & Pierce, N. (2003). A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. *New England Journal of Medicine*, *349*(14), 1341-1348. https://www.nejm.org/doi/full/10.1056/NEJMoa035060

294.) MacDonald, S. E., Dover, D. C., Hill, M. D., Kirton, A., Simmonds, K. A., & Svenson, L. W. (2018). Is varicella vaccination associated with pediatric arterial ischemic stroke? A population-based cohort study. *Vaccine*, *36*(20), 2764-2767. https://www.sciencedirect.com/science/article/pii/S0264410X1830481X

295.) Vichnin, M., Bonanni, P., Klein, N. P., Garland, S. M., Block, S. L., Kjaer, S. K., ... & Lievano, F. (2015). An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. *The Pediatric infectious disease journal*, *34*(9), 983-991. https://pubmed.ncbi.nlm.nih.gov/26107345/

296.) Gaudinski, M. R., Houser, K. V., Morabito, K. M., Hu, Z., Yamshchikov, G., Rothwell, R. S., ... & Hendel, C. S. (2018). Safety, tolerability, and immunogenicity of two Zika virus DNA

vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. *The Lancet*, *391*(10120), 552-562.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379903/

297.) Descamps, D., Hardt, K., Spiessens, B., Izurieta, P., Verstraeten, T., Breuer, T., & Dubin, G. (2009). Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. *Human vaccines*, *5*(5), 332-340.
https://www.tandfonline.com/doi/pdf/10.4161/hv.5.5.7211

298.)Moreira, E. D., Block, S. L., Ferris, D., Giuliano, A. R., Iversen, O. E., Joura, E. A., ... & Bosch, F. X. (2016). Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. *Pediatrics*, *138*(2), e20154387.
https://pediatrics.aappublications.org/content/138/2/e20154387.full

299.) Tseng, H. F., Liu, A., Sy, L., Marcy, S. M., Fireman, B., Weintraub, E., ... & Daley, M. F. (2012). Safety of zoster vaccine in adults from a large managed‐care cohort: a Vaccine Safety Datalink study. *Journal of internal medicine*, *271*(5), 510-520.
https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2796.2011.02474.x

300.) Simberkoff, M. S., Arbeit, R. D., Johnson, G. R., Oxman, M. N., Boardman, K. D., Williams, H. M., ... & Neuzil, K. (2010). Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. *Annals of internal medicine*, *152*(9), 545-554.
https://www.acpjournals.org/doi/full/10.7326/0003-4819-152-9-201005040-00004?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

301.) Modjarrad, K., Lin, L., George, S. L., Stephenson, K. E., Eckels, K. H., De La Barrera, R. A., ... & Mills, K. (2018). Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. *The Lancet*, *391*(10120), 563-571.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33106-9/fulltext?elsca1=etoc

302.) da Costa, V. G., Marques-Silva, A. C., Floriano, V. G., & Moreli, M. L. (2014). Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials. *Vaccine*, *32*(39), 4885-4892.
https://www.sciencedirect.com/science/article/pii/S0264410X14009347

303.) Ljungman, P., Fridell, E., Lönqvist, B., Bolme, P., Böttiger, M., Gahrton, G., ... & Wahren, B. (1989). Efficacy and safety of vaccination of marrow transplant recipients with a live

attenuated measles, mumps, and rubella vaccine. *Journal of Infectious Diseases*, *159*(4), 610-615. https://academic.oup.com/jid/article-abstract/159/4/610/797533

304.) Shinefield, H. R., Black, S. B., Staehle, B. O., Matthews, H., Adelman, T., Ensor, K., ... & Vessey, S. R. (2002). Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. *The Pediatric infectious disease journal*, *21*(6), 555-561. https://journals.lww.com/pidj/Abstract/2002/06000/Vaccination_with_measles,_mumps_and_rubella.14.aspx

305.) Weibel, R. E., Buynak, E. B., McLean, A. A., & Hilleman, M. R. (1975). Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. *Pediatrics*, *56*(3), 380-387. https://pediatrics.aappublications.org/content/56/3/380

306.) Davidkin, I., & Valle, M. (1998). Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. *Vaccine*, *16*(20), 2052-2057. https://www.sciencedirect.com/science/article/pii/S0264410X98000814

307.) Ogbuanu, I. U., Kutty, P. K., Hudson, J. M., Blog, D., Abedi, G. R., Goodell, S., ... & Schulte, C. (2012). Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. *Pediatrics*, *130*(6), e1567-e1574. https://pediatrics.aappublications.org/content/130/6/e1567.short

308.) Arbeter, A. M., Baker, L., Starr, S. E., Levine, B. L., Books, E., & Plotkin, S. A. (1986). Combination measles, mumps, rubella, and varicella vaccine. *Pediatrics*, *78*(4), 742-747. https://pediatrics.aappublications.org/content/78/4/742

309.) Nelson, G. E., Aguon, A., Valencia, E. Q., Oliva, R., Guerrero, M. L., Reyes, R., ... & Monforte, M. N. (2013). Epidemiology of a Mumps Outbreak in a Highly Vaccinated Island Population and Use of Third Measles-Mumps-Rubella Vaccine Dose for Outbreak Control–Guam 2009—2010. *The Pediatric infectious disease journal*, *32*(4), 374. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893844/

310.) Cardemil, C. V., Dahl, R. M., James, L., Wannemuehler, K., Gary, H. E., Shah, M., ... & Quinlisk, P. (2017). Effectiveness of a third dose of MMR vaccine for mumps outbreak control. *New England Journal of Medicine*, *377*(10), 947-956. https://www.nejm.org/doi/full/10.1056/NEJMoa1703309

311.) Ramsay, M. E. B., Moffatt, D., & O'connor, M. (1994). Measles vaccine: a 27–year follow–up. *Epidemiology & Infection*, *112*(2), 409-412. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2271445/pdf/epidinfect00044-0172.pdf

312.) Aaby, P., Shaheen, S. O., Heyes, C. B., Goudiaby, A., Hall, A. J., Shiell, A. W., ... & Marchant, A. (2000). Early BCG vaccination and reduction in atopy in Guinea-Bissau. *Clinical and experimental allergy*, *30*(5), 644-650. https://pubmed.ncbi.nlm.nih.gov/10792355/

313.) Aaby, P., Bukh, J., Lisse, I. M., & Smits, A. J. (1984). Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. *Journal of infection*, *8*(1), 13-21. https://www.sciencedirect.com/science/article/abs/pii/S016344538493192X

314.) Kixmöller, M., Ritzmann, M., Eddicks, M., Saalmüller, A., Elbers, K., & Fachinger, V. (2008). Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2. *Vaccine*, *26*(27-28), 3443-3451. https://www.sciencedirect.com/science/article/pii/S0264410X08004854

315.) Raes, M., Strens, D., Vergison, A., Verghote, M., & Standaert, B. (2011). Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. *The Pediatric infectious disease journal*, *30*(7), e120-e125. https://journals.lww.com/pidj/Abstract/2011/07000/Reduction_in_Pediatric_Rotavirus_related.33.aspx

316.) Lievano, F., Galea, S. A., Thornton, M., Wiedmann, R. T., Manoff, S. B., Tran, T. N., ... & Plotkin, S. A. (2012). Measles, mumps, and rubella virus vaccine (M–M–R™ II): A review of 32 years of clinical and postmarketing experience. *Vaccine*, *30*(48), 6918-6926. https://www.sciencedirect.com/science/article/pii/S0264410X1201273X

317.) Rückinger, S., van der Linden, M., Reinert, R. R., von Kries, R., Burckhardt, F., & Siedler, A. (2009). Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. *Vaccine*, *27*(31), 4136-4141. https://www.sciencedirect.com/science/article/pii/S0264410X09006112

318.) Howard, A. W., Viskontas, D., & Sabbagh, C. (1999). Reduction in osteomyelitis and septic arthritis related to Haemophilus influenzae type B vaccination. *Journal of pediatric orthopedics*, *19*(6), 705-709. https://journals.lww.com/pedorthopaedics/Abstract/1999/11000/Reduction_in_Osteomyelitis_and_Septic_Arthritis.3.aspx

319.) Jardine, A., Menzies, R. I., & McIntyre, P. B. (2010). Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. *The Pediatric infectious disease journal*, *29*(7), 607-612. https://journals.lww.com/pidj/Abstract/2010/07000/Reduction_in_Hospitalizations_for_Pneumonia.7.aspx

320. Cummings, T., Zimet, G. D., Brown, D., Tu, W., Yang, Z., Fortenberry, J. D., & Shew, M. L. (2012). Reduction of HPV infections through vaccination among at-risk urban adolescents. *Vaccine*, *30*(37), 5496-5499. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423324/

321.) Biselli, R., Fattorossi, A., Matricardi, P. M., Nisini, R., Stroffolini, T., & d'Amelio, R. (1993). Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. *Vaccine*, *11*(5), 578-581. https://www.sciencedirect.com/science/article/pii/0264410X9390236Q

322.) Wu, J., Ke, C., Lau, E. H., Song, Y., Cheng, K. L., Zou, L., ... & Yen, H. L. (2019). Influenza H5/H7 virus vaccination in poultry and reduction of zoonotic infections, Guangdong Province, China, 2017–18. *Emerging infectious diseases*, *25*(1), 116. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302570/

323.) Wilcock, D. M., Gharkholonarehe, N., Van Nostrand, W. E., Davis, J., Vitek, M. P., & Colton, C. A. (2009). Amyloid reduction by amyloid-β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. *Journal of Neuroscience*, *29*(25), 7957-7965. https://www.jneurosci.org/content/29/25/7957.full

324.) Sudfeld, C. R., Navar, A. M., & Halsey, N. A. (2010). Effectiveness of measles vaccination and vitamin A treatment. *International journal of epidemiology*, *39*(suppl_1), i48-i55. https://academic.oup.com/ije/article/39/suppl_1/i48/699532

325.) Puig-Barberà, J., Marquez-Calderon, S., Masoliver-Fores, A., Lloria-Paes, F., Ortega-Dicha, A., Gil-Martín, M., & Calero-Martínez, M. J. (1997). Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in Spain. *Journal of Epidemiology & Community Health*, *51*(5), 526-530. https://jech.bmj.com/content/jech/51/5/526.full.pdf

326.) Domínguez, À., Salleras, L., Carmona, G., & Batalla, J. (2003). Effectiveness of a mass hepatitis A vaccination program in preadolescents. *Vaccine*, *21*(7-8), 698-701. https://www.sciencedirect.com/science/article/pii/S0264410X02005832

327.) Frenzel, E., Chemaly, R. F., Ariza-Heredia, E., Jiang, Y., Shah, D. P., Thomas, G., ... & Raad, I. (2016). Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients. *American journal of infection control*, *44*(9), 1016-1021. https://www.sciencedirect.com/science/article/abs/pii/S0196655316002820

328.) Antunes, J. L. F., Waldman, E. A., Borrell, C., & Paiva, T. M. (2007). Effectiveness of influenza vaccination and its impact on health inequalities. *International journal of epidemiology*, *36*(6), 1319-1326. https://academic.oup.com/ije/article/36/6/1319/821771

329.) Nguyen, T. H., Vu, M. H., Nguyen, V. C., Nguyen, L. H., Toda, K., Nguyen, T. N., ... & Hennessey, K. A. (2014). A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination. *Vaccine*, *32*(2), 217-222. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699283/

330.) Heymann, A. D., Shapiro, Y., Chodick, G., Shalev, V., Kokia, E., Kramer, E., & Shemer, J. (2004). Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. *Diabetes care*, *27*(11), 2581-2584. https://care.diabetesjournals.org/content/27/11/2581.long?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_Care_TrendMD_0

331.) Gwack, J., Park, S. K., Lee, E. H., Park, B., Choi, Y., & Yoo, K. Y. (2011). Hepatitis B vaccination and liver cancer mortality reduction in Korean children and adolescents. *Asian Pacific Journal of Cancer Prevention*, *12*(9), 2205-2208. http://journal.waocp.org/article_25861_9a69bffdb85840a6a0d794236207b310.pdf

332.) Zhang, L., Xu, A., Yan, B., Song, L., Li, M., Xiao, Z., ... & Li, L. (2010). A significant reduction in hepatitis B virus infection among the children of Shandong Province, China: the effect of 15 years of universal infant hepatitis B vaccination. *International Journal of Infectious Diseases*, *14*(6), e483-e488. https://www.sciencedirect.com/science/article/pii/S1201971209003270

333.) Gwini, S. M., Coupland, C. A., & Siriwardena, A. N. (2011). The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. *Vaccine*, *29*(6), 1145-1149. https://www.sciencedirect.com/science/article/pii/S0264410X1001755X

334.) Zlamy, M., Kofler, S., Orth, D., Würzner, R., Heinz-Erian, P., Streng, A., & Prelog, M. (2013). The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. *BMC Infectious Diseases*, *13*(1), 112. https://link.springer.com/article/10.1186/1471-2334-13-112

335.) Atkins, K. E., Shim, E., Pitzer, V. E., & Galvani, A. P. (2012). Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. *Vaccine*, *30*(3), 552-564. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.720.1500&rep=rep1&type=pdf

336.) Domínguez, A., Oviedo, M., Carmona, G., Batalla, J., Bruguera, M., Salleras, L., & Plasencia, A. (2008). Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction. *Vaccine*, *26*(14), 1737-1741. https://www.sciencedirect.com/science/article/pii/S0264410X08001059

337.) Vacchino, M. N. (2008). Incidence of hepatitis A in Argentina after vaccination. *Journal of viral hepatitis*, *15*, 47-50. http://sgc.anlis.gob.ar/bitstream/123456789/466/1/JournalofViralHepatitis%2C2008%2C15Suppl2%2C47-50..pdf

338.) Nichol, K. L., Margolis, K. L., Wuorenma, J., & Von Sternberg, T. (1994). The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. *New England journal of medicine*, *331*(12), 778-784. https://www.nejm.org/doi/full/10.1056/NEJM199409223311206

339.) Wang, C. S., Wang, S. T., Lai, C. T., Lin, L. J., & Chou, P. (2007). Impact of influenza vaccination on major cause-specific mortality. *Vaccine*, *25*(7), 1196-1203. https://www.sciencedirect.com/science/article/pii/S0264410X06011340

340.) Rosenthal, S. R., Loewinsohn, E., Graham, M. L., Liveright, D., Thorne, M. G., Johnson, V., & Baison, H. C. (1961). BCG vaccination against tuberculosis in Chicago: a twenty-year study statistically analyzed. *Pediatrics*, *28*(4), 622-641. https://pediatrics.aappublications.org/content/28/4/622

341.) Eythorsson, E., Sigurdsson, S., Hrafnkelsson, B., Erlendsdóttir, H., Haraldsson, Á., & Kristinsson, K. G. (2018). Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study. *BMC infectious diseases*, *18*(1), 505. https://link.springer.com/article/10.1186/s12879-018-3416-y

342.) Sigurdsson, S., Eythorsson, E., Hrafnkelsson, B., Erlendsdóttir, H., Kristinsson, K. G., & Haraldsson, Á. (2018). Reduction in all-cause acute otitis media in children< 3 years of age in primary care following vaccination with 10-valent pneumococcal Haemophilus influenzae protein-D conjugate vaccine: a whole-population study. *Clinical Infectious Diseases*, *67*(8), 1213-1219. https://academic.oup.com/cid/article/67/8/1213/4956759

343.) Costantino, C., Restivo, V., Tramuto, F., Casuccio, A., & Vitale, F. (2018). Universal rotavirus vaccination program in Sicily: Reduction in health burden and cost despite low vaccination coverage. *Human vaccines & immunotherapeutics*, *14*(9), 2297-2302. https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1471306

344.) Van Effelterre, T., Soriano-Gabarro, M., Debrus, S., Newbern, E. C., & Gray, J. (2010). A mathematical model of the indirect effects of rotavirus vaccination. *Epidemiology & Infection*, *138*(6), 884-897. https://pubmed.ncbi.nlm.nih.gov/20028612/ & https://sci-hub.st/10.1017/S0950268809991245

345.) Loomba, R. S., Aggarwal, S., Shah, P. H., & Arora, R. R. (2012). Influenza vaccination and cardiovascular morbidity and mortality: analysis of 292 383 patients. *Journal of cardiovascular pharmacology and therapeutics*, *17*(3), 277-283. https://pubmed.ncbi.nlm.nih.gov/22172681/

346.) Rodríguez, A. P., Dickinson, F., Baly, A., & Martinez, R. (1999). The epidemiological impact of antimeningococcal B vaccination in Cuba. *Memorias do Instituto Oswaldo Cruz*, *94*(4), 433-440. https://pubmed.ncbi.nlm.nih.gov/10445998/

347.) Keitel, W. A., Cate, T. R., & Couch, R. B. (1988). Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. *American journal of epidemiology*, *127*(2), 353-364. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.954.438&rep=rep1&type=pdf

348.) Wilde, J. A., McMillan, J. A., Serwint, J., Butta, J., O'Riordan, M. A., & Steinhoff, M. C. (1999). Effectiveness of influenza vaccine in health care professionals: a randomized trial. *Jama*, *281*(10), 908-913. https://jamanetwork.com/journals/jama/fullarticle/189023

349.) Madjid, M., Awan, I., Ali, M., Frazier, L., & Casscells, W. (2005). Influenza and atherosclerosis: vaccination for cardiovascular disease prevention. *Expert opinion on biological therapy*, *5*(1), 91-96. https://www.tandfonline.com/doi/abs/10.1517/14712598.5.1.91

350.) Smith, M. A., Lew, J. B., Walker, R. J., Brotherton, J. M., Nickson, C., & Canfell, K. (2011). The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. *Vaccine*, *29*(48), 9112-9122. https://www.sciencedirect.com/science/article/pii/S0264410X11003392

351.) Looijmans-Van den Akker, I., Verheij, T. J., Buskens, E., Nichol, K. L., Rutten, G. E., & Hak, E. (2006). Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. *Diabetes care*, *29*(8), 1771-1776. https://care.diabetesjournals.org/content/29/8/1771

352.) Davey, H. M., Muscatello, D. J., Wood, J. G., Snelling, T. L., Ferson, M. J., & Macartney, K. K. (2015). Impact of high coverage of monovalent human rotavirus vaccine on Emergency Department presentations for rotavirus gastroenteritis. *Vaccine*, *33*(14), 1726-1730. https://www.sciencedirect.com/science/article/pii/S0264410X15001498

353.) Örtqvist, Å., Granath, F., Askling, J., & Hedlund, J. (2007). Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. *European Respiratory Journal*, *30*(3), 414-422. https://erj.ersjournals.com/content/30/3/414

354.) Nichol, K. L., Wuorenma, J., & Von Sternberg, T. (1998). Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. *Archives of internal medicine*, *158*(16), 1769-1776. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/209078

355.) Mouchet, J., Salvo, F., Raschi, E., Poluzzi, E., Antonazzo, I. C., De Ponti, F., & Begaud, B. (2018). Hepatitis B vaccination and the putative risk of central demyelinating diseases–A systematic review and meta-analysis. *Vaccine*, *36*(12), 1548-1555. https://www.sciencedirect.com/science/article/pii/S0264410X1830210X & https://sci-hub.st/https://doi.org/10.1016/j.vaccine.2018.02.036

356.) Ojal, J., Flasche, S., Hammitt, L. L., Akech, D., Kiti, M. C., Kamau, T., ... & Auranen, K. (2017). Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: a mathematical model based on pre-vaccination data. *Vaccine*, *35*(35), 4561-4568. https://www.sciencedirect.com/science/article/pii/S0264410X17309155

357.) Siriwardena, A. N., Gwini, S. M., & Coupland, C. A. (2010). Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case–control study. *Cmaj*, *182*(15), 1617-1623. https://www.cmaj.ca/content/cmaj/182/15/1617.full.pdf

358.) Clark, A., Tate, J., Parashar, U., Jit, M., Hasso-Agopsowicz, M., Henschke, N., ... & Sanderson, C. (2019). Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. *The Lancet Global Health*, *7*(11), e1541-e1552. https://www.sciencedirect.com/science/article/pii/S2214109X19304127

359.) Huang, J., Ou, H. Y., Lin, J., Karnchanasorn, R., Feng, W., Samoa, R., ... & Chiu, K. C. (2015). The impact of hepatitis B vaccination status on the risk of diabetes, implicating diabetes

risk reduction by successful vaccination. *PLoS One*, *10*(10), e0139730. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139730

360.) Patriarca, P. A., Weber, J. A., Parker, R. A., Hall, W. N., Kendal, A. P., Bregman, D. J., & Schonberger, L. B. (1985). Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. *Jama*, *253*(8), 1136-1139. https://jamanetwork.com/journals/jama/article-abstract/396999

361.) Christenson, B., & Böttiger, M. (1991). Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. *Vaccine*, *9*(5), 326-329. https://www.sciencedirect.com/science/article/pii/0264410X9190058E

362.) Harboe, Z. B., Dalby, T., Weinberger, D. M., Benfield, T., Mølbak, K., Slotved, H. C., ... & Valentiner-Branth, P. (2014). Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. *Clinical Infectious Diseases*, *59*(8), 1066-1073. https://academic.oup.com/cid/article/59/8/1066/444898

363.) Shuler, C. M., Fiore, A. E., Neeman, R., Bell, B. P., Kuhnert, W., Watkins, S., ... & Arnold, K. E. (2009). Reduction in hepatitis B virus Seroprevalence among US-born children of foreign-born Asian parents—benefit of universal infant hepatitis B vaccination. *Vaccine*, *27*(43), 5942-5947. https://www.sciencedirect.com/science/article/pii/S0264410X09011220

364.) Dey, A., Wang, H., Menzies, R., & Macartney, K. (2012). Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. *Medical journal of Australia*, *197*(8), 453-457. https://onlinelibrary.wiley.com/doi/abs/10.5694/mja12.10062

365.) Meireles, L. C., Marinho, R. T., & Van Damme, P. (2015). Three decades of hepatitis B control with vaccination. *World journal of hepatology*, *7*(18), 2127. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550866/

366.) Paulke-Korinek, M., Kollaritsch, H., Aberle, S. W., Zwazl, I., Schmidle-Loss, B., Vécsei, A., & Kundi, M. (2013). Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. *Vaccine*, *31*(24), 2686-2691. https://www.sciencedirect.com/science/article/pii/S0264410X13004209

367.) Baussano, I., Lazzarato, F., Ronco, G., Dillner, J., & Franceschi, S. (2013). Benefits of catch‐up in vaccination against human papillomavirus in medium‐and low‐income countries.

International journal of cancer, *133*(8), 1876-1881. https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.28197

368.) Jokinen, J., Rinta-Kokko, H., Siira, L., Palmu, A. A., Virtanen, M. J., Nohynek, H., ... & Nuorti, J. P. (2015). Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. *PloS one*, *10*(3), e0120290. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120290

369.) Hung, I. F., Leung, A. Y., Chu, D. W., Leung, D., Cheung, T., Chan, C. K., ... & Chan, S. (2010). Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. *Clinical Infectious Diseases*, *51*(9), 1007-1016. https://academic.oup.com/cid/article/51/9/1007/292115

370.) Eisenhut, M., Paranjothy, S., Abubakar, I., Bracebridge, S., Lilley, M., Mulla, R., ... & McEvoy, M. (2009). BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. *Vaccine*, *27*(44), 6116-6120. http://srvupt.hucff.ufrj.br/joomla/attachments/article/90/632_PUB_Art_Eisenhut_Vaccine_2009.pdf

371.) Baxter, R., Ray, G. T., & Fireman, B. H. (2010). Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. *Vaccine*, *28*(45), 7267-7272. https://www.sciencedirect.com/science/article/pii/S0264410X10012703

372.) Sáfadi, M. A. P., Berezin, E. N., Munford, V., Almeida, F. J., de Moraes, J. C., Pinheiro, C. F., & Racz, M. L. (2010). Hospital-based surveillance to evaluate the impact of rotavirus vaccination in São Paulo, Brazil. *The Pediatric infectious disease journal*, *29*(11), 1019-1022. https://journals.lww.com/pidj/Abstract/2010/11000/Hospital_based_Surveillance_to_Evaluate_the_Impact.10.aspx

373.) Smeeth, L., Thomas, S. L., Hall, A. J., Hubbard, R., Farrington, P., & Vallance, P. (2004). Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine*, *351*(25), 2611-2618. https://www.nejm.org/doi/full/10.1056/NEJMoa041747

374.) Linhares, A. C., & Justino, M. C. A. (2014). Rotavirus vaccination in Brazil: effectiveness and health impact seven years post-introduction. *Expert review of vaccines*, *13*(1), 43-57. https://www.tandfonline.com/doi/full/10.1586/14760584.2014.861746?scroll=top&needAccess=true

375.) Chaturvedi, A. K., Graubard, B. I., Broutian, T., Pickard, R. K., Tong, Z. Y., Xiao, W., ... & Gillison, M. L. (2018). Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. *Journal of Clinical Oncology*, *36*(3), 262. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773841/

376.) Alberti, K. P., King, L. A., Burny, M. E., Ilunga, B. K., & Grais, R. F. (2010). Reactive vaccination as an effective tool for measles outbreak control in measles mortality reduction settings, Democratic Republic of Congo, 2005–2006. *International Health*, *2*(1), 65-68. https://academic.oup.com/inthealth/article/2/1/65/857124

377.) Asghar, Z., Coupland, C., & Siriwardena, N. (2015). Influenza vaccination and risk of stroke: self-controlled case-series study. *Vaccine*, *33*(41), 5458-5463. http://eprints.lincoln.ac.uk/id/eprint/18624/1/IPVASTIAcaseseries_vaccine_prepublication.pdf

378.) Elbasha, E. H., Dasbach, E. J., & Insinga, R. P. (2007). Model for assessing human papillomavirus vaccination strategies. *Emerging infectious diseases*, *13*(1), 28-41. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725801/

379.) Hak, E., Buskens, E., van Essen, G. A., de Bakker, D. H., Grobbee, D. E., Tacken, M. A., ... & Verheij, T. J. (2005). Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. *Archives of internal medicine*, *165*(3), 274-280. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/486405

380.) Nichol, K. L., & Goodman, M. (2002). Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years. *Vaccine*, *20*, S21-S24. https://www.sciencedirect.com/science/article/pii/S0264410X0200124X

381.) Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., & Margolis, H. S. (2005). A mathematical model to estimate global hepatitis B disease burden and vaccination impact. *International journal of epidemiology*, *34*(6), 1329-1339. https://academic.oup.com/ije/article/34/6/1329/707548

382.) Hak, E., Nordin, J., Wei, F., Mullooly, J., Poblete, S., Strikas, R., & Nichol, K. L. (2002). Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. *Clinical Infectious Diseases*, *35*(4), 370-377. https://academic.oup.com/cid/article/35/4/370/566795

383.) Wu, H. H., Chang, Y. Y., Kuo, S. C., & Chen, Y. T. (2019). Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders—A propensity score-matched follow-up study. *PloS one*, *14*(7), e0219172. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0219172

384.) Fedson, D. S., Wajda, A., Nicol, J. P., Hammond, G. W., Kaiser, D. L., & Roos, L. L. (1993). Clinical effectiveness of influenza vaccination in Manitoba. *Jama*, *270*(16), 1956-1961. https://jamanetwork.com/journals/jama/article-abstract/408981

385.) Rose, M. A., Damm, O., Greiner, W., Knuf, M., Wutzler, P., Liese, J. G., ... & Kochmann, T. F. (2014). The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. *BMC Infectious Diseases*, *14*, 40-40. https://link.springer.com/article/10.1186/1471-2334-14-40

386.) Taira, A. V., Neukermans, C. P., & Sanders, G. D. (2004). Evaluating human papillomavirus vaccination programs. *Emerging Infectious Diseases*, *10*(11), 1915-1924. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328990/

387.) Brisson, M., Bénard, É., Drolet, M., Bogaards, J. A., Baussano, I., Vänskä, S., ... & Canfell, K. (2016). Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. *The Lancet Public Health*, *1*(1), e8-e17. https://www.sciencedirect.com/science/article/pii/S2468266716300019

388.) Udell, J. A., Zawi, R., Bhatt, D. L., Keshtkar-Jahromi, M., Gaughran, F., Phrommintikul, A., ... & Cannon, C. P. (2013). Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. *Jama*, *310*(16), 1711-1720. https://jamanetwork.com/journals/jama/article-abstract/1758749

389.) Griffin, M. R., Zhu, Y., Moore, M. R., Whitney, C. G., & Grijalva, C. G. (2013). US hospitalizations for pneumonia after a decade of pneumococcal vaccination. *New England Journal of Medicine*, *369*(2), 155-163. https://www.nejm.org/doi/full/10.1056/NEJMoa1209165

390.) Miller, E., Andrews, N. J., Waight, P. A., Slack, M. P., & George, R. C. (2011). Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. *The Lancet infectious diseases*, *11*(10), 760-768. https://www.sciencedirect.com/science/article/abs/pii/S1473309911700901

391.) Armstrong, B. G., Mangtani, P., Fletcher, A., Kovats, S., McMichael, A., Pattenden, S., & Wilkinson, P. (2004). Effect Of Influenza Vaccination On Excess Deaths Occurring During Periods Of High Circulation Of Influenza: Cohort Study In Elderly People. *BMJ: British Medical Journal*, 660-663. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517645/

392.) Lamontagne, F., Garant, M. P., Carvalho, J. C., Lanthier, L., Smieja, M., & Pilon, D. (2008). Pneumococcal vaccination and risk of myocardial infarction. *Cmaj*, *179*(8), 773-777. https://www.cmaj.ca/content/cmaj/179/8/773.full.pdf

393.) Fireman, B., Lee, J., Lewis, N., Bembom, O., Van Der Laan, M., & Baxter, R. (2009). Influenza vaccination and mortality: differentiating vaccine effects from bias. *American journal of epidemiology*, *170*(5), 650-656. https://academic.oup.com/aje/article/170/5/650/102527

394.) Rinta-Kokko, H., Palmu, A. A., Auranen, K., Nuorti, J. P., Toropainen, M., Siira, L., ... & Jokinen, J. (2018). Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. *Vaccine*, *36*(15), 1934-1940. https://www.sciencedirect.com/science/article/pii/S0264410X1830327X

395.) Dagan, R., Givon-Lavi, N., Zamir, O., Sikuler-Cohen, M., Guy, L., Janco, J., ... & Fraser, D. (2002). Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. *The Journal of infectious diseases*, *185*(7), 927-936. https://academic.oup.com/jid/article/185/7/927/802502

396.) Sigurdsson, S., Kristinsson, K. G., Erlendsdóttir, H., Hrafnkelsson, B., & Haraldsson, Á. (2015). Decreased incidence of respiratory infections in children after vaccination with ten-valent pneumococcal vaccine. *The Pediatric infectious disease journal*, *34*(12), 1385-1390. https://www.landlaeknir.is/servlet/file/store93/item28102/Decreased_Incidence_of_Respiratory_Infections_PIDJ%202015.pdf

397.) Tanuseputro, P., Zagorski, B., Chan, K. J., & Kwong, J. C. (2011). Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. *Vaccine*, *29*(47), 8580-8584. https://www.sciencedirect.com/science/article/pii/S0264410X11014307

398.) Ladhani, S. N., Andrews, N., Parikh, S. R., Campbell, H., White, J., Edelstein, M., ... & Ramsay, M. E. (2020). Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. *New England Journal of Medicine*, *382*(4), 309-317. https://www.nejm.org/doi/full/10.1056/NEJMoa1901229

399.) Weir, R. E., Gorak-Stolinska, P., Floyd, S., Lalor, M. K., Stenson, S., Branson, K., ... & Dockrell, H. M. (2008). Persistence of the immune response induced by BCG vaccination. *BMC Infectious Diseases*, *8*(1), 1-9. https://link.springer.com/article/10.1186/1471-2334-8-9

400.) Saadeh-Navarro, E., Garza-González, E., Salazar-Montalvo, R. G., Rodríguez-López, J. M., Mendoza-Flores, L., & Camacho-Ortiz, A. (2016). Association between early influenza vaccination and the reduction of influenza-like syndromes in health care providers. *American journal of infection control*, *44*(2), 250-252. https://www.sciencedirect.com/science/article/abs/pii/S0196655315010391

401.) Fairley, C. K., Hocking, J. S., Gurrin, L. C., Chen, M. Y., Donovan, B., & Bradshaw, C. S. (2009). Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. *Sexually transmitted infections*, *85*(7), 499-502. https://sti.bmj.com/content/85/7/499.short

402.) Girmay, A., & Dadi, A. F. (2019). Being unvaccinated and having a contact history increased the risk of measles infection during an outbreak: a finding from measles outbreak investigation in rural district of Ethiopia. *BMC infectious diseases*, *19*(1), 1-6. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-3973-8

403.) Scheifele, D., Halperin, S., Law, B., & King, A. (2005). Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001–2003. *Cmaj*, *172*(1), 53-56. https://www.cmaj.ca/content/cmaj/172/1/53.full.pdf

404.) Glanz, J. M., McClure, D. L., Magid, D. J., Daley, M. F., France, E. K., Salmon, D. A., & Hambidge, S. J. (2009). Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. *Pediatrics*, *123*(6), 1446-1451. https://pediatrics.aappublications.org/content/123/6/1446.short & https://sci-hub.st/https://doi.org/10.1542/peds.2008-2150

405.) Hickman, C. J., Hyde, T. B., Sowers, S. B., Mercader, S., McGrew, M., Williams, N. J., ... & Tamin, A. (2011). Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. *The Journal of infectious diseases*, *204*(suppl_1), S549-S558. https://academic.oup.com/jid/article/204/suppl_1/S549/2193805

406.) Davtyan, H., Ghochikyan, A., Petrushina, I., Hovakimyan, A., Davtyan, A., Poghosyan, A., ... & Larsen, A. K. (2013). Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. *Journal of Neuroscience*, *33*(11), 4923-4934. https://www.jneurosci.org/content/jneuro/33/11/4923.full.pdf

407.) Verreault, R., Laurin, D., Lindsay, J., & De Serres, G. (2001). Past exposure to vaccines and subsequent risk of Alzheimer's disease. *Cmaj*, *165*(11), 1495-1498. https://www.cmaj.ca/content/cmaj/165/11/1495.full.pdf

408.) Barile, J. P., Kuperminc, G. P., Weintraub, E. S., Mink, J. W., & Thompson, W. W. (2012). Thimerosal exposure in early life and neuropsychological outcomes 7–10 years later. *Journal of pediatric psychology*, *37*(1), 106-118. https://academic.oup.com/jpepsy/article/37/1/106/902491

409.) Ni, Y. H., & Chen, D. S. (2010). Hepatitis B vaccination in children: the Taiwan experience. *Pathologie Biologie*, *58*(4), 296-300. https://www.sciencedirect.com/science/article/abs/pii/S0369811409002284

410.) MacLennan, J. M., Shackley, F., Heath, P. T., Deeks, J. J., Flamank, C., Herbert, M., ... & Moxon, E. R. (2000). Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. *Jama*, *283*(21), 2795-2801. https://jamanetwork.com/journals/jama/article-abstract/192761

411.) Ambühl, P. M., Tissot, A. C., Fulurija, A., Maurer, P., Nussberger, J., Sabat, R., ... & Pfister, T. (2007). A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. *Journal of hypertension*, *25*(1), 63-72. https://journals.lww.com/jhypertension/Abstract/2007/01000/A_vaccine_for_hypertension_based_on_virus_like.11.aspx

412.) Belshe, R. B., Stevens, C., Gorse, G. J., Buchbinder, S., Weinhold, K., Sheppard, H., ... & Flores, J. (2001). Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher-and lower-risk volunteers. *The Journal of infectious diseases*, *183*(9), 1343-1352. https://academic.oup.com/jid/article/183/9/1343/930655

413.) Ramsauer, K., Schwameis, M., Firbas, C., Müllner, M., Putnak, R. J., Thomas, S. J., ... & Tangy, F. (2015). Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. *The Lancet infectious diseases*, *15*(5), 519-527. https://www.sciencedirect.com/science/article/abs/pii/S1473309915700435

414.) Oliveira, G. A., Wetzel, K., Calvo-Calle, J. M., Nussenzweig, R., Schmidt, A., Birkett, A., ... & Luty, A. J. (2005). Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. *Infection and immunity*, *73*(6), 3587-3597. https://iai.asm.org/content/73/6/3587.full

415.) Hung, I. F., Leung, A. Y., Chu, D. W., Leung, D., Cheung, T., Chan, C. K., ... & Yuen, K. Y. (2010). Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. *Clinical Infectious Diseases*, *51*(9), 1007-1016. https://academic.oup.com/cid/article/51/9/1007/292115

416.) Fife, K. H., Wheeler, C. M., Koutsky, L. A., Barr, E., Brown, D. R., Schiff, M. A., ... & Tadesse, A. (2004). Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. *Vaccine*, *22*(21-22), 2943-2952. https://www.sciencedirect.com/science/article/pii/S0264410X04000179

417.) Rudenko, L., Desheva, J., Korovkin, S., Mironov, A., Rekstin, A., Grigorieva, E., ... & Katlinsky, A. (2008). Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I–II clinical trials). *Influenza and other respiratory viruses*, *2*(6), 203-209. https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1750-2659.2008.00064.x

418.) Richmond, P. C., Marshall, H. S., Nissen, M. D., Jiang, Q., Jansen, K. U., Garcés-Sánchez, M., ... & Eiden, J. (2012). Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. *The Lancet infectious diseases*, *12*(8), 597-607. https://www.sciencedirect.com/science/article/abs/pii/S1473309912700877

419.) Belmusto-Worn, V. E., Sanchez, J. L., McCARTHY, K. A. R. E. N., Nichols, R., Bautista, C. T., Magill, A. J., ... & Baldeon, M. E. (2005). Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax™ and YF-VAX®) in healthy infants and children in Peru. *The American journal of tropical medicine and hygiene*, *72*(2), 189-197. https://apps.dtic.mil/dtic/tr/fulltext/u2/a468921.pdf

420.) Zhu, F. C., Liang, Z. L., Li, X. L., Ge, H. M., Meng, F. Y., Mao, Q. Y., ... & Gao, F. (2013). Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. *The Lancet*, *381*(9871), 1037-1045. https://www.sciencedirect.com/science/article/abs/pii/S0140673612617644

421.) Gordon, D. L., Sajkov, D., Woodman, R. J., Honda-Okubo, Y., Cox, M. M., Heinzel, S., & Petrovsky, N. (2012). Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. *Vaccine*, *30*(36), 5407-5416. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410954/

422.) Kang, S., Kim, K. H., Kim, Y. T., Kim, J. H., Song, Y. S., Shin, S. H., ... & Park, S. Y. (2008). Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, placebo-controlled trial in 176 Korean subjects. *International Journal of Gynecological Cancer*, *18*(5), 1013-1019. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1525-1438.2007.01123.x

423.) Shinefield, H., Black, S., Ray, P., Fireman, B., Schwalbe, J., & Lewis, E. (2002). Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. *The Pediatric infectious disease journal*, *21*(3), 182-186. https://journals.lww.com/pidj/Abstract/2002/03000/Efficacy,_immunogenicity_and_safety_of_heptavalent.3.aspx

424.) Li, Y. P., Liang, Z. L., Gao, Q., Huang, L. R., Mao, Q. Y., Wen, S. Q., ... & Wang, J. Z. (2012). Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. *Vaccine*, *30*(22), 3295-3303. https://www.sciencedirect.com/science/article/pii/S0264410X1200357X

425.) Roestenberg, M., Remarque, E., De Jonge, E., Hermsen, R., Blythman, H., Leroy, O., ... & Kocken, C. H. (2008). Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02. *PloS one*, *3*(12), e3960. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0003960

426.) Chokephaibulkit, K., Sirivichayakul, C., Sabchareon, A., Pancharoen, C., Bouckenooghe, A., Gailhardou, S., ... & Feroldi, E. (2010). Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2-to 5-year-olds and naive 12-to 24-month-olds: multicenter randomized controlled trial. *The Pediatric infectious disease journal*, *29*(12), 1111-1117. https://journals.lww.com/pidj/Abstract/2010/12000/Safety_and_Immunogenicity_of_a_Single.11.aspx

427.) Sow, P. S., Watson-Jones, D., Kiviat, N., Changalucha, J., Mbaye, K. D., Brown, J., ... & Kapiga, S. (2013). Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25-year-old HIV-seronegative African girls and young women.

The Journal of infectious diseases, *207*(11), 1753-1763. https://academic.oup.com/jid/article/207/11/1753/794223

428.) Martinón-Torres, F., Safadi, M. A. P., Martinez, A. C., Marquez, P. I., Torres, J. C. T., Weckx, L. Y., ... & Toneatto, D. (2017). Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial. *Vaccine*, *35*(28), 3548-3557. https://www.sciencedirect.com/science/article/pii/S0264410X1730631X

429.) Doherty, J. F., Pinder, M., Tornieporth, N., Carton, C., Vigneron, L., Milligan, P., ... & Momin, P. (1999). A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS, S/SBAS2 in semi-immune adults in The Gambia. *The American journal of tropical medicine and hygiene*, *61*(6), 865-868. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.619.1172&rep=rep1&type=pdf

430.) Polhemus, M. E., Magill, A. J., Cummings, J. F., Kester, K. E., Ockenhouse, C. F., Lanar, D. E., ... & Robinson, S. A. (2007). Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2. 1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. *Vaccine*, *25*(21), 4203-4212. https://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=1020&context=usarmyresearch

431.) Lin, J. T., Zhang, J. S., Su, N., Xu, J. G., Wang, N., Chen, J. T., ... & Liu, Y. (2007). Safety and immunogenicity from a Phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. *Antiviral Therapy*, *12*, 1107-1113. https://www.intmedpress.com/serveFile.cfm?sUID=bba35bb3-9126-4c66-ae0f-4e96b8291dea&origin=publication_detail

432.) Stoute, J. A., Gombe, J., Withers, M. R., Siangla, J., McKinney, D., Onyango, M., ... & Stewart, V. A. (2007). Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. *Vaccine*, *25*(1), 176-184. https://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=1338&context=usarmyresearch

433.) Genton, B., Al-Yaman, F., Anders, R., Saul, A., Brown, G., Pye, D., ... & Adiguma, T. (2000). Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. *Vaccine*, *18*(23), 2504-2511. https://www.sciencedirect.com/science/article/pii/S0264410X00000360

434.) Skinner, S. R., Szarewski, A., Romanowski, B., Garland, S. M., Lazcano-Ponce, E., Salmerón, J., ... & Kitchener, H. (2014). Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. *The Lancet*, *384*(9961), 2213-2227. http://hpvawareness.org/wp-content/uploads/2020/02/Skinner.pdf

435.) Ciszewski, A., Bilinska, Z. T., Brydak, L. B., Kepka, C., Kruk, M., Romanowska, M., ... & Ruzyllo, W. (2008). Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. *European heart journal*, *29*(11), 1350-1358. https://academic.oup.com/eurheartj/article/29/11/1350/636428

436.) Langley, J. M., Frenette, L., Ferguson, L., Riff, D., Sheldon, E., Risi, G., ... & Fries, L. (2010). Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. *The Journal of infectious diseases*, *201*(11), 1644-1653. https://academic.oup.com/jid/article/201/11/1644/850859

437.) Simasathien, S., Thomas, S. J., Watanaveeradej, V., Nisalak, A., Barberousse, C., Innis, B. L., ... & Gibbons, R. V. (2008). Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. *The American journal of tropical medicine and hygiene*, *78*(3), 426-433. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.524.6106&rep=rep1&type=pdf

438.) Tsang, P., Gorse, G. J., Strout, C. B., Sperling, M., Greenberg, D. P., Ozol-Godfrey, A., ... & Landolfi, V. (2014). Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults≥ 65 years of age: A randomized, controlled, phase II trial. *Vaccine*, *32*(21), 2507-2517. https://www.sciencedirect.com/science/article/pii/S0264410X13013583

439.) Lacey, C. J. N., Thompson, H. S. G., Monteiro, E. F., O'neill, T., Davies, M. L., Holding, F. P., ... & Roberts, J. S. C. (1999). Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. *The Journal of infectious diseases*, *179*(3), 612-618. https://academic.oup.com/jid/article/179/3/612/807294

440.) Curns, A. T., Steiner, C. A., Barrett, M., Hunter, K., Wilson, E., & Parashar, U. D. (2010). Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. *The Journal of infectious diseases*, *201*(11), 1617-1624. https://academic.oup.com/jid/article/201/11/1617/850599

441.) Lin, F. Y. C., Ho, V. A., Khiem, H. B., Trach, D. D., Bay, P. V., Thanh, T. C., ... & Schneerson, R. (2001). The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. *New England Journal of Medicine*, *344*(17), 1263-1269. https://www.nejm.org/doi/full/10.1056/nejm200104263441701

442.) Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., ... & Bassat, Q. (2004). Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. *The Lancet*, *364*(9443), 1411-1420. https://www.sciencedirect.com/science/article/abs/pii/S0140673604172231

443.) Chakravarty, J., Kumar, S., Trivedi, S., Rai, V. K., Singh, A., Ashman, J. A., ... & Cowgill, K. D. (2011). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+ MPL-SE vaccine for use in the prevention of visceral leishmaniasis. *Vaccine*, *29*(19), 3531-3537. https://www.sciencedirect.com/science/article/pii/S0264410X11003446

444.) Jones, R. L., Froeschle, J. E., Atmar, R. L., Matthews, J. S., Sanders, R., Pardalos, J., ... & Lang, J. (2001). Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. *Vaccine*, *19*(32), 4635-4643. https://www.sciencedirect.com/science/article/pii/S0264410X01002389

445.) Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Dzharullaeva, A. S., Tukhvatulina, N. M., Shcheblyakov, D. V., ... & Scherbinin, D. N. (2017). Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. *Human vaccines & immunotherapeutics*, *13*(3), 613-620. https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1238535

446.) Wilkin, T., Lee, J. Y., Lensing, S. Y., Stier, E. A., Goldstone, S. E., Berry, J. M., ... & Saah, A. (2010). Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. *The Journal of infectious diseases*, *202*(8), 1246-1253. https://academic.oup.com/jid/article/202/8/1246/928077

447.) Cooper, C., Klein, M., Walmsley, S., Haase, D., MacKinnon-Cameron, D., Marty, K., ... & Scheifele, D. (2012). High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N12009 and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. *HIV clinical trials*, *13*(1), 23-32. https://www.tandfonline.com/doi/abs/10.1310/hct1301-23

448.) Arbyn, M., & Xu, L. (2018). Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. *Expert Review of Vaccines*, *17*(12), 1085-1091. https://www.sciensano.be/sites/default/files/arbyn2018exprevvaccines.pdf

449.) Guirakhoo, F., Kitchener, S., Morrison, D., Forrat, R., McCarthy, K., Nichols, R., ... & Bedford, P. (2006). Live attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all. *Human vaccines*, *2*(2), 60-67. https://www.tandfonline.com/doi/pdf/10.4161/hv.2.2.2555

450.) Aguilo, N., Uranga, S., Marinova, D., Monzon, M., Badiola, J., & Martin, C. (2016). MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. *Tuberculosis*, *96*, 71-74. https://www.sciencedirect.com/science/article/pii/S1472979215301992

451.) Linhares, A. D. C., Gabbay, Y. B., Mascarenhas, J. D., De Freitas, R. B., Oliveira, C. S., Bellesi, N., ... & Valente, S. A. (1996). Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. *Bulletin of the World Health Organization*, *74*(5), 491. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2486862/pdf/bullwho00403-0042.pdf

452.) Li, Y. P., Liang, Z. L., Xia, J. L., Wu, J. Y., Wang, L., Song, L. F., ... & Yao, X. (2014). Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. *The Journal of infectious diseases*, *209*(1), 46-55. https://academic.oup.com/jid/article/209/1/46/2192871

453.) Scharpé, J., Peetermans, W. E., Vanwalleghem, J., Maes, B., Bammens, B., Claes, K., ... & Evenepoel, P. (2009). Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. *American journal of kidney diseases*, *54*(1), 77-85. https://www.sciencedirect.com/science/article/abs/pii/S0272638609000493

454.) Kenter, G. G., Welters, M. J., Valentijn, A. R. P., Löwik, M. J., Berends-van der Meer, D. M., Vloon, A. P., ... & Offringa, R. (2008). Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. *Clinical cancer research*, *14*(1), 169-177. https://clincancerres.aacrjournals.org/content/14/1/169.short

455.) Romanowski, B., Schwarz, T. F., Ferguson, L. M., Peters, K., Dionne, M., Schulze, K., ... & Schuind, A. (2011). Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a

randomized study. *Human vaccines*, *7*(12), 1374-1386. https://www.tandfonline.com/doi/full/10.4161/hv.7.12.18322

456.) Kimura, T., McKolanis, J. R., Dzubinski, L. A., Islam, K., Potter, D. M., Salazar, A. M., ... & Finn, O. J. (2013). MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. *Cancer prevention research*, *6*(1), 18-26. https://cancerpreventionresearch.aacrjournals.org/content/6/1/18.long#sec-14

457.) Sedegah, M., Tamminga, C., McGrath, S., House, B., Ganeshan, H., Lejano, J., ... & Belmonte, M. (2011). Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. *PloS one*, *6*(10), e24586-e24586. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024586

458.) Abdulla, S., Oberholzer, R., Juma, O., Kubhoja, S., Machera, F., Membi, C., ... & Salim, N. (2008). Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants. *New England Journal of Medicine*, *359*(24), 2533-2544. https://www.nejm.org/doi/full/10.1056/nejmoa0807773

459.) Brookes, R. H., Hill, P. C., Owiafe, P. K., Ibanga, H. B., Jeffries, D. J., Donkor, S. A., ... & McShane, H. (2008). Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. *PloS one*, *3*(8), e2921-e2921. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002921

460.) Peltola, H., Heinonen, O. P., Valle, M., Paunio, M., Virtanen, M., Karanko, V., & Cantell, K. (1994). The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. *New England journal of medicine*, *331*(21), 1397-1402. https://www.nejm.org/doi/full/10.1056/NEJM199411243312101

461.) Van Der Wielen, M., Vertruyen, A., Froesner, G., Ibáñez, R., Hunt, M., Herzog, C., & Van Damme, P. (2007). Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1–16 years. *The Pediatric infectious disease journal*, *26*(8), 705-710. https://journals.lww.com/pidj/Abstract/2007/08000/Immunogenicity_and_Safety_of_a_Pediatric_Dose_of_a.9.aspx

462.) Arroyo, J., Miller, C., Catalan, J., Myers, G. A., Ratterree, M. S., Trent, D. W., & Monath, T. P. (2004). ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. *Journal of virology*, *78*(22), 12497-12507. https://jvi.asm.org/content/jvi/78/22/12497.full.pdf

463.) Piedra, P. A., Cron, S. G., Jewell, A., Hamblett, N., McBride, R., Palacio, M. A., ... & Group, P. F. P. V. S. (2003). Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. *Vaccine*, *21*(19-20), 2448-2460. https://www.sciencedirect.com/science/article/pii/S0264410X03000987

464.) Low, N., Kraemer, S., Schneider, M., & Restrepo, A. M. H. (2008). Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. *Vaccine*, *26*(3), 383-398. https://www.sciencedirect.com/science/article/pii/S0264410X07012790

465.) Jaoko, W., Nakwagala, F. N., Anzala, O., Manyonyi, G. O., Birungi, J., Nanvubya, A., ... & Matu, L. (2008). Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. *Vaccine*, *26*(22), 2788-2795. https://www.sciencedirect.com/science/article/pii/S0264410X08002776

466.) Coler, R. N., Duthie, M. S., Hofmeyer, K. A., Guderian, J., Jayashankar, L., Vergara, J., ... & Bailor, H. R. (2015). From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+ GLA-SE. *Clinical & Translational Immunology*, *4*(4), e35-e35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488838/

467.) George, S. L., Wong, M. A., Dube, T. J., Boroughs, K. L., Stovall, J. L., Luy, B. E., ... & Frey, S. E. (2015). Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. *The Journal of infectious diseases*, *212*(7), 1032-1041. https://academic.oup.com/jid/article/212/7/1032/841673

468.) Neuzil, K. M., Thiem, V. D., Janmohamed, A., Huong, V. M., Tang, Y., Diep, N. T. N., ... & LaMontagne, D. S. (2011). Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. *Jama*, *305*(14), 1424-1431. https://jamanetwork.com/journals/jama/article-abstract/896683

469.) Villar, L. Á., Rivera-Medina, D. M., Arredondo-García, J. L., Boaz, M., Starr-Spires, L., Thakur, M., ... & Dayan, G. H. (2013). Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds: a randomized, controlled, phase II trial in Latin America. *The Pediatric infectious disease journal*, *32*(10), 1102-1109. https://journals.lww.com/pidj/FullText/2013/10000/Safety_and_Immunogenicity_of_a_Recombinant.18.aspx

470.) Zangiabadian, M., Nejadghaderi, S. A., Mirsaeidi, M., Hajikhani, B., Goudarzi, M., Goudarzi, H., ... & Nasiri, M. J. (2020). Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis. *Scientific Reports*, *10*(1), 1-8. https://www.nature.com/articles/s41598-020-77679-7#Abs1

471.) Belshe, R., Lee, M. S., Walker, R. E., Stoddard, J., & Mendelman, P. M. (2004). Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. *Expert review of vaccines*, *3*(6), 643-654. https://www.tandfonline.com/doi/abs/10.1586/14760584.3.6.643

472.) O'Brien, K. L., Swift, A. J., Winkelstein, J. A., Santosham, M., Stover, B., Luddy, R., ... & Lederman, H. M. (2000). Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 among infants with sickle cell disease. *Pediatrics*, *106*(5), 965-972. https://pediatrics.aappublications.org/content/106/5/965.short

473.) Greenough, T. C., Cunningham, C. K., Muresan, P., McManus, M., Persaud, D., Fenton, T., ... & Luzuriaga, K. (2008). Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. *Vaccine*, *26*(52), 6883-6893. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845914/

474.) Loxton, A. G., Knaul, J. K., Grode, L., Gutschmidt, A., Meller, C., Eisele, B., ... & Hesseling, A. C. (2017). Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. *Clinical and Vaccine Immunology*, *24*(2). https://cvi.asm.org/content/24/2/e00439-16.full

475.) Averhoff, F., Mahoney, F., Coleman, P., Schatz, G., Hurwitz, E., & Margolis, H. (1998). Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. *American journal of preventive medicine*, *15*(1), 1-8. https://www.sciencedirect.com/science/article/abs/pii/S0749379798000038

476.) Nascimento, E., Fernandes, D. F., Vieira, E. P., Campos-Neto, A., Ashman, J. A., Alves, F. P., ... & Pine, S. O. (2010). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+ MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. *Vaccine*, *28*(40), 6581-6587. https://www.sciencedirect.com/science/article/pii/S0264410X10010741

477.) Katz, D. E., Coster, T. S., Wolf, M. K., Trespalacios, F. C., Cohen, D., Robins, G., ... & Hale, T. L. (2004). Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. *Infection and Immunity*, *72*(2), 923-930. https://iai.asm.org/content/iai/72/2/923.full.pdf

478.) Gossger, N., Snape, M. D., Yu, L. M., Finn, A., Bona, G., Esposito, S., ... & Kieninger, D. (2012). Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. *Jama*, *307*(6), 573-582. https://jamanetwork.com/journals/jama/fullarticle/1104956

479.) Magnus, P., Brubakk, O., Nyland, H., Wold, B. H., Gjessing, H. K., Brandt, I., ... & Stene-Larsen, G. (2009). Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome. *Vaccine*, *27*(1), 23-27. https://www.sciencedirect.com/science/article/pii/S0264410X08014333

480.) von Krempelhuber, A., Vollmar, J., Pokorny, R., Rapp, P., Wulff, N., Petzold, B., ... & Chaplin, P. (2010). A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®. *Vaccine*, *28*(5), 1209-1216. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814951/

481.) Creech, C. B., Dekker, C. L., Ho, D., Phillips, S., Mackey, S., Murray-Krezan, C., ... & Versteege, I. (2013). Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. *Human vaccines & immunotherapeutics*, *9*(12), 2548-2557. https://www.tandfonline.com/doi/full/10.4161/hv.26038

482.) Osorio, J. E., Velez, I. D., Thomson, C., Lopez, L., Jimenez, A., Haller, A. A., ... & Luy, B. E. (2014). Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. *The Lancet Infectious Diseases*, *14*(9), 830-838. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648257/

483.) Spycher, B. D., Silverman, M., Egger, M., Zwahlen, M., & Kuehni, C. E. (2009). Routine vaccination against pertussis and the risk of childhood asthma: a population-based cohort study. *Pediatrics*, *123*(3), 944-950. https://pediatrics.aappublications.org/content/123/3/944.short

484.) Mrozek-Budzyn, D., Majewska, R., & Kiełtyka, A. (2015). Early exposure to thimerosal-containing vaccines and children's cognitive development. A 9-year prospective birth cohort study in Poland. *European journal of pediatrics*, *174*(3), 383-391. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334107/ & https://link.springer.com/article/10.1007%2Fs00431-014-2412-5

485.) Satti, I. N., Osman, H. Y., Daifalla, N. S., Younis, S. A., Khalil, E. A. G., Zijlstra, E. E., ... & Ghalib, H. W. (2001). Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. *Vaccine*, *19*(15-16), 2100-2106. https://www.sciencedirect.com/science/article/pii/S0264410X00004011

486.) Baker, C. J., Paoletti, L. C., Wessels, M. R., Guttormsen, H. K., Rench, M. A., Hickman, M. E., & Kasper, D. L. (1999). Safety and immunogenicity of capsular polysaccharide—tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. *The Journal of infectious diseases*, *179*(1), 142-150. https://academic.oup.com/jid/article/179/1/142/877598

487.) Dupont, J., Altclas, J., Lepetic, A., Lombardo, M., Vázquez, V., Salgueira, C., ... & Janowicz, Z. (2006). A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. *Vaccine*, *24*(49-50), 7167-7174. https://www.sciencedirect.com/science/article/pii/S0264410X06007924

488.) Hosking, J., Rasanathan, K., Mow, F. C., Jackson, C., Martin, D., O'Hallahan, J., ... & Crengle, S. (2007). Immunogenicity, reactogenicity, and safety of a P1. 7b, 4 strain-specific serogroup B meningococcal vaccine given to preteens. *Clinical and Vaccine Immunology*, *14*(11), 1393-1399. https://cvi.asm.org/content/14/11/1393

489.) Panchanathan, V., Kumar, S., Yeap, W., Devi, S., Ismail, R., Sarijan, S., ... & Pang, T. (2001). Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits. *Bulletin of the World Health Organization*, *79*, 811-817. https://www.scielosp.org/article/bwho/2001.v79n9/811-817/

490.) Vesikari, T., Karvonen, A., Puustinen, L., Zeng, S. Q., Szakal, E. D., Delem, A., & De Vos, B. (2004). Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. *The Pediatric infectious disease journal*, *23*(10), 937-943. https://journals.lww.com/pidj/Abstract/2004/10000/Efficacy_of_RIX4414_Live_Attenuated_Human.10.aspx

491.) Fan, S., Gao, Y., Shinya, K., Li, C. K., Li, Y., Shi, J., ... & Song, J. (2009). Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. *PLoS pathogens*, *5*(5), e1000409. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1000409

492.) Turley, C. B., Rupp, R. E., Johnson, C., Taylor, D. N., Wolfson, J., Tussey, L., ... & Shaw, A. (2011). Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2. 4xM2e) in healthy adults. *Vaccine*, *29*(32), 5145-5152. https://www.sciencedirect.com/science/article/pii/S0264410X11007614#

493.) McKenzie, R., Walker, R. I., Nabors, G. S., Van De Verg, L. L., Carpenter, C., Gomes, G., ... & Jackson, W. J. (2006). Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. *Vaccine*, *24*(18), 3735-3745. https://www.sciencedirect.com/science/article/pii/S0264410X05006651

494.) Huttner, A., Hatz, C., van den Dobbelsteen, G., Abbanat, D., Hornacek, A., Frölich, R., ... & van den Nieuwenhof, I. (2017). Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. *The Lancet infectious diseases*, *17*(5), 528-537. https://www.sciencedirect.com/science/article/abs/pii/S1473309917301081

495.) Jin, C., Gibani, M. M., Moore, M., Juel, H. B., Jones, E., Meiring, J., ... & Hill, J. (2017). Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. *The Lancet*, *390*(10111), 2472-2480. https://www.sciencedirect.com/science/article/pii/S0140673617321499

496.) Amodio, E., Casuccio, A., Tramuto, F., Costantino, C., Marrella, A., Maida, C. M., ... & Restivo, V. (2020). Varicella vaccination as useful strategy for reducing the risk of varicella-related hospitalizations in both vaccinated and unvaccinated cohorts (Italy, 2003–2018). *Vaccine*, *38*(35), 5601-5606. https://www.sciencedirect.com/science/article/pii/S0264410X20308793

497.) Fu, C., Dong, Z., Shen, J., Yang, Z., Liao, Y., Hu, W., ... & Shaman, J. (2018). Rotavirus gastroenteritis infection among children vaccinated and unvaccinated with rotavirus vaccine in Southern China: a population-based assessment. *JAMA network open*, *1*(4), e181382-e181382. https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2698629

498.) Prelog, M., Gorth, P., Zwazl, I., Kleines, M., Streng, A., Zlamy, M., ... & Wiedermann, U. (2016). Universal mass vaccination against rotavirus: indirect effects on rotavirus infections in neonates and unvaccinated young infants not eligible for vaccination. *The Journal of infectious diseases*, *214*(4), 546-555. https://academic.oup.com/jid/article/214/4/546/1751072

499.) Zerbo, O., Bartlett, J., Goddard, K., Fireman, B., Lewis, E., & Klein, N. P. (2019). Acellular Pertussis Vaccine Effectiveness Over Time. *Pediatrics*, *144*(1), e20183466. https://pediatrics.aappublications.org/content/144/1/e20183466.full

500.) Sanyaolu, A., Okorie, C., Marinkovic, A., Ayodele, O., Abbasi, A. F., Prakash, S., ... & Chan, H. (2019). Measles outbreak in unvaccinated and partially vaccinated children and adults in the United States and Canada (2018-2019): a narrative review of cases. *INQUIRY: The Journal of Health Care Organization, Provision, and Financing*, *56*, 0046958019894098. https://journals.sagepub.com/doi/full/10.1177/0046958019894098

501.) Phadke, V. K., Bednarczyk, R. A., Salmon, D. A., & Omer, S. B. (2016). Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. *Jama*, *315*(11), 1149-1158. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007135/?source=post_page-----6df1b46c14cc----------

502.) Foppa, I. M., Cheng, P. Y., Reynolds, S. B., Shay, D. K., Carias, C., Bresee, J. S., ... & Fry, A. M. (2015). Deaths averted by influenza vaccination in the US during the seasons 2005/06 through 2013/14. *Vaccine*, *33*(26), 3003-3009. https://www.sciencedirect.com/science/article/pii/S0264410X15002315

503.) Domínguez, A., Soldevila, N., Toledo, D., Godoy, P., Espejo, E., Fernandez, M. A., ... & Astray, J. (2017). The effectiveness of influenza vaccination in preventing hospitalisations of elderly individuals in two influenza seasons: a multicentre case–control study, Spain, 2013/14 and 2014/15. *Eurosurveillance*, *22*(34), 30602. https://www.eurosurveillance.org/docserver/fulltext/eurosurv-22-34-3.pdf?expires=1603251873&id=id&accname=guest&checksum=FCAE2CB8ABB21481B60187DBBC3EBB62

504.) Bonmarin, I., Belchior, E., & Lévy-Bruhl, D. (2015). Impact of influenza vaccination on mortality in the French elderly population during the 2000–2009 period. *Vaccine*, *33*(9), 1099-1101. https://www.sciencedirect.com/science/article/pii/S0264410X15000420

505.) Kostova, D., Reed, C., Finelli, L., Cheng, P. Y., Gargiullo, P. M., Shay, D. K., ... & Bresee, J. S. (2013). Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011. *PLoSO*, *8*(6), e66312. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066312

506.) Reed, C., Kim, I. K., Singleton, J. A., Chaves, S. S., Flannery, B., Finelli, L., ... & Cox, N. (2014). Estimated influenza illnesses and hospitalizations averted by vaccination—United States, 2013–14 influenza season. *MMWR. Morbidity and mortality weekly report*, *63*(49), 1151. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584537/

507.) Bresee, J., Reed, C., Kim, I. K., Finelli, L., Fry, A., Chaves, S. S., ... & Singleton, J. (2013). Estimated influenza illnesses and hospitalizations averted by influenza vaccination—United States, 2012–13 influenza season. *MMWR. Morbidity and mortality weekly report*, *62*(49), 997.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585588/

508.) Darvishian, M., Bijlsma, M. J., Hak, E., & van den Heuvel, E. R. (2014). Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. *The Lancet Infectious Diseases*, *14*(12), 1228-1239. https://www.sciencedirect.com/science/article/abs/pii/S1473309914709600

509.) Thomsen, R. W., Öztürk, B., Pedersen, L., Nicolaisen, S. K., Petersen, I., Olsen, J., & Sørensen, H. T. (2020). Hospital records of pain, fatigue, or circulatory symptoms in girls exposed to human papillomavirus vaccination: cohort, self-controlled case series, and population time trend studies. *American journal of epidemiology*, *189*(4), 277-285. https://academic.oup.com/aje/article/189/4/277/5695267

510.) Reed, C., Meltzer, M. I., Finelli, L., & Fiore, A. (2012). Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. *Vaccine*, *30*(11), 1993-1998. https://www.sciencedirect.com/science/article/pii/S0264410X11020470

511.) Talbot, H. K., Griffin, M. R., Chen, Q., Zhu, Y., Williams, J. V., & Edwards, K. M. (2011). Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. *Journal of Infectious Diseases*, *203*(4), 500-508. https://academic.oup.com/jid/article/203/4/500/2192197

512.) Mina, M. J., Kula, T., Leng, Y., Li, M., De Vries, R. D., Knip, M., ... & Larman, H. B. (2019). Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. *Science*, *366*(6465), 599-606. https://science.sciencemag.org/content/366/6465/599

513.) Chen, Q., Griffin, M. R., Nian, H., Zhu, Y., Williams, J. V., Edwards, K. M., & Talbot, H. K. (2015). Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged≥ 50 years. *The Journal of infectious diseases*, *211*(7), 1045-1050. https://academic.oup.com/jid/article/211/7/1045/2910526

514.) Petousis-Harris, H., Paynter, J., Morgan, J., Saxton, P., McArdle, B., Goodyear-Smith, F., & Black, S. (2017). Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. *The Lancet*, *390*(10102), 1603-1610. https://www.sciencedirect.com/science/article/abs/pii/S0140673617314496

515.) Harling, R., White, J. M., Ramsay, M. E., Macsween, K. F., & van den Bosch, C. (2005). The effectiveness of the mumps component of the MMR vaccine: a case control study. *Vaccine*, *23*(31), 4070-4074. https://www.sciencedirect.com/science/article/pii/S0264410X04007881

516.) de Andrade, A. L. S. S., de Andrade, J. G., Martelli, C. M. T., e Silva, S. A., de Oliveira, R. M., Costa, M. S. N., ... & Fabio, J. L. D. (2004). Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. *International journal of epidemiology*, *33*(1), 173-181. https://academic.oup.com/ije/article/33/1/173/668186

517.) Davis, R. L., Kramarz, P., Bohlke, K., Benson, P., Thompson, R. S., Mullooly, J., ... & Marcy, S. M. (2001). Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. *Archives of pediatrics & adolescent medicine*, *155*(3), 354-359. https://jamanetwork.com/journals/jamapediatrics/article-abstract/190443

518.) Nandi, A., Shet, A., Behrman, J. R., Black, M. M., Bloom, D. E., & Laxminarayan, R. (2019). Anthropometric, cognitive, and schooling benefits of measles vaccination: Longitudinal cohort analysis in Ethiopia, India, and Vietnam. *Vaccine*, *37*(31), 4336-4343. https://www.sciencedirect.com/science/article/pii/S0264410X19307868?via%3Dihub

519.) Smith, M. J., & Woods, C. R. (2010). On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes. *Pediatrics*, *125*(6), 1134-1141. https://vaccines.org.il/images/c/cd/On-time-Vaccine-Receipt-in-the-First-Year-Does-Not-Adversely-Affect-Neuropsychological-Outcomes.pdf

520.) Estívariz, C. F., Jafari, H., Sutter, R. W., John, T. J., Jain, V., Agarwal, A., ... & Awale, J. (2012). Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6–9 months in Moradabad, India: a community-based, randomised controlled trial. *The Lancet infectious diseases*, *12*(2), 128-135. https://www.sciencedirect.com/science/article/abs/pii/S1473309911701906

521.) Shah, M. P., Tate, J. E., Mwenda, J. M., Steele, A. D., & Parashar, U. D. (2017). Estimated reductions in hospitalizations and deaths from childhood diarrhea following implementation of rotavirus vaccination in Africa. *Expert review of vaccines*, *16*(10), 987-995. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829907/

522.) Kuter, B. J., Hoffman Brown, M. L., Hartzel, J., Williams, W. R., Eves, K. A., Black, S., ... & Thear, M. (2006). Safety and Immunogenicity of a Combination: Measles, Mumps, Rubella and Varicella Vaccine (ProQuad®). *Human Vaccines*, *2*(5), 205-214. https://www.tandfonline.com/doi/pdf/10.4161/hv.2.5.3246

523.) Davidkin, I., Jokinen, S., Broman, M., Leinikki, P., & Peltola, H. (2008). Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. *The*

Journal of infectious diseases, *197*(7), 950-956. https://academic.oup.com/jid/article/197/7/950/798890

524.) Xu, Z. Y., Liu, C. B., Francis, D. P., Purcell, R. H., Gun, Z. L., Duan, S. C., ... & Maynard, J. E. (1985). Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. *Pediatrics*, *76*(5), 713-718. https://pediatrics.aappublications.org/content/76/5/713.short

525.) Bines, J. E., Danchin, M., Jackson, P., Handley, A., Watts, E., Lee, K. J., ... & Justice, F. (2015). Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. *The Lancet Infectious Diseases*, *15*(12), 1389-1397. https://www.sciencedirect.com/science/article/abs/pii/S1473309915002273

526.) Mendy, M., Peterson, I., Hossin, S., Peto, T., Jobarteh, M. L., Jeng-Barry, A., ... & Whittle, H. (2013). Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. *PloS one*, *8*(3), e58029. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0058029

527.) Ni, Y. H., Chang, M. H., Wu, J. F., Hsu, H. Y., Chen, H. L., & Chen, D. S. (2012). Minimization of hepatitis B infection by a 25-year universal vaccination program. *Journal of hepatology*, *57*(4), 730-735. https://www.sciencedirect.com/science/article/abs/pii/S0168827812004217

528.) Moutschen, M., Léonard, P., Sokal, E. M., Smets, F., Haumont, M., Mazzu, P., ... & Denis, M. (2007). Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults. *Vaccine*, *25*(24), 4697-4705. https://www.sciencedirect.com/science/article/pii/S0264410X07004185

529.) Tauber, E., Kollaritsch, H., Korinek, M., Rendi-Wagner, P., Jilma, B., Firbas, C., ... & Klade, C. S. (2007). Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. *The Lancet*, *370*(9602), 1847-1853. https://www.sciencedirect.com/science/article/abs/pii/S0140673607617802

530.) Cutts, F. T., Zaman, S. M. A., Enwere, G. Y., Jaffar, S., Levine, O. S., Okoko, J. B., ... & McAdam, K. P. (2005). Efficacy of nine-valent pneumococcal conjugate vaccine against

pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. *The Lancet*, *365*(9465), 1139-1146. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.631.6121&rep=rep1&type=pdf

531.) Sacarlal, J., Aide, P., Aponte, J. J., Renom, M., Leach, A., Mandomando, I., ... & Vekemans, J. (2009). Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children. *Journal of Infectious Diseases*, *200*(3), 329-336. https://academic.oup.com/jid/article/200/3/329/900220

532.) Vélez, I. D., Gilchrist, K., Martínez, S., Ramírez-Pineda, J. R., Ashman, J. A., Alves, F. P., ... & Cowgill, K. D. (2009). Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. *Vaccine*, *28*(2), 329-337. https://www.sciencedirect.com/science/article/pii/S0264410X09015758

533.) Luo, Z., Li, L., & Ruan, B. (2012). Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. *International Journal of Infectious Diseases*, *16*(2), e82-e88. https://www.sciencedirect.com/science/article/pii/S1201971211002384

534.) Ward, J. I., Cherry, J. D., Chang, S. J., Partridge, S., Lee, H., Treanor, J., ... & Edelman, R. (2005). Efficacy of an acellular pertussis vaccine among adolescents and adults. *New England Journal of Medicine*, *353*(15), 1555-1563. https://www.nejm.org/doi/full/10.1056/NEJMoa050824

535.) Oster, P., Lennon, D., O'Hallahan, J., Mulholland, K., Reid, S., & Martin, D. (2005). MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. *Vaccine*, *23*(17-18), 2191-2196. https://www.sciencedirect.com/science/article/pii/S0264410X05000691

536.) Hawkridge, T., Scriba, T. J., Gelderbloem, S., Smit, E., Tameris, M., Moyo, S., ... & Fletcher, H. A. (2008). Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. *The Journal of infectious diseases*, *198*(4), 544-552. https://academic.oup.com/jid/article/198/4/544/832539

537.) McMahon, B. J., Bulkow, L. R., Singleton, R. J., Williams, J., Snowball, M., Homan, C., & Parkinson, A. J. (2011). Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch‐up immunization program. *Hepatology*, *54*(3), 801-807. https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.24442

538.) Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., & Demicheli, V. (2005). Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. *The Lancet*, *366*(9492), 1165-1174. https://www.sciencedirect.com/science/article/abs/pii/S0140673605673394

539.) Wilkinson, K., Wei, Y., Szwajcer, A., Rabbani, R., Zarychanski, R., Abou-Setta, A. M., & Mahmud, S. M. (2017). Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis. *Vaccine*, *35*(21), 2775-2780. https://www.sciencedirect.com/science/article/pii/S0264410X17304449

540.) Cortese, M. M., Tate, J. E., Simonsen, L., Edelman, L., & Parashar, U. D. (2010). Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. *The Pediatric infectious disease journal*, *29*(6), 489-494. https://journals.lww.com/pidj/Abstract/2010/06000/Reduction_in_Gastroenteritis_in_United_States.3.aspx

541.) Wijnans, L., Dodd, C. N., Weibel, D., & Sturkenboom, M. (2017). Bell's palsy and influenza (H1N1) pdm09 containing vaccines: A self-controlled case series. *PloS one*, *12*(5), e0175539. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175539

542.) Fitzwater, S. P., Chandran, A., Santosham, M., & Johnson, H. L. (2012). The worldwide impact of the seven-valent pneumococcal conjugate vaccine. *The Pediatric infectious disease journal*, *31*(5), 501-508. https://journals.lww.com/pidj/fulltext/2012/05000/The_Worldwide_Impact_of_the_Seven_valent.16.aspx

543.) Patel, M. M., Glass, R., Desai, R., Tate, J. E., & Parashar, U. D. (2012). Fulfilling the promise of rotavirus vaccines: how far have we come since licensure?. *The Lancet infectious diseases*, *12*(7), 561-570. https://www.sciencedirect.com/science/article/abs/pii/S1473309912700294

544.) Simonsen, L., Taylor, R. J., Young-Xu, Y., Haber, M., May, L., & Klugman, K. P. (2011). Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. *mBio*, *2*(1), e00309-e00310. https://mbio.asm.org/content/mbio/2/1/e00309-10.full.pdf

545.) Bar-Zeev, N., Kapanda, L., Tate, J. E., Jere, K. C., Iturriza-Gomara, M., Nakagomi, O., ... & French, N. (2015). Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after

programmatic roll-out: an observational and case-control study. *The Lancet infectious diseases*, *15*(4), 422-428. https://www.sciencedirect.com/science/article/pii/S1473309914710606

546.) Tabrizi, S. N., Brotherton, J. M., Kaldor, J. M., Skinner, S. R., Cummins, E., Liu, B., ... & Garland, S. M. (2012). Fall in human papillomavirus prevalence following a national vaccination program. *The Journal of infectious diseases*, *206*(11), 1645-1651. https://academic.oup.com/jid/article/206/11/1645/896918

547.) Karafillakis, E., Hassounah, S., & Atchison, C. (2015). Effectiveness and impact of rotavirus vaccines in Europe, 2006–2014. *Vaccine*, *33*(18), 2097-2107. https://www.sciencedirect.com/science/article/pii/S0264410X15003047

548.) Liang, X., Bi, S., Yang, W., Wang, L., Cui, G., Cui, F., ... & Wang, F. (2013). Reprint of: Epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination. *Vaccine*, *31*, J21-J28. https://www.sciencedirect.com/science/article/pii/S0264410X13010967

549.) Gurgel, R. G., Bohland, A. K., Vieira, S. C., Oliveira, D. M., Fontes, P. B., Barros, V. F., ... & Correia, J. B. (2009). Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. *Gastroenterology*, *137*(6), 1970-1975. https://www.gastrojournal.org/article/S0016-5085(09)01245-1/fulltext

550.) Patel, M., Pedreira, C., De Oliveira, L. H., Tate, J., Orozco, M., Mercado, J., ... & Balmaseda, A. (2009). Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. *Jama*, *301*(21), 2243-2251. https://jamanetwork.com/journals/jama/article-abstract/184013

551.) Cowgill, K. D., Ndiritu, M., Nyiro, J., Slack, M. P., Chiphatsi, S., Ismail, A., ... & Feikin, D. R. (2006). Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. *Jama*, *296*(6), 671-678. https://jamanetwork.com/journals/jama/article-abstract/203139

552.) Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E. (2004). Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. *The Lancet*, *364*(9431), 365-367. https://www.sciencedirect.com/science/article/abs/pii/S0140673604167251

553.) Cohen, C., White, J. M., Savage, E. J., Glynn, J. R., Choi, Y., Andrews, N., ... & Ramsay, M. E. (2007). Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. *Emerging infectious diseases*, *13*(1), 12-17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913658/

554.) Foster, D. A., Talsma, A., Furumoto-Dawson, A., Ohmit, S. E., Margulies, J. R., Arden, N. H., & Monto, A. S. (1992). Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. *American journal of epidemiology*, *136*(3), 296-307. https://academic.oup.com/aje/article-abstract/136/3/296/96003

555.) Strassburg, M. A., Greenland, S., Sorvillo, F. J., Lieb, L. E., & Habel, L. A. (1986). Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. *Vaccine*, *4*(1), 38-44. https://www.sciencedirect.com/science/article/pii/S0264410X86800020

556.) Ohmit, S. E., & Monto, A. S. (1995). Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. *International journal of epidemiology*, *24*(6), 1240-1248. https://academic.oup.com/ije/article-abstract/24/6/1240/754188

557.) Herrera, G. A., Iwane, M. K., Cortese, M., Brown, C., Gershman, K., Shupe, A., ... & Bridges, C. B. (2007). Influenza vaccine effectiveness among 50–64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003–2004. *Vaccine*, *25*(1), 154-160. https://www.sciencedirect.com/science/article/pii/S0264410X06008838

558.) Domnich, A., Arata, L., Amicizia, D., Puig-Barberà, J., Gasparini, R., & Panatto, D. (2017). Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. *Vaccine*, *35*(4), 513-520. https://www.sciencedirect.com/science/article/pii/S0264410X1631218X

559.) Henao-Restrepo, A. M., Longini, I. M., Egger, M., Dean, N. E., Edmunds, W. J., Camacho, A., ... & Enwere, G. (2015). Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. *The Lancet*, *386*(9996), 857-866. https://www.sciencedirect.com/science/article/pii/S0140673615611175

560.) Remschmidt, C., Wichmann, O., & Harder, T. (2014). Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. *BMC Medicine*, *1*(12), 1-14. https://link.springer.com/article/10.1186/s12916-014-0244-9

561.) Vázquez, M., LaRussa, P. S., Gershon, A. A., Niccolai, L. M., Muehlenbein, C. E., Steinberg, S. P., & Shapiro, E. D. (2004). Effectiveness over time of varicella vaccine. *Jama*, *291*(7), 851-855. https://jamanetwork.com/journals/jama/fullarticle/198218

562.) Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995). The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. *Annals of Internal medicine*, *123*(7), 518-527. https://www.acpjournals.org/doi/full/10.7326/0003-4819-123-7-199510010-00008

563.) Bolan, G., Broome, C. V., Facklam, R. R., Plikaytis, B. D., Fraser, D. W., & Schlech 3rd, W. F. (1986). Pneumococcal vaccine efficacy in selected populations in the United States. *Annals of Internal Medicine*, *104*(1), 1-6. https://www.acpjournals.org/doi/abs/10.7326/0003-4819-104-1-1

564.) Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., ... & Mulligan, R. C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proceedings of the National Academy of Sciences*, *90*(8), 3539-3543. https://www.pnas.org/content/pnas/90/8/3539.full.pdf

565.) Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., ... & Kholodenko, D. (1999). Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature*, *400*(6740), 173-177. https://www.nature.com/articles/22124

566.) Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., ... & Schadendorf, D. (1998). Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells. *Nature medicine*, *4*(3), 328-332. https://www.nature.com/articles/nm0398-328#Abs1

567.) Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., ... & Benenson, M. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *New England Journal of Medicine*, *361*(23), 2209-2220. https://www.nejm.org/doi/full/10.1056/NEJMoa0908492

568.) Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., ... & Facklam, R. R. (2003). Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. *New England Journal of Medicine*, *348*(18), 1737-1746. https://www.nejm.org/doi/full/10.1056/NEJMoa022823

569.) Hoiseth, S. K., & Stocker, B. A. D. (1981). Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. *Nature*, *291*(5812), 238-239. https://www.nature.com/articles/291238a0

570.) Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., ... & Levy, R. (1996). Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells. *Nature medicine*, *2*(1), 52-58. https://www.nature.com/articles/nm0196-52

571.) Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., ... & Parkhurst, M. R. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nature medicine*, *4*(3), 321-327. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2064864/

572.) Colditz, G. A., Brewer, T. F., Berkey, C. S., Wilson, M. E., Burdick, E., Fineberg, H. V., & Mosteller, F. (1994). Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. *Jama*, *271*(9), 698-702. https://jamanetwork.com/journals/jama/article-abstract/366365

573.) Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., ... & Weinberg, A. (2005). A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *New England Journal of Medicine*, *352*(22), 2271-2284. https://www.nejm.org/doi/full/10.1056/NEJMoa051016

574.) Mulpuru, S., Li, L., Ye, L., Hatchette, T., Andrew, M. K., Ambrose, A., ... & ElSherif, M. (2019). Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD. *Chest*, *155*(1), 69-78. https://journal.chestnet.org/article/S0012-3692(18)32725-9/fulltext

575.) Modin, D., Jørgensen, M. E., Gislason, G., Jensen, J. S., Køber, L., Claggett, B., ... & Biering-Sørensen, T. (2019). Influenza vaccine in heart failure: cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. *Circulation*, *139*(5), 575-586. https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.036788 & https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036788

576.) Tapia, M. D., Sow, S. O., Tamboura, B., Tégueté, I., Pasetti, M. F., Kodio, M., ... & Traoré, A. (2016). Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. *The Lancet infectious diseases*, *16*(9), 1026-1035.

https://www.sciencedirect.com/science/article/pii/S1473309916300548

577.) Shay, D. K., Chillarige, Y., Kelman, J., Forshee, R. A., Foppa, I. M., Wernecke, M., ... & Worrall, C. (2017). Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US medicare beneficiaries in preventing postinfluenza deaths during 2012–2013 and 2013–2014. *The Journal of infectious diseases*, *215*(4), 510-517. https://academic.oup.com/jid/article/215/4/510/3058746

578.) Steinhoff, M. C., Katz, J., Englund, J. A., Khatry, S. K., Shrestha, L., Kuypers, J., ... & Kozuki, N. (2017). Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. *The Lancet infectious diseases*, *17*(9), 981-989. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2817%2930252-9/fulltext

579.) Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., ... & Connor, K. (2000). Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. *Nature*, *408*(6815), 982-985. https://www.nature.com/articles/35050116

580.) Chang, M. H., Chen, C. J., Lai, M. S., Hsu, H. M., Wu, T. C., Kong, M. S., ... & Chen, D. S. (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. *New England Journal of Medicine*, *336*(26), 1855-1859. https://www.nejm.org/doi/full/10.1056/NEJM199706263362602

581.) Vesikari, T., Matson, D. O., Dennehy, P., Van Damme, P., Santosham, M., Rodriguez, Z., ... & Shinefield, H. R. (2006). Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. *New England Journal of Medicine*, *354*(1), 23-33. https://www.nejm.org/doi/full/10.1056/nejmoa052664

582.) Ruiz-Palacios, G. M., Pérez-Schael, I., Velázquez, F. R., Abate, H., Breuer, T., Clemens, S. C., ... & Cervantes, Y. (2006). Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. *New England Journal of Medicine*, *354*(1), 11-22. https://www.nejm.org/doi/full/10.1056/nejmoa052434

583.) Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., ... & Jansen, K. U. (2002). A controlled trial of a human papillomavirus type 16 vaccine. *New England Journal of Medicine*, *347*(21), 1645-1651. https://www.nejm.org/doi/full/10.1056/NEJMoa020586

584.) Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., ... & Skjeldestad, F. E. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and

18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. *The lancet oncology*, *6*(5), 271-278. https://www.sciencedirect.com/science/article/abs/pii/S1470204505701017

585.) Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., ... & de Carvalho, N. S. (2007). Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. *The Lancet*, *369*(9580), 2161-2170. https://www.sciencedirect.com/science/article/abs/pii/S0140673607609465

586.) Paterson, M. J., Caldera, J. R., Nguyen, C., Sharma, P., Castro, A. M., Kolar, S. L., ... & Liu, G. Y. (2020). Harnessing antifungal immunity in pursuit of a Staphylococcus aureus vaccine strategy. *PLoS Pathogens*, *16*(8), e1008733-e1008733. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446838/

587.) Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., ... & Taddeo, F. J. (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *New England Journal of Medicine*, *356*(19), 1928-1943. https://www.nejm.org/doi/full/10.1056/nejmoa061760

588.) Villa, L. L., Perez, G., Kjaer, S. K., Paavonen, J., Lehtinen, M., Munoz, N., ... & Garcia, P. (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *New England Journal of Medicine*, *356*(19), 1915-1927. https://www.nejm.org/doi/full/10.1056/nejmoa061741

589.) Kjaer, S. K., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., ... & Ault, K. A. (2009). A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. *Cancer prevention research*, *2*(10), 868-878. https://cancerpreventionresearch.aacrjournals.org/content/2/10/868.full

590.) Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., ... & Roteli-Martins, C. M. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *The lancet*, *364*(9447), 1757-1765. https://www.sciencedirect.com/science/article/abs/pii/S0140673604173984

591.) Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., ... & Amigorena, S. (1998). Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell

derived exosomes. *Nature medicine*, *4*(5), 594-600. https://www.nature.com/articles/nm0598-594#Abs1

592.) Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Eerola, M., Haapakoski, J., ... & Kohberger, R. (2001). Efficacy of a pneumococcal conjugate vaccine against acute otitis media. *New England Journal of Medicine*, *344*(6), 403-409. https://www.nejm.org/doi/full/10.1056/nejm200102083440602

593.) Donnelly, J. J., Ulmer, J. B., Shiver, J. W., & Liu, M. A. (1997). DNA vaccines. *Annual review of immunology*, *15*(1), 617-648. https://www.annualreviews.org/doi/abs/10.1146/annurev.immunol.15.1.617?journalCode=immunol

594.) Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., ... & Bröcker, E. B. (1999). Vaccination with mage-3A1 peptide–pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *The Journal of experimental medicine*, *190*(11), 1669-1678. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2195739/

595.) Daniel, M. D., Kirchhoff, F., Czajak, S. C., Sehgal, P. K., & Desrosiers, R. C. (1992). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. *Science*, *258*(5090), 1938-1941. https://science.sciencemag.org/content/258/5090/1938.abstract

596.) Paavonen, J., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S. N., Apter, D., ... & Hedrick, J. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *The Lancet*, *374*(9686), 301-314. https://www.sciencedirect.com/science/article/abs/pii/S0140673609612484

597.) Mendelman, P. M., Cordova, J., & Cho, I. (2001). Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. *Vaccine*, *19*(17-19), 2221-2226. https://www.sciencedirect.com/science/article/pii/S0264410X00004497

598.) King, G. E., Markowitz, L. E., Patriarca, P. A., & Dales, L. G. (1991). Clinical efficacy of measles vaccine during the 1990 measles epidemic. *The Pediatric infectious disease journal*, *10*(12), 883-888. https://europepmc.org/article/med/1766702 & https://sci-hub.do/10.1097/00006454-199112000-00001

599.) Bridges, C. B., Thompson, W. W., Meltzer, M. I., Reeve, G. R., Talamonti, W. J., Cox, N. J., ... & Fukuda, K. (2000). Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. *Jama*, *284*(13), 1655-1663. https://jamanetwork.com/journals/jama/article-abstract/193139

600.) Peto, T. J., Mendy, M. E., Lowe, Y., Webb, E. L., Whittle, H. C., & Hall, A. J. (2014). Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program. *BMC infectious diseases*, *14*(1), 7. https://link.springer.com/article/10.1186/1471-2334-14-7

601.) Sims, R. V., Steinmann, W. C., McConville, J. H., King, L. R., Zwick, W. C., & Schwartz, J. S. (1988). The clinical effectiveness of pneumococcal vaccine in the elderly. *Annals of Internal Medicine*, *108*(5), 653-657. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.955.2298&rep=rep1&type=pdf

602.) Nichol, K. L. (2003). The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. *Vaccine*, *21*(16), 1769-1775. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.564.186&rep=rep1&type=pdf

603.) Vu, T., Farish, S., Jenkins, M., & Kelly, H. (2002). A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. *Vaccine*, *20*(13-14), 1831-1836. https://www.sciencedirect.com/science/article/pii/S0264410X02000415

604.) Maciosek, M. V., Solberg, L. I., Coffield, A. B., Edwards, N. M., & Goodman, M. J. (2006). Influenza vaccination: health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. *American journal of preventive medicine*, *31*(1), 72-79. https://www.sciencedirect.com/science/article/abs/pii/S0749379706001206

605.) Lugauer, S., Heininger, U., Cherry, J. D., & Stehr, K. (2002). Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. *European journal of pediatrics*, *161*(3), 142-146. https://link.springer.com/article/10.1007%2Fs00431-001-0893-5 & https://sci-hub.do/https://doi.org/10.1007/s00431-001-0893-5

606.) Bisgard, K. M., Rhodes, P., Connelly, B. L., Bi, D., Hahn, C., Patrick, S., ... & Ehresmann, K. R. (2005). Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998–2001. *Pediatrics*, *116*(2), e285-e294.

https://www.researchgate.net/profile/Kris_Bisgard/publication/7685486_Pertussis_Vaccine_Effectiveness_Among_Children_6_to_59_Months_of_Age_in_the_United_States_1998-2001/links/5674267008ae125516e09a53/Pertussis-Vaccine-Effectiveness-Among-Children-6-to-59-Months-of-Age-in-the-United-States-1998-2001.pdf

607.) Salmaso, S., Mastrantonio, P., Tozzi, A. E., Stefanelli, P., Anemona, A., degli Atti, M. L. C., ... & Stage III Working Group. (2001). Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. *Pediatrics*, *108*(5), e81-e81. https://pediatrics.aappublications.org/content/108/5/e81.short

608.) Levine, M. M., Ferreccio, C., Abrego, P., San Martin, O., Ortiz, E., & Cryz, S. (1999). Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. *Vaccine*, *17*, S22-S27. https://www.sciencedirect.com/science/article/pii/S0264410X99002315

609.) Yu, X. Y., Chen, Z. P., Wang, S. Y., Pan, H. R., Wang, Z. F., Zhang, Q. F., ... & Huang, S. J. (2019). Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years. *Vaccine*, *37*(32), 4581-4586. https://www.sciencedirect.com/science/article/pii/S0264410X1930444X

610.) Préziosi, M. P., & Halloran, M. E. (2003). Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. *Vaccine*, *21*(17-18), 1853-1861. https://pubmed.ncbi.nlm.nih.gov/12706669/

611.) Préziosi, M. P., & Halloran, M. E. (2003). Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. *Clinical infectious diseases*, *37*(6), 772-779. http://courses.washington.edu/b578a/readings/PreziosiHalloran2003a.pdf

612.) Olsson, S. E., Kjaer, S. K., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., Wheeler, C. M., ... & García, P. (2009). Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. *Human vaccines*, *5*(10), 696-704. https://www.tandfonline.com/doi/pdf/10.4161/hv.5.10.9515

613.) Vessey, S. R., Chan, C. Y., Kuter, B. J., Kaplan, K. M., Waters, M., Kutzler, D. P., ... & Li, S. (2001). Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. *The Journal of pediatrics*, *139*(2), 297-304. https://www.sciencedirect.com/science/article/abs/pii/S0022347601445586

614.) Manzoli, L., Schioppa, F., Boccia, A., & Villari, P. (2007). The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. *The Pediatric infectious disease journal*, *26*(2), 97-106. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.319.5548&rep=rep1&type=pdf

615.) Snelling, T. L., Schultz, R., Graham, J., Roseby, R., Barnes, G. L., Andrews, R. M., & Carapetis, J. R. (2009). Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. *Clinical infectious diseases*, *49*(3), 428-431. https://academic.oup.com/cid/article/49/3/428/498586

616.) van Boven, M., Kretzschmar, M., Wallinga, J., O'Neill, P. D., Wichmann, O., & Hahné, S. (2010). Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population. *Journal of the Royal Society Interface*, *7*(52), 1537-1544. https://royalsocietypublishing.org/doi/pdf/10.1098/rsif.2010.0086

617.) van Boven, M., Ruijs, W. L., Wallinga, J., O'Neill, P. D., & Hahne, S. (2013). Estimation of vaccine efficacy and critical vaccination coverage in partially observed outbreaks. *PLoS Comput Biol*, *9*(5), e1003061. https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1003061

618.) Van de Velde, N., Brisson, M., & Boily, M. C. (2007). Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. *American journal of epidemiology*, *165*(7), 762-775. https://academic.oup.com/aje/article/165/7/762/158234

619.) Lagos, R., Horwitz, I., Toro, J., San Martin, O., Abrego, P., Bustamante, C., ... & Levine, M. M. (1996). Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. *The Pediatric infectious disease journal*, *15*(3), 216-222. https://journals.lww.com/pidj/Abstract/1996/03000/Large_scale,_postlicensure,_selective_vaccination.8.aspx

620.) Joura, E. A., Leodolter, S., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., ... & Steben, M. (2007). Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. *The Lancet*, *369*(9574), 1693-1702. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.629.2073&rep=rep1&type=pdf

621.) Conaty, S., Watson, L., Dinnes, J., & Waugh, N. (2004). The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies

and comparison with results from randomised controlled trials. *Vaccine*, *22*(23-24), 3214-3224. https://pubmed.ncbi.nlm.nih.gov/15297076/

622.) Sullivan, K. M., Halpin, T. J., Marks, J. S., & Kim-Farley, R. (1985). Effectiveness of mumps vaccine in a school outbreak. *American Journal of Diseases of Children*, *139*(9), 909-912. https://jamanetwork.com/journals/jamapediatrics/article-abstract/512361

623.) Backer, J. A., Wallinga, J., Meijer, A., Donker, G. A., Van der Hoek, W., & Van Boven, M. (2019). The impact of influenza vaccination on infection, hospitalisation and mortality in the Netherlands between 2003 and 2015. *Epidemics*, *26*, 77-85. https://www.sciencedirect.com/science/article/pii/S1755436517301895

624.) Fry, A. M., Kim, I. K., Reed, C., Thompson, M., Chaves, S. S., Finelli, L., & Bresee, J. (2014). Modeling the effect of different vaccine effectiveness estimates on the number of vaccine-prevented influenza-associated hospitalizations in older adults. *Clin Infect Dis*, *59*(3), 406-9. https://www.researchgate.net/profile/Inkyu_Kim/publication/262111962_Modeling_the_Effect_of_Different_Vaccine_Effectiveness_Estimates_on_the_Number_of_Vaccine-Prevented_Influenza-Associated_Hospitalizations_in_Older_Adults/links/0deec53c9698e9b43e000000.pdf

625.) Jackson, M. L., Jackson, L. A., Kieke, B., McClure, D., Gaglani, M., Murthy, K., ... & Flannery, B. (2015). Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. *Vaccine*, *33*(39), 5181-5187. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843472/

626.) Arinaminpathy, N., Kim, I. K., Gargiullo, P., Haber, M., Foppa, I. M., Gambhir, M., & Bresee, J. (2017). Estimating direct and indirect protective effect of influenza vaccination in the United States. *American journal of epidemiology*, *186*(1), 92-100. https://academic.oup.com/aje/article/186/1/92/3089949

627.) Jackson, M. L., Phillips, C. H., Benoit, J., Jackson, L. A., Gaglani, M., Murthy, K., ... & Flannery, B. (2018). Burden of medically attended influenza infection and cases averted by vaccination–United States, 2013/14 through 2015/16 influenza seasons. *Vaccine*, *36*(4), 467-472. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843364/

628.) Sur, D., Ochiai, R. L., Bhattacharya, S. K., Ganguly, N. K., Ali, M., Manna, B., ... & Puri, M. K. (2009). A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. *New England Journal of Medicine*, *361*(4), 335-344. https://www.nejm.org/doi/full/10.1056/nejmoa0807521

629.) Palmu, A. A., Jokinen, J., Borys, D., Nieminen, H., Ruokokoski, E., Siira, L., ... & Schuerman, L. (2013). Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. *The Lancet*, *381*(9862), 214-222. https://www.sciencedirect.com/science/article/abs/pii/S0140673612618546

630.) Palmu, A. A., Jokinen, J., Nieminen, H., Syrjänen, R., Ruokokoski, E., Puumalainen, T., ... & Kilpi, T. M. (2014). Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. *The Lancet Respiratory Medicine*, *2*(9), 717-727. https://core.ac.uk/download/pdf/33454644.pdf

631.) Hayward, A., Harling, R., Wetten, S., Johnson, A., Munro, S., Smedley, J., ... & Watson, J. (2006). Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. *Bmj*, *333*(7581), 1241-1246. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1702427/

632.) Black, S. B., Shinefield, H. R., Ling, S., Hansen, J., Fireman, B., Spring, D., ... & Hackell, J. (2002). Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. *The Pediatric infectious disease journal*, *21*(9), 810-815. https://journals.lww.com/pidj/Abstract/2002/09000/Effectiveness_of_heptavalent_pneumococcal.5.aspx

633.) Whitney, C. G., Pilishvili, T., Farley, M. M., Schaffner, W., Craig, A. S., Lynfield, R., ... & Reingold, A. (2006). Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. *The Lancet*, *368*(9546), 1495-1502. https://www.sciencedirect.com/science/article/abs/pii/S0140673606696372

634.) Pilishvili, T., Lexau, C., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., ... & Smith, P. J. (2010). Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. *The Journal of infectious diseases*, *201*(1), 32-41. https://academic.oup.com/jid/article/201/1/32/872151

635.) Shapiro, E. D., Berg, A. T., Austrian, R., Schroeder, D., Parcells, V., Margolis, A., ... & Clemens, J. D. (1991). The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. *New England Journal of Medicine*, *325*(21), 1453-1460. https://www.nejm.org/doi/full/10.1056/NEJM199111213252101

636.) Boom, J. A., Tate, J. E., Sahni, L. C., Rench, M. A., Hull, J. J., Gentsch, J. R., ... & Parashar, U. D. (2010). Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. *Pediatrics*, *125*(2), e199-e207. https://pediatrics.aappublications.org/content/125/2/e199.short

637.) Wang, F. T., Mast, T. C., Glass, R. J., Loughlin, J., & Seeger, J. D. (2010). Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. *Pediatrics*, *125*(2), e208-e213. https://pediatrics.aappublications.org/content/125/2/e208.short

638.) Boom, J. A., Tate, J. E., Sahni, L. C., Rench, M. A., Quaye, O., Mijatovic-Rustempasic, S., ... & Parashar, U. D. (2010). Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. *The Pediatric infectious disease journal*, *29*(12), 1133-1135. https://journals.lww.com/pidj/fulltext/2010/12000/SUSTAINED_PROTECTION_FROM_PENTAVALENT_ROTAVIRUS.16.aspx

639.) Tate, J. E., Panozzo, C. A., Payne, D. C., Patel, M. M., Cortese, M. M., Fowlkes, A. L., & Parashar, U. D. (2009). Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. *Pediatrics*, *124*(2), 465-471. https://www.researchgate.net/profile/Ashley_Fowlkes/publication/26651080_Decline_and_Change_in_Seasonality_of_US_Rotavirus_Activity_After_the_Introduction_of_Rotavirus_Vaccine/links/57a3480c08aef3c1a7b4b34d/Decline-and-Change-in-Seasonality-of-US-Rotavirus-Activity-After-the-Introduction-of-Rotavirus-Vaccine.pdf

640.) Desai, S. N., Esposito, D. B., Shapiro, E. D., Dennehy, P. H., & Vázquez, M. (2010). Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. *Vaccine*, *28*(47), 7501-7506. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127692/

641.) Braeckman, T., Van, K. H., Meyer, N., Pirçon, J. Y., Soriano-Gabarró, M., Heylen, E., ... & Van, P. D. (2012). Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. *BMJ (Clinical research ed.)*, *345*, e4752. https://www.bmj.com/content/345/bmj.e4752.short

642.) Field, E. J., Vally, H., Grimwood, K., & Lambert, S. B. (2010). Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. *Pediatrics*, *126*(3), e506-e512. https://research-repository.griffith.edu.au/bitstream/handle/10072/60164/93564_1.pdf?sequence=1

643.) de Palma, O., Cruz, L., Ramos, H., de Baires, A., Villatoro, N., Pastor, D., ... & Esposito, D. H. (2010). Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. *Bmj*, *340*, c2825. https://www.bmj.com/content/340/bmj.c2825.long

644.) Paulke-Korinek, M., Rendi-Wagner, P., Kundi, M., Kronik, R., & Kollaritsch, H. (2010). Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. *The Pediatric infectious disease journal*, *29*(4), 319-323. https://journals.lww.com/pidj/Abstract/2010/04000/Universal_Mass_Vaccination_Against_Rotavirus.9.aspx

645.) Buttery, J. P., Lambert, S. B., Grimwood, K., Nissen, M. D., Field, E. J., Macartney, K. K., ... & Kirkwood, C. D. (2011). Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. *The Pediatric infectious disease journal*, *30*(1), S25-S29. https://journals.lww.com/pidj/Fulltext/2011/01001/Reduction_in_Rotavirus_associated_Acute.6.aspx

646.) Tate, J. E., Mutuc, J. D., Panozzo, C. A., Payne, D. C., Cortese, M. M., Cortes, J. E., ... & Parashar, U. D. (2011). Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. *The Pediatric infectious disease journal*, *30*(1), S30-S34. https://journals.lww.com/pidj/fulltext/2011/01001/Sustained_Decline_in_Rotavirus_Detections_in_the.7.aspx

647.) Bégué, R. E., & Perrin, K. (2010). Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. *Pediatrics*, *126*(1), e40-e45. https://pediatrics.aappublications.org/content/126/1/e40.short

648.) Payne, D. C., Staat, M. A., Edwards, K. M., Szilagyi, P. G., Weinberg, G. A., Hall, C. B., ... & Lopman, B. A. (2011). Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006–2009. *Clinical Infectious Diseases*, *53*(3), 245-253. https://academic.oup.com/cid/article/53/3/245/289062

649.) Cortese, M. M., LeBlanc, J., White, K. E., Jerris, R. C., Stinchfield, P., Preston, K. L., ... & Buttery, V. (2011). Leveraging state immunization information systems to measure the effectiveness of rotavirus vaccine. *Pediatrics*, *128*(6), e1474-e1481. https://pediatrics.aappublications.org/content/128/6/e1474.short

650.) Chang, H. G. H., Smith, P. F., Tserenpuntsag, B., Markey, K., Parashar, U., & Morse, D. L. (2010). Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. *Vaccine*, *28*(3), 754-758. https://www.sciencedirect.com/science/article/pii/S0264410X09016053

651.) Cortes, J. E., Curns, A. T., Tate, J. E., Cortese, M. M., Patel, M. M., Zhou, F., & Parashar, U. D. (2011). Rotavirus vaccine and health care utilization for diarrhea in US children. *N Engl J Med*, *365*, 1108-1117. https://www.nejm.org/doi/full/10.1056/Nejmoa1000446

652.) Lambert, S. B., Faux, C. E., Hall, L., Birrell, F. A., Peterson, K. V., Selvey, C. E., ... & Grimwood, K. (2009). Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. *Medical journal of Australia*, *191*(3), 157-160. https://www.mja.com.au/system/files/issues/191_03_030809/lam10091_fm.pdf

653.) Cortese, M. M., Immergluck, L. C., Held, M., Jain, S., Chan, T., Grizas, A. P., ... & Gautam, R. (2013). Effectiveness of monovalent and pentavalent rotavirus vaccine. *Pediatrics*, *132*(1), e25-e33. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074617/

654.) Clark, H. F., Lawley, D., Mallette, L. A., DiNubile, M. J., & Hodinka, R. L. (2009). Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. *Clinical and Vaccine Immunology*, *16*(3), 382-386. https://cvi.asm.org/content/16/3/382.full

655.) Castilla, J., Beristain, X., Martínez-Artola, V., Navascués, A., Cenoz, M. G., Álvarez, N., ... & Barricarte, A. (2012). Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. *Vaccine*, *30*(3), 539-543. https://www.sciencedirect.com/science/article/pii/S0264410X11018676

656.) Vesikari, T., Karvonen, A., Prymula, R., Schuster, V., Tejedor, J. C., Cohen, R., ... & Bouckenooghe, A. (2007). Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. *The Lancet*, *370*(9601), 1757-1763. https://www.researchgate.net/profile/Javier_De_Aristegui/publication/299354901_Efficacy_of_human_rotavirus_vaccine_against_rotavirus_gastroenteritis_during_the_fi_rst_2_years_of_life_in_European_infants-_randomised_double-blind_controlled_study_Lancet_2007/links/56f1b2b508aee9c94cfd7206/Efficacy-of-human-rotavirus-vaccine-against-rotavirus-gastroenteritis-during-the-fi-rst-2-years-of-life-in-European-infants-randomised-double-blind-controlled-study-Lancet-2007.pdf

657.) Tate, J. E., Cortese, M. M., Payne, D. C., Curns, A. T., Yen, C., Esposito, D. H., ... & Parashar, U. D. (2011). Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. *The Pediatric infectious disease journal*, *30*(1), S56-S60. https://journals.lww.com/pidj/fulltext/2011/01001/Uptake,_Impact,_and_Effectiveness_of_Rotavirus.12.aspx

658.) Mast, T. C., Khawaja, S., Espinoza, F., Paniagua, M., Del Carmen, L. P., Cardellino, A., & Sánchez, E. (2011). Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. *The Pediatric infectious disease journal*, *30*(11), e209-e215. https://journals.lww.com/pidj/Abstract/2011/11000/Case_control_Study_of_the_Effectiveness_of.34.aspx

659.) Lopman, B. A., Curns, A. T., Yen, C., & Parashar, U. D. (2011). Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. *Journal of Infectious Diseases*, *204*(7), 980-986. https://academic.oup.com/jid/article/204/7/980/810889

660.) Justino, M. C. A., Linhares, A. C., Lanzieri, T. M., Miranda, Y., Mascarenhas, J. D. A. P., Abreu, E., ... & Meyer, N. (2011). Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil. *The Pediatric infectious disease journal*, *30*(5), 396-401. https://www.researchgate.net/profile/Eduardo_Ortega-Barria/publication/49676486_Effectiveness_of_the_Monovalent_G1P8_Human_Rotavirus_Vaccine_Against_Hospitalization_for_Severe_G2P4_Rotavirus_Gastroenteritis_in_Belem_Brazil/links/5b84730d92851c1e1236c617/Effectiveness-of-the-Monovalent-G1P8-Human-Rotavirus-Vaccine-Against-Hospitalization-for-Severe-G2P4-Rotavirus-Gastroenteritis-in-Belem-Brazil.pdf

661.) Vesikari, T., Karvonen, A., Ferrante, S. A., Kuter, B. J., & Ciarlet, M. (2010). Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. *The Pediatric infectious disease journal*, *29*(10), 957-963. https://journals.lww.com/pidj/Abstract/2010/10000/Sustained_Efficacy_of_the_Pentavalent_Rotavirus.14.aspx

662.) Armah, G. E., Sow, S. O., Breiman, R. F., Dallas, M. J., Tapia, M. D., Feikin, D. R., ... & Levine, M. M. (2010). Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised,

double-blind, placebo-controlled trial. *The Lancet*, *376*(9741), 606-614. https://www.sciencedirect.com/science/article/abs/pii/S0140673610608896

663.) Linhares, A. C., Velázquez, F. R., Pérez-Schael, I., Sáez-Llorens, X., Abate, H., Espinoza, F., ... & Rivera, L. (2008). Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. *The Lancet*, *371*(9619), 1181-1189. http://repositorio.uchile.cl/bitstream/handle/2250/128395/Linhares_Alexandre_C.pdf?sequence=1;Efficacy

664.) Yen, C., Tate, J. E., Wenk, J. D., Harris, J. M., & Parashar, U. D. (2011). Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. *Pediatrics*, *127*(1), e9-e15. https://pediatrics.aappublications.org/content/127/1/e9.short

665.) Cherry, J. D., & Zahn, M. (2018). Clinical characteristics of measles in previously vaccinated and unvaccinated patients in California. *Clinical Infectious Diseases*, *67*(9), 1315-1319. https://academic.oup.com/cid/article/67/9/1315/5034094

666.) Anekwe, T. D., Newell, M. L., Tanser, F., Pillay, D., & Bärnighausen, T. (2015). The causal effect of childhood measles vaccination on educational attainment: a mother fixed-effects study in rural South Africa. *Vaccine*, *33*(38), 5020-5026. https://www.sciencedirect.com/science/article/pii/S0264410X15005484

667.) Bester, J. C. (2016). Measles and measles vaccination: a review. *JAMA pediatrics*, *170*(12), 1209-1215. https://jamanetwork.com/journals/jamapediatrics/article-abstract/2555881

668.) Barrabeig, I., Rovira, A., Rius, C., Muñoz, P., Soldevila, N., Batalla, J., & Domínguez, À. (2011). Effectiveness of measles vaccination for control of exposed children. *The Pediatric infectious disease journal*, *30*(1), 78-80. https://journals.lww.com/pidj/fulltext/2011/01000/EFFECTIVENESS_OF_MEASLES_VACCINATION_FOR_CONTROL.22.aspx

669.) Ruuskanen, O., Salmi, T. T., & Halonen, P. (1978). Measles vaccination after exposure to natural measles. *The Journal of pediatrics*, *93*(1), 43-46. https://www.sciencedirect.com/science/article/abs/pii/S0022347678805976

670.) Phua, K. B., Lim, F. S., Lau, Y. L., Nelson, E. A. S., Huang, L. M., Quak, S. H., ... & Oostvogels, L. C. (2009). Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. *Vaccine*, *27*(43), 5936-5941. https://www.sciencedirect.com/science/article/pii/S0264410X0901127X

671.) do Carmo, G. M. I., Yen, C., Cortes, J., Siqueira, A. A., de Oliveira, W. K., Cortez-Escalante, J. J., ... & Patel, M. (2011). Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. *PLoS Med*, *8*(4), e1001024. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001024

672.) Shui, I. M., Baggs, J., Patel, M., Parashar, U. D., Rett, M., Belongia, E. A., ... & Weintraub, E. (2012). Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. *Jama*, *307*(6), 598-604. https://jamanetwork.com/journals/jama/article-abstract/1104957

673.) Farez, M. F., & Correale, J. (2011). Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. *Journal of neurology*, *258*(7), 1197-1206. https://www.researchgate.net/profile/Mauricio_Farez2/publication/50833219_Immunizations_and_risk_of_multiple_sclerosis_Systematic_review_and_meta-analysis/links/55f5ef0008ae6a34f66320fe.pdf

674.) Ascherio, A., Zhang, S. M., Hernán, M. A., Olek, M. J., Coplan, P. M., Brodovicz, K., & Walker, A. M. (2001). Hepatitis B vaccination and the risk of multiple sclerosis. *New England Journal of Medicine*, *344*(5), 327-332. https://www.nejm.org/doi/full/10.1056/nejm200102013440502

675.) Sadovnick, A. D., & Scheifele, D. W. (2000). School-based hepatitis B vaccination programme and adolescent multiple sclerosis. *The Lancet*, *355*(9203), 549-550. https://www.sciencedirect.com/science/article/abs/pii/S0140673699029918

676.) Mikaeloff, Y., Caridade, G., Rossier, M., Suissa, S., & Tardieu, M. (2007). Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. *Archives of pediatrics & adolescent medicine*, *161*(12), 1176-1182. https://jamanetwork.com/journals/jamapediatrics/article-abstract/571612

677.) DeStefano, F., Verstraeten, T., & Chen, R. T. (2002). Hepatitis B vaccine and risk of multiple sclerosis. *Expert review of vaccines*, *1*(4), 461-466. https://www.tandfonline.com/doi/abs/10.1586/14760584.1.4.461

678.) Monteyne, P., & André, F. E. (2000). Is there a causal link between hepatitis B vaccination and multiple sclerosis?. *Vaccine*, *18*(19), 1994-2001. https://www.sciencedirect.com/science/article/pii/S0264410X99005332

679.) Confavreux, C., Suissa, S., Saddier, P., Bourdès, V., & Vukusic, S. (2001). Vaccinations and the risk of relapse in multiple sclerosis. *New England journal of medicine*, *344*(5), 319-326. https://www.nejm.org/doi/full/10.1056/NEJM200102013440501

680.) DeStefano, F., Verstraeten, T., Jackson, L. A., Okoro, C. A., Benson, P., Black, S. B., ... & Chen, R. T. (2003). Vaccinations and risk of central nervous system demyelinating diseases in adults. *Archives of Neurology*, *60*(4), 504-509. https://jamanetwork.com/journals/jamaneurology/article-abstract/784047

681.) Martínez-Sernández, V., & Figueiras, A. (2013). Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. *Journal of neurology*, *260*(8), 1951-1959. https://link.springer.com/article/10.1007/s00415-012-6716-y

682.) Langer-Gould, A., Qian, L., Tartof, S. Y., Brara, S. M., Jacobsen, S. J., Beaber, B. E., ... & Tseng, H. F. (2014). Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. *JAMA neurology*, *71*(12), 1506-1513. https://jamanetwork.com/journals/jamaneurology/article-abstract/1917549

683.) Scheller, N. M., Svanström, H., Pasternak, B., Arnheim-Dahlström, L., Sundström, K., Fink, K., & Hviid, A. (2015). Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. *Jama*, *313*(1), 54-61. https://jamanetwork.com/journals/jama/article-abstract/2088853

684.) Jefferson, T., Rudin, M., & DiPietrantonj, C. (2003). Systematic review of the effects of pertussis vaccines in children. *Vaccine*, *21*(17-18), 2003-2014. https://www.sciencedirect.com/science/article/pii/S0264410X02007703

685.) Tamma, P. D., Ault, K. A., del Rio, C., Steinhoff, M. C., Halsey, N. A., & Omer, S. B. (2009). Safety of influenza vaccination during pregnancy. *American journal of obstetrics and gynecology*, *201*(6), 547-552. https://www.ajog.org/article/S0002-9378(09)01108-9/fulltext

686.) Macartney, K. K., Chiu, C., Georgousakis, M., & Brotherton, J. M. (2013). Safety of human papillomavirus vaccines: a review. *Drug safety*, *36*(6), 393-412. https://link.springer.com/article/10.1007/s40264-013-0039-5

687.) Principi, N., & Esposito, S. (2018). Aluminum in vaccines: Does it create a safety problem?. *Vaccine*, *36*(39), 5825-5831. https://www.sciencedirect.com/science/article/pii/S0264410X18311654

688.) Agorastos, T., Chatzigeorgiou, K., Brotherton, J. M., & Garland, S. M. (2009). Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. *Vaccine*, *27*(52), 7270-7281. https://www.sciencedirect.com/science/article/pii/S0264410X09014443

689.) Zuckerman, J. N. (2006). Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. *Journal of medical virology*, *78*(2), 169-177. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20524

690.) Kuno‐Sakai, H., & Kimura, M. (2004). Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. *Pediatrics international*, *46*(6), 650-655. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1442-200x.2004.01970.x

691.) Pellegrini, M., Nicolay, U., Lindert, K., Groth, N., & Della Cioppa, G. (2009). MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. *Vaccine*, *27*(49), 6959-6965. https://www.sciencedirect.com/science/article/pii/S0264410X09013103

692.) Seagroatt, V. (2005). MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. *Bmj*, *330*(7500), 1120-1121. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC557892/

693.) Arnold, W., Busch, R., Arnold, A., Ritscher, B., Neiss, A., & Niedermeyer, H. P. (2007). The influence of measles vaccination on the incidence of otosclerosis in Germany. *European archives of oto-rhino-laryngology*, *264*(7), 741-748. https://link.springer.com/article/10.1007%2Fs00405-007-0253-9#Sec5

694.) Balicer, R. D., Grotto, I., Mimouni, M., & Mimouni, D. (2007). Is childhood vaccination associated with asthma? A meta-analysis of observational studies. *Pediatrics*, *120*(5), e1269-e1277. https://pediatrics.aappublications.org/content/120/5/e1269.long

695.) Epoke, J., Eko, F., & Mboto, C. I. (1990). Vaccinated versus unvaccinated children: how they fare in first five years of life. *Tropical and geographical medicine*, *42*(2), 182-184. https://europepmc.org/article/med/2260220

696.) Sherrid, A. M., Ruck, C. E., Sutherland, D., Cai, B., & Kollmann, T. R. (2017). Lack of broad functional differences in immunity in fully vaccinated vs. unvaccinated children. *Pediatric Research*, *81*(4), 601-608.
https://www.nature.com/articles/pr2016272/

697.) Tozzi, A. E., Ravà, L., degli Atti, M. L. C., & Salmaso, S. (2003). Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. *Pediatrics*, *112*(5), 1069-1075.
https://pediatrics.aappublications.org/content/112/5/1069.short

698.) McNamara, L. A., Skoff, T., Faulkner, A., Miller, L., Kudish, K., Kenyon, C., ... & Briere, E. (2017). Reduced severity of pertussis in persons with age-appropriate pertussis vaccination—United States, 2010–2012. *Clinical Infectious Diseases*, *65*(5), 811-818.
https://academic.oup.com/cid/article/65/5/811/3939810

699.) Griffin, M. R., Monto, A. S., Belongia, E. A., Treanor, J. J., Chen, Q., Chen, J., ... & Petrie, J. G. (2011). Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 US communities. *PloS one*, *6*(8), e23085.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0023085

700.) Glanz, J. M., McClure, D. L., Magid, D. J., Daley, M. F., France, E. K., & Hambidge, S. J. (2010). Parental refusal of varicella vaccination and the associated risk of varicella infection in children. *Archives of pediatrics & adolescent medicine*, *164*(1), 66-70.
https://jamanetwork.com/journals/jamapediatrics/article-abstract/382631

701.) Orlíková, H., Malý, M., Lexová, P., Šebestová, H., Limberková, R., Jurzykowská, L., & Kynčl, J. (2016). Protective effect of vaccination against mumps complications, Czech Republic, 2007–2012. *BMC Public Health*, *16*(1), 293.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818515/

702.) Tessmer, A., Welte, T., Schmidt-Ott, R., Eberle, S., Barten, G., Suttorp, N., & Schaberg, T. (2011). Influenza vaccination is associated with reduced severity of community-acquired pneumonia. *European Respiratory Journal*, *38*(1), 147-153.
https://erj.ersjournals.com/content/38/1/147.full

703.) Vellozzi, C., Iqbal, S., Stewart, B., Tokars, J., & DeStefano, F. (2014). Cumulative risk of Guillain–Barré syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic. *American journal of public health*, *104*(4), 696-701.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025712/

704.) Kim, J., Bell, C., Sun, M., Kliewer, G., Xu, L., McInerney, M., ... & Yang, H. (2016). Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. *Cmaj*, *188*(12), E281-E288. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008954/

705.) Legge, A., Dodds, L., MacDonald, N. E., Scott, J., & McNeil, S. (2014). Rates and determinants of seasonal influenza vaccination in pregnancy and association with neonatal outcomes. *Cmaj*, *186*(4), E157-E164. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940592/

706.) Vaarala, O., Jokinen, J., Lahdenkari, M., & Leino, T. (2017). Rotavirus vaccination and the risk of celiac disease or type 1 diabetes in Finnish children at early life. *The Pediatric infectious disease journal*, *36*(7), 674-675. https://pubmed.ncbi.nlm.nih.gov/28399059/

707.) Bawankule, R., Singh, A., Kumar, K., & Shetye, S. (2017). Does measles vaccination reduce the risk of acute respiratory infection (ARI) and diarrhea in children: a multi-country study?. *PloS one*, *12*(1), e0169713. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226778/

708.) Schurink-Van't Klooster, T. M., de Ridder, M. A. J., Kemmeren, J. M., van der Lei, J., Dekker, F., Sturkenboom, M., & de Melker, H. E. (2015). Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands. *European journal of pediatrics*, *174*(5), 641-649. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412283/

709.) Schurink-Van't Klooster, T. M., Kemmeren, J. M., van der Maas, N. A. T., van de Putte, E. M., ter Wolbeek, M., Nijhof, S. L., ... & de Melker, H. E. (2018). No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls. *Vaccine*, *36*(45), 6796-6802. https://www.sciencedirect.com/science/article/pii/S0264410X18312684?via%3Dihub

710.) Griffin, J. B., Yu, L., Watson, D., Turner, N., Walls, T., Howe, A. S., ... & Petousis-Harris, H. (2018). Pertussis immunisation in pregnancy safety (PIPS) study: a retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. *Vaccine*, *36*(34), 5173-5179. https://www.sciencedirect.com/science/article/pii/S0264410X18309411?via%3Dihub

711.) Ray, P., Black, S., Shinefield, H., Dillon, A., Schwalbe, J., Holmes, S., ... & Wassilak, S. (1997). Risk of chronic arthropathy among women after rubella vaccination. *Jama*, *278*(7), 551-556. https://jamanetwork.com/journals/jama/article-abstract/417992

712.) Klein, N. P., Aukes, L., Lee, J., Fireman, B., Shapira, S. K., Slade, B., ... & Summar, M. (2011). Evaluation of immunization rates and safety among children with inborn errors of metabolism. *Pediatrics*, *127*(5), e1139-e1146. https://pediatrics.aappublications.org/content/127/5/e1139

713.) Klein, N. P., Lewis, E., Baxter, R., Weintraub, E., Glanz, J., Naleway, A., ... & Fireman, B. (2012). Measles-containing vaccines and febrile seizures in children age 4 to 6 years. *Pediatrics*, *129*(5), 809-814. https://pediatrics.aappublications.org/content/129/5/809

714.) Jefferson, T., Rudin, M., & Di Pietrantonj, C. (2004). Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. *The Lancet infectious diseases*, *4*(2), 84-90. https://www.sciencedirect.com/science/article/abs/pii/S1473309904009272

715.) Abraham, S., Juel, H. B., Bang, P., Cheeseman, H. M., Dohn, R. B., Cole, T., ... & McFarlane, L. R. (2019). Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. *The Lancet Infectious Diseases*, *19*(10), 1091-1100. https://www.sciencedirect.com/science/article/abs/pii/S1473309919302798

716.) Rivera, L., Pedersen, R. S., Peña, L., Olsen, K. J., Andreasen, L. V., Kromann, I., ... & Thierry-Carstensen, B. (2017). Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. *The Lancet Infectious Diseases*, *17*(7), 745-753. https://www.sciencedirect.com/science/article/pii/S1473309917301779

717.) Lin, J., Zhang, J., Dong, X., Fang, H., Chen, J., Su, N., ... & Yang, M. (2006). Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. *The Lancet*, *368*(9540), 991-997. https://www.sciencedirect.com/science/article/abs/pii/S0140673606692945

718.) Caldeira, D., Rodrigues, B., David, C., Costa, J., Pinto, F. J., & Ferreira, J. J. (2019). The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. *Expert review of vaccines*, *18*(11), 1211-1217. https://www.tandfonline.com/doi/abs/10.1080/14760584.2019.1690459

719.) Bresson, J. L., Perronne, C., Launay, O., Gerdil, C., Saville, M., Wood, J., ... & Zambon, M. C. (2006). Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. *The Lancet*, *367*(9523), 1657-1664. https://www.sciencedirect.com/science/article/abs/pii/S014067360668656X

720.) Lindblad, E. B. (2004). Aluminium adjuvants—in retrospect and prospect. *Vaccine*, *22*(27-28), 3658-3668. https://pubmed.ncbi.nlm.nih.gov/15315845/

721.) Vajo, Z., Tamas, F., Sinka, L., & Jankovics, I. (2010). Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial. *The Lancet*, *375*(9708), 49-55. https://www.researchgate.net/profile/Zoltan_Vajo/publication/40695731_Safety_and_immunogenicity_of_a_2009_pandemic_influenza_A_H1N1_vaccine_when_administered_alone_or_simultaneously_with_the_seasonal_influenza_vaccine_for_the_2009-10_influenza_season_A_multicentre_rando/links/5cee1bd5458515026a63993e/Safety-and-immunogenicity-of-a-2009-pandemic-influenza-A-H1N1-vaccine-when-administered-alone-or-simultaneously-with-the-seasonal-influenza-vaccine-for-the-2009-10-influenza-season-A-multicentre-rand.pdf

722.) Nolan, T. M., Richmond, P. C., Skeljo, M. V., Pearce, G., Hartel, G., Formica, N. T., ... & Basser, R. L. (2008). Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. *Vaccine*, *26*(33), 4160-4167. https://www.sciencedirect.com/science/article/pii/S0264410X08006920

723.) Madhi, S. A., Cutland, C. L., Jose, L., Koen, A., Govender, N., Wittke, F., ... & Narasimhan, V. (2016). Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. *The Lancet infectious diseases*, *16*(8), 923-934. https://www.sciencedirect.com/science/article/abs/pii/S1473309916001523

724.) Giannini, S. L., Hanon, E., Moris, P., Van Mechelen, M., Morel, S., Dessy, F., ... & Martin, M. T. (2006). Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. *Vaccine*, *24*(33-34), 5937-5949. https://www.sciencedirect.com/science/article/pii/S0264410X06007092

725.) Nolan, T., Richmond, P. C., Formica, N. T., Höschler, K., Skeljo, M. V., Stoney, T., ... & Ryan, D. (2008). Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. *Vaccine*, *26*(50), 6383-6391. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.497.2128&rep=rep1&type=pdf

726.) Torresi, J., McCarthy, K., Feroldi, E., & Méric, C. (2010). Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. *Vaccine*, *28*(50), 7993-8000. https://pubmed.ncbi.nlm.nih.gov/20934459/

727.) Gołoś, A., & Lutyńska, A. (2015). Aluminium-adjuvanted vaccines–a review of the current state of knowledge. *Przegl Epidemiol*, *69*(4), 731-4. http://www.przeglepidemiol.pzh.gov.pl/files/peissues/Przegl-Epidem-4-2015-z-okladka.pdf#page=71

728.) Blyth, C. C., Jacoby, P., Effler, P. V., Kelly, H., Smith, D. W., Borland, M. L., ... & Richmond, P. C. (2016). Influenza vaccine effectiveness and uptake in children at risk of severe disease. *The Pediatric infectious disease journal*, *35*(3), 309-315. http://saigaiin.sakura.ne.jp/sblo_files/saigaiin/image/Influenza_Vaccine_Effectiveness_and_Uptake_in.18.pdf

729.) McCullers, J. A., Van De Velde, L. A., Allison, K. J., Branum, K. C., Webby, R. J., & Flynn, P. M. (2010). Recipients of vaccine against the 1976 “swine flu” have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. *Clinical infectious diseases*, *50*(11), 1487-1492. https://academic.oup.com/cid/article/50/11/1487/506717

730.) Xie, H., Li, X., Gao, J., Lin, Z., Jing, X., Plant, E., ... & Ye, Z. (2011). Revisiting the 1976 “swine flu” vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice. *Clinical infectious diseases*, *53*(12), 1179-1187. https://academic.oup.com/cid/article/53/12/1179/400216

731.) Gonzalez, M., Pirez, M. C., Ward, E., Dibarboure, H., Garcia, A., & Picolet, H. (2000). Safety and immunogenicity of a paediatric presentation of an influenza vaccine. *Archives of disease in childhood*, *83*(6), 488-491. https://adc.bmj.com/content/83/6/488.full

732.) Lin, S. Y., Wu, E. T., Lin, C. H., Shyu, M. K., & Lee, C. N. (2013). The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan. *PLoS One*, *8*(6), e62983.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0062983

733.) Treanor, J. J., Schiff, G. M., Hayden, F. G., Brady, R. C., Hay, C. M., Meyer, A. L., ... & Cox, M. (2007). Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. *Jama*, *297*(14), 1577-1582. https://jamanetwork.com/journals/jama/article-abstract/206533

734.) Munoz, F. M., Greisinger, A. J., Wehmanen, O. A., Mouzoon, M. E., Hoyle, J. C., Smith, F. A., & Glezen, W. P. (2005). Safety of influenza vaccination during pregnancy. *American journal of obstetrics and gynecology*, *192*(4), 1098-1106. https://www.sciencedirect.com/science/article/abs/pii/S0002937804021027

735.) McMillan, M., Porritt, K., Kralik, D., Costi, L., & Marshall, H. (2015). Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. *Vaccine*, *33*(18), 2108-2117. https://www.sciencedirect.com/science/article/pii/S0264410X15002686

736.) Nunes, M. C., Aqil, A. R., Omer, S. B., & Madhi, S. A. (2016). The effects of influenza vaccination during pregnancy on birth outcomes: a systematic review and meta-analysis. *American journal of perinatology*, *33*(11), 1104-1114. https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0036-1586101

737.) Monto, A. S., Ohmit, S. E., Petrie, J. G., Johnson, E., Truscon, R., Teich, E., ... & Victor, J. C. (2009). Comparative efficacy of inactivated and live attenuated influenza vaccines. *New England Journal of Medicine*, *361*(13), 1260-1267. https://www.nejm.org/doi/full/10.1056/nejmoa0808652

738.) Ortiz, J. R., Englund, J. A., & Neuzil, K. M. (2011). Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. *Vaccine*, *29*(27), 4439-4452. https://www.sciencedirect.com/science/article/pii/S0264410X11005937

739.) Michiels, B., Govaerts, F., Remmen, R., Vermeire, E., & Coenen, S. (2011). A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. *Vaccine*, *29*(49), 9159-9170. https://www.sciencedirect.com/science/article/pii/S0264410X11012175

740.) Moro, P. L., Broder, K., Zheteyeva, Y., Walton, K., Rohan, P., Sutherland, A., ... & Vellozzi, C. (2011). Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event

Reporting System, 1990-2009. *American journal of obstetrics and gynecology*, *204*(2), *146.e1–146.e7.* https://www.sciencedirect.com/science/article/abs/pii/S0002937810011051

741.) Monath, T. P., Guirakhoo, F., Nichols, R., Yoksan, S., Schrader, R., Murphy, C., ... & Johnson, C. (2003). Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. *The Journal of infectious diseases*, *188*(8), 1213-1230. https://academic.oup.com/jid/article/188/8/1213/895814

742.) Giles, M. L., Krishnaswamy, S., Macartney, K., & Cheng, A. (2019). The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review. *Human vaccines & immunotherapeutics*, *15*(3), 687-699. https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1540807

743.) Sakala, I. G., Honda-Okubo, Y., Fung, J., & Petrovsky, N. (2016). Influenza immunization during pregnancy: Benefits for mother and infant. *Human vaccines & immunotherapeutics*, *12*(12), 3065-3071. https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1215392

744.) Steinhoff, M. C., Omer, S. B., Roy, E., El Arifeen, S., Raqib, R., Dodd, C., ... & Zaman, K. (2012). Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. *Cmaj*, *184*(6), 645-653. https://www.cmaj.ca/content/cmaj/184/6/645.full.pdf

745.) Källén, B., & Olausson, P. O. (2012). Vaccination against H1N1 influenza with Pandemrix® during pregnancy and delivery outcome: a Swedish register study. *BJOG: An International Journal of Obstetrics & Gynaecology*, *119*(13), 1583-1590. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/j.1471-0528.2012.03470.x

746.) Richards, J. L., Hansen, C., Bredfeldt, C., Bednarczyk, R. A., Steinhoff, M. C., Adjaye-Gbewonyo, D., ... & Omer, S. B. (2013). Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. *Clinical Infectious Diseases*, *56*(9), 1216-1222. https://academic.oup.com/cid/article/56/9/1216/294242

747.) Chambers, C. D., Johnson, D., Xu, R., Luo, Y., Louik, C., Mitchell, A. A., ... & OTIS Collaborative Research Group. (2013). Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. *Vaccine*, *31*(44), 5026-5032.

http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/About/H1N1_Vaccine_OTIS_final_2013.pdf

748.) Spada, E., Romanò, L., Tosti, M. E., Zuccaro, O., Paladini, S., Chironna, M., ... & Negrone, F. S. (2014). Hepatitis B immunity in teenagers vaccinated as infants: an Italian 17‐year follow‐up study. *Clinical Microbiology and Infection*, *20*(10), O680-O686. https://onlinelibrary.wiley.com/doi/full/10.1111/1469-0691.12591

749.) Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Crasta, P. D., Messier, M., & Hardt, K. (2013). Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. *Human vaccines & immunotherapeutics*, *9*(8), 1679-1684. https://www.tandfonline.com/doi/full/10.4161/hv.24844

750.) Ameratunga, R., Gillis, D., Gold, M., Linneberg, A., & Elwood, J. M. (2017). Evidence refuting the existence of autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA). *The Journal of Allergy and Clinical Immunology: In Practice*, *5*(6), 1551-1555. https://www.jaci-inpractice.org/action/showPdf?pii=S2213-2198%2817%2930517-2

751.) Phillips, A., Patel, C., Pillsbury, A., Brotherton, J., & Macartney, K. (2018). Safety of human papillomavirus vaccines: an updated review. *Drug safety*, *41*(4), 329-346. https://link.springer.com/article/10.1007/s40264-017-0625-z

752.) Van Der Meeren, O., Behre, U., & Crasta, P. (2016). Immunity to hepatitis B persists in adolescents 15–16 years of age vaccinated in infancy with three doses of hepatitis B vaccine. *Vaccine*, *34*(24), 2745-2749. https://www.sciencedirect.com/science/article/pii/S0264410X16301426

753.) Schillie, S. F., & Murphy, T. V. (2013). Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. *Vaccine*, *31*(21), 2506-2516. https://www.sciencedirect.com/science/article/pii/S0264410X12017653

754.) Kwong, J. C., Campitelli, M. A., Gubbay, J. B., Peci, A., Winter, A. L., Olsha, R., ... & Crowcroft, N. S. (2013). Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010–2011 season. *Clinical infectious diseases*, *57*(6), 820-827. https://academic.oup.com/cid/article/57/6/820/330306

755.) Cowling, B. J., Chan, K. H., Feng, S., Chan, E. L., Lo, J. Y., Peiris, J. M., & Chiu, S. S. (2014). The effectiveness of influenza vaccination in preventing hospitalizations in children in Hong Kong, 2009–2013. *Vaccine*, *32*(41), 5278-5284.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165553/

756.) Cowling, B. J., Ng, S., Ma, E. S., Fang, V. J., So, H. C., Wai, W., ... & Chiu, S. S. (2012). Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. *Clinical Infectious Diseases*, *55*(5), 695-702. https://academic.oup.com/cid/article/55/5/695/352104

757.) Sundaram, M. E., McClure, D. L., VanWormer, J. J., Friedrich, T. C., Meece, J. K., & Belongia, E. A. (2013). Influenza vaccination is not associated with detection of noninfluenza respiratory viruses in seasonal studies of influenza vaccine effectiveness. *Clinical infectious diseases*, *57*(6), 789-793. https://academic.oup.com/cid/article/57/6/789/329048

758.) Pierse, N., Kelly, H., Thompson, M. G., Bissielo, A., Radke, S., Huang, Q. S., ... & Turner, N. (2016). Influenza vaccine effectiveness for hospital and community patients using control groups with and without non-influenza respiratory viruses detected, Auckland, New Zealand 2014. *Vaccine*, *34*(4), 503-509. https://www.sciencedirect.com/science/article/pii/S0264410X15017673

759.) Nichol, K. L., Lind, A., Margolis, K. L., Murdoch, M., McFadden, R., Hauge, M., ... & Drake, M. (1995). The effectiveness of vaccination against influenza in healthy, working adults. *New England Journal of Medicine*, *333*(14), 889-893. https://www.nejm.org/doi/full/10.1056/NEJM199510053331401

760.) Kjaer, S. K., Nygård, M., Dillner, J., Brooke Marshall, J., Radley, D., Li, M., ... & Tryggvadottir, L. (2018). A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. *Clinical Infectious Diseases*, *66*(3), 339-345. https://academic.oup.com/cid/article/66/3/339/4283361

761.) Ochoa-Gondar, O., Vila-Corcoles, A., Rodriguez-Blanco, T., Gomez-Bertomeu, F., Figuerola-Massana, E., Raga-Luria, X., & Hospital-Guardiola, I. (2014). Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged≥ 60 years: 3 years of follow-up in the CAPAMIS study. *Clinical infectious diseases*, *58*(7), 909-917. https://academic.oup.com/cid/article/58/7/909/413020

762.) Vázquez, M., LaRussa, P. S., Gershon, A. A., Steinberg, S. P., Freudigman, K., & Shapiro, E. D. (2001). The effectiveness of the varicella vaccine in clinical practice. *New England Journal of Medicine*, *344*(13), 955-960. https://www.nejm.org/doi/full/10.1056/nejm200103293441302

763.) De Wals, P., Deceuninck, G., Lefebvre, B., Boulianne, N., & De Serres, G. (2011). Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. *The Pediatric infectious disease journal*, *30*(7), 566-569. https://journals.lww.com/pidj/Abstract/2011/07000/Effectiveness_of_Serogroup_C_Meningococcal.7.aspx

764.) Izurieta, H. S., Strebel, P. M., & Blake, P. A. (1997). Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. *Jama*, *278*(18), 1495-1499. https://jamanetwork.com/journals/jama/article-abstract/418876

765.) Black, S., Shinefield, H., Ray, P., Lewis, E., Hansen, J., Schwalbe, J., ... & Guess, H. (1999). Postmarketing evaluation of the safety and effectiveness of varicella vaccine. *The Pediatric infectious disease journal*, *18*(12), 1041-1046. https://journals.lww.com/pidj/Abstract/1999/12000/Postmarketing_evaluation_of_the_safety_and.3.aspx

766.) Baxter, R., Bartlett, J., Fireman, B., Lewis, E., & Klein, N. P. (2017). Effectiveness of vaccination during pregnancy to prevent infant pertussis. *Pediatrics*, *139*(5). e20164091 https://vaccines.org.il/images/a/a1/E20164091.full.pdf

767.) Jefferson, T., Smith, S., Demicheli, V., Harnden, A., Rivetti, A., & Di Pietrantonj, C. (2005). Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. *The lancet*, *365*(9461), 773-780. https://www.sciencedirect.com/science/article/abs/pii/S0140673605179847

768.) Leval, A., Herweijer, E., Ploner, A., Eloranta, S., Fridman Simard, J., Dillner, J., ... & Arnheim-Dahlström, L. (2013). Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. *Journal of the National Cancer Institute*, *105*(7), 469-474. https://academic.oup.com/jnci/article/105/7/469/912767

769.) Watson, B., Seward, J., Yang, A., Witte, P., Lutz, J., Chan, C., ... & Levenson, R. (2000). Postexposure effectiveness of varicella vaccine. *Pediatrics*, *105*(1), 84-88. https://pediatrics.aappublications.org/content/105/1/84

770.) Clements, D. A., Moreira, S. P., Coplan, P. M., Bland, C. L., & Walter, E. B. (1999). Postlicensure study of varicella vaccine effectiveness in a day-care setting. *The Pediatric infectious disease journal*, *18*(12), 1047-1050. https://journals.lww.com/pidj/Abstract/1999/12000/Postlicensure_study_of_varicella_vaccine.4.aspx

771.) Van Herck, K., Van Damme, P., Lievens, M., & Stoffel, M. (2004). Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. *Journal of medical virology*, *72*(2), 194-196. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10574

772.) Averhoff, F., Shapiro, C. N., Bell, B. P., Hyams, I., Burd, L., Deladisma, A., ... & Lundberg, M. (2001). Control of hepatitis A through routine vaccination of children. *Jama*, *286*(23), 2968-2973. https://jamanetwork.com/journals/jama/fullarticle/194479

773.) Ferreira, C. T., da Silveira, T. R., Vieira, S. M., Taniguchi, A., & Pereira-Lima, J. (2003). Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. *Journal of pediatric gastroenterology and nutrition*, *37*(3), 258-261. https://journals.lww.com/jpgn/Fulltext/2003/09000/The_Insulin_Like_Growth_Factor_Axis_in_Children.11.aspx

774.) Ashur, Y., Adler, R., Rowe, M., & Shouval, D. (1999). Comparison of immunogenicity of two hepatitis A vaccines—VAQTA® and HAVRIX®—in young adults. *Vaccine*, *17*(18), 2290-2296. https://www.sciencedirect.com/science/article/pii/S0264410X98004800

775.) Andrade, A. L., da Silva Vieira, M. A., Minamisava, R., Toscano, C. M., de Lima Souza, M. B., Fiaccadori, F., ... & Sartori, A. M. (2018). Single-dose varicella vaccine effectiveness in Brazil: A case-control study. *Vaccine*, *36*(4), 479-483. https://www.sciencedirect.com/science/article/pii/S0264410X17317516

776.) Woudenberg, T., van der Maas, N. A., Knol, M. J., de Melker, H., van Binnendijk, R. S., & Hahné, S. J. (2017). Effectiveness of early measles, mumps, and rubella vaccination among 6–14-month-old infants during an epidemic in the Netherlands: an observational cohort study. *The Journal of infectious diseases*, *215*(8), 1181-1187. https://academic.oup.com/jid/article/215/8/1181/3079109

777.) Rieck, T., Feig, M., an der Heiden, M., Siedler, A., & Wichmann, O. (2017). Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. *Eurosurveillance*, *22*(17), 30521. https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/22/17/eurosurv-22-30521-4.pdf?expires=1603500677&id=id&accname=guest&checksum=8C80766E905BACF39BC868B693B86A32

778.) Palefsky, J. M., Giuliano, A. R., Goldstone, S., Moreira Jr, E. D., Aranda, C., Jessen, H., ... & Marshall, J. B. (2011). HPV vaccine against anal HPV infection and anal intraepithelial

neoplasia. *New England Journal of Medicine*, *365*(17), 1576-1585. https://www.nejm.org/doi/full/10.1056/Nejmoa1010971

779.) Arciuolo, R. J., Jablonski, R. R., Zucker, J. R., & Rosen, J. B. (2017). Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting—New York City, 2013. *Clinical Infectious Diseases*, *65*(11), 1843-1847. https://academic.oup.com/cid/article/65/11/1843/4210618

780.) Ludvigsson, J. F., Ström, P., Lundholm, C., Cnattingius, S., Ekbom, A., Örtqvist, Å., ... & Stephansson, O. (2016). Risk for congenital malformation with H1N1 influenza vaccine: a cohort study with sibling analysis. *Annals of internal medicine*, *165*(12), 848-855. https://www.acpjournals.org/doi/full/10.7326/M16-0139

781.) Spinner, C., Ding, L., Bernstein, D. I., Brown, D., Franco, E. L., Covert, C., & Kahn, J. A. (2019). Human papillomavirus vaccine effectiveness and herd protection in young women. *Pediatrics*, *143*(2), e20181902. https://pediatrics.aappublications.org/content/143/2/e20181902

782.) Parikh, S. R., Andrews, N. J., Beebeejaun, K., Campbell, H., Ribeiro, S., Ward, C., ... & Ladhani, S. N. (2016). Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. *The Lancet*, *388*(10061), 2775-2782. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31921-3/fulltext?elsca1=etoc

783.) Belongia, E. A., Simpson, M. D., King, J. P., Sundaram, M. E., Kelley, N. S., Osterholm, M. T., & McLean, H. Q. (2016). Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. *The Lancet Infectious Diseases*, *16*(8), 942-951. https://www.sciencedirect.com/science/article/abs/pii/S1473309916001298

784.) Thompson, M. G., Kwong, J. C., Regan, A. K., Katz, M. A., Drews, S. J., Azziz-Baumgartner, E., ... & Simmonds, K. (2019). Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010–2016. *Clinical Infectious Diseases*, *68*(9), 1444-1453. https://academic.oup.com/cid/article/68/9/1444/5126390

785.) Kudo, R., Yamaguchi, M., Sekine, M., Adachi, S., Ueda, Y., Miyagi, E., ... & Enomoto, T. (2019). Bivalent human papillomavirus vaccine effectiveness in a Japanese population: high

vaccine-type–specific effectiveness and evidence of cross-protection. *The Journal of infectious diseases*, *219*(3), 382-390. https://academic.oup.com/jid/article/219/3/382/5115492

786.) Marin, M., Marti, M., Kambhampati, A., Jeram, S. M., & Seward, J. F. (2016). Global Varicella Vaccine Effectiveness: A Meta-analysis. *Pediatrics*, *137*(3), e20153741. https://pediatrics.aappublications.org/content/137/3/e20153741.full

787.) Azman, A. S., Parker, L. A., Rumunu, J., Tadesse, F., Grandesso, F., Deng, L. L., ... & Ontweka, L. (2016). Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. *The Lancet Global Health*, *4*(11), e856-e863. https://www.sciencedirect.com/science/article/pii/S2214109X1630211X

788.) Thompson, M. G., Pierse, N., Huang, Q. S., Prasad, N., Duque, J., Newbern, E. C., ... & McArthur, C. (2018). Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015. *Vaccine*, *36*(39), 5916-5925. https://www.sciencedirect.com/science/article/pii/S0264410X18309976

789.) Russell, K., Chung, J. R., Monto, A. S., Martin, E. T., Belongia, E. A., McLean, H. Q., ... & Jackson, M. L. (2018). Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. *Vaccine*, *36*(10), 1272-1278. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812289/

790.) Poehling, K. A., Caspard, H., Peters, T. R., Belongia, E. A., Congeni, B., Gaglani, M., ... & Naleway, A. L. (2018). 2015–2016 vaccine effectiveness of live attenuated and inactivated influenza vaccines in children in the United States. *Clinical Infectious Diseases*, *66*(5), 665-672. https://academic.oup.com/cid/article/66/5/665/4344919

791.) Woestenberg, P. J., King, A. J., Van Benthem, B. H., Donken, R., Leussink, S., Van Der Klis, F. R., ... & Bogaards, J. A. (2018). Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors. *The Journal of infectious diseases*, *217*(2), 213-222. https://academic.oup.com/jid/article/217/2/213/4617853

792.) Kuter, B., Matthews, H., Shinefield, H., Black, S., Dennehy, P., Watson, B., ... & Chan, I. (2004). Ten year follow-up of healthy children who received one or two injections of varicella vaccine. *The Pediatric infectious disease journal*, *23*(2), 132-137.

https://journals.lww.com/pidj/Abstract/2004/02000/Ten_year_follow_up_of_healthy_children_who.9.aspx

793.) Shapiro, E. D., Vazquez, M., Esposito, D., Holabird, N., Steinberg, S. P., Dziura, J., ... & Gershon, A. A. (2011). Effectiveness of 2 doses of varicella vaccine in children. *Journal of Infectious Diseases*, *203*(3), 312-315. https://academic.oup.com/jid/article/203/3/312/2192149

794.) Seward, J. F., Marin, M., & Vázquez, M. (2008). Varicella vaccine effectiveness in the US vaccination program: a review. *The Journal of infectious diseases*, *197*(Supplement_2), S82-S89. https://academic.oup.com/jid/article/197/Supplement_2/S82/849104

795.) Larrauri, A., Cano, R., García, M., & De Mateo, S. (2005). Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. *Vaccine*, *23*(32), 4097-4100. https://www.sciencedirect.com/science/article/pii/S0264410X05004032

796.) Monto, A. S., Hornbuckle, K., & Ohmit, S. E. (2001). Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. *American Journal of Epidemiology*, *154*(2), 155-160. https://academic.oup.com/aje/article/154/2/155/80515

797.) Kelly, H., Carville, K., Grant, K., Jacoby, P., Tran, T., & Barr, I. (2009). Estimation of influenza vaccine effectiveness from routine surveillance data. *PLoS One*, *4*(3), e5079. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005079

798.) Zaman, K., Roy, E., Arifeen, S. E., Rahman, M., Raqib, R., Wilson, E., ... & Steinhoff, M. C. (2008). Effectiveness of maternal influenza immunization in mothers and infants. New England Journal of Medicine, 359(15), 1555-1564. https://www.nejm.org/doi/full/10.1056/NEJMoa0708630

799.) Shuler, C. M., Iwamoto, M., Bridges, C. B., Marin, M., Neeman, R., Gargiullo, P., ... & Terebuh, P. D. (2007). Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003–2004. *Pediatrics*, *119*(3), e587-e595. https://pediatrics.aappublications.org/content/119/3/e587.short

800.) Allison, M. A., Daley, M. F., Crane, L. A., Barrow, J., Beaty, B. L., Allred, N., ... & Kempe, A. (2006). Influenza vaccine effectiveness in healthy 6-to 21-month-old children during the 2003-2004 season. *The Journal of pediatrics*, *149*(6), 755-762. https://www.sciencedirect.com/science/article/abs/pii/S0022347606005786

801.) Eisenberg, K. W., Szilagyi, P. G., Fairbrother, G., Griffin, M. R., Staat, M., Shone, L. P., ... & Lofthus, G. (2008). Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003–2004 and 2004–2005 influenza seasons. *Pediatrics*, *122*(5), 911-919. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695734/

802.) Ahmed, A. H., Nicholson, K. G., Nguyen-van Tam, J. S., & Pearson, J. C. G. (1997). Effectiveness of influenza vaccine in reducing hospital admissions during the 1989–90 epidemic. Epidemiology & Infection, 118(1), 27-33. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808769/pdf/9042032.pdf

803.) Juretzko, P., Von Kries, R., Hermann, M., von König, C. W., Weil, J., & Giani, G. (2002). Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. *Clinical infectious diseases*, *35*(2), 162-167. https://academic.oup.com/cid/article/35/2/162/398201

804.) Hennessy, S., Strom, B. L., Bilker, W. B., Zhengle, L., Chao-Min, W., Hui-Lian, L., ... & Karabatsos, N. (1996). Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. *The Lancet*, *347*(9015), 1583-1586. https://www.sciencedirect.com/science/article/abs/pii/S0140673696910752

805.) Glanz, J. M., Newcomer, S. R., Daley, M. F., DeStefano, F., Groom, H. C., Jackson, M. L., ... & Nordin, J. D. (2018). Association between estimated cumulative vaccine antigen exposure through the first 23 months of life and non–vaccine-targeted infections from 24 through 47 months of age. *Jama*, *319*(9), 906-913. https://jamanetwork.com/journals/jama/article-abstract/2673970

806.) Karwowski, M. P., Stamoulis, C., Wenren, L. M., Faboyede, G. M., Quinn, N., Gura, K. M., ... & Woolf, A. D. (2018). Blood and hair aluminum levels, vaccine history, and early infant development: a cross-sectional study. *Academic pediatrics*, *18*(2), 161-165. http://vaccinepapers.org/wp-content/uploads/Blood-and-Hair-Aluminum-Levels-Vaccine-History-and-Early-Infant-Development-A-Cross-Sectional-Study.pdf

807.) Shimabukuro, T. T., Su, J. R., Marquez, P. L., Mba-Jonas, A., Arana, J. E., & Cano, M. V. (2019). Safety of the 9-valent human papillomavirus vaccine. *Pediatrics*, *144*(6), e20191791. https://pediatrics.aappublications.org/content/144/6/e20191791

808.) Ofori-Anyinam, O., Leroux-Roels, G., Drame, M., Aerssens, A., Maes, C., Amanullah, A., ... & Innis, B. L. (2017). Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate

administration, in adults≥ 50 years of age: results from a phase III, randomized, non-inferiority trial. *Vaccine*, *35*(46), 6321-6328. https://www.sciencedirect.com/science/article/pii/S0264410X17312288

809.) Grimaldi-Bensouda, L., Rossignol, M., Kone-Paut, I., Krivitzky, A., Lebrun-Frenay, C., Clet, J., ... & Fain, O. (2017). Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. *Journal of autoimmunity*, *79*, 84-90. https://www.sciencedirect.com/science/article/pii/S0896841116302141

810.) Garland, S. M., Brotherton, J. M. L., Moscicki, A. B., Kaufmann, A. M., Stanley, M., Bhatla, N., ... & Palefsky, J. M. (2017). HPV vaccination of immunocompromised hosts. *Papillomavirus Research*, *4*, 35-38. https://www.sciencedirect.com/science/article/pii/S2405852117300253

811.) Mouchet, J., Salvo, F., Raschi, E., Poluzzi, E., Antonazzo, I. C., De Ponti, F., & Begaud, B. (2018). Human papillomavirus vaccine and demyelinating diseases—A systematic review and meta-analysis. *Pharmacological research*, *132*, 108-118. https://www.sciencedirect.com/science/article/abs/pii/S1043661818302883

812.) Principi, N., & Esposito, S. (2019). Vaccine-preventable diseases, vaccines and Guillain-Barre'syndrome. *Vaccine*, *37*(37), 5544-5550. https://www.gbs-cidp.org/wp-content/uploads/2018/06/2018-Vaccines-and-GBS-Vaccine-218-epub.pdf & https://sci-hub.se/https://doi.org/10.1016/j.vaccine.2018.05.119

813.) Hapfelmeier, A., Gasperi, C., Donnachie, E., & Hemmer, B. (2019). A large case-control study on vaccination as risk factor for multiple sclerosis. *Neurology*, *93*(9), e908-e916. https://n.neurology.org/content/93/9/e908.abstract

814.) Deceuninck, G., Sauvageau, C., Gilca, V., Boulianne, N., & De Serres, G. (2018). Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine. *Expert review of vaccines*, *17*(1), 99-102. https://www.tandfonline.com/doi/abs/10.1080/14760584.2018.1388168

815.) Jiang, H. Y., Shi, Y. D., Zhang, X., Pan, L. Y., Xie, Y. R., Jiang, C. M., ... & Ruan, B. (2019). Human papillomavirus vaccination and the risk of autoimmune disorders: a systematic review and meta-analysis. *Vaccine*, *37*(23), 3031-3039. https://www.researchgate.net/profile/Hai_Yin_Jiang/publication/332669182_Human_papillomavirus_vaccination_and_the_risk_of_autoimmune_disorders_A_systematic_review_and_meta-analysis/links/5dbe62a0299bf1a47b0f3316/Human-papillomavirus-vaccination-and-the-risk-of-autoimmune-disorders-A-systematic-review-and-meta-analysis.pdf

816.) Willame, C., Gadroen, K., Bramer, W., Weibel, D., & Sturkenboom, M. (2020). Systematic Review and Meta-analysis of Postlicensure Observational Studies on Human Papillomavirus Vaccination and Autoimmune and Other Rare Adverse Events. *The Pediatric infectious disease journal*, *39*(4), 287-293. https://journals.lww.com/pidj/Abstract/2020/04000/Systematic_Review_and_Meta_analysis_of.6.aspx

817.) Campbell, J. D., Edelman, R., King Jr, J. C., Papa, T., Ryall, R., & Rennels, M. B. (2002). Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide–diphtheria toxoid conjugate vaccine given to healthy adults. *The Journal of infectious diseases*, *186*(12), 1848-1851. https://academic.oup.com/jid/article/186/12/1848/2191482

818.) Kunisaki, K. M., & Janoff, E. N. (2009). Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. *The Lancet infectious diseases*, *9*(8), 493-504. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2775097/

819.) Riley, I. D., Andrews, M., Howard, R., Tarr, P. I., Pfeiffer, M., Challands, P., ... & Douglas, R. M. (1977). Immunisation with a polyvalent pneumococcal vaccine: reduction of adult respiratory mortality in a New Guinea Highlands community. *The Lancet*, *309*(8026), 1338-1341. https://www.sciencedirect.com/science/article/abs/pii/S0140673677925521

820.) Potter, J., Stott, D. J., Roberts, M. A., Elder, A. G., O'donnell, B., Knight, P. V., & Carman, W. F. (1997). Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. *Journal of Infectious Diseases*, *175*(1), 1-6. https://academic.oup.com/jid/article/175/1/1/825903

821.) Barker, W. H., & Mullooly, J. P. (1980). Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalizations and deaths. *Jama*, *244*(22), 2547-2549. https://jamanetwork.com/journals/jama/article-abstract/372794

822.) Howells, C. H. L., Vesselinova-Jenkins, C. K., Evans, A. D., & James, J. (1975). Influenza vaccination and mortality from bronchopneumonia in the elderly. *The Lancet*, *305*(7903), 381-383. https://www.sciencedirect.com/science/article/abs/pii/S014067367591291X

823.) Gross, P. A., Quinnan, G. V., Rodstein, M., LaMontagne, J. R., Kaslow, R. A., Saah, A. J., ... & Gaerlan, P. (1988). Association of influenza immunization with reduction in mortality in an elderly population: a prospective study. *Archives of internal medicine*, *148*(3), 562-565. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/609540

824.) Higgins, J. P., Soares-Weiser, K., López-López, J. A., Kakourou, A., Chaplin, K., Christensen, H., ... & Reingold, A. L. (2016). Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. *BMJ*, *355*, i5170. https://www.bmj.com/content/355/bmj.i5170.long

825.) Nichol, K. L., Baken, L., & Nelson, A. (1999). Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. *Annals of internal medicine*, *130*(5), 397-403. https://www.acpjournals.org/doi/full/10.7326/0003-4819-130-5-199903020-00003

826.) Aaby, P., Samb, B., Simondon, F., Seck, A. M. C., Knudsen, K., & Whittle, H. (1995). Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. *Bmj*, *311*(7003), 481-485. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550544/pdf/bmj00606-0023.pdf

827.) van Wijhe, M., McDonald, S. A., de Melker, H. E., Postma, M. J., & Wallinga, J. (2016). Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis. *The Lancet Infectious Diseases*, *16*(5), 592-598. https://www.sciencedirect.com/science/article/abs/pii/S147330991600027X

828.) McGovern, M. E., & Canning, D. (2015). Vaccination and all-cause child mortality from 1985 to 2011: global evidence from the Demographic and Health Surveys. *American journal of epidemiology*, *182*(9), 791-798. https://academic.oup.com/aje/article/182/9/791/96333

829.) Bar-Zeev, N., King, C., Phiri, T., Beard, J., Mvula, H., Crampin, A. C., ... & Costello, A. (2018). Impact of monovalent rotavirus vaccine on diarrhoea-associated post-neonatal infant mortality in rural communities in Malawi: a population-based birth cohort study. *The Lancet Global Health*, *6*(9), e1036-e1044. https://www.sciencedirect.com/science/article/pii/S2214109X18303140

830.) Fisker, A. B., Rodrigues, A., Martins, C., Ravn, H., Byberg, S., Thysen, S., ... & Aaby, P. (2015). Reduced all-cause child mortality after general measles vaccination campaign in rural Guinea-Bissau. *The Pediatric infectious disease journal*, *34*(12), 1369-1376. https://journals.lww.com/pidj/FullText/2015/12000/Reduced_All_cause_Child_Mortality_After_General.19.aspx

831.) Christenson, B., Lundbergh, P., Hedlund, J., & Örtqvist, Å. (2001). Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. *The Lancet*, *357*(9261), 1008-1011. https://www.sciencedirect.com/science/article/abs/pii/S0140673600042379

832.) Aaby, P., Roth, A., Ravn, H., Napirna, B. M., Rodrigues, A., Lisse, I. M., ... & Biering-Sørensen, S. (2011). Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?. *Journal of Infectious Diseases*, *204*(2), 245-252. https://academic.oup.com/jid/article/204/2/245/833883

833.) Benn, C. S., Fisker, A. B., Whittle, H. C., & Aaby, P. (2016). Revaccination with live attenuated vaccines confer additional beneficial nonspecific effects on overall survival: a review. *EBioMedicine*, *10*, 312-317. https://www.sciencedirect.com/science/article/pii/S2352396416303218

834.) Herzog, N. S., Bratzler, D. W., Houck, P. M., Jiang, H., Nsa, W., Shook, C., & Weingarten, S. R. (2003). Effects of previous influenza vaccination on subsequent readmission and mortality in elderly patients hospitalized with pneumonia. *The American journal of medicine*, *115*(6), 454-461. https://www.sciencedirect.com/science/article/abs/pii/S0002934303004406

835.) Hviid, A., Wohlfahrt, J., Stellfeld, M., & Melbye, M. (2005). Childhood vaccination and nontargeted infectious disease hospitalization. *Jama*, *294*(6), 699-705. https://jamanetwork.com/journals/jama/article-abstract/201371

836.) Vila‐Córcoles, A., Ochoa, O., De Diego, C., Valdivieso, A., Herreros, I., Bobé, F., ... & Saun, N. (2008). Effects of annual influenza vaccination on winter mortality in elderly people with chronic pulmonary disease. *International journal of clinical practice*, *62*(1), 10-17. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1742-1241.2007.01414.x

837.) de Diego, C., Vila-Corcoles, A., Ochoa, O., Rodriguez-Blanco, T., Salsench, E., Hospital, I., ... & EPIVAC Study Group. (2009). Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. *European heart journal*, *30*(2), 209-216. https://academic.oup.com/eurheartj/article/30/2/209/448166

838.) Roy, P., Vekemans, J., Clark, A., Sanderson, C., Harris, R. C., & White, R. G. (2019). Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study. *The Lancet Global Health*, *7*(12), e1655-e1663. https://www.sciencedirect.com/science/article/pii/S2214109X19304449

839.) Spaude, K. A., Abrutyn, E., Kirchner, C., Kim, A., Daley, J., & Fisman, D. N. (2007). Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. *Archives of internal medicine*, *167*(1), 53-59. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/411463

840.) Vila-Córcoles, A., Ochoa-Gondar, O., Hospital, I., Ansa, X., Vilanova, A., Rodríguez, T., ... & EVAN Study Group. (2006). Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. *Clinical infectious diseases*, *43*(7), 860-868. https://academic.oup.com/cid/article/43/7/860/370087

841.) Carman, W. F., Elder, A. G., Wallace, L. A., McAulay, K., Walker, A., Murray, G. D., & Stott, D. J. (2000). Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. *The Lancet*, *355*(9198), 93-97. https://www.thelancet.com/journals/lancet/article/PIIS0140673699051909/fulltext

842.) Lemaitre, M., Meret, T., Rothan‐Tondeur, M., Belmin, J., Lejonc, J. L., Luquel, L., ... & Veyssier, P. (2009). Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster‐randomized trial. *Journal of the American Geriatrics Society*, *57*(9), 1580-1586. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1532-5415.2009.02402.x

843.) Tate, J. E., Patel, M. M., Steele, A. D., Gentsch, J. R., Payne, D. C., Cortese, M. M., ... & De Oliveira, L. H. (2010). Global impact of rotavirus vaccines. *Expert review of vaccines*, *9*(4), 395-407. https://www.researchgate.net/profile/Daniel_Payne2/publication/43048857_Global_impact_of_rotavirus_vaccines/links/02e7e515a3b4e0e376000000/Global-impact-of-rotavirus-vaccines.pdf

844.) Christenson, B., Pauksen, K., & Sylvan, S. P. (2008). Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. *Virology Journal*, *5*(1), 52. https://link.springer.com/article/10.1186/1743-422X-5-52

845.) Zhang, Y. Y., Tang, X. F., Du, C. H., Wang, B. B., Bi, Z. W., & Dong, B. R. (2016). Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis. *Human Vaccines & Immunotherapeutics*, *12*(12), 3056-3064. https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1221552

846.) Aaby, P., Garly, M. L., Bale, C., Martins, C., Jensen, H., Lisse, I., & Whittle, H. (2003). Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study. *The Pediatric infectious disease journal*, *22*(9), 798-805. https://journals.lww.com/pidj/Abstract/2003/09000/Survival_of_previously_measles_vaccinated_and.10.aspx

847.) Pollard, S. L., Malpica-Llanos, T., Friberg, I. K., Fischer-Walker, C., Ashraf, S., & Walker, N. (2015). Estimating the herd immunity effect of rotavirus vaccine. *Vaccine*, *33*(32), 3795-3800. https://www.sciencedirect.com/science/article/pii/S0264410X15008658

848.) Bayard, V., DeAntonio, R., Contreras, R., Tinajero, O., Castrejon, M. M., Ortega-Barría, E., & Colindres, R. E. (2012). Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. *International Journal of Infectious Diseases*, *16*(2), e94-e98. https://www.sciencedirect.com/science/article/pii/S1201971211001822

849.) Hviid, A., Stellfeld, M., Wohlfahrt, J., & Melbye, M. (2004). Childhood vaccination and type 1 diabetes. *New England Journal of Medicine*, *350*(14), 1398-1404. https://www.nejm.org/doi/10.1056/NEJMoa032665?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov

850.) Zangwill, K. M., Eriksen, E., Lee, M., Lee, J., Marcy, S. M., Friedland, L. R., ... & Ward, J. I. (2008). A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. *Pediatrics*, *122*(6), e1179-e1185. https://pediatrics.aappublications.org/content/122/6/e1179.long#abstract-1

851.) Hviid, A. (2006). Postlicensure epidemiology of childhood vaccination: the Danish experience. *Expert review of vaccines*, *5*(5), 641-649. https://www.tandfonline.com/doi/abs/10.1586/14760584.5.5.641

852.) Nichol, K. L., Baken, L., Wuorenma, J., & Nelson, A. (1999). The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. *Archives of internal medicine*, *159*(20), 2437-2442. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485170

853.) Nichol, K. L., Margolis, K. L., Wouremna, J., & Von Sternberg, T. (1996). Effectiveness of influenza vaccine in the elderly. *Gerontology*, *42*(5), 274-279. https://www.karger.com/Article/PDF/213803

854.) Fukuta, H., Goto, T., Wakami, K., Kamiya, T., & Ohte, N. (2019). The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. *Heart Failure Reviews*, *24*(1), 109-114. https://link.springer.com/article/10.1007%2Fs10741-018-9736-6

855.) Blaya-Nováková, V., Prado-Galbarro, F. J., & Sarría-Santamera, A. (2016). Effects of annual influenza vaccination on mortality in patients with heart failure. *The European Journal of Public Health*, *26*(5), 890-892. https://academic.oup.com/eurpub/article/26/5/890/2197631

856.) Amouzou, A., Habi, O., Bensaïd, K., & Niger Countdown Case Study Working Group. (2012). Reduction in child mortality in Niger: a Countdown to 2015 country case study. *The Lancet*, *380*(9848), 1169-1178. https://www.sciencedirect.com/science/article/abs/pii/S0140673612613762

857.) Myint, T. T. H., Madhava, H., Balmer, P., Christopoulou, D., Attal, S., Menegas, D., ... & Bonnet, E. (2013). The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. *Advances in therapy*, *30*(2), 127-151. https://link.springer.com/article/10.1007/s12325-013-0007-6

858.) Goldhaber-Fiebert, J. D., Lipsitch, M., Mahal, A., Zaslavsky, A. M., & Salomon, J. A. (2010). Quantifying child mortality reductions related to measles vaccination. *PLoS One*, *5*(11), e13842. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0013842

859.) Chang, Y. C., Chou, Y. J., Liu, J. Y., Yeh, T. F., & Huang, N. (2012). Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan–a representative population-based comparative study. *Journal of Infection*, *65*(3), 231-238. https://www.sciencedirect.com/science/article/abs/pii/S0163445312001260

860.) McIntyre, P. B., O'Brien, K. L., Greenwood, B., & Van De Beek, D. (2012). Effect of vaccines on bacterial meningitis worldwide. *The Lancet*, *380*(9854), 1703-1711. https://www.sciencedirect.com/science/article/abs/pii/S0140673612611878

861.) Rieckmann, A., Villumsen, M., Sørup, S., Haugaard, L. K., Ravn, H., Roth, A., ... & Aaby, P. (2017). Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971–2010. *International journal of epidemiology*, *46*(2), 695-705. https://academic.oup.com/ije/article/46/2/695/2622844

862.) Byberg, S., Thysen, S. M., Rodrigues, A., Martins, C., Cabral, C., Careme, M., ... & Fisker, A. B. (2017). A general measles vaccination campaign in urban Guinea-Bissau: Comparing child mortality among participants and non-participants. *Vaccine*, *35*(1), 33-39. https://www.sciencedirect.com/science/article/pii/S0264410X16311112

863.) Vila-Corcoles, A., Ochoa-Gondar, O., Llor, C., Rodríguez, T., & Gómez, A. (2005). Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. *European Respiratory Journal*, *26*(6), 1086-1091. https://erj.ersjournals.com/content/26/6/1086

864.) Voordouw, B. C., van der Linden, P. D., Simonian, S., van der Lei, J., Sturkenboom, M. C., & Stricker, B. H. (2003). Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. *Archives of Internal Medicine*, *163*(9), 1089-1094. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/215483

865.) Mooney, J. D., Weir, A., McMenamin, J., Ritchie, L. D., Macfarlane, T. V., Simpson, C. R., ... & Clarke, S. C. (2008). The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. *BMC infectious diseases*, *8*(1), 53. https://link.springer.com/article/10.1186/1471-2334-8-53#citeas

866.) Epstein, S. L., Kong, W. P., Misplon, J. A., Lo, C. Y., Tumpey, T. M., Xu, L., & Nabel, G. J. (2005). Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. *Vaccine*, *23*(46-47), 5404-5410. https://www.sciencedirect.com/science/article/pii/S0264410X05005463

867.) Franco, E. L., & Harper, D. M. (2005). Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. *Vaccine*, *23*(17-18), 2388-2394. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001024

868.) Bond, T. C., Spaulding, A. C., Krisher, J., & McClellan, W. (2012). Mortality of dialysis patients according to influenza and pneumococcal vaccination status. *American journal of kidney diseases*, *60*(6), 959-965. https://www.sciencedirect.com/science/article/abs/pii/S0272638612007512

869.) Rodriguez-Blanco, T., Vila-Corcoles, A., de Diego, C., Ochoa-Gondar, O., Valdivieso, E., Bobe, F., ... & Clotas, L. (2012). Relationship between annual influenza vaccination and winter mortality in diabetic people over 65 years. *Human vaccines & immunotherapeutics*, *8*(3), 363-370. https://www.tandfonline.com/doi/pdf/10.4161/hv.18548

870.) Hutchison, B. G., Oxman, A. D., & Shannon, H. S. (1999). Clinical effectiveness of pneumococcal vaccine. *Can Fam Physician*, *45*, 2381-2393. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2328641/pdf/canfamphys00044-0123.pdf

871.) Smit, P., Oberholzer, D., Hayden-Smith, S., Koornhof, H. J., & Hilleman, M. R. (1977). Protective efficacy of pneumococcal polysaccharide vaccines. *Jama*, *238*(24), 2613-2616. https://jamanetwork.com/journals/jama/article-abstract/357169

872.) Tsai, Y. H., Hsieh, M. J., Chang, C. J., Wen, Y. W., Hu, H. C., Chao, Y. N., ... & Huang, C. C. (2015). The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old—Taiwan's PPV vaccination program. *Vaccine*, *33*(25), 2897-2902. https://www.researchgate.net/profile/Yhu_Chering_Huang/publication/258039536_The_Efficacy_of_23-Valent_Pneumococcal_Polysaccharide_Vaccine_in_Preventing_Pneumonia_and_Invasive_Pneumococcal_Disease_in_the_Elderly_Aged_75_Years_and_Older_in_Taiwan/links/55c9451108aeb97567477a9c.pdf

873.) Bhutta, Z. A., Das, J. K., Walker, N., Rizvi, A., Campbell, H., Rudan, I., & Black, R. E. (2013). Interventions to address deaths from childhood pneumonia and diarrhoea equitably: what works and at what cost?. *The Lancet*, *381*(9875), 1417-1429. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.843.9651&rep=rep1&type=pdf

874.) King, C., Bar-Zeev, N., Phiri, T., Beard, J., Mvula, H., Crampin, A., ... & Whitney, C. (2020). Population impact and effectiveness of sequential 13-valent pneumococcal conjugate and monovalent rotavirus vaccine introduction on infant mortality: prospective birth cohort studies from Malawi. *BMJ global health*, *5*(9), e002669. https://gh.bmj.com/content/bmjgh/5/9/e002669.full.pdf

875.) Pomfret, T. C., Gagnon Jr, J. M., & Gilchrist, A. T. (2011). Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. *Journal of clinical pharmacy and therapeutics*, *36*(1), 1-9. https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2710.2009.01150.x

876.) Christensen, H., Hickman, M., Edmunds, W. J., & Trotter, C. L. (2013). Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. *Vaccine*, *31*(23), 2638-2646. https://www.sciencedirect.com/science/article/pii/S0264410X13003691

877.) Fisker, A. B., Hornshøj, L., Rodrigues, A., Balde, I., Fernandes, M., Benn, C. S., & Aaby, P. (2014). Effects of the introduction of new vaccines in Guinea-Bissau on vaccine coverage, vaccine timeliness, and child survival: an observational study. *The lancet global health*, *2*(8), e478-e487. https://www.sciencedirect.com/science/article/pii/S2214109X14702748

878.) Hu, P. J., Chen, C. H., Wong, C. S., Chen, T. T., Wu, M. Y., & Sung, L. C. (2021). Influenza vaccination reduces incidence of peripheral arterial occlusive disease in elderly patients with chronic kidney disease. *Scientific reports*, *11*(1), 1-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921588/

879.) Nandi, A., Kumar, S., Shet, A., Bloom, D. E., & Laxminarayan, R. (2020). Childhood vaccinations and adult schooling attainment: Long-term evidence from India's Universal Immunization Programme. *Social Science & Medicine (1982)*, *250*, 112885-112885. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103780/

880.) Bloom, D. E., Canning, D., & Shenoy, E. S. (2011). The effect of vaccination on children's physical and cognitive development in the Philippines. *Applied Economics*, *44*(21), 2777-2783. http://vaccinepapers.org/wp-content/uploads/The-effect-of-vaccination-on-childrens-physical-and-cognitive-development-in-the-Philippines.pdf

881.) Hedlund, J., Christenson, B., Lundbergh, P., & Örtqvist, Å. (2003). Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. *Vaccine*, *21*(25-26), 3906-3911. https://www.sciencedirect.com/science/article/pii/S0264410X03002962

882.) Garland, S. M., Kjaer, S. K., Muñoz, N., Block, S. L., Brown, D. R., DiNubile, M. J., ... & Saah, A. J. (2016). Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. *Reviews of Infectious Diseases*, *63*(4), 519-527. https://academic.oup.com/cid/article/63/4/519/2566619

883.) Palmu, A. A., Kilpi, T. M., Rinta-Kokko, H., Nohynek, H., Toropainen, M., Nuorti, J. P., & Jokinen, J. (2015). Pneumococcal conjugate vaccine and clinically suspected invasive pneumococcal disease. *Pediatrics*, *136*(1), e22-e27. https://pediatrics.aappublications.org/content/136/1/e22

884.) Piedra, P. A., Gaglani, M. J., Kozinetz, C. A., Herschler, G., Riggs, M., Griffith, M., ... & Glezen, W. P. (2005). Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. *Vaccine*, *23*(13), 1540-1548. https://www.sciencedirect.com/science/article/pii/S0264410X04007297

885.) Breiman, R. F., Streatfield, P. K., Phelan, M., Shifa, N., Rashid, M., & Yunus, M. (2004). Effect of infant immunisation on childhood mortality in rural Bangladesh: analysis of health and demographic surveillance data. *The Lancet*, *364*(9452), 2204-2211. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1007.1375&rep=rep1&type=pdf

886.) Mangtani, P., Cumberland, P., Hodgson, C. R., Roberts, J. A., Cutts, F. T., & Hall, A. J. (2004). A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. *The Journal of infectious diseases*, *190*(1), 1-10. https://academic.oup.com/jid/article/190/1/1/2191376

887.) Ruben, F. L. (2004). Inactivated influenza virus vaccines in children. *Clinical infectious diseases*, *38*(5), 678-688. https://academic.oup.com/cid/article/38/5/678/280593

888.) Wang, I. K., Lin, C. L., Chang, Y. C., Lin, P. C., Liang, C. C., Liu, Y. L., ... & Sung, F. C. (2013). Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. *Vaccine*, *31*(4), 718-724. https://www.sciencedirect.com/science/article/pii/S0264410X12016106

889.) Santos, V. S., Marques, D. P., Martins-Filho, P. R., Cuevas, L. E., & Gurgel, R. Q. (2016). Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis. *Infectious Diseases of Poverty*, *5*(1), 1-12. https://link.springer.com/article/10.1186/s40249-016-0173-2#citeas

890.) Coudeville, L., Paree, F., Lebrun, T., & Sailly, J. C. (1999). The value of varicella vaccination in healthy children: cost–benefit analysis of the situation in France. *Vaccine*, *17*(2), 142-151. https://www.sciencedirect.com/science/article/pii/S0264410X98001613

891.) Tait, D. R., Hatherill, M., Van Der Meeren, O., Ginsberg, A. M., Van Brakel, E., Salaun, B., ... & Demoitié, M. A. (2019). Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. *New England Journal of Medicine*, *381*(25), 2429-2439. https://www.nejm.org/doi/full/10.1056/NEJMoa1909953

892.) Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., ... & Moodie, Z. (2018). Effect of dengue serostatus on dengue vaccine safety and efficacy. *New England Journal of Medicine*, *379*(4), 327-340. https://www.nejm.org/doi/full/10.1056/NEJMoa1800820

893.) Kalies, H., Verstraeten, T., Grote, V., Meyer, N., Siedler, A., Schmitt, H. J., ... & Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland Study Group. (2004).

Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. *The Pediatric infectious disease journal*, *23*(10), 944-950. https://journals.lww.com/pidj/Abstract/2004/10000/Four_and_One_Half_Year_Follow_up_of_the.11.aspx

894.) Pittman, P. R., Hahn, M., Lee, H. S., Koca, C., Samy, N., Schmidt, D., ... & Silbernagl, G. (2019). Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox. *New England Journal of Medicine*, *381*(20), 1897-1908. https://www.nejm.org/doi/full/10.1056/NEJMoa1817307

895.) Zhang, J., Zhang, X. F., Huang, S. J., Wu, T., Hu, Y. M., Wang, Z. Z., ... & Guo, M. (2015). Long-term efficacy of a hepatitis E vaccine. *New England Journal of Medicine*, *372*(10), 914-922. https://www.nejm.org/doi/full/10.1056/NEJMoa1406011

896.) French, N., Gordon, S. B., Mwalukomo, T., White, S. A., Mwafulirwa, G., Longwe, H., ... & Gilks, C. F. (2010). A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. *New England Journal of Medicine*, *362*(9), 812-822. https://www.nejm.org/doi/full/10.1056/NEJMoa0903029

897.) Monath, T. P., Fowler, E., Johnson, C. T., Balser, J., Morin, M. J., Sisti, M., & Trent, D. W. (2011). An inactivated cell-culture vaccine against yellow fever. *New England Journal of Medicine*, *364*(14), 1326-1333. https://www.nejm.org/doi/full/10.1056/NEJMoa1009303

898.) Valenciano, M., Kissling, E., Cohen, J. M., Oroszi, B., Barret, A. S., Rizzo, C., ... & Horvath, J. K. (2011). Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. *PLoS Med*, *8*(1), e1000388. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000388

899.) Puig-Barberà, J., Arnedo-Pena, A., Pardo-Serrano, F., Tirado-Balaguer, M. D., Pérez-Vilar, S., Silvestre-Silvestre, E., ... & of the Surveillance, T. M. (2010). Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case–control study. *Vaccine*, *28*(47), 7460-7467. https://www.sciencedirect.com/science/article/pii/S0264410X10013526

900.) Bines, J. E., At Thobari, J., Satria, C. D., Handley, A., Watts, E., Cowley, D., ... & Byars, G. (2018). Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. *New England Journal of Medicine*, *378*(8), 719-730. https://www.nejm.org/doi/full/10.1056/NEJMoa1706804

901.) Deceuninck, G., De Serres, G., Boulianne, N., Lefebvre, B., & De Wals, P. (2015). Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. *Vaccine*, *33*(23), 2684-2689. https://pubmed.ncbi.nlm.nih.gov/25887086/

902.) Yugoslav Typhoid Commission. (1964). A controlled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol-inactivated typhoid vaccines in Yugoslavia: Report. *Bulletin of the World Health Organization*, *30*(5), 623. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2554987/pdf/bullwho00290-0003.pdf

903.) Breteler, J. K., Tam, J. S., Jit, M., Ket, J. C., & De Boer, M. R. (2013). Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: a systematic review and meta-analysis. *Vaccine*, *31*(45), 5168-5177. https://www.sciencedirect.com/science/article/pii/S0264410X13011687

904.) Ntshoe, G. M., McAnerney, J. M., Tempia, S., Blumberg, L., Moyes, J., Buys, A., ... & Harris, B. N. (2014). Influenza epidemiology and vaccine effectiveness among patients with influenza-like illness, viral watch sentinel sites, South Africa, 2005–2009. *PloS one*, *9*(4), e94681. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094681

905.) Gustafsson, L., Hallander, H. O., Olin, P., Reizenstein, E., & Storsaeter, J. (1996). A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. *New England Journal of Medicine*, *334*(6), 349-356. https://www.nejm.org/doi/full/10.1056/nejm199602083340602

906.) Schmitt, H. J., von König, C. H. W., Neiss, A., Bogaerts, H., Bock, H. L., Schulte-Wissermann, H., ... & Clemens, R. (1996). Efficacy of acellular pertussis vaccine in early childhood after household exposure. *Jama*, *275*(1), 37-41. https://jamanetwork.com/journals/jama/article-abstract/393535

907.) Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A. E., Anemona, A., ... & Klein, D. L. (1996). A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. *New England journal of medicine*, *334*(6), 341-349. https://www.nejm.org/doi/full/10.1056/NEJM199602083340601

908.) Liese, J. G., Meschievitz, C. K., Harzer, E., Froeschle, J., Hosbach, P., HOPPE, J. E., ... & Belohradsky, B. H. (1997). Efficacy of a two-component acellular pertussis vaccine in infants. *The Pediatric infectious disease journal*, *16*(11), 1038-1044. https://journals.lww.com/pidj/Abstract/1997/11000/Efficacy_of_a_two_component_acellular_pertussis.7.aspx

909.) Stehr, K., Cherry, J. D., Heininger, U., Schmitt-Grohé, S., Überall, M., Laussucq, S., ... & Pertussis Vaccine Study Group. (1998). A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. *Pediatrics*, *101*(1), 1-11. https://pediatrics.aappublications.org/content/101/1/1.short

910.) Storsaeter, J., & Olin, P. (1992). Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. *Vaccine*, *10*(3), 142-144. https://www.sciencedirect.com/science/article/pii/0264410X92900022

911.) Grimaldi‐Bensouda, L., Guillemot, D., Godeau, B., Bénichou, J., Lebrun‐Frenay, C., Papeix, C., ... & Nicolino, M. (2014). Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. *Journal of Internal Medicine*, *275*(4), 398-408. https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.12155

912.) Mitkus, R. J., King, D. B., Hess, M. A., Forshee, R. A., & Walderhaug, M. O. (2011). Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. *Vaccine*, *29*(51), 9538-9543. http://vaccinepapers.org/wp-content/uploads/FDA-aluminum-paper.pdf

913.) Keith, L. S., Jones, D. E., & Chou, C. H. (2002). Aluminum toxicokinetics regarding infant diet and vaccinations. *Vaccine*, *20*, S13-S17. https://www.sciencedirect.com/science/article/pii/S0264410X02001652

914.) Feikin, D. R., Lezotte, D. C., Hamman, R. F., Salmon, D. A., Chen, R. T., & Hoffman, R. E. (2000). Individual and community risks of measles and pertussis associated with personal exemptions to immunization. *Jama*, *284*(24), 3145-3150. https://jamanetwork.com/journals/jama/article-abstract/193407

915.) Omer, S. B., Salmon, D. A., Orenstein, W. A., Dehart, M. P., & Halsey, N. (2009). Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. *New England Journal of Medicine*, *360*(19), 1981-1988. https://www.nejm.org/doi/full/10.1056/nejmsa0806477

916.) Glanz, J. M., McClure, D. L., O'Leary, S. T., Narwaney, K. J., Magid, D. J., Daley, M. F., & Hambidge, S. J. (2011). Parental decline of pneumococcal vaccination and risk of pneumococcal related disease in children. *Vaccine*, *29*(5), 994-999. https://www.sciencedirect.com/science/article/pii/S0264410X10017299

917.) Omer, S. B., Pan, W. K., Halsey, N. A., Stokley, S., Moulton, L. H., Navar, A. M., ... & Salmon, D. A. (2006). Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. *Jama*, *296*(14), 1757-1763. https://jamanetwork.com/journals/jama/article-abstract/203593

918.) Huang, W. T., Gargiullo, P. M., Broder, K. R., Weintraub, E. S., Iskander, J. K., Klein, N. P., ... & Vaccine Safety Datalink Team. (2010). Lack of association between acellular pertussis vaccine and seizures in early childhood. *Pediatrics*, *126*(2), 263-269. https://www.kdheks.gov/immunize/download/Lack_of_Association_Between_Acellular_Pertussis.pdf

919.) Daley, M. F., Yih, W. K., Glanz, J. M., Hambidge, S. J., Narwaney, K. J., Yin, R., ... & Jacobsen, S. J. (2014). Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP–IPV) vaccine. *Vaccine*, *32*(25), 3019-3024. https://www.sciencedirect.com/science/article/pii/S0264410X14004320

920.) Sukumaran, L., McCarthy, N. L., Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Jackson, L., ... & Kawai, A. T. (2018). Infant hospitalizations and mortality after maternal vaccination. *Pediatrics*, *141*(3), e20173310. https://pediatrics.aappublications.org/content/141/3/e20173310

921.) Sukumaran, L., McCarthy, N. L., Kharbanda, E. O., McNeil, M. M., Naleway, A. L., Klein, N. P., ... & Weintraub, E. S. (2015). Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. *Jama*, *314*(15), 1581-1587. https://jamanetwork.com/journals/jama/article-abstract/2463256

922.) Berenson, A. B., Hirth, J. M., Rahman, M., Laz, T. H., Rupp, R. E., & Sarpong, K. O. (2016). Maternal and infant outcomes among women vaccinated against pertussis during pregnancy. *Human vaccines & immunotherapeutics*, *12*(8), 1965-1971. https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1157241

923.) Sukumaran, L., McCarthy, N. L., Kharbanda, E. O., Weintraub, E., Vazquez-Benitez, G., McNeil, M. M., ... & Lugg, M. M. (2015). Safety of tetanus, diphtheria, and acellular pertussis and influenza vaccinations in pregnancy. *Obstetrics and gynecology*, *126*(5), 1069.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618722/

924.) Fortner, K. B., Swamy, G. K., Broder, K. R., Jimenez-Truque, N., Zhu, Y., Moro, P. L., ... & Yoder, S. (2018). Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women. *Vaccine*, *36*(42), 6354-6360.
https://www.sciencedirect.com/science/article/pii/S0264410X18309423

925.) McHugh, L., Marshall, H. S., Perrett, K. P., Nolan, T., Wood, N., Lambert, S. B., ... & Andrews, R. M. (2019). The safety of influenza and pertussis vaccination in pregnancy in a cohort of Australian mother-infant pairs, 2012–2015: the FluMum study. *Clinical Infectious Diseases*, *68*(3), 402-408.
https://digital.library.adelaide.edu.au/dspace/bitstream/2440/118229/2/hdl_118229.pdf

926.) Becerra-Culqui, T. A., Getahun, D., Chiu, V., Sy, L. S., & Tseng, H. F. (2020). The Association of Prenatal Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccination With Attention-Deficit/Hyperactivity Disorder. *American journal of epidemiology*, *189*(10), 1163-1172.
https://academic.oup.com/aje/article-abstract/189/10/1163/5831421

927.) Yang, Y. T., & Shaw, J. (2018). Sudden infant death syndrome, attention-deficit/hyperactivity disorder and vaccines: Longitudinal population analyses. *Vaccine*, *36*(5), 595-598.
https://www.sciencedirect.com/science/article/pii/S0264410X17318273

928.) Ben-Shimol, S., Greenberg, D., Givon-Lavi, N., Elias, N., Glikman, D., Rubinstein, U., & Dagan, R. (2012). Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. *Vaccine*, *30*(46), 6600-6607.
https://www.sciencedirect.com/science/article/pii/S0264410X12011917

929.) Black, R. E., Huber, D. H., & Curlin, G. T. (1980). Reduction of neonatal tetanus by mass immunization of non-pregnant women: duration of protection provided by one or two doses of aluminium-adsorbed tetanus toxoid. *Bulletin of the World Health Organization*, *58*(6), 927.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396004/pdf/bullwho00429-0117.pdf

930.) Rahman, M., Chen, L. C., Chakraborty, J., Yunus, M., Chowdhury, A. I., Sarder, A. M., ... & Curlin, G. T. (1982). Use of tetanus toxoid for the prevention of neonatal tetanus. 1. Reduction of neonatal mortality by immunization of non-pregnant and pregnant women in rural Bangladesh. *Bulletin of the World Health Organization*, *60*(2), 261-267.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2535950/pdf/bullwho00104-0103.pdf

931.) Dagan, R., Muallem, M., Melamed, R., Leroy, O., & Yagupsky, P. (1997). Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. *The Pediatric infectious disease journal*, *16*(11), 1060-1064.
https://pubmed.ncbi.nlm.nih.gov/9384340/

932.) Glanz, J. M., Narwaney, K. J., Newcomer, S. R., Daley, M. F., Hambidge, S. J., Rowhani-Rahbar, A., ... & Lugg, M. M. (2013). Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age. *JAMA pediatrics*, *167*(11), 1060-1064.
https://jamanetwork.com/journals/jamapediatrics/fullarticle/1735653

933.) Glanz, J. M., Clarke, C. L., Xu, S., Daley, M. F., Shoup, J. A., Schroeder, E. B., ... & DeStefano, F. (2020). Association Between Rotavirus Vaccination and Type 1 Diabetes in Children. *JAMA pediatrics*, *174*(5), 455-462.
https://jamanetwork.com/journals/jamapediatrics/article-abstract/2762009

934.) McNeil, M. M., Duderstadt, S. K., Sabatier, J. F., Ma, G. G., & Duffy, J. (2019). Vaccination and risk of lone atrial fibrillation in the active component United States military. *Human vaccines & immunotherapeutics*, *15*(3), 669-676.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988888/

935.) Prymula, R., Esposito, S., Zuccotti, G. V., Xie, F., Toneatto, D., Kohl, I., & Dull, P. M. (2014). A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I) Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. *Human vaccines & immunotherapeutics*, *10*(7), 1993-2004.
https://www.tandfonline.com/doi/full/10.4161/hv.28666

936.) Groom, H. C., Irving, S. A., Koppolu, P., Smith, N., Vazquez-Benitez, G., Kharbanda, E. O., ... & Kawai, A. T. (2018). Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. *Vaccine*, *36*(41), 6111-6116.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325631/

937.) Naleway, A. L., Mittendorf, K. F., Irving, S. A., Henninger, M. L., Crane, B., Smith, N., ... & Gee, J. (2018). Primary Ovarian Insufficiency and Adolescent Vaccination. *Pediatrics*, *142*(3), e20180943.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719304/

938.) Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Sheth, S. S., Zhu, J., Naleway, A. L., ... & Jackson, M. L. (2018). Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy. *Obstetrics and Gynecology*, *132*(1), 35-44. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019196/

939.) Duclos, P. (2003). Safety of immunisation and adverse events following vaccination against hepatitis B. *Expert opinion on drug safety*, *2*(3), 225-231. https://www.tandfonline.com/doi/abs/10.1517/14740338.2.3.225

940.) Van Den Ende, C., Marano, C., Van Ahee, A., Bunge, E. M., & De Moerlooze, L. (2017). The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. *Expert review of vaccines*, *16*(8), 811-832. https://www.tandfonline.com/doi/pdf/10.1080/14760584.2017.1338568

941.) Verstraeten, T., Descamps, D., David, M. P., Zahaf, T., Hardt, K., Izurieta, P., ... & Breuer, T. (2008). Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. *Vaccine*, *26*(51), 6630-6638. https://www.sciencedirect.com/science/article/pii/S0264410X08012759

942.) Gee, J., Naleway, A., Shui, I., Baggs, J., Yin, R., Li, R., ... & Klein, N. P. (2011). Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. *Vaccine*, *29*(46), 8279-8284. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.455.1319&rep=rep1&type=pdf

943.) Haber, P., Sejvar, J., Mikaeloff, Y., & DeStefano, F. (2009). Vaccines and guillain-barre syndrome. *Drug Safety*, *32*(4), 309-323. https://link.springer.com/article/10.2165/00002018-200932040-00005

944.) Tseng, H. F., Sy, L. S., Liu, I. L. A., Qian, L., Marcy, S. M., Weintraub, E., ... & Naleway, A. (2013). Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. *Vaccine*, *31*(22), 2578-2583. https://www.sciencedirect.com/science/article/pii/S0264410X13003757

945.) Suzuki, S., & Hosono, A. (2018). No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. *Papillomavirus Research*, *5*, 96-103. https://www.sciencedirect.com/science/article/pii/S2405852117300708

946.) Cornu, C., Yzebe, D., Leophonte, P., Gaillat, J., Boissel, J. P., & Cucherat, M. (2001). Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. *Vaccine*, *19*(32), 4780-4790. https://www.sciencedirect.com/science/article/pii/S0264410X01002171

947.) Sever, J. L., Brenner, A. I., Gale, A. D., Lyle, J. M., Moulton, L. H., Ward, B. J., & West, D. J. (2004). Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). *Pharmacoepidemiology and drug safety*, *13*(12), 825-840. https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.936

948.) Miller, E. R., Moro, P. L., Cano, M., & Shimabukuro, T. T. (2015). Deaths following vaccination: what does the evidence show?. *Vaccine*, *33*(29), 3288-3292. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599698/

949.) Moro, P. L., Arana, J., Cano, M., Lewis, P., & Shimabukuro, T. T. (2015). Deaths reported to the vaccine adverse event reporting system, United States, 1997–2013. *Clinical Infectious Diseases*, *61*(6), 980-987. https://academic.oup.com/cid/article/61/6/980/451431?fbclid=IwAR0-QbQtGFjtJmy6QHoe2EipX1on5oVu-bAiK5i6GabasgFcJ8erhad5uyQ

950.) McCarthy, N. L., Weintraub, E., Vellozzi, C., Duffy, J., Gee, J., Donahue, J. G., ... & Lugg, M. M. (2013). Mortality rates and cause-of-death patterns in a vaccinated population. *American journal of preventive medicine*, *45*(1), 91-97. https://www.ajpmonline.org/article/S0749-3797(13)00225-0/abstract

951.) Moro, P. L., Jankosky, C., Menschik, D., Lewis, P., Duffy, J., Stewart, B., & Shimabukuro, T. T. (2015). Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013. *The Journal of pediatrics*, *166*(4), 992-997. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500451/

952.) Vennemann, M. M. T., Höffgen, M., Bajanowski, T., Hense, H. W., & Mitchell, E. A. (2007). Do immunisations reduce the risk for SIDS? A meta-analysis. *Vaccine*, *25*(26), 4875-4879. https://www.sciencedirect.com/science/article/pii/S0264410X07002800

953.) Jonville‐Béra, A. P., Autret‐Leca, E., Barbeillon, F., Paris‐Llado, J., & French Reference Centers for SIDS. (2001). Sudden unexpected death in infants under 3 months of age and vaccination status–a case‐control study. *British journal of clinical pharmacology*, *51*(3), 271-276. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2125.2001.00341.x

954.) Leshem, E., Lopman, B., Glass, R., Gentsch, J., Bányai, K., Parashar, U., & Patel, M. (2014). Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. *The lancet infectious diseases*, *14*(9), 847-856. https://www.sciencedirect.com/science/article/abs/pii/S1473309914708321

955.) Ewald, H., Briel, M., Vuichard, D., Kreutle, V., Zhydkov, A., & Gloy, V. (2016). The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials. *Deutsches Ärzteblatt International*, *113*(9), 139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802351/

956.) Vasileiou, E., Sheikh, A., Butler, C., El Ferkh, K., Von Wissmann, B., McMenamin, J., ... & Tian, L. (2017). Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. *Clinical Infectious Diseases*, *65*(8), 1388-1395. https://academic.oup.com/cid/article/65/8/1388/3862448

957.) Gsell, P. S., Camacho, A., Kucharski, A. J., Watson, C. H., Bagayoko, A., Nadlaou, S. D., ... & Doumbia, M. (2017). Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. *The Lancet infectious diseases*, *17*(12), 1276-1284. https://www.sciencedirect.com/science/article/pii/S1473309917305418

958.) Kjærgaard, J., Stensballe, L. G., Birk, N. M., Nissen, T. N., Foss, K. T., Thøstesen, L. M., Pihl, G. T., Andersen, A., Kofoed, P. E., Pryds, O., & Greisen, G. (2016). Lack of a Negative Effect of BCG-Vaccination on Child Psychomotor Development: Results from the Danish Calmette Study - A Randomised Clinical Trial. *PloS one*, *11*(4), e0154541. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849633/

959.) Kelly, C., Arnold, R., Galloway, Y., & O'Hallahan, J. (2007). A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. *American journal of epidemiology*, *166*(7), 817-823. http://u2.lege.net/whale.to/vaccine/Kelly%202007.pdf

960.) Galloway, Y., Stehr-Green, P., McNicholas, A., & O'Hallahan, J. (2009). Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. *International journal of epidemiology*, *38*(2), 413-418. https://academic.oup.com/ije/article/38/2/413/655457

961.) Adlhoch, C., Hoehne, M., Littmann, M., Marques, A. M., Lerche, A., Dehnert, M., ... & Koch, J. (2013). Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010–2011. *The Pediatric Infectious Disease Journal*, *32*(2), e82-e89. https://journals.lww.com/pidj/FullText/2013/02000/Rotavirus_Vaccine_Effectiveness_and_Case_control.37.aspx

962.) Chang, W. C., Yen, C., Wu, F. T., Huang, Y. C., Lin, J. S., Huang, F. C., ... & Parashar, U. D. (2014). Effectiveness of 2 rotavirus vaccines against rotavirus disease in Taiwanese infants. *The Pediatric Infectious Disease Journal*, *33*(3), e81-e86. https://journals.lww.com/pidj/Fulltext/2014/03000/Effectiveness_of_2_Rotavirus_Vaccines_Against.22.aspx

963.) Payne, D. C., Boom, J. A., Staat, M. A., Edwards, K. M., Szilagyi, P. G., Klein, E. J., ... & Johnston, S. H. (2013). Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children< 5 years of age, 2009–2011. *Clinical infectious diseases*, *57*(1), 13-20. https://academic.oup.com/cid/article/57/1/13/278400

964.) Lucas, M. E., Deen, J. L., Von Seidlein, L., Wang, X. Y., Ampuero, J., Puri, M., ... & Cavailler, P. (2005). Effectiveness of mass oral cholera vaccination in Beira, Mozambique. *New England Journal of Medicine*, *352*(8), 757-767. https://www.nejm.org/doi/full/10.1056/NEJMoa043323

965.) Khatib, A. M., Ali, M., Von Seidlein, L., Kim, D. R., Hashim, R., Reyburn, R., ... & Aguado, M. T. (2012). Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. *The Lancet infectious diseases*, *12*(11), 837-844. https://www.sciencedirect.com/science/article/abs/pii/S1473309912701962

966.) Thiem, V. D., Deen, J. L., Von Seidlein, L., Anh, D. D., Park, J. K., Ali, M., ... & Clemens, J. D. (2006). Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. *Vaccine*, *24*(20), 4297-4303. https://www.sciencedirect.com/science/article/pii/S0264410X06002726

967.) Qadri, F., Chowdhury, M. I., Faruque, S. M., Salam, M. A., Ahmed, T., Begum, Y. A., ... & Killeen, K. P. (2007). Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. *Vaccine*, *25*(2), 231-238.

https://www.sciencedirect.com/science/article/pii/S0264410X06009704

968.) Fraser, A., Paul, M., Goldberg, E., Acosta, C. J., & Leibovici, L. (2007). Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. *Vaccine*, *25*(45), 7848-7857.
https://www.sciencedirect.com/science/article/pii/S0264410X07009413

969.) Belongia, E. A., Kieke, B. A., Donahue, J. G., Greenlee, R. T., Balish, A., Foust, A., ... & Shay, D. K. (2009). Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. *The Journal of infectious diseases*, *199*(2), 159-167. https://academic.oup.com/jid/article/199/2/159/2191822

970.) Ohmit, S. E., Thompson, M. G., Petrie, J. G., Thaker, S. N., Jackson, M. L., Belongia, E. A., ... & Jackson, L. (2014). Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. *Clinical infectious diseases*, *58*(3), 319-327.
https://academic.oup.com/cid/article/58/3/319/339797

971.) Jonesteller, C. L., Burnett, E., Yen, C., Tate, J. E., & Parashar, U. D. (2017). Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006–2016. *Clinical Infectious Diseases*, *65*(5), 840-850.
https://academic.oup.com/cid/article/65/5/840/3746914

972.) Gastañaduy, P. A., Steenhoff, A. P., Mokomane, M., Esona, M. D., Bowen, M. D., Jibril, H., ... & Parashar, U. D. (2016). Effectiveness of monovalent rotavirus vaccine after programmatic implementation in Botswana: a multisite prospective case-control study. *Clinical Infectious Diseases*, *62*(suppl_2), S161-S167.
https://academic.oup.com/cid/article/62/suppl_2/S161/2478859

973.) Dos Santos, G., Tahrat, H., & Bekkat-Berkani, R. (2018). Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. *Human vaccines & immunotherapeutics*, *14*(8), 1853-1866.
https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1446719

974.) Vamos, E. P., Pape, U. J., Curcin, V., Harris, M. J., Valabhji, J., Majeed, A., & Millett, C. (2016). Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. *CMAJ*, *188*(14), E342-E351.
https://www.cmaj.ca/content/188/14/E342.short

975.) Shakya, M., Colin-Jones, R., Theiss-Nyland, K., Voysey, M., Pant, D., Smith, N., ... & Clarke, J. (2019). Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. *New England Journal of Medicine*, *381*(23), 2209-2218. https://www.nejm.org/doi/full/10.1056/NEJMoa1905047

976.) Correia, J. B., Patel, M. M., Nakagomi, O., Montenegro, F. M., Germano, E. M., Correia, N. B., ... & Nakagomi, T. (2010). Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P [4] strains in Brazil. *The Journal of infectious diseases*, *201*(3), 363-369. https://academic.oup.com/jid/article/201/3/363/894862

977.) Angelo, M. G., David, M. P., Zima, J., Baril, L., Dubin, G., Arellano, F., & Struyf, F. (2014). Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programme. *pharmacoepidemiology and drug safety*, *23*(5), 466-479. https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.3554

978.) Gee, J., Weinbaum, C., Sukumaran, L., & Markowitz, L. E. (2016). Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. *Human vaccines & immunotherapeutics*, *12*(6), 1406-1417. https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1168952

979.) Luna, J., Plata, M., Gonzalez, M., Correa, A., Maldonado, I., Nossa, C., ... & Saah, A. (2013). Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. *PLoS one*, *8*(12), e83431. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083431

980.) Katayose, M., Hosoya, M., Haneda, T., Yamaguchi, H., Kawasaki, Y., Sato, M., & Wright, P. F. (2011). The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. *Vaccine*, *29*(9), 1844-1849. https://www.sciencedirect.com/science/article/pii/S0264410X10018220

981.) Daley, M. F., Clarke, C. L., Glanz, J. M., Xu, S., Hambidge, S. J., Donahue, J. G., ... & Jackson, M. L. (2018). The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. *Pharmacoepidemiology and drug safety*, *27*(1), 59-68. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437673/

982.) Haber, P., Moro, P. L., Ng, C., Lewis, P. W., Hibbs, B., Schillie, S. F., ... & Cano, M. V. (2018). Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine adverse event reporting system (VAERS), 2005–2015. *Vaccine*, *36*(4), 559-564. https://www.sciencedirect.com/science/article/pii/S0264410X1731722X?via%3Dihub

983.) Moro, P. L., Zheteyeva, Y., Barash, F., Lewis, P., & Cano, M. (2018). Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990–2016. *Vaccine*, *36*(1), 50-54. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626541/

984.) Arana, J., Mba-Jonas, A., Jankosky, C., Lewis, P., Moro, P. L., Shimabukuro, T. T., & Cano, M. (2017). Reports of postural orthostatic tachycardia syndrome after human papillomavirus vaccination in the vaccine adverse event reporting system. *Journal of Adolescent Health*, *61*(5), 577-582. https://www.researchgate.net/profile/Jorge_Arana3/publication/320709890_Reports_of_Postural_Orthostatic_Tachycardia_Syndrome_After_Human_Papillomavirus_Vaccination_in_the_Vaccine_Adverse_Event_Reporting_System/links/5a563b2ca6fdcc30f86d31a2/Reports-of-Postural-Orthostatic-Tachycardia-Syndrome-After-Human-Papillomavirus-Vaccination-in-the-Vaccine-Adverse-Event-Reporting-System.pdf

985.) Arana, J. E., Harrington, T., Cano, M., Lewis, P., Mba-Jonas, A., Rongxia, L., ... & Shimabukuro, T. T. (2018). Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015. *Vaccine*, *36*(13), 1781-1788. http://emesinitiative.org/wp-content/uploads/2019/07/Arana-J.-E.-Harrington-T.-Cano-M.-Lewis-P.-Mba-Jonas-A.-Rongxia-L.-...-Shimabukuro-T.-T.-2018.-Post-licensure-safety-monitoring-of-quadrivalent-human-papillomavirus-vaccine-in-the.pdf

986.) McCarthy, N. L., Sukumaran, L., Newcomer, S., Glanz, J., Daley, M. F., McClure, D., ... & Weintraub, E. (2017). Patterns of childhood immunization and all-cause mortality. *Vaccine*, *35*(48), 6643-6648. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506838/

987.) Gee, J., Sukumaran, L., Weintraub, E., & Vaccine Safety Datalink Team. (2017). Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink. *Vaccine*, *35*(43), 5756-5758. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719547/

988.) Andrews, N., Stowe, J., & Miller, E. (2017). No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. *Vaccine*, *35*(13), 1729-1732. https://www.sciencedirect.com/science/article/pii/S0264410X17301561

989.) Vickers, E. R., McClure, D. L., Naleway, A. L., Jacobsen, S. J., Klein, N. P., Glanz, J. M., ... & Belongia, E. A. (2017). Risk of venous thromboembolism following influenza vaccination in adults aged 50 years and older in the Vaccine Safety Datalink. *Vaccine*, *35*(43), 5872-5877. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508529/

990.) Naleway, A. L., Crane, B., Smith, N., Daley, M. F., Donahue, J., Gee, J., ... & Tseng, H. F. (2016). Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008–2011. *Vaccine*, *34*(1), 167-171. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710959/

991.) Yih, W. K., Greene, S. K., Zichittella, L., Kulldorff, M., Baker, M. A., de Jong, J. L., ... & McMahill-Walraven, C. N. (2016). Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females. *Vaccine*, *34*(1), 172-178. https://www.sciencedirect.com/science/article/pii/S0264410X15013778

992.) Lipkind, H. S., Vazquez-Benitez, G., Nordin, J. D., Romitti, P. A., Naleway, A. L., Klein, N. P., ... & Sukumaran, L. (2017). Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. *Obstetrics and gynecology*, *130*(3), 599. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496947/

993.) DeSilva, M., Vazquez-Benitez, G., Nordin, J. D., Lipkind, H. S., Klein, N. P., Cheetham, T. C., ... & McCarthy, N. L. (2017). Maternal Tdap vaccination and risk of infant morbidity. *Vaccine*, *35*(29), 3655-3660. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506841/

994.) Duffy, J., Lewis, M., Harrington, T., Baxter, R., Belongia, E. A., Jackson, L. A., ... & Daley, M. F. (2017). Live attenuated influenza vaccine use and safety in children and adults with asthma. *Annals of Allergy, Asthma & Immunology*, *118*(4), 439-444. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6674979/

995.) Gaglani, M. J., Piedra, P. A., Riggs, M., Herschler, G., Fewlass, C., & Glezen, W. P. (2008). Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. *The Pediatric infectious disease journal*, *27*(5), 444-452. https://pubmed.ncbi.nlm.nih.gov/18401289/

996.) Kharbanda, E. O., Vazquez-Benitez, G., Romitti, P. A., Naleway, A. L., Cheetham, T. C., Lipkind, H. S., ... & McCarthy, N. (2017). First trimester influenza vaccination and risks for major structural birth defects in offspring. *The Journal of pediatrics*, *187*, 234-239. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506840/

997.) Myers, T. R., McNeil, M. M., Ng, C. S., Li, R., Lewis, P. W., & Cano, M. V. (2017). Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010–2015. *Vaccine*, *35*(14), 1758-1763. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444082/

998.) Su, J. R., Leroy, Z., Lewis, P. W., Haber, P., Marin, M., Leung, J., ... & Shimabukuro, T. T. (2017). Safety of second-dose single-antigen varicella vaccine. *Pediatrics*, *139*(3), e20162536. https://pediatrics.aappublications.org/content/pediatrics/139/3/e20162536.full.pdf

999.) Moro, P., Baumblatt, J., Lewis, P., Cragan, J., Tepper, N., & Cano, M. (2017). Surveillance of adverse events after seasonal influenza vaccination in pregnant women and their infants in the Vaccine Adverse Event Reporting System, July 2010–May 2016. *Drug safety*, *40*(2), 145-152. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602065/

1000.) Holland, D., Booy, R., De Looze, F., Eizenberg, P., McDonald, J., Karrasch, J., ... & Weber, F. (2008). Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. *The Journal of infectious diseases*, *198*(5), 650-658. https://academic.oup.com/jid/article/198/5/650/865335

1001.) Liang, Z., & Wang, J. (2014). EV71 vaccine, an invaluable gift for children. *Clinical & translational immunology*, *3*(10), e28. https://asi.onlinelibrary.wiley.com/doi/full/10.1038/cti.2014.24

1002.) Laksono, B. M., de Vries, R. D., Verburgh, R. J., Visser, E. G., de Jong, A., Fraaij, P. L., ... & van Zelm, M. C. (2018). Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands. *Nature communications*, *9*(1), 1-10. https://www.nature.com/articles/s41467-018-07515-0.pdf?origin=ppub

1003.) Petrova, V. N., Sawatsky, B., Han, A. X., Laksono, B. M., Walz, L., Parker, E., ... & Kellam, P. (2019). Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. *Science Immunology*, *4*(41), eaay6125. https://microbiology.med.uky.edu/sites/default/files/McGilli%20Article%202.pdf

1004.) Blok, B. A., Arts, R. J., van Crevel, R., Benn, C. S., & Netea, M. G. (2015). Trained innate immunity as underlying mechanism for the long‐term, nonspecific effects of vaccines. *Journal of leukocyte biology*, *98*(3), 347-356. https://jlb.onlinelibrary.wiley.com/doi/full/10.1189/jlb.5RI0315-096R

1005.) Campbell, H., Andrews, N., Brown, K. E., & Miller, E. (2007). Review of the effect of measles vaccination on the epidemiology of SSPE. *International journal of epidemiology*, *36*(6), 1334-1348. https://academic.oup.com/ije/article/36/6/1334/821076

1006.) Mina, M. J., Metcalf, C. J. E., De Swart, R. L., Osterhaus, A. D. M. E., & Grenfell, B. T. (2015). Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. *Science*, *348*(6235), 694-699. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823017/

1007.) de Swart, R. L., de Vries, R. D., Rennick, L. J., van Amerongen, G., McQuaid, S., Verburgh, R. J., ... & Ludlow, M. (2017). Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection. *NPJ vaccines*, *2*(1), 1-11. https://www.nature.com/articles/s41541-017-0022-8.pdf?origin=ppub

1008.) Griffin, D. E. (2018). Measles vaccine. *Viral immunology*, *31*(2), 86-95. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863094/

1009.) Loevinsohn, G., Rosman, L., & Moss, W. J. (2019). Measles Seroprevalence and Vaccine Responses in Human Immunodeficiency Virus–infected Adolescents and Adults: A Systematic Review. *Clinical Infectious Diseases*, *69*(5), 836-844. https://academic.oup.com/cid/article-abstract/69/5/836/5188002

1010.) Shafie, A. A., Ahmad, N., Naidoo, J., Foo, C. Y., Wong, C., Pugh, S., & Tan, K. K. (2020). Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia-an economic evaluation. *Human Vaccines & Immunotherapeutics*, *16*(7), 1719-1727. https://www.tandfonline.com/doi/full/10.1080/21645515.2019.1701911?src=recsys

1011.) Nandi, A., Deolalikar, A. B., Bloom, D. E., & Laxminarayan, R. (2019). Haemophilus influenzae type b vaccination and anthropometric, cognitive, and schooling outcomes among Indian children. *Annals of the New York Academy of Sciences*, *1449*(1), 70-82. https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/nyas.14127

1012.) Knobel, D. L., Arega, S., Reininghaus, B., Simpson, G. J., Gessner, B. D., Stryhn, H., & Conan, A. (2017). Rabies vaccine is associated with decreased all-cause mortality in dogs. *Vaccine*, *35*(31), 3844-3849. https://www.sciencedirect.com/science/article/pii/S0264410X1730765X

1013.) Weibel, R. E., Buynak, E. B., McLean, A. A., & Hilleman, M. R. (1975). Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. *Pediatrics*, *56*(3), 380-387. https://pediatrics.aappublications.org/content/56/3/380

1014.) Weibel, R. E., Buynak, E. B., Stokes, J., & Hilleman, M. R. (1972). Measurement of immunity following live mumps (5 years), measles (3 years), and rubella (2½ years) virus vaccines. *Pediatrics*, *49*(3), 334-341. https://pediatrics.aappublications.org/content/49/3/334

1015.) Dhiman, N., Ovsyannikova, I. G., Ryan, J. E., Jacobson, R. M., Vierkant, R. A., Pankratz, V. S., ... & Poland, G. A. (2005). Correlations among measles virus‐specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles–mumps–rubella‐II (MMR‐II) vaccination. *Clinical & Experimental Immunology*, *142*(3), 498-504. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2249.2005.02931.x

1016.) Pedersen, I. R., Mordhorst, C. H., Ewald, T., & Von Magnus, H. (1986). Long-term antibody response after measles vaccination in an isolated arctic society in Greenland. *Vaccine*, *4*(3), 173-178. https://www.sciencedirect.com/science/article/pii/0264410X8690006X

1017.) Date, A. A., Kyaw, M. H., Rue, A. M., Julie, K., Obrecht, L., Krohn, T., ... & Dayan, G. H. (2008). Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. *Journal of Infectious Diseases*, *197*(12), 1662-1668. https://academic.oup.com/jid/article/197/12/1662/865762

1018.) Ljungman, P., Fridell, E., Lönqvist, B., Bolme, P., Böttiger, M., Gahrton, G., ... & Wahren, B. (1989). Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. *Journal of Infectious Diseases*, *159*(4), 610-615. https://academic.oup.com/jid/article-abstract/159/4/610/797533

1019.) Güriş, D., McCready, J., Watson, J. C., Atkinson, W. L., Heath, J. L., Bellini, W. J., & Polloi, A. (1996). Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. *The Pediatric infectious disease journal*,

15(12), 1082-1086.
https://journals.lww.com/pidj/Abstract/1996/12000/Measles_Vaccine_Effectiveness_and_Duration_of.5.aspx

1020.) Carryn, S., Feyssaguet, M., Povey, M., & Di Paolo, E. (2019). Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. *Vaccine*, *37*(36), 5323-5331.
https://www.sciencedirect.com/science/article/pii/S0264410X19309405

1021.) Kaaijk, P., Wijmenga-Monsuur, A. J., van Houten, M. A., Veldhuijzen, I. K., Ten Hulscher, H. I., Kerkhof, J., ... & van Binnendijk, R. S. (2020). A third dose of measles-mumps-rubella vaccine to improve immunity against mumps in young adults. *The Journal of Infectious Diseases*, *221*(6), 902-909.
https://academic.oup.com/jid/article/221/6/902/5476427

1022.) Hawkes, D., Benhamu, J., Sidwell, T., Miles, R., & Dunlop, R. A. (2015). Revisiting adverse reactions to vaccines: a critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA). *Journal of autoimmunity*, *59*, 77-84.
https://www.researchgate.net/profile/David_Hawkes2/publication/273833672_Revisiting_adverse_reactions_to_vaccines_A_critical_appraisal_of_Autoimmune_Syndrome_Induced_by_Adjuvants_ASIA/links/59e7d09e458515c3630fb305/Revisiting-adverse-reactions-to-vaccines-A-critical-appraisal-of-Autoimmune-Syndrome-Induced-by-Adjuvants-ASIA.pdf

1023.) Lisse, I. M., Aaby, P., Knudsen, K., Whittle, H., & Andersen, H. (1994). Long term impact of high titer Edmonston-Zagreb measles vaccine on T lymphocyte subsets. *The Pediatric infectious disease journal*, *13*(2), 109-112.
https://europepmc.org/article/med/8190534

1024.) Agur, Z., Cojocaru, L., Mazor, G., Anderson, R. M., & Danon, Y. L. (1993). Pulse mass measles vaccination across age cohorts. *Proceedings of the National Academy of Sciences*, *90*(24), 11698-11702.
https://www.pnas.org/content/pnas/90/24/11698.full.pdf

1025.) Liao, H. Y., Wang, S. C., Ko, Y. A., Lin, K. I., Ma, C., Cheng, T. J. R., & Wong, C. H. (2020). Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes. *Proceedings of the National Academy of Sciences*, *117*(30), 17757-17763.
https://www.pnas.org/content/117/30/17757

1026.) Pleguezuelos, O., Dille, J., de Groen, S., Oftung, F., Niesters, H. G., Islam, M. A., ... & Perez, A. F. (2020). Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial. *Annals of Internal Medicine*, *172*(7), 453-462. https://www.mfprac.com/web2020/07literature/literature/Infectious_Dis/InfluenzaVaccineUniversal_Pleguezuelos.pdf

1027.) McLean, H. Q., Caspard, H., Griffin, M. R., Gaglani, M., Peters, T. R., Poehling, K. A., ... & Belongia, E. A. (2018). Association of prior vaccination with influenza vaccine effectiveness in children receiving live attenuated or inactivated vaccine. *JAMA network open*, *1*(6), e183742-e183742. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2709714

1028.) Omer, S. B. (2017). Maternal immunization. *New England Journal of Medicine*, *376*(13), 1256-1267. https://medicinainternaelsalvador.com/wp-content/uploads/2017/04/Maternal-Immunization.pdf

1029.) Nunes, M. C., Cutland, C. L., Jones, S., Hugo, A., Madimabe, R., Simoes, E. A., ... & Madhi, S. A. (2016). Duration of infant protection against influenza illness conferred by maternal immunization: secondary analysis of a randomized clinical trial. *JAMA pediatrics*, *170*(9), 840-847. https://jamanetwork.com/journals/jamapediatrics/article-abstract/2531457

1030.) Regan, A. K., De Klerk, N., Moore, H. C., Omer, S. B., Shellam, G., & Effler, P. V. (2016). Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant women: a retrospective cohort study. *Vaccine*, *34*(32), 3649-3656. https://www.sciencedirect.com/science/article/pii/S0264410X1630322X

1031.) August, A., Glenn, G. M., Kpamegan, E., Hickman, S. P., Jani, D., Lu, H., ... & Fries, L. F. (2017). A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. *Vaccine*, *35*(30), 3749-3759. https://www.sciencedirect.com/science/article/pii/S0264410X17306813

1032.) Venkatraman, N., Anagnostou, N., Bliss, C., Bowyer, G., Wright, D., Lövgren-Bengtsson, K., ... & Hill, A. V. (2017). Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. *Vaccine*, *35*(45), 6208-6217. https://www.sciencedirect.com/science/article/pii/S0264410X17312483

1033.) Ogwang, C., Afolabi, M., Kimani, D., Jagne, Y. J., Sheehy, S. H., Bliss, C. M., ... & Anagnostou, N. A. (2013). Safety and immunogenicity of heterologous prime-boost

immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. *PloS one*, *8*(3), e57726. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057726

1034.) Kimiya, T., Shinjoh, M., Anzo, M., Takahashi, H., Sekiguchi, S., Sugaya, N., & Takahashi, T. (2018). Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case-control study design and a traditional case-control study design. *European Journal of Pediatrics*, *177*(7), 1009-1017. https://link.springer.com/article/10.1007/s00431-018-3145-7

1035.) Quach, T. H. T., Mallis, N. A., & Cordero, J. F. (2020). Influenza Vaccine Efficacy and Effectiveness in Pregnant Women: Systematic Review and Meta-analysis. *Maternal and Child Health Journal*, *24*(2), 229-240. https://link.springer.com/article/10.1007/s10995-019-02844-y

1036.) Mohammed, H., Roberts, C. T., Grzeskowiak, L. E., Giles, L. C., Dekker, G. A., & Marshall, H. S. (2020). Safety and protective effects of maternal influenza vaccination on pregnancy and birth outcomes: A prospective cohort study. *EClinicalMedicine*, *26*, 100522. https://www.sciencedirect.com/science/article/pii/S2589537020302662

1037.) McHugh, L., Andrews, R. M., Lambert, S. B., Viney, K. A., Wood, N., Perrett, K. P., ... & O'Grady, K. A. F. (2017). Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy, 2012–2014: The FluMum study. *Vaccine*, *35*(10), 1403-1409. https://www.sciencedirect.com/science/article/pii/S0264410X1730155X

1038.) Fell, D. B., Wilson, K., Ducharme, R., Hawken, S., Sprague, A. E., Kwong, J. C., ... & Walker, M. C. (2016). Infant respiratory outcomes associated with prenatal exposure to maternal 2009 A/H1N1 influenza vaccination. *PloS one*, *11*(8), e0160342. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160342

1039.) Zerbo, O., Modaressi, S., Chan, B., Goddard, K., Lewis, N., Bok, K., ... & Baxter, R. (2017). No association between influenza vaccination during pregnancy and adverse birth outcomes. *Vaccine*, *35*(24), 3186-3190. https://www.sciencedirect.com/science/article/pii/S0264410X17305753

1040.) Regan, A. K., Moore, H. C., De Klerk, N., Omer, S. B., Shellam, G., Mak, D. B., & Effler, P. V. (2016). Seasonal trivalent influenza vaccination during pregnancy and the incidence of stillbirth: population-based retrospective cohort study. *Clinical Infectious Diseases*, *62*(10), 1221-1227.

https://academic.oup.com/cid/article/62/10/1221/2462656

1041.) Regan, A. K., De Klerk, N., Moore, H. C., Omer, S. B., Shellam, G., & Effler, P. V. (2016). Effect of maternal influenza vaccination on hospitalization for respiratory infections in newborns. *The Pediatric infectious disease journal*, *35*(10), 1097-1103. https://pubmed.ncbi.nlm.nih.gov/27314823/

1042.) Shakib, J. H., Korgenski, K., Presson, A. P., Sheng, X., Varner, M. W., Pavia, A. T., & Byington, C. L. (2016). Influenza in infants born to women vaccinated during pregnancy. *Pediatrics*, *137*(6), e20152360. https://pediatrics.aappublications.org/content/pediatrics/137/6/e20152360.full.pdf

1043.) Regan, A. K., Tracey, L. E., Blyth, C. C., Richmond, P. C., & Effler, P. V. (2016). A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy. *Vaccine*, *34*(20), 2299-2304. https://www.sciencedirect.com/science/article/pii/S0264410X16300810

1044.) Naidu, M. A., Muljadi, R., Davies-Tuck, M. L., Wallace, E. M., & Giles, M. L. (2016). The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study. *American journal of obstetrics and gynecology*, *215*(2), 237-e1. https://www.ajog.org/article/S0002-9378(16)00448-8/fulltext

1045.) Ohfuji, S., Deguchi, M., Tachibana, D., Koyama, M., Takagi, T., Yoshioka, T., ... & Kondo, K. (2018). Protective effect of maternal influenza vaccination on influenza in their infants: a prospective cohort study. *The Journal of Infectious Diseases*, *217*(6), 878-886. https://academic.oup.com/jid/article/217/6/878/4693945

1046.) Olsen, S. J., Mirza, S. A., Vonglokham, P., Khanthamaly, V., Chitry, B., Pholsena, V., ... & Corwin, A. (2016). The effect of influenza vaccination on birth outcomes in a cohort of pregnant women in Lao PDR, 2014–2015. *Reviews of Infectious Diseases*, *63*(4), 487-494. https://academic.oup.com/cid/article/63/4/487/2595014

1047.) Mutsaerts, E., Madhi, S. A., Cutland, C. L., Jones, S., Hugo, A., Trenor, S., ... & Nunes, M. C. (2016). Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial. *Expert review of vaccines*, *15*(8), 1055-1062. https://www.tandfonline.com/doi/pdf/10.1080/14760584.2016.1192473

1048.) Manske, J. M. (2014). Efficacy and effectiveness of maternal influenza vaccination during pregnancy: a review of the evidence. *Maternal and child health journal*, *18*(7), 1599-1609. https://pubmed.ncbi.nlm.nih.gov/24272875/

1049.) Thompson, M. G., Li, D. K., Shifflett, P., Sokolow, L. Z., Ferber, J. R., Kurosky, S., ... & Kauffman, T. L. (2014). Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010–2011 and 2011–2012 influenza seasons. *Clinical infectious diseases*, *58*(4), 449-457. https://academic.oup.com/cid/article/58/4/449/347103

1050.) Benowitz, I., Esposito, D. B., Gracey, K. D., Shapiro, E. D., & Vázquez, M. (2010). Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. *Clinical Infectious Diseases*, *51*(12), 1355-1361. https://academic.oup.com/cid/article/51/12/1355/316344

1051.) Nordin, J. D., Kharbanda, E. O., Benitez, G. V., Lipkind, H., Vellozzi, C., DeStefano, F., & Datalink, V. S. (2014). Maternal influenza vaccine and risks for preterm or small for gestational age birth. *The Journal of pediatrics*, *164*(5), 1051-1057. https://www.sciencedirect.com/science/article/abs/pii/S0022347614000651

1052.) Oppermann, M., Fritzsche, J., Weber-Schoendorfer, C., Keller-Stanislawski, B., Allignol, A., Meister, R., & Schaefer, C. (2012). A (H1N1) v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. *Vaccine*, *30*(30), 4445-4452. https://www.sciencedirect.com/science/article/pii/S0264410X12006275

1053.) Loubet, P., Kerneis, S., Anselem, O., Tsatsaris, V., Goffinet, F., & Launay, O. (2014). Should expectant mothers be vaccinated against flu? A safety review. *Expert opinion on drug safety*, *13*(12), 1709-1720. https://www.tandfonline.com/doi/full/10.1517/14740338.2014.977252

1054.) Fell, D. B., Platt, R. W., Lanes, A., Wilson, K., Kaufman, J. S., Basso, O., & Buckeridge, D. (2015). Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. *BJOG: An International Journal of Obstetrics & Gynaecology*, *122*(1), 17-26. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.12977

1055.) Omer, S. B., Clark, D. R., Madhi, S. A., Tapia, M. D., Nunes, M. C., Cutland, C. L., ... & Steinhoff, M. C. (2020). Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials. *The Lancet Respiratory Medicine*, *8*(6), 597-608. https://www.sciencedirect.com/science/article/pii/S2213260019304795

1056.) Oboho, I. K., Reed, C., Gargiullo, P., Leon, M., Aragon, D., Meek, J., ... & Bargsten, M. (2016). Benefit of early initiation of influenza antiviral treatment to pregnant women

hospitalized with laboratory-confirmed influenza. *The Journal of infectious diseases*, *214*(4), 507-515.
https://academic.oup.com/jid/article/214/4/507/2237788

1057.) Jarvis, J. R., Dorey, R. B., Warricker, F. D., Alwan, N. A., & Jones, C. E. (2020). The effectiveness of influenza vaccination in pregnancy in relation to child health outcomes: Systematic review and meta-analysis. *Vaccine*, *38*(7), 1601-1613.
https://www.sciencedirect.com/science/article/pii/S0264410X19317207

1058.) Foo, D. Y., Sarna, M., Pereira, G., Moore, H. C., Fell, D. B., & Regan, A. K. (2020). Early childhood health outcomes following in utero exposure to influenza vaccines: a systematic review. *Pediatrics*, *146*(2), e20200375.
https://www.researchgate.net/profile/Minda_Sarna/publication/343241157_Early_Childhood_Health_Outcomes_Following_In_Utero_Exposure_to_Influenza_Vaccines_A_Systematic_Review/links/5f294590299bf134049ee673/Early-Childhood-Health-Outcomes-Following-In-Utero-Exposure-to-Influenza-Vaccines-A-Systematic-Review.pdf

1059.) Chen, M. W., Cheng, T. J. R., Huang, Y., Jan, J. T., Ma, S. H., Alice, L. Y., ... & Ho, D. D. (2008). A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. *Proceedings of the National Academy of Sciences*, *105*(36), 13538-13543.
https://www.pnas.org/content/105/36/13538?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Proc_Natl_Acad_Sci_U_S_A_TrendMD_0

1060.) Chen, J. R., Yu, Y. H., Tseng, Y. C., Chiang, W. L., Chiang, M. F., Ko, Y. A., ... & Lin, K. I. (2014). Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. *Proceedings of the National Academy of Sciences*, *111*(7), 2476-2481.
https://www.pnas.org/content/111/7/2476.short?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Proc_Natl_Acad_Sci_U_S_A_TrendMD_0

1061.) Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., ... & Sy, S. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. *The Lancet*, *395*(10224), 575-590.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30068-4/fulltext

1062.) Liebowitz, D., Gottlieb, K., Kolhatkar, N. S., Garg, S. J., Asher, J. M., Nazareno, J., ... & Tucker, S. N. (2020). Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. *The Lancet. Infectious diseases*, *20*(4), 435-444. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30584-5/fulltext

1063.) Clarke, D. K., Xu, R., Matassov, D., Latham, T. E., Ota-Setlik, A., Gerardi, C. S., ... & Tremblay, M. (2020). Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. *The Lancet. Infectious diseases*, *20*(4), 455-466. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30614-0/fulltext

1064.) Lanzieri, T. M., Linhares, A. C., Costa, I., Kolhe, D. A., Cunha, M. H., Ortega-Barria, E., & Colindres, R. E. (2011). Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. *International Journal of Infectious Diseases*, *15*(3), e206-e210. https://www.sciencedirect.com/science/article/pii/S1201971210025427

1065.) Colmegna, I., Useche, M. L., Rodriguez, K., McCormack, D., Alfonso, G., Patel, A., ... & Ward, B. J. (2020). Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. *The Lancet Rheumatology*, *2*(1), e14-e23. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(19)30094-3/fulltext

1066.) Qadri, F., Akhtar, M., Bhuiyan, T. R., Chowdhury, M. I., Ahmed, T., Rafique, T. A., ... & Wiklund, G. (2020). Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial. *The Lancet Infectious Diseases*, *20*(2), 208-219. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30571-7/fulltext

1067.) Lu, Y., Liang, X. F., Wang, F. Z., Yan, L., Li, R. C., Li, Y. P., ... & Zhuang, H. (2017). Hepatitis B vaccine alone may be enough for preventing hepatitis B virus transmission in neonates of HBsAg (+)/HBeAg (−) mothers. *Vaccine*, *35*(1), 40-45. https://www.sciencedirect.com/science/article/pii/S0264410X16311239

1068.) VanCott, J. L., Prada, A. E., McNeal, M. M., Stone, S. C., Basu, M., Huffer, B., ... & Choi, A. H. C. (2006). Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT (R192G) or orally with live rhesus rotavirus vaccine candidates. *Journal of virology*, *80*(10), 4949-4961. https://jvi.asm.org/content/80/10/4949.long

1069.) Burnett, E., Jonesteller, C. L., Tate, J. E., Yen, C., & Parashar, U. D. (2017). Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. *The Journal of infectious diseases*, *215*(11), 1666-1672. https://academic.oup.com/jid/article/215/11/1666/3738521

1070.) Abeid, K. A., Jani, B., Cortese, M. M., Kamugisha, C., Mwenda, J. M., Pandu, A. S., ... & Saleh, A. A. (2017). Monovalent rotavirus vaccine effectiveness and impact on rotavirus hospitalizations in Zanzibar, Tanzania: data from the first 3 years after introduction. *The Journal of infectious diseases*, *215*(2), 183-191. https://academic.oup.com/jid/article/215/2/183/2514392#86767324

1071.) Markkula, J., Hemming-Harlo, M., Salminen, M. T., Savolainen-Kopra, C., Pirhonen, J., Al-Hello, H., & Vesikari, T. (2017). Rotavirus epidemiology 5–6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly. *Infectious Diseases*, *49*(5), 388-395. https://www.tandfonline.com/doi/abs/10.1080/23744235.2016.1275773

1072.) Lawrence, J., He, S., Martin, J., Schödel, F., Ciarlet, M., & Murray, A. V. (2014). Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects. *Human vaccines & immunotherapeutics*, *10*(8), 2247-2254. https://www.tandfonline.com/doi/full/10.4161/hv.29107

1073.) Standaert, B., Strens, D., Alwan, A., & Raes, M. (2016). Medium-to long-term impact of rotavirus vaccination on hospital care in Belgium: a 7-year follow-up of the Rotavirus Belgium Impact Study (RotaBIS). *Infectious diseases and therapy*, *5*(1), 31-44. https://www.researchgate.net/profile/Danielle_Strens/publication/288933572_Medium-_to_Long-Term_Impact_of_Rotavirus_Vaccination_on_Hospital_Care_in_Belgium_A_7-Year_Follow-Up_of_the_Rotavirus_Belgium_Impact_Study_RotaBIS/links/56eaba7508aee3ae24a27fb5/Medium-to-Long-Term-Impact-of-Rotavirus-Vaccination-on-Hospital-Care-in-Belgium-A-7-Year-Follow-Up-of-the-Rotavirus-Belgium-Impact-Study-RotaBIS.pdf

1074.) Baker, J. M., Tate, J. E., Steiner, C. A., Haber, M. J., Parashar, U. D., & Lopman, B. A. (2019). Longer-term direct and indirect effects of infant rotavirus vaccination across all ages in the United States in 2000–2013: analysis of a large hospital discharge data set. *Clinical Infectious Diseases*, *68*(6), 976-983. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182126/

1075.) Thomas, S. L., Walker, J. L., Fenty, J., Atkins, K. E., Elliot, A. J., Hughes, H. E., ... & Andrews, N. J. (2017). Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted. *Vaccine*, *35*(4), 680-686. https://www.sciencedirect.com/science/article/pii/S0264410X16311197

1076.) Reyes, J. F., Wood, J. G., Beutels, P., Macartney, K., McIntyre, P., Menzies, R., ... & Newall, A. T. (2017). Beyond expectations: post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. *Vaccine*, *35*(2), 345-352. https://www.sciencedirect.com/science/article/pii/S0264410X16311185

1077.) Pardo-Seco, J., Cebey-López, M., Martinón-Torres, N., Salas, A., Gómez-Rial, J., Rodriguez-Tenreiro, C., ... & Martinón-Torres, F. (2015). Impact of rotavirus vaccination on childhood hospitalization for seizures. *The Pediatric infectious disease journal*, *34*(7), 769-773. https://www.researchgate.net/profile/Jacobo_Pardo-Seco/publication/275660907_Impact_of_Rotavirus_Vaccination_on_Childhood_Hospitalization_for_Seizures/links/5cd91dbba6fdccc9dda6ba3b/Impact-of-Rotavirus-Vaccination-on-Childhood-Hospitalization-for-Seizures.pdf

1078.) Payne, D. C., Englund, J. A., Weinberg, G. A., Halasa, N. B., Boom, J. A., Staat, M. A., ... & Chappell, J. (2019). Association of Rotavirus Vaccination With Inpatient and Emergency Department Visits Among Children Seeking Care for Acute Gastroenteritis, 2010-2016. *JAMA Network Open*, *2*(9), e1912242-e1912242. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2752101

1079.) Atchison, C. J., Stowe, J., Andrews, N., Collins, S., Allen, D. J., Nawaz, S., ... & Ladhani, S. N. (2016). Rapid declines in age group–specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England and Wales. *The Journal of infectious diseases*, *213*(2), 243-249. https://academic.oup.com/jid/article/213/2/243/2459331

1080.) McGrath, E. J., Thomas, R., Duggan, C., & Asmar, B. I. (2014). Pentavalent rotavirus vaccine in infants with surgical gastrointestinal disease. *Journal of pediatric gastroenterology and nutrition*, *59*(1), 44-48. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624282/

1081.) Inns, T., Trindall, A., Dunling-Hall, S., & Shankar, A. G. (2016). Introduction of a new rotavirus vaccine: initial results of uptake and impact on laboratory confirmed cases in Anglia and Essex, United Kingdom, July 2015. *Human vaccines & immunotherapeutics*, *12*(4), 1040-1044.

https://www.tandfonline.com/doi/full/10.1080/21645515.2015.1108501

1082.) Baker, J. M., Dahl, R. M., Cubilo, J., Parashar, U. D., & Lopman, B. A. (2019). Effects of the rotavirus vaccine program across age groups in the United States: analysis of national claims data, 2001–2016. *BMC infectious diseases*, *19*(1), 186. https://link.springer.com/article/10.1186/s12879-019-3816-7#citeas

1083.) Dahl, R. M., Curns, A. T., Tate, J. E., & Parashar, U. D. (2018). Effect of Rotavirus Vaccination on Acute Diarrheal Hospitalizations Among Low and Very Low Birth Weight US Infants, 2001–2015. *The Pediatric infectious disease journal*, *37*(8), 817-822. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545588/

1084.) Maguire, J. E., Glasgow, K., Glass, K., Roczo-Farkas, S., Bines, J. E., Sheppeard, V., ... & Quinn, H. E. (2019). Rotavirus epidemiology and monovalent rotavirus vaccine effectiveness in Australia: 2010–2017. *Pediatrics*, *144*(4), e20191024. https://pediatrics.aappublications.org/content/144/4/e20191024?utm_source=highwire&utm_medium=email&utm_campaign=Pediatrics_etoc&sso=1&sso_redirect_count=1&nfstatus=401&nftoken=00000000-0000-0000-0000-000000000000&nfstatusdescription=ERROR%3A+No+local+token

1085.) Stowe, J., Andrews, N., Ladhani, S., & Miller, E. (2016). The risk of intussusception following monovalent rotavirus vaccination in England: a self-controlled case-series evaluation. *Vaccine*, *34*(32), 3684-3689. https://www.sciencedirect.com/science/article/pii/S0264410X16302043

1086.) Hemming-Harlo, M., Markkula, J., Huhti, L., Salminen, M., & Vesikari, T. (2016). Decrease of rotavirus gastroenteritis to a low level without resurgence for five years after universal RotaTeq vaccination in Finland. *The Pediatric infectious disease journal*, *35*(12), 1304-1308. https://journals.lww.com/pidj/Abstract/2016/12000/Decrease_of_Rotavirus_Gastroenteritis_to_a_Low.6.aspx

1087.) Tate, J. E., Yen, C., Steiner, C. A., Cortese, M. M., & Parashar, U. D. (2016). Intussusception rates before and after the introduction of rotavirus vaccine. *Pediatrics*, *138*(3), e20161082. https://pediatrics.aappublications.org/content/pediatrics/138/3/e20161082.full.pdf

1088.) Shah, M. P., Dahl, R. M., Parashar, U. D., & Lopman, B. A. (2018). Annual changes in rotavirus hospitalization rates before and after rotavirus vaccine implementation in the United States. *PloS one*, *13*(2), e0191429.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191429

1089.) Thrall, S., Doll, M. K., Nhan, C., Gonzales, M., Perreault, T., Lamer, P., & Quach, C. (2015). Evaluation of pentavalent rotavirus vaccination in neonatal intensive care units. *Vaccine*, *33*(39), 5095-5102. https://www.sciencedirect.com/science/article/pii/S0264410X15011299

1090.) Muhsen, K., Kassem, E., Rubenstein, U., Goren, S., Ephros, M., Cohen, D., & Shulman, L. M. (2016). Incidence of rotavirus gastroenteritis hospitalizations and genotypes, before and five years after introducing universal immunization in Israel. *Vaccine*, *34*(48), 5916-5922. https://www.sciencedirect.com/science/article/pii/S0264410X16309379

1091.) Javid, P. J., Sanchez, S. E., Jacob, S., McNeal, M. M., Horslen, S. P., & Englund, J. A. (2014). The safety and immunogenicity of rotavirus vaccination in infants with intestinal failure. *Journal of the Pediatric Infectious Diseases Society*, *3*(1), 57-65. https://academic.oup.com/jpids/article/3/1/57/925794

1092.) Standaert, B., Gomez, J. A., Raes, M., Debrus, S., Velázquez, F. R., & Postma, M. J. (2013). Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. *PLoS One*, *8*(1), e53864. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053864

1093.) Marlow, R., Muir, P., Vipond, B., Lyttle, M., Trotter, C., & Finn, A. (2015). Assessing the impacts of the first year of rotavirus vaccination in the United Kingdom. *Eurosurveillance*, *20*(48), 30077. https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/20/48/eurosurv-20-48-6.pdf?expires=1603675164&id=id&accname=guest&checksum=5443BCA0655CAE34082341D0D536EE12

1094.) Sheridan, S. L., Ware, R. S., Grimwood, K., & Lambert, S. B. (2016). Febrile seizures in the era of rotavirus vaccine. *Journal of the Pediatric Infectious Diseases Society*, *5*(2), 206-209. https://academic.oup.com/jpids/article/5/2/206/2580045

1095.) Fang, A. Y., & Tingay, D. G. (2012). Early observations in the use of oral rotavirus vaccination in infants with functional short gut syndrome. *Journal of paediatrics and child health*, *48*(6), 512-516. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1440-1754.2011.02227.x

1096.) Hemming-Harlo, M., Vesikari, T., Uhari, M., Renko, M., Salminen, M., Torcel-Pagnon, L., ... & Bricout, H. (2017). Sustained high effectiveness of RotaTeq on hospitalizations

attributable to rotavirus-associated gastroenteritis during 4 years in Finland. *Journal of the Pediatric Infectious Diseases Society*, *6*(4), 317-323. https://academic.oup.com/jpids/article/6/4/317/2290961

1097.) Mujuru, H. A., Burnett, E., Nathoo, K. J., Ticklay, I., Gonah, N. A., Mukaratirwa, A., ... & Mwenda, J. M. (2019). Monovalent Rotavirus Vaccine Effectiveness Against Rotavirus Hospitalizations Among Children in Zimbabwe. *Clinical Infectious Diseases*, *69*(8), 1339-1344. https://academic.oup.com/cid/article/69/8/1339/5258061

1098.) Omenaca, F., Sarlangue, J., Szenborn, L., Nogueira, M., Suryakiran, P. V., Smolenov, I. V., ... & ROTA-054 Study Group. (2012). Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. *The Pediatric infectious disease journal*, *31*(5), 487-493. https://journals.lww.com/pidj/fulltext/2012/05000/Safety,_Reactogenicity_and_Immunogenicity_of_the.14.aspx

1099.) Anderson, E. J., Shippee, D. B., Weinrobe, M. H., Davila, M. D., Katz, B. Z., Reddy, S., ... & Noskin, G. A. (2013). Indirect protection of adults from rotavirus by pediatric rotavirus vaccination. *Clinical Infectious Diseases*, *56*(6), 755-760. https://academic.oup.com/cid/article/56/6/755/310406

1100.) Ray, P., Black, S., Shinefield, H., Dillon, A., Carpenter, D., Lewis, E., ... & Vaccine Safety Datalink Team. (2011). Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. *Vaccine*, *29*(38), 6592-6597. https://www.sciencedirect.com/science/article/pii/S0264410X11010061

1101.) Donegan, K., Beau-Lejdstrom, R., King, B., Seabroke, S., Thomson, A., & Bryan, P. (2013). Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. *Vaccine*, *31*(43), 4961-4967. http://qna.files.parliament.uk/qna-attachments/773017/original/MHRA%20CPRD%20study%20HPV%20and%20CFS.pdf

1102.) Willhite, C. C., Karyakina, N. A., Yokel, R. A., Yenugadhati, N., Wisniewski, T. M., Arnold, I. M., ... & Krewski, D. (2014). Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. *Critical reviews in toxicology*, *44*(sup4), 1-80.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997813/

1103.) Lindblad, E. B. (2004). Aluminium compounds for use in vaccines. *Immunology and cell biology*, *82*(5), 497-505.
http://sf.uploads.ru/7fRoN.pdf

1104.) Ni, Y. H., Huang, L. M., Chang, M. H., Yen, C. J., Lu, C. Y., You, S. L., ... & Chen, D. S. (2007). Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. *Gastroenterology*, *132*(4), 1287-1293.
https://www.gastrojournal.org/article/S0016-5085(07)00414-3/fulltext

1105.) Chen, C. Y., Hsu, H. Y., Liu, C. C., Chang, M. H., & Ni, Y. H. (2010). Stable seroepidemiology of hepatitis B after universal immunization in Taiwan: A 3-year study of national surveillance of primary school students. *Vaccine*, *28*(34), 5605-5608.
https://www.sciencedirect.com/science/article/pii/S0264410X10008297

1106.) Chen, C. L., Yang, J. Y., Lin, S. F., Sun, C. A., Bai, C. H., You, S. L., ... & Chen, D. S. (2015). Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. *Journal of hepatology*, *63*(2), 354-363.
https://www.sciencedirect.com/science/article/abs/pii/S0168827815001919

1107.) Chen, S. M., Kung, C. M., Yang, W. J., & Wang, H. L. (2011). Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan. *Journal of clinical virology*, *52*(1), 11-16.
https://www.sciencedirect.com/science/article/abs/pii/S1386653211002605

1108.) Chen, D. S. (2009). Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. *Journal of hepatology*, *50*(4), 805-816.
https://www.sciencedirect.com/science/article/pii/S0168827809000579

1109.) Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Leroux‐Roels, G., Kuriyakose, S., Leyssen, M., & Jacquet, J. M. (2011). Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. *Journal of viral hepatitis*, *18*(5), 369-375.
https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2893.2010.01312.x

1110.) Chang, M. H., Chen, T. H. H., Hsu, H. M., Wu, T. C., Kong, M. S., Liang, D. C., ... & Chen, D. S. (2005). Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. *Clinical cancer research*, *11*(21), 7953-7957.
https://clincancerres.aacrjournals.org/content/11/21/7953.full

1111.) Ni, Y. H., Chang, M. H., Huang, L. M., Chen, H. L., Hsu, H. Y., Chiu, T. Y., ... & Chen, D. S. (2001). Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Annals of internal medicine*, *135*(9), 796-800. https://www.acpjournals.org/doi/abs/10.7326/0003-4819-135-9-200111060-00009

1112.) Chun-Chieh, C. H. E. N., Chi-Hua, Y. E. N., Wei-Ya, W. U., Suh-Woan, H. U., Shiuan-Chih, C. H. E. N., Bell, W. R., & Meng-Chih, L. E. E. (2007). Epidemiology of hepatitis B virus infection among young adults in Taiwan, China after public vaccination program. *Chinese medical journal*, *120*(13), 1155-1158. https://journals.lww.com/cmj/Fulltext/2007/07010/Epidemiology_of_hepatitis_B_virus_infection_among.8.aspx

1113.) Chiang, C. J., Yang, Y. W., You, S. L., Lai, M. S., & Chen, C. J. (2013). Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. *Jama*, *310*(9), 974-976. https://jamanetwork.com/journals/jama/article-abstract/1734688

1114.) Su, F. H., Chen, J. D., Cheng, S. H., Lin, C. H., Liu, Y. H., & Chu, F. Y. (2007). Seroprevalence of Hepatitis‐B infection amongst Taiwanese university students 18 years following the commencement of a national Hepatitis‐B vaccination program. *Journal of medical virology*, *79*(2), 138-143. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20771

1115.) Chang, M. H., You, S. L., Chen, C. J., Liu, C. J., Lee, C. M., Lin, S. M., ... & Chen, D. S. (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. *Journal of the National Cancer Institute*, *101*(19), 1348-1355. https://academic.oup.com/jnci/article/101/19/1348/1074629

1116.) Chien, Y. C., Jan, C. F., Kuo, H. S., & Chen, C. J. (2006). Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. *Epidemiologic reviews*, *28*(1), 126-135. https://academic.oup.com/epirev/article/28/1/126/570747

1117.) Qu, C., Chen, T., Fan, C., Zhan, Q., Wang, Y., Lu, J., ... & Zhu, J. (2014). Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. *PLoS Med*, *11*(12), e1001774. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001774

1118.) Pezzotti, P., Bellino, S., Prestinaci, F., Iacchini, S., Lucaroni, F., Camoni, L., ... & Rezza, G. (2018). The impact of immunization programs on 10 vaccine preventable diseases in Italy: 1900–2015. *Vaccine*, *36*(11), 1435-1443. https://www.vaccinarsintoscana.org/assets/uploads/files/149/original-article-vaccine.pdf

1119.) Van der Sande, M. A., Waight, P. A., Mendy, M., Zaman, S., Kaye, S., Sam, O., ... & Bah, E. (2007). Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. *PloS one*, *2*(8), e753. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000753

1120.) Chang, M. H., Shau, W. Y., Chen, C. J., Wu, T. C., Kong, M. S., Liang, D. C., ... & Taiwan Childhood Hepatoma Study Group. (2000). Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. *Jama*, *284*(23), 3040-3042. https://jamanetwork.com/journals/jama/article-abstract/193365

1121.) Chen, H. L., Chang, M. H., Ni, Y. H., Hsu, H. Y., Lee, P. L., Lee, C. Y., & Chen, D. S. (1996). Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. *Jama*, *276*(11), 906-908. https://jamanetwork.com/journals/jama/article-abstract/408009

1122.) Lin, H. H., Wang, L. Y., Hu, C. T., Huang, S. C., Huang, L. C., Lin, S. S., ... & Chen, C. L. (2003). Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. *Journal of medical virology*, *69*(4), 471-474. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10333

1123.) Hsu, H. M., Lu, C. F., Lee, S. C., Lin, S. R., & Chen, D. S. (1999). Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. *The Journal of infectious diseases*, *179*(2), 367-370. https://academic.oup.com/jid/article/179/2/367/998572

1124.) Manam, S., Ledwith, B. J., Barnum, A. B., Troilo, P. J., Pauley, C. J., Harper, L. B., ... & Pacchione, S. J. (2000). Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. *Intervirology*, *43*(4-6), 273-281. https://www.karger.com/Article/Abstract/53994

1125.) Graham, B. S., Enama, M. E., Nason, M. C., Gordon, I. J., Peel, S. A., Ledgerwood, J. E., ... & Koup, R. A. (2013). DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. *PloS one*, *8*(4), e59340. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059340

1126.) Loeb, M., Russell, M. L., Moss, L., Fonseca, K., Fox, J., Earn, D. J., ... & Vooght, M. (2010). Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. *Jama*, *303*(10), 943-950. https://jamanetwork.com/journals/jama/article-abstract/185509

1127.) King Jr, J. C., Stoddard, J. J., Gaglani, M. J., Moore, K. A., Magder, L., McClure, E., ... & Neuzil, K. (2006). Effectiveness of school-based influenza vaccination. *New England Journal of Medicine*, *355*(24), 2523-2532. https://www.nejm.org/doi/full/10.1056/NEJMoa055414

1128.) Rhorer, J., Ambrose, C. S., Dickinson, S., Hamilton, H., Oleka, N. A., Malinoski, F. J., & Wittes, J. (2009). Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. *Vaccine*, *27*(7), 1101-1110. https://www.sciencedirect.com/science/article/pii/S0264410X08016526

1129.) Kwong, J. C., Stukel, T. A., Lim, J., McGeer, A. J., Upshur, R. E. G., Johansen, H., ... & Svenson, L. W. (2008). The effect of universal influenza immunization on mortality and health care use. *PLoS medicine*, *5*(10), e211. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0050211

1130.) Vesikari, T., Fleming, D. M., Aristegui, J. F., Vertruyen, A., Ashkenazi, S., Rappaport, R., ... & Forrest, B. D. (2006). Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. *Pediatrics*, *118*(6), 2298-2312. https://www.researchgate.net/profile/Bruce_Forrest/publication/6655540_Safety_Efficacy_and_Effectiveness_of_Cold-Adapted_Influenza_Vaccine-Trivalent_Against_Community-Acquired_Culture-Confirmed_Influenza_in_Young_Children_Attending_Day_Care/links/00b7d525401a5b1db2000000/Safety-Efficacy-and-Effectiveness-of-Cold-Adapted-Influenza-Vaccine-Trivalent-Against-Community-Acquired-Culture-Confirmed-Influenza-in-Young-Children-Attending-Day-Care.pdf

1131.) Jordan, R., Connock, M., Albon, E., Fry-Smith, A., Olowokure, B., Hawker, J., & Burls, A. (2006). Universal vaccination of children against influenza: are there indirect benefits to the community?: a systematic review of the evidence. *Vaccine*, *24*(8), 1047-1062. https://www.sciencedirect.com/science/article/pii/S0264410X05009576

1132.) Basta, N. E., Chao, D. L., Halloran, M. E., Matrajt, L., & Longini Jr, I. M. (2009). Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. *American journal of epidemiology*, *170*(6), 679-686. https://academic.oup.com/aje/article/170/6/679/124525

1133.) Cowling, B. J., Ng, S., Ma, E. S., Cheng, C. K., Wai, W., Fang, V. J., ... & Leung, G. M. (2010). Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. *Clinical infectious diseases*, *51*(12), 1370-1379. https://academic.oup.com/cid/article/51/12/1370/316441

1134.) Glezen, W. P. (2006). Herd protection against influenza. *Journal of Clinical Virology*, *37*(4), 237-243. https://www.sciencedirect.com/science/article/abs/pii/S1386653206003179

1135.) Nichol, K. L., Heilly, S. J., Greenberg, M. E., & Ehlinger, E. (2009). Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50–64 years. *Clinical Infectious Diseases*, *48*(3), 292-298. https://academic.oup.com/cid/article/48/3/292/304381

1136.) Piedra, P. A., Gaglani, M. J., Kozinetz, C. A., Herschler, G. B., Fewlass, C., Harvey, D., ... & Glezen, W. P. (2007). Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. *Pediatrics*, *120*(3), e553-e564. https://pediatrics.aappublications.org/content/120/3/e553.short

1137.) Ambrose, C. S., Wu, X., Knuf, M., & Wutzler, P. (2012). The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. *Vaccine*, *30*(5), 886-892. https://www.sciencedirect.com/science/article/pii/S0264410X11019001

1138.) Glezen, W. P., Gaglani, M. J., Kozinetz, C. A., & Piedra, P. A. (2010). Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. *The Journal of infectious diseases*, *202*(11), 1626-1633. https://academic.oup.com/jid/article/202/11/1626/944004

1139.) Vynnycky, E., Pitman, R., Siddiqui, R., Gay, N., & Edmunds, W. J. (2008). Estimating the impact of childhood influenza vaccination programmes in England and Wales. *Vaccine*, *26*(41), 5321-5330. https://www.sciencedirect.com/science/article/pii/S0264410X08008554

1140.) Halloran, M. E., Piedra, P. A., Longini Jr, I. M., Gaglani, M. J., Schmotzer, B., Fewlass, C., ... & Glezen, W. P. (2007). Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003–2004. *Vaccine*, *25*(20), 4038-4045. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883284/

1141.) Ambrose, C. S., Yi, T., Walker, R. E., & Connor, E. M. (2008). Duration of protection provided by live attenuated influenza vaccine in children. *The Pediatric infectious disease journal*, *27*(8), 744-748. https://journals.lww.com/pidj/Abstract/2008/08000/Duration_of_Protection_Provided_by_Live_Attenuated.13.aspx

1142.) Rolfes, M. A., Flannery, B., Chung, J. R., O'Halloran, A., Garg, S., Belongia, E. A., ... & Alden, N. B. (2019). Effects of influenza vaccination in the United States during the 2017–2018 influenza season. *Clinical Infectious Diseases*, *69*(11), 1845-1853. https://academic.oup.com/cid/article/69/11/1845/5305915

1143.) Pitman, R. J., White, L. J., & Sculpher, M. (2012). Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. *Vaccine*, *30*(6), 1208-1224. https://www.sciencedirect.com/science/article/pii/S0264410X11019025

1144.) Usher, N. T., Chang, S., Howard, R. S., Martinez, A., Harrison, L. H., Santosham, M., & Aronson, N. E. (2019). Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial. *JAMA network open*, *2*(9), e1912014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763973/

1145.) Arinaminpathy, N., Ratmann, O., Koelle, K., Epstein, S. L., Price, G. E., Viboud, C., ... & Grenfell, B. T. (2012). Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. *Proceedings of the National Academy of Sciences*, *109*(8), 3173-3177. https://www.pnas.org/content/109/8/3173.long

1146.) Pannaraj, P. S., Wang, H. L., Rivas, H., Wiryawan, H., Smit, M., Green, N., ... & Mascola, L. (2014). School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance. *Clinical infectious diseases*, *59*(3), 325-332. https://academic.oup.com/cid/article/59/3/325/2895634

1147.) Charu, V., Viboud, C., Simonsen, L., Sturm-Ramirez, K., Shinjoh, M., Chowell, G., ... & Sugaya, N. (2011). Influenza-related mortality trends in Japanese and American seniors: evidence for the indirect mortality benefits of vaccinating schoolchildren. *PloS one*, *6*(11), e26282. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026282

1148.) Roush, S. W., Murphy, T. V., & Vaccine-Preventable Disease Table Working Group. (2007). Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. *Jama*, *298*(18), 2155-2163. https://jamanetwork.com/journals/jama/fullarticle/209448

1149.) Kawai, S., Nanri, S., Ban, E., Inokuchi, M., Tanaka, T., Tokumura, M., ... & Sugaya, N. (2011). Influenza vaccination of schoolchildren and influenza outbreaks in a school. *Clinical infectious diseases*, *53*(2), 130-136. https://academic.oup.com/cid/article/53/2/130/286341

1150.) Hull, H. F., & Ambrose, C. S. (2011). The impact of school-located influenza vaccination programs on student absenteeism: a review of the US literature. *The Journal of School Nursing*, *27*(1), 34-42. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.827.5029&rep=rep1&type=pdf

1151.) Grijalva, C. G., Zhu, Y., Simonsen, L., Mitchel, E., & Griffin, M. R. (2010). The population impact of a large school-based influenza vaccination campaign. *PLoS One*, *5*(11), e15097. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0015097

1152.) Grijalva, C. G., Zhu, Y., & Griffin, M. R. (2009). Evidence of effectiveness from a large county-wide school-based influenza immunization campaign. *Vaccine*, *27*(20), 2633-2636. https://www.sciencedirect.com/science/article/pii/S0264410X09002904

1153.) Graitcer, S. B., Dube, N. L., Basurto-Davila, R., Smith, P. F., Ferdinands, J., Thompson, M., ... & Sears, S. (2012). Effects of immunizing school children with 2009 influenza A (H1N1) monovalent vaccine on absenteeism among students and teachers in Maine. *Vaccine*, *30*(32), 4835-4841. https://www.sciencedirect.com/science/article/pii/S0264410X12006810

1154.) Mears, C. J., Lawler, E. N., Sanders III, L. D., & Katz, B. Z. (2009). Efficacy of LAIV-T on absentee rates in a school-based health center sample. *Journal of Adolescent Health*, *45*(1), 91-94. https://www.sciencedirect.com/science/article/abs/pii/S1054139X08006745

1155.) Yin, J. K., Heywood, A. E., Georgousakis, M., King, C., Chiu, C., Isaacs, D., & Macartney, K. K. (2017). Systematic review and meta-analysis of indirect protection afforded by vaccinating children against seasonal influenza: implications for policy. *Clinical Infectious Diseases*, *65*(5), 719-728. https://academic.oup.com/cid/article/65/5/719/3798575

1156.) Wongsurakiat, P., Maranetra, K. N., Wasi, C., Kositanont, U., Dejsomritrutai, W., & Charoenratanakul, S. (2004). Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. *Chest*, *125*(6), 2011-2020. https://www.sciencedirect.com/science/article/abs/pii/S0012369216589703

1157.) Andrews, N. J., Waight, P. A., Burbidge, P., Pearce, E., Roalfe, L., Zancolli, M., ... & Goldblatt, D. (2014). Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. *The Lancet infectious diseases*, *14*(9), 839-846. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.653.842&rep=rep1&type=pdf

1158.) Mao, C., Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Wiley, D. J., ... & Barr, E. (2006). Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. *Obstetrics & Gynecology*, *107*(1), 18-27. https://journals.lww.com/greenjournal/Fulltext/2006/01000/Efficacy_of_Human_Papillomavirus_16_Vaccine_to.6.aspx

1159.) Skowronski, D. M., Hottes, T. S., Chong, M., De Serres, G., Scheifele, D. W., Ward, B. J., ... & Petric, M. (2011). Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. *Pediatrics*, *128*(2), e276-e289. https://pediatrics.aappublications.org/content/128/2/e276.short

1160.) Mayet, A., Ligier, C., Gache, K., Manet, G., Nivoix, P., Dia, A., ... & Piarroux, M. (2011). Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces—2009–2010. *Vaccine*, *29*(14), 2576-2581. https://www.sciencedirect.com/science/article/pii/S0264410X11001071

1161.) Morales, M., Tangermann, R. H., & Wassilak, S. G. (2016). Progress toward polio eradication—worldwide, 2015–2016. *Morbidity and mortality weekly report*, *65*(18), 470-473. https://www.cdc.gov/mmwr/volumes/65/wr/mm6518a4.htm

1162.) Puig-Barbera, J., Diez-Domingo, J., Hoyos, S. P., Varea, A. B., & Vidal, D. G. (2004). Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. *Vaccine*, *23*(3), 283-289. https://www.sciencedirect.com/science/article/pii/S0264410X04005353

1163.) Lu, H. L., Ding, Y., Goyal, H., & Xu, H. G. (2019). Association between rotavirus vaccination and risk of intussusception among neonates and infants: A systematic review and meta-analysis. *JAMA network open*, *2*(10), e1912458-e1912458. https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2752349

1164.) Sørup, S., Benn, C. S., Poulsen, A., Krause, T. G., Aaby, P., & Ravn, H. (2014). Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. *Jama*, *311*(8), 826-835. https://jamanetwork.com/journals/jama/article-abstract/1832541

1165.) Atwell, J. E., Van Otterloo, J., Zipprich, J., Winter, K., Harriman, K., Salmon, D. A., ... & Omer, S. B. (2013). Nonmedical vaccine exemptions and pertussis in California, 2010. *Pediatrics*, *132*(4), 624-630. https://pediatrics.aappublications.org/content/132/4/624.short

1166.) DDi Pietrantonj, C., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2020). Vaccines for measles, mumps, rubella, and varicella in children. *The Cochrane Database of Systematic Reviews*, *4*, CD004407-CD004407. https://www.skepticalraptor.com/blog/wp-content/uploads/2020/06/Pietrantonj_et_al-2020-Cochrane_Database_of_Systematic_Reviews.pdf

1167.) Imdad, A., Tserenpuntsag, B., Blog, D. S., Halsey, N. A., Easton, D. E., & Shaw, J. (2013). Religious exemptions for immunization and risk of pertussis in New York State, 2000–2011. *Pediatrics*, *132*(1), 37-43. https://www.researchgate.net/profile/Boldtsetseg_Tserenpuntsag/publication/237017921_Religious_Exemptions_for_Immunization_and_Risk_of_Pertussis_in_New_York_State_2000-2011/links/558d447008aeada955664133/Religious-Exemptions-for-Immunization-and-Risk-of-Pertussis-in-New-York-State-2000-2011.pdf

1168.) Omer, S. B., Enger, K. S., Moulton, L. H., Halsey, N. A., Stokley, S., & Salmon, D. A. (2008). Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. *American journal of epidemiology*, *168*(12), 1389-1396. https://academic.oup.com/aje/article/168/12/1389/155084

1169.) Li, R. C., Huang, T., Li, Y., Wang, L. H., Tao, J., Fu, B., ... & Luan, I. (2016). Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. *Human vaccines & immunotherapeutics*, *12*(3), 785-793. https://www.tandfonline.com/doi/full/10.1080/21645515.2015.1085143

1170.) Bravo, L., Chitraka, A., Liu, A., Choudhury, J., Kumar, K., Berezo, L., ... & Bernardo, R. (2014). Reactogenicity and safety of the human rotavirus vaccine, Rotarix™ in The Philippines, Sri Lanka, and India: a post-marketing surveillance study. *Human vaccines & immunotherapeutics*, *10*(8), 2276-2283. https://www.tandfonline.com/doi/pdf/10.4161/hv.29280

1171.) Phua, K. B., Lim, F. S., Lau, Y. L., Nelson, E. A. S., Huang, L. M., Quak, S. H., ... & Suryakiran, P. V. (2012). Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. *Vaccine*, *30*(30), 4552-4557. https://www.sciencedirect.com/science/article/pii/S0264410X12004069

1172.) Klein, N. P., Lewis, E., Fireman, B., Hambidge, S. J., Naleway, A., Nelson, J. C., ... & Weintraub, E. (2015). Safety of measles-containing vaccines in 1-year-old children. *Pediatrics*, *135*(2), e321-e329. https://pediatrics.aappublications.org/content/135/2/e321.short

1173.) Mo, Z., Ma, X., Luo, P., Mo, Y., Kaplan, S. S., Shou, Q., ... & V260-024 Study Group. (2019). Immunogenicity of pentavalent rotavirus vaccine in Chinese infants. *Vaccine*, *37*(13), 1836-1843. https://www.sciencedirect.com/science/article/pii/S0264410X19302130

1174.) Vesikari, T. (2012). Rotavirus vaccination: a concise review. *Clinical microbiology and infection*, *18*, 57-63. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1469-0691.2012.03981.x

1175.) Majumder, M. S., Cohn, E. L., Mekaru, S. R., Huston, J. E., & Brownstein, J. S. (2015). Substandard vaccination compliance and the 2015 measles outbreak. *JAMA pediatrics*, *169*(5), 494-495. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2203906

1176.) Bradford, W. D., & Mandich, A. (2015). Some state vaccination laws contribute to greater exemption rates and disease outbreaks in the United States. *Health Affairs*, *34*(8), 1383-1390. https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.2014.1428

1177.) Muhsen, K., Shulman, L., Kasem, E., Rubinstein, U., Shachter, J., Kremer, A., ... & Cohen, D. (2010). Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study. *Human vaccines*, *6*(6), 450-454. https://www.tandfonline.com/doi/pdf/10.4161/hv.6.6.11759

1178.) Lo, N. C., & Hotez, P. J. (2017). Public health and economic consequences of vaccine hesitancy for measles in the United States. *JAMA pediatrics*, *171*(9), 887-892. https://jamanetwork.com/journals/jamapediatrics/article-abstract/2643169

1179.) Aloe, C., Kulldorff, M., & Bloom, B. R. (2017). Geospatial analysis of nonmedical vaccine exemptions and pertussis outbreaks in the United States. *Proceedings of the National Academy of Sciences*, *114*(27), 7101-7105. https://www.pnas.org/content/114/27/7101

1180.) Naghavi, M., Barlas, Z., Siadaty, S., Naguib, S., Madjid, M., & Casscells, W. (2000). Association of influenza vaccination and reduced risk of recurrent myocardial infarction. *Circulation*, *102*(25), 3039-3045. https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.102.25.3039

1181.) Omer, S. B., Goodman, D., Steinhoff, M. C., Rochat, R., Klugman, K. P., Stoll, B. J., & Ramakrishnan, U. (2011). Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. *PLoS Med*, *8*(5), e1000441. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000441

1182.) Zhu, T., Carcaillon, L., Martinez, I., Cambou, J. P., Kyndt, X., Guillot, K., ... & Emmerich, J. (2009). Association of influenza vaccination with reduced risk of venous thromboembolism. *Thrombosis and haemostasis*, *102*(12), 1259-1264. https://www.thieme-connect.com/products/ejournals/abstract/10.1160/TH09-04-0222

1183.) Ngabo, F., Tate, J. E., Gatera, M., Rugambwa, C., Donnen, P., Lepage, P., ... & Parashar, U. D. (2016). Effect of pentavalent rotavirus vaccine introduction on hospital admissions for diarrhoea and rotavirus in children in Rwanda: a time-series analysis. *The Lancet Global Health*, *4*(2), e129-e136. https://www.sciencedirect.com/science/article/pii/S2214109X15002703

1184.) Msimang, V. M., Page, N., Groome, M. J., Moyes, J., Cortese, M. M., Seheri, M., ... & Cohen, C. (2013). Impact of rotavirus vaccine on childhood diarrheal hospitalization after introduction into the South African public immunization program. *The Pediatric infectious disease journal*, *32*(12), 1359-1364. https://journals.lww.com/pidj/fulltext/2013/12000/Impact_of_Rotavirus_Vaccine_on_Childhood_Diarrheal.22.aspx

1185.) Enweronu-Laryea, C. C., Armah, G., Sagoe, K. W., Ansong, D., Addo-Yobo, E., Diamenu, S. K., ... & Tate, J. E. (2018). Sustained impact of rotavirus vaccine introduction on rotavirus gastroenteritis hospitalizations in children< 5 years of age, Ghana, 2009–2016. *Vaccine*, *36*(47), 7131-7134. https://pubmed.ncbi.nlm.nih.gov/29752020/

1186.) Bennett, A., Pollock, L., Jere, K. C., Pitzer, V. E., Parashar, U., Tate, J. E., ... & Iturriza-Gomara, M. (2018). Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction. *Vaccine*, *36*(47), 7142-7148. https://www.sciencedirect.com/science/article/pii/S0264410X18305139

1187.) Groome, M. J., Page, N., Cortese, M. M., Moyes, J., Zar, H. J., Kapongo, C. N., ... & Seheri, M. (2014). Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. *The Lancet Infectious Diseases*, *14*(11), 1096-1104. https://www.sciencedirect.com/science/article/abs/pii/S1473309914709405

1188.) Zaman, K., Fleming, J. A., Victor, J. C., Yunus, M., Bari, T. I. A., Azim, T., ... & Icenogle, J. P. (2016). Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: a randomized trial. *The Journal of infectious diseases*, *213*(11), 1686-1693. https://academic.oup.com/jid/article/213/11/1686/2459288

1189.) Rahajamanana, V. L., Raboba, J. L., Rakotozanany, A., Razafindraibe, N. J., Andriatahirintsoa, E. J. P. R., Razafindrakoto, A. C., ... & Mwenda, J. M. (2018). Impact of rotavirus vaccine on all-cause diarrhea and rotavirus hospitalizations in Madagascar. *Vaccine*, *36*(47), 7198-7204. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867203/

1190.) Clarke, M. F., Davidson, G. P., Gold, M. S., & Marshall, H. S. (2011). Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination. *Vaccine*, *29*(29-30), 4663-4667. https://www.sciencedirect.com/science/article/pii/S0264410X1100675X

1191.) Enweronu-Laryea, C. C., Boamah, I., Sifah, E., Diamenu, S. K., & Armah, G. (2014). Decline in severe diarrhea hospitalizations after the introduction of rotavirus vaccination in Ghana: a prevalence study. *BMC infectious diseases*, *14*(1), 431. https://link.springer.com/article/10.1186/1471-2334-14-431

1192.) Lyamuya, F., Michael, F., Jani, B., Fungo, Y., Chambo, A., Chami, I., ... & Kamugisha, C. (2018). Trends in diarrhea hospitalizations among infants at three hospitals in Tanzania before and after rotavirus vaccine introduction. *Vaccine*, *36*(47), 7157-7164. https://www.sciencedirect.com/science/article/pii/S0264410X17316158

1193.) Groome, M. J., Tate, J. E., Arnold, M., Chitnis, M., Cox, S., de Vos, C., ... & Maharaj, A. (2020). Evaluation of intussusception after oral monovalent rotavirus vaccination in South Africa. *Clinical Infectious Diseases*, *70*(8), 1606-1612. https://academic.oup.com/cid/article/70/8/1606/5498228#201725546

1194.) Maphalala, G., Phungwayo, N., Masona, G., Lukhele, N., Tsegaye, G., Dube, N., ... & Tate, J. E. (2018). Early impact of rotavirus vaccine in under 5 year old children hospitalized due to diarrhea, Swaziland. *Vaccine*, *36*(47), 7210-7214. https://www.sciencedirect.com/science/article/pii/S0264410X17309805

1195.) de Deus, N., Chilaúle, J. J., Cassocera, M., Bambo, M., Langa, J. S., Sitoe, E., ... & Bero, D. M. (2018). Early impact of rotavirus vaccination in children less than five years of age in Mozambique. *Vaccine*, *36*(47), 7205-7209. https://www.researchgate.net/profile/Jeronimo_Langa3/publication/320938334_Early_impact_of_rotavirus_vaccination_in_children_less_than_five_years_of_age_in_Mozambique/links/5aa1005a45851543e6398260/Early-impact-of-rotavirus-vaccination-in-children-less-than-five-years-of-age-in-Mozambique.pdf

1196.) Tate, J. E., Mwenda, J. M., Armah, G., Jani, B., Omore, R., Ademe, A., ... & Mihigo, R. (2018). Evaluation of intussusception after monovalent rotavirus vaccination in Africa. *New England Journal of Medicine*, *378*(16), 1521-1528. https://www.nejm.org/doi/full/10.1056/NEJMoa1713909

1197.) Tate, J. E., Burton, A. H., Boschi-Pinto, C., Steele, A. D., Duque, J., & Parashar, U. D. (2012). 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. *The Lancet infectious diseases*, *12*(2), 136-141. https://www.sciencedirect.com/science/article/abs/pii/S1473309911702535

1198.) Lau, Y. L., Nelson, E. A. S., Poon, K. H., Chan, P. K., Chiu, S., Sung, R., ... & Lee, T. L. (2013). Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. *Vaccine*, *31*(18), 2253-2259. https://www.sciencedirect.com/science/article/pii/S0264410X13002600

1199.) Armah, G. E., Kapikian, A. Z., Vesikari, T., Cunliffe, N., Jacobson, R. M., Burlington, D. B., & Ruiz Jr, L. P. (2013). Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. *The Journal of infectious diseases*, *208*(3), 423-431.

https://academic.oup.com/jid/article/208/3/423/2192530?view=extract

1200.) Weldegebriel, G., Mwenda, J. M., Chakauya, J., Daniel, F., Masresha, B., Parashar, U. D., & Tate, J. E. (2018). Impact of rotavirus vaccine on rotavirus diarrhoea in countries of East and Southern Africa. *Vaccine*, *36*(47), 7124-7130. https://www.sciencedirect.com/science/article/pii/S0264410X17314585

1201.) Carlin, J. B., Macartney, K. K., Lee, K. J., Quinn, H. E., Buttery, J., Lopert, R., ... & McIntyre, P. B. (2013). Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. *Clinical Infectious Diseases*, *57*(10), 1427-1434. https://academic.oup.com/cid/article/57/10/1427/288694

1202.) Givon-Lavi, N., Ben-Shimol, S., Cohen, R., Greenberg, D., & Dagan, R. (2015). Rapid impact of rotavirus vaccine introduction to the National Immunization Plan in Southern Israel: Comparison between 2 distinct populations. *Vaccine*, *33*(16), 1934-1940. https://www.sciencedirect.com/science/article/pii/S0264410X15002510

1203.) Makgatho, E., Patel, F., Solomon, F., Groome, M. J., Lala, S. G., Vallabh, P., & Dangor, Z. (2019). The Burden of Acute Diarrheal Disease in Young Hospitalized Urban South African Children Five Years After Rotavirus Vaccine Introduction: A Retrospective Descriptive Study. *The Pediatric infectious disease journal*, *38*(7), 752-756. https://journals.lww.com/pidj/Fulltext/2019/07000/The_Burden_of_Acute_Diarrheal_Disease_in_Young.22.aspx

1204.) Vellozzi, C., Burwen, D. R., Dobardzic, A., Ball, R., Walton, K., & Haber, P. (2009). Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. *Vaccine*, *27*(15), 2114-2120. https://www.sciencedirect.com/science/article/pii/S0264410X09002047

1205.) Fisch, A., Cadilhac, P., Vidor, E., Prazuck, T., Dublanchet, A., & Lafaix, C. (1996). Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. *Vaccine*, *14*(12), 1132-1136. https://www.sciencedirect.com/science/article/pii/0264410X96000448

1206.) Zhang, Z., Liang, Z., Zeng, J., Zhang, J., He, P., Su, J., ... & Zeng, G. (2019). Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis B vaccine and group A meningococcal polysaccharide vaccine: a phase 4, open-label, single-center, randomized, noninferiority trial. *The Journal of infectious diseases*, *220*(3), 392-399. https://academic.oup.com/jid/article-abstract/220/3/392/5395971

1207.) Wolfson, L. J., Strebel, P. M., Gacic-Dobo, M., Hoekstra, E. J., McFarland, J. W., Hersh, B. S., & Measles Initiative. (2007). Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. *The Lancet*, *369*(9557), 191-200. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60107-X/fulltext

1208.) Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. *Nature reviews Drug discovery*, *17*(4), 261. https://www.nature.com/articles/nrd.2017.243#Sec21

1209.) D'Alise, A. M., Leoni, G., Cotugno, G., Troise, F., Langone, F., Fichera, I., ... & Bignone, V. (2019). Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. *Nature communications*, *10*(1), 1-12. https://www.nature.com/articles/s41467-019-10594-2#Abs1

1210.) Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C., & Hill, A. V. (2017). Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. *Scientific reports*, *7*, 46621. https://www.nature.com/articles/srep46621#Sec11

1211.) Buonsanti, C., Balocchi, C., Harfouche, C., Corrente, F., Stampino, L. G., Mancini, F., ... & De Gregorio, E. (2016). Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. *Scientific reports*, *6*(1), 1-12. https://www.nature.com/articles/srep29063

1212.) Siscovick, D. S., Raghunathan, T. E., Lin, D., Weinmann, S., Arbogast, P., Lemaitre, R. N., ... & Cobb, L. A. (2000). Influenza vaccination and the risk of primary cardiac arrest. *American journal of epidemiology*, *152*(7), 674-677. https://academic.oup.com/aje/article/152/7/674/75235

1213.) Rosa, B. R., Cunha, A., & Medronho, R. A. (2019). Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis. *BMJ open*, *9*(3), e019368. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429993/

1214.) de Vries, I. J. M., Lesterhuis, W. J., Scharenborg, N. M., Engelen, L. P., Ruiter, D. J., Gerritsen, M. J. P., ... & Figdor, C. G. (2003). Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. *Clinical cancer research*, *9*(14), 5091-5100. https://pubmed.ncbi.nlm.nih.gov/14613986/

1215.) Gaucher, D., Therrien, R., Kettaf, N., Angermann, B. R., Boucher, G., Filali-Mouhim, A., ... & Akondy, R. (2008). Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. *The Journal of experimental medicine*, *205*(13), 3119-3131. https://europepmc.org/articles/pmc2605227/bin/jem.20082292_index.html

1216.) Okada, E., Sasaki, S., Ishii, N., Aoki, I., Yasuda, T., Nishioka, K., ... & Okuda, K. (1997). Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. *The Journal of Immunology*, *159*(7), 3638-3647. https://www.jimmunol.org/content/159/7/3638.short

1217.) Cox, R. J., Brokstad, K. A., & Ogra, P. L. (2004). Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. *Scandinavian journal of immunology*, *59*(1), 1-15. https://onlinelibrary.wiley.com/doi/full/10.1111/j.0300-9475.2004.01382.x

1218.) Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., ... & Larocque, D. (2009). AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. *The Journal of immunology*, *183*(10), 6186-6197. https://www.jimmunol.org/content/183/10/6186#sec-1

1219.) Calarota, S., Bratt, G., Nordlund, S., Hinkula, J., Leandersson, A. C., Sandström, E., & Wahren, B. (1998). Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. *The Lancet*, *351*(9112), 1320-1325. https://www.sciencedirect.com/science/article/abs/pii/S0140673697094403

1220.) Horwitz, M. A., Lee, B. W., Dillon, B. J., & Harth, G. (1995). Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. *Proceedings of the National Academy of Sciences*, *92*(5), 1530-1534. https://www.pnas.org/content/pnas/92/5/1530.full.pdf

1221.) Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., ... & Hoffman, E. (2000). Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. *Proceedings of the National Academy of Sciences*, *97*(22), 12198-12203. https://www.pnas.org/content/97/22/12198.full

1222.) Avigan, D., Vasir, B., Gong, J., Borges, V., Wu, Z., Uhl, L., ... & Giallambardo, N. (2004). Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. *Clinical Cancer Research*, *10*(14), 4699-4708. https://clincancerres.aacrjournals.org/content/10/14/4699.short

1223.) Wang, S., Yu, Y., Geng, S., Wang, D., Zhang, L., Xie, X., ... & Hu, Y. (2014). A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model. *Alzheimer's Research & Therapy*, *6*(3), 26. https://link.springer.com/article/10.1186/alzrt256

1224.) Moore, D. L., Le Saux, N., Scheifele, D., Halperin, S. A., & Canadian Paediatric Society/Health Canada Immunization Monitoring Program Active (IMPACT. (2004). Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993–2002. *The Pediatric infectious disease journal*, *23*(6), 568-571. https://journals.lww.com/pidj/Fulltext/2004/06000/Increase_in_deaths_from_pertussis_among_young.18.aspx

1225.) Lavallée, P., Perchaud, V., Gautier-Bertrand, M., Grabli, D., & Amarenco, P. (2002). Association between influenza vaccination and reduced risk of brain infarction. *Stroke*, *33*(2), 513-518. https://www.ahajournals.org/doi/pdf/10.1161/hs0202.102328

1226.) Berkovic, S. F., Harkin, L., McMahon, J. M., Pelekanos, J. T., Zuberi, S. M., Wirrell, E. C., ... & Scheffer, I. E. (2006). De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. *The Lancet Neurology*, *5*(6), 488-492. https://media.ellinikahoaxes.gr/uploads/2020/04/berkovic2006.pdf

1227.) Sabin, A. B., Michaels, R. H., Spigland, I., Pelon, W., Rhim, J. S., & WEHR, R. E. (1961). Community-wide use of oral poliovirus vaccine: effectiveness of the Cincinnati Program. *American journal of diseases of children*, *101*(5), 546-567. https://jamanetwork.com/journals/jamapediatrics/article-abstract/499834

1228.) Phrommintikul, A., Kuanprasert, S., Wongcharoen, W., Kanjanavanit, R., Chaiwarith, R., & Sukonthasarn, A. (2011). Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. *European heart journal*, *32*(14), 1730-1735. https://academic.oup.com/eurheartj/article/32/14/1730/527838

1229.) Esposito, S., Marchisio, P., Cavagna, R., Gironi, S., Bosis, S., Lambertini, L., ... & Principi, N. (2003). Effectiveness of influenza vaccination of children with recurrent respiratory

tract infections in reducing respiratory-related morbidity within the households. *Vaccine*, *21*(23), 3162-3168. https://www.sciencedirect.com/science/article/pii/S0264410X03002536

1230.) Colquhoun, A. J., Nicholson, K. G., Botha, J. L., & Raymond, N. T. (1997). Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. *Epidemiology & Infection*, *119*(3), 335-341. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809006/pdf/9440437.pdf

1231.) Eick, A. A., Uyeki, T. M., Klimov, A., Hall, H., Reid, R., Santosham, M., & O'Brien, K. L. (2011). Maternal influenza vaccination and effect on influenza virus infection in young infants. *Archives of pediatrics & adolescent medicine*, *165*(2), 104-111. https://jamanetwork.com/journals/jamapediatrics/article-abstract/384298

1232.) Hardelid, P., Ghebremichael-Weldeselassie, Y., Whitaker, H., Rait, G., Gilbert, R., & Petersen, I. (2018). Effectiveness of live attenuated influenza vaccine in preventing amoxicillin prescribing in preschool children: a self-controlled case series study. *Journal of Antimicrobial Chemotherapy*, *73*(3), 779-786. https://academic.oup.com/jac/article/73/3/779/4711771

1233.) Mølgaard‐Nielsen, D., Fischer, T. K., Krause, T. G., & Hviid, A. (2019). Effectiveness of maternal immunization with trivalent inactivated influenza vaccine in pregnant women and their infants. *Journal of internal medicine*, *286*(4), 469-480. https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.12947

1234.) Gale, J. L., Thapa, P. B., Wassilak, S. G., Bobo, J. K., Mendelman, P. M., & Foy, H. M. (1994). Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine: a population-based case-control study. *Jama*, *271*(1), 37-41. https://www.researchgate.net/profile/Prakash_Thapa10/publication/15296341_Risk_of_serious_acute_neurological_illness_after_immunization_with_diphtheria-tetanus-pertussis_vaccine_A_population-based_case-control_study/links/57deb95308ae5292a37f3a25.pdf

1235.) Onorato, I. M., Wassilak, S. G., & Meade, B. (1992). Efficacy of whole-cell pertussis vaccine in preschool children in the United States. *Jama*, *267*(20), 2745-2749. https://jamanetwork.com/journals/jama/article-abstract/397408

1236.) van den Noort, S., Altrocchi, P., Brin, M., Ferguson, J., Hanley, D., Jacobs, L., ... & Tindall, R. (1992). Assessment: DTP vaccination: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*, *42*(3), 471-471. https://n.neurology.org/content/42/3/471.short

1237.) Dube, E., Vivion, M., & MacDonald, N. E. (2015). Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications. *Expert review of vaccines*, *14*(1), 99-117. https://mde.biologia.gr/ferma/wp-content/uploads/sites/13/2017/03/Vaccine-hesitancy-vaccine.pdf

1238.) Colzani, E., McDonald, S. A., Carrillo-Santisteve, P., Busana, M. C., Lopalco, P., & Cassini, A. (2014). Impact of measles national vaccination coverage on burden of measles across 29 Member States of the European Union and European Economic Area, 2006–2011. *Vaccine*, *32*(16), 1814-1819. https://www.sciencedirect.com/science/article/pii/S0264410X14001571

1239.) Bell, J. A., Hantover, M. J., Heuner, R. J., & Loosli, C. G. (1956). Efficacy of Trivalent Adenovirus (APC) Vaccine in Naval Recruits: Progress Report. *Journal of the American Medical Association*, *161*(16), 1521-1525. https://jamanetwork.com/journals/jama/article-abstract/322897

1240.) Hilleman, M. R. (1958). Efficacy of and indications for use of adenovirus vaccine. *American Journal of Public Health and the Nations Health*, *48*(2), 153-158. https://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.48.2.153

1241.) Thomas, E. W., & Gleesen, G. A. (1953). A long-term evaluation of the efficacy of mapharsen and typhoid vaccine, including a comparison with penicillin, in the treatment of early syphilis. *American Journal of Syphilis*, *37*(5), 458-65. https://www.cabdirect.org/cabdirect/abstract/19542700524

1242.) Francis, T. (1955). Evaluation of the 1954 poliomyelitis vaccine field trial: further studies of results determining the effectiveness of poliomyelitis vaccine (Salk) in preventing paralytic poliomyelitis. *Journal of the American Medical Association*, *158*(14), 1266-1270. https://jamanetwork.com/journals/jama/article-abstract/301691 & https://sci-hub.se/10.1001/jama.1955.02960140028004

1243.) Smetana, J., Chlibek, R., Shaw, J., Splino, M., & Prymula, R. (2018). Influenza vaccination in the elderly. *Human vaccines & immunotherapeutics*, *14*(3), 540-549. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861798/

1244.) Gastañaduy, P. A., Funk, S., Lopman, B. A., Rota, P. A., Gambhir, M., Grenfell, B., & Paul, P. (2020). Factors Associated With Measles Transmission in the United States During the Postelimination Era. *JAMA pediatrics*, *174*(1), 56-62.

https://jamanetwork.com/journals/jamapediatrics/fullarticle/2755836

1245.) Thysen, S. M., Benn, C. S., Gomes, V. F., Rudolf, F., Wejse, C., Roth, A., ... & Fisker, A. (2020). Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort study. *BMJ open*, *10*(2), e035595. https://bmjopen.bmj.com/content/10/2/e035595 & https://bmjopen.bmj.com/content/bmjopen/10/2/e035595.draft-revisions.pdf

1246.) Sitepu, F. Y., Depari, E., Mudatsir, M., & Harapan, H. (2020). Being unvaccinated and contact with measles cases as the risk factors of measles outbreak, North Sumatera, Indonesia. *Clinical Epidemiology and Global Health*, *8*(1), 239-243. https://www.sciencedirect.com/science/article/pii/S2213398419302453

1247.) Burnett, E., Parashar, U. D., & Tate, J. E. (2020). Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children< 5 years old: 2006–2019. *The Journal of infectious diseases*, *222*(10), 1731-1739. https://academic.oup.com/jid/article/222/10/1731/5755890

1248.) Hagan, J. E., Takashima, Y., Sarankhuu, A., Dashpagma, O., Jantsansengee, B., Pastore, R., ... & Anderson, R. (2017). Risk factors for measles virus infection among adults during a large outbreak in postelimination era in Mongolia, 2015. *The Journal of infectious diseases*, *216*(10), 1187-1195. https://academic.oup.com/jid/article/216/10/1187/4508191

1249.) Atkinson, W. L., Orenstein, W. A., & Krugman, S. (1992). The resurgence of measles in the United States, 1989-1990. *Annual review of medicine*, *43*(1), 451-463. https://www.annualreviews.org/doi/pdf/10.1146/annurev.me.43.020192.002315

1250.) Aaby, P., Bhuiya, A., Nahar, L., Knudsen, K., de Francisco, A., & Strong, M. (2003). The survival benefit of measles immunization may not be explained entirely by the prevention of measles disease: a community study from rural Bangladesh. *International Journal of Epidemiology*, *32*(1), 106-115. https://academic.oup.com/ije/article/32/1/106/642823

1251.) Sugerman, D. E., Barskey, A. E., Delea, M. G., Ortega-Sanchez, I. R., Bi, D., Ralston, K. J., ... & LeBaron, C. W. (2010). Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. *Pediatrics*, *125*(4), 747-755. https://pediatrics.aappublications.org/content/125/4/747.short

1252.) Salemi, S., & D'Amelio, R. (2010). Could autoimmunity be induced by vaccination?. *International reviews of immunology*, *29*(3), 247-269. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.905.8384&rep=rep1&type=pdf

1253.) Kühtreiber, W. M., Tran, L., Kim, T., Dybala, M., Nguyen, B., Plager, S., ... & Zheng, H. (2018). Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. *npj Vaccines*, *3*(1), 1-14. https://www.nature.com/articles/s41541-018-0062-8?fbclid=IwAR0BohbqgA9mDMavOKfkvBxKQpOyAJLvOM8TPPaeCxXnxgZZ01thXqrN76E

1254.) Schattner, A. (2005). Consequence or coincidence?: The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. *Vaccine*, *23*(30), 3876-3886. https://www.sciencedirect.com/science/article/pii/S0264410X05003506

1255.) Morgan, E., Halliday, S. R., Campbell, G. R., Cardwell, C. R., & Patterson, C. C. (2016). Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies. *Diabetologia*, *59*, 237-243. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.798.8625&rep=rep1&type=pdf

1256.) Hummel, M., Füchtenbusch, M., Schenker, M., & Ziegler, A. G. (2000). No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. *Diabetes care*, *23*(7), 969-974. https://care.diabetesjournals.org/content/diacare/23/7/969.full.pdf

1257.) Karvonen, M., Cepaitis, Z., & Tuomilehto, J. (1999). Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study. *Bmj*, *318*(7192), 1169-1172. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC27850/

1258.) Duderstadt, S. K., Rose Jr, C. E., Real, T. M., Sabatier, J. F., Stewart, B., Ma, G., ... & McNeil, M. M. (2012). Vaccination and risk of type 1 diabetes mellitus in active component US Military, 2002–2008. *Vaccine*, *30*(4), 813-819. https://www.sciencedirect.com/science/article/pii/S0264410X11017373 & https://sci-hub.se/https://doi.org/10.1016/j.vaccine.2011.10.087

1259.) Hyöty, H., Hiltunen, M., Reunanen, A., Leinikki, P., Vesikari, T., Lounamaa, R., ... & Fagerlund, A. (1993). Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the

mumps-measles-rubella vaccine in Finland. *Diabetologia*, *36*(12), 1303-1308. https://link.springer.com/article/10.1007/BF00400810

1260.) Heijbel, H., Chen, R. T., & Dahlquist, G. (1997). Cumulative incidence of childhood-onset IDDM is unaffected by pertussis immunization. *Diabetes Care*, *20*(2), 173-175. https://www.researchgate.net/profile/Robert_Chen7/publication/14099093_Cumulative_Incidence_of_Childhood-Onset_IDDM_is_Unaffected_by_Pertussis_Immunization/links/0046353b47f7eb7375000000.pdf

1261.) Beyerlein, A., Strobl, A. N., Winkler, C., Carpus, M., Knopff, A., Donnachie, E., ... & Ziegler, A. G. (2017). Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: Results from prospective cohort data. *Vaccine*, *35*(14), 1735-1741. https://www.sciencedirect.com/science/article/pii/S0264410X17302621

1262.) Rogers, M. A., Basu, T., & Kim, C. (2019). Lower incidence rate of type 1 diabetes after receipt of the rotavirus vaccine in the United States, 2001–2017. *Scientific reports*, *9*(1), 1-8. https://www.nature.com/articles/s41598-019-44193-4?fbclid=IwAR301082EbB7ODJcL0fDVU63furt0h7vOMefMibzGISYDDM4nmOz8276WWU

1263.) Feiring, B., Laake, I., Bakken, I. J., Greve-Isdahl, M., Wyller, V. B., Håberg, S. E., ... & Trogstad, L. (2017). HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: a nationwide register-based study from Norway. *Vaccine*, *35*(33), 4203-4212. https://www.sciencedirect.com/science/article/pii/S0264410X17308083

1264.) Imai, C., Toizumi, M., Hall, L., Lambert, S., Halton, K., & Merollini, K. (2018). A systematic review and meta-analysis of the direct epidemiological and economic effects of seasonal influenza vaccination on healthcare workers. *PloS one*, *13*(6), e0198685. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198685

1265.) Frederick, J., Brown, A. C., Cummings, D. A., Gaydos, C. A., Gibert, C. L., Gorse, G. J., ... & Radonovich, L. J. (2018). Protecting healthcare personnel in outpatient settings: the influence of mandatory versus nonmandatory influenza vaccination policies on workplace absenteeism during multiple respiratory virus seasons. *infection control & hospital epidemiology*, *39*(4), 452-461. https://pdfs.semanticscholar.org/c5d5/ff03dd72f36ad42713a1ddf9a8cd87b9305d.pdf

1266.) Joshi, A. Y., Iyer, V. N., Sauver, J. L. S., Jacobson, R. M., & Boyce, T. G. (2009). Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: a case–control study. *Vaccine*, *27*(33), 4457-4461.

https://www.sciencedirect.com/science/article/pii/S0264410X09007427

1267.) Carroll-Pankhurst, C., Engels, E. A., Strickler, H. D., Goedert, J. J., Wagner, J., & Mortimer Jr, E. A. (2001). Thirty-five year mortality following receipt of SV40-contaminated polio vaccine during the neonatal period. *British journal of cancer*, *85*(9), 1295-1297. https://www.nature.com/articles/6692065

1268.) Strickler, H. D., Rosenberg, P. S., Devesa, S. S., Hertel, J., Fraumeni Jr, J. F., & Goedert, J. J. (1998). Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. *Jama*, *279*(4), 292-295. https://jamanetwork.com/journals/jama/article-abstract/187182

1269.) Engels, E. A., Katki, H. A., Nielsen, N. M., Winther, J. F., Hjalgrim, H., Gjerris, F., ... & Frisch, M. (2003). Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40. *Journal of the National Cancer Institute*, *95*(7), 532-539. https://academic.oup.com/jnci/article/95/7/532/2520688

1270.) Rollison, D. E., Page, W. F., Crawford, H., Gridley, G., Wacholder, S., Martin, J., ... & Engels, E. A. (2004). Case-control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine. *American journal of epidemiology*, *160*(4), 317-324. https://academic.oup.com/aje/article/160/4/317/165832

1271.) Shah, K. V. (2007). SV40 and human cancer: a review of recent data. *International journal of cancer*, *120*(2), 215-223. https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.22425

1272.) Einstein, M. H., Baron, M., Levin, M. J., Chatterjee, A., Edwards, R. P., Zepp, F., ... & Dubin, G. (2009). Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. *Human vaccines*, *5*(10), 705-719. https://www.tandfonline.com/doi/pdf/10.4161/hv.5.10.9518

1273.) Dudley, M. Z., Halsey, N. A., Omer, S. B., Orenstein, W. A., T O'Leary, S., Limaye, R. J., & Salmon, D. A. (2020). The state of vaccine safety science: systematic reviews of the evidence. *The Lancet Infectious Diseases*, *20*(5), e80-e89. https://www.sciencedirect.com/science/article/abs/pii/S1473309920301304 & https://web.archive.org/web/20211118144426/https://sci-hubtw.hkvisa.net/10.1016/S1473-3099%2820%2930130-4

1274.) Engels, E. A. (2005). Cancer risk associated with receipt of vaccines contaminated with simian virus 40: epidemiologic research. *Expert review of vaccines*, *4*(2), 197-206.

https://www.researchgate.net/profile/Eric_Engels/publication/7851332_Cancer_risk_associated_with_receipt_of_vaccines_contaminated_with_simian_virus_40_Epidemiologic_research/links/572b554908aef5d48d327707/Cancer-risk-associated-with-receipt-of-vaccines-contaminated-with-simian-virus-40-Epidemiologic-research.pdf

1275.) Gilewski, T., Adluri, S., Ragupathi, G., Zhang, S., Yao, T. J., Panageas, K., ... & Livingston, P. O. (2000). Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. *Clinical Cancer Research*, *6*(5), 1693-1701. https://clincancerres.aacrjournals.org/content/6/5/1693.long

1276.) Lee, M. S., Kim, D. H., Kim, H., Lee, H. S., Kim, C. Y., Park, T. S., ... & Ahn, Y. O. (1998). Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. *International journal of epidemiology*, *27*(2), 316-319. https://academic.oup.com/ije/article/27/2/316/703594

1277.) Diefenbach, C. S., Gnjatic, S., Sabbatini, P., Aghajanian, C., Hensley, M. L., Spriggs, D. R., ... & Jungbluth, A. A. (2008). Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. *Clinical Cancer Research*, *14*(9), 2740-2748. https://clincancerres.aacrjournals.org/content/14/9/2740.short

1278.) Slade, B. A., Leidel, L., Vellozzi, C., Woo, E. J., Hua, W., Sutherland, A., ... & Markowitz, L. E. (2009). Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. *Jama*, *302*(7), 750-757. https://jamanetwork.com/journals/jama/fullarticle/184421

1279.) Zuo, Z., Qi, F., Yang, J., Wang, X., Wu, Y., Wen, Y., ... & Yao, Z. B. (2017). Immunization with Bacillus Calmette-Guérin (BCG) alleviates neuroinflammation and cognitive deficits in APP/PS1 mice via the recruitment of inflammation-resolving monocytes to the brain. *Neurobiology of Disease*, *101*, 27-39. https://www.sciencedirect.com/science/article/abs/pii/S096999611730030X

1280.) Shapira, M. Y., Zeira, E., Adler, R., & Shouval, D. (2001). Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. *Journal of hepatology*, *34*(1), 123-127. https://www.sciencedirect.com/science/article/abs/pii/S0168827800000829

1281.) Harder, T., Wichmann, O., Klug, S. J., van der Sande, M. A., & Wiese-Posselt, M. (2018). Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. *BMC medicine*, *16*(1), 110.

https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1098-3#citeas

1282.) Davis, M. M., Patel, M. S., & Gebremariam, A. (2004). Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. *Pediatrics*, *114*(3), 786-792. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.518.8323&rep=rep1&type=pdf

1283.) Zhou, F., Harpaz, R., Jumaan, A. O., Winston, C. A., & Shefer, A. (2005). Impact of varicella vaccination on health care utilization. *Jama*, *294*(7), 797-802. https://jamanetwork.com/journals/jama/fullarticle/201405

1284.) Seward, J. F., Watson, B. M., Peterson, C. L., Mascola, L., Pelosi, J. W., Zhang, J. X., ... & Jumaan, A. O. (2002). Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. *Jama*, *287*(5), 606-611. https://jamanetwork.com/journals/jama/fullarticle/194613

1285.) Seward, J. F., Zhang, J. X., Maupin, T. J., Mascola, L., & Jumaan, A. O. (2004). Contagiousness of varicella in vaccinated cases: a household contact study. *Jama*, *292*(6), 704-708. https://jamanetwork.com/journals/jama/article-abstract/199235

1286.) Lopez, A. S., Zhang, J., Brown, C., & Bialek, S. (2011). Varicella-related hospitalizations in the United States, 2000–2006: the 1-dose varicella vaccination era. *Pediatrics*, *127*(2), 238-245. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865884/

1287.) Malleson, P., & Bennett, J. (1977). Whooping-cough admissions to a paediatric hospital over ten years. The protective value of immunisation: The Protective Value of Immunisation. *The Lancet*, *309*(8005), 237-239. https://www.sciencedirect.com/science/article/abs/pii/S0140673677910297

1288.) Patel, R. A., Binns, H. J., & Shulman, S. T. (2004). Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. *The Journal of pediatrics*, *144*(1), 68-74. https://www.sciencedirect.com/science/article/abs/pii/S0022347603007170

1289.) Marin, M., Meissner, H. C., & Seward, J. F. (2008). Varicella prevention in the United States: a review of successes and challenges. *Pediatrics*, *122*(3), e744-e751. https://pediatrics.aappublications.org/content/122/3/e744.short

1290.) Mrkvan, T., Pelton, S. I., Ruiz-Guiñazú, J., Palmu, A. A., & Borys, D. (2018). Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience. *Expert review of vaccines*, *17*(9), 797-818. https://www.tandfonline.com/doi/pdf/10.1080/14760584.2018.1516551

1291.) Falkenhorst, G., Remschmidt, C., Harder, T., Hummers-Pradier, E., Wichmann, O., & Bogdan, C. (2017). Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. *PLoS One*, *12*(1), e0169368. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169368#abstract0

1292.) Demicheli, V., & Tiberti, D. (2003). The effectiveness and safety of hepatitis A vaccine: a systematic review. *Vaccine*, *21*(19-20), 2242-2245. https://www.sciencedirect.com/science/article/pii/S0264410X0300135X

1293.) Hutchison, B. G., Oxman, A. D., Shannon, H. S., Lloyd, S., Altmayer, C. A., & Thomas, K. (1999). Clinical effectiveness of pneumococcal vaccine. Meta-analysis. *Canadian Family Physician Medecin de Famille Canadien*, *45*, 2381-2393. https://www.researchgate.net/profile/Kurien_Thomas/publication/12759414_Clinical_effectiveness_of_pneumococcal_vaccine_Meta-analysis/links/0046352ef6985ec4a9000000/Clinical-effectiveness-of-pneumococcal-vaccine-Meta-analysis.pdf

1294.) Yoon, D., Lee, J. H., Lee, H., & Shin, J. Y. (2021). Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study. BMJ, 372, m4931. https://www.bmj.com/content/372/bmj.m4931.full

1295.) Scott, D. A., Komjathy, S. F., Hu, B. T., Baker, S., Supan, L. A., Monahan, C. A., ... & Lockhart, S. P. (2007). Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. *Vaccine*, *25*(33), 6164-6166. https://www.sciencedirect.com/science/article/pii/S0264410X07006792

1296.) Thompson, A., Lamberth, E., Severs, J., Scully, I., Tarabar, S., Ginis, J., ... & Watson, W. (2019). Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. *Vaccine*, *37*(42), 6201-6207. https://www.sciencedirect.com/science/article/pii/S0264410X19311120

1297.) Frenck, R. W., Gurtman, A., Rubino, J., Smith, W., van Cleeff, M., Jayawardene, D., ... & Schmöle-Thoma, B. (2012). Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. *Clinical and Vaccine Immunology*, *19*(8), 1296-1303.

https://cvi.asm.org/content/19/8/1296#sec-18

1298.) Steens, A., Bergsaker, M. A. R., Aaberge, I. S., Rønning, K., & Vestrheim, D. F. (2013). Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. *Vaccine*, *31*(52), 6232-6238.
https://www.sciencedirect.com/science/article/pii/S0264410X13014084

1299.) Dotres, C. P., Puga, R., Ricardo, Y., Broño, C. R., Paredes, B., Echemendía, V., ... & Group, L. P. (2014). Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: A randomized phase I clinical trial. *Vaccine*, *32*(41), 5266-5270.
https://www.researchgate.net/profile/Dagmar_Rivera/publication/264640928_Safety_and_preliminary_immunogenicity_of_Cuban_pneumococcal_conjugate_vaccine_candidate_in_healthy_children_A_randomized_phase_I_clinical_trial/links/5a5e79c9a6fdcc68fa992a3b/Safety-and-preliminary-immunogenicity-of-Cuban-pneumococcal-conjugate-vaccine-candidate-in-healthy-children-A-randomized-phase-I-clinical-trial.pdf

1300.) Clarke, E., Bashorun, A. O., Okoye, M., Umesi, A., Hydara, M. B., Adigweme, I., ... & Tate, A. (2020). Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia—Results of a phase 1/2 randomized, double-blinded, controlled trial. *Vaccine*, *38*(2), 399-410.
https://www.sciencedirect.com/science/article/pii/S0264410X1931148X

1301.) Bhutta, Z. A., Capeding, M. R., Bavdekar, A., Marchetti, E., Ariff, S., Soofi, S. B., ... & Khan, R. M. Q. (2014). Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. *The Lancet infectious diseases*, *14*(2), 119-129.
https://www.sciencedirect.com/science/article/abs/pii/S147330991370241X

1302.) McFetridge, R., Sobanjo-ter Meulen, A., Folkerth, S. D., Hoekstra, J. A., Dallas, M., Hoover, P. A., ... & Hartzel, J. S. (2015). Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. *Vaccine*, *33*(24), 2793-2799.
https://www.sciencedirect.com/science/article/pii/S0264410X15004788

1303.) Bryant, K. A., Block, S. L., Baker, S. A., Gruber, W. C., Scott, D. A., & PCV13 Infant Study Group. (2010). Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. *Pediatrics*, *125*(5), 866-875.
https://pediatrics.aappublications.org/content/125/5/866.short

1304.) Kieninger, D. M., Kueper, K., Steul, K., Juergens, C., Ahlers, N., Baker, S., ... & Scott, D. A. (2010). Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. *Vaccine*, *28*(25), 4192-4203. https://www.sciencedirect.com/science/article/pii/S0264410X10005013

1305.) Vanderkooi, O. G., Scheifele, D. W., Girgenti, D., Halperin, S. A., Patterson, S. D., Gruber, W. C., ... & Canadian PCV13 Study Group. (2012). Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. *The Pediatric infectious disease journal*, *31*(1), 72-77. https://journals.lww.com/pidj/fulltext/2012/01000/Safety_and_Immunogenicity_of_a_13_valent.19.aspx

1306.) McLaughlin, J. M., Jiang, Q., Isturiz, R. E., Sings, H. L., Swerdlow, D. L., Gessner, B. D., ... & Ramirez, J. A. (2018). Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. *Clinical Infectious Diseases*, *67*(10), 1498-1506. https://academic.oup.com/cid/article/67/10/1498/5000157

1307.) Gessner, B. D., Jiang, Q., Van Werkhoven, C. H., Sings, H. L., Webber, C., Scott, D., ... & Bonten, M. J. (2019). A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. *Vaccine*, *37*(38), 5777-5787. https://www.sciencedirect.com/science/article/pii/S0264410X18307631

1308.) Kilpi, T. M., Jokinen, J., Puumalainen, T., Nieminen, H., Ruokokoski, E., Rinta-Kokko, H., ... & Borys, D. (2018). Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial. *Vaccine*, *36*(39), 5891-5901. https://www.sciencedirect.com/science/article/pii/S0264410X18311290

1309.) Gessner, B. D., Jiang, Q., Van Werkhoven, C. H., Sings, H. L., Webber, C., Scott, D., ... & Jodar, L. (2019). A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. *Vaccine*, *37*(30), 4147-4154. https://www.sciencedirect.com/science/article/pii/S0264410X19307029

1310.) McLaughlin, J. M., Jiang, Q., Gessner, B. D., Swerdlow, D. L., Sings, H. L., Isturiz, R. E., & Jodar, L. (2019). Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. *Vaccine*, *37*(43), 6310-6316. https://www.sciencedirect.com/science/article/pii/S0264410X19311351

1311.) Kolditz, M., Schmitt, J., Pletz, M. W., & Tesch, F. (2019). Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of all-cause pneumonia in adults aged≥ 60 years: a population-based, retrospective cohort study. *Clinical Infectious Diseases*, *68*(12), 2117-2119. https://academic.oup.com/cid/article/68/12/2117/5194155

1312.) Hsu, K., Pelton, S., Karumuri, S., Heisey-Grove, D., Klein, J., & Massachusetts Department of Public Health Epidemiologists. (2005). Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. *The Pediatric infectious disease journal*, *24*(1), 17-23. https://journals.lww.com/pidj/Abstract/2005/01000/Population_Based_Surveillance_for_Childhood.4.aspx

1313.) Esposito, S., Pugni, L., Bosis, S., Proto, A., Cesati, L., Bianchi, C., ... & Principi, N. (2005). Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre-and full-term infants. *Vaccine*, *23*(14), 1703-1708. https://www.sciencedirect.com/science/article/pii/S0264410X04007340

1314.) Bonhoeffer, J., Siegrist, C. A., & Heath, P. T. (2006). Immunisation of premature infants. *Archives of disease in childhood*, *91*(11), 929-935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2082954/

1315.) Black, S., & Shinefield, H. (2002). Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. *European journal of pediatrics*, *161*(2), S127-S131. https://link.springer.com/article/10.1007%2Fs00431-002-1064-z

1316.) Omeñaca, F., Merino, J. M., Tejedor, J. C., Constantopoulos, A., Papaevangelou, V., Kafetzis, D., ... & Borys, D. (2011). Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. *Pediatrics*, *128*(2), e290-e298. https://www.researchgate.net/profile/Felix_Omenaca/publication/51465305_Immunization_of_Preterm_Infants_With_10-Valent_Pneumococcal_Conjugate_Vaccine/links/56f2735308aee4c87198c306/Immunization-of-Preterm-Infants-With-10-Valent-Pneumococcal-Conjugate-Vaccine.pdf

1317.) De Wals, P., Robin, E., Fortin, E., Thibeault, R., Ouakki, M., & Douville-Fradet, M. (2008). Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. *The Pediatric infectious disease journal*, *27*(11), 963-968. https://journals.lww.com/pidj/Abstract/2008/11000/Pneumonia_After_Implementation_of_the_Pneumococcal.3.aspx

1318.) Zhang, J., Zhang, X. F., Zhou, C., Wang, Z. Z., Huang, S. J., Yao, X., ... & Xia, N. S. (2014). Protection against hepatitis E virus infection by naturally acquired and vaccine‐induced immunity. *Clinical microbiology and infection*, *20*(6), O397-O405. https://onlinelibrary.wiley.com/doi/full/10.1111/1469-0691.12419

1319.) Aristegui, J., Bernaola, E., Pocheville, I., García, C., Arranz, L., Durán, G., ... & Garrote, E. (2007). Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. *European Journal of Clinical Microbiology & Infectious Diseases*, *26*(5), 303-310. https://www.researchgate.net/profile/Javier_De_Aristegui/publication/6370809_Reduction_in_pediatric_invasive_pneumococcal_disease_in_the_Basque_Country_and_Navarre_Spain_after_introduction_of_the_heptavalent_pneumococcal_conjugate_vaccine/links/558be2b108aee43bf6ad05f6/Reduction-in-pediatric-invasive-pneumococcal-disease-in-the-Basque-Country-and-Navarre-Spain-after-introduction-of-the-heptavalent-pneumococcal-conjugate-vaccine.pdf

1320.) De Jong, M. C., & Kimman, T. G. (1994). Experimental quantification of vaccine-induced reduction in virus transmission. *Vaccine*, *12*(8), 761-766. https://www.sciencedirect.com/science/article/pii/0264410X94902291

1321.) Poehling, K. A., Szilagyi, P. G., Grijalva, C. G., Martin, S. W., LaFleur, B., Mitchel, E., ... & Griffin, M. R. (2007). Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. *Pediatrics*, *119*(4), 707-715. https://pediatrics.aappublications.org/content/119/4/707.short

1322.) Hariri, S., Bennett, N. M., Niccolai, L. M., Schafer, S., Park, I. U., Bloch, K. C., ... & Abdullah, N. (2015). Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States–2008–2012. *Vaccine*, *33*(13), 1608-1613. https://www.hps.com.au/wp-content/uploads/2018/01/Knowledge-Centre-Volume-114-2-20171220.pdf

1323.) Koplan, J. P., Schoenbaum, S. C., Weinstein, M. C., & Fraser, D. W. (1979). Pertussis vaccine—an analysis of benefits, risks and costs. *New England journal of medicine*, *301*(17), 906-911. https://www.researchgate.net/profile/Stephen_Schoenbaum/publication/23095067_Pertussis_Vaccine_-_An_Analysis_of_Benefits_Risks_and_Costs/links/02e7e537f49bc4fa14000000/Pertussis-Vaccine-An-Analysis-of-Benefits-Risks-and-Costs.pdf

1324.) Markowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., McQuillan, G., & Unger, E. R. (2013). Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. *The Journal of infectious diseases*, *208*(3), 385-393. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.422.7510&rep=rep1&type=pdf

1325.) Tate, J. E., Haynes, A., Payne, D. C., Cortese, M. M., Lopman, B. A., Patel, M. M., & Parashar, U. D. (2013). Trends in national rotavirus activity before and after introduction of rotavirus vaccine into the national immunization program in the United States, 2000 to 2012. *The Pediatric infectious disease journal*, *32*(7), 741-744. https://journals.lww.com/pidj/Abstract/2013/07000/Trends_in_National_Rotavirus_Activity_Before_and.12.aspx

1326.) Dunne, E. F., Naleway, A., Smith, N., Crane, B., Weinmann, S., Braxton, J., ... & Markowitz, L. E. (2015). Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012–2013. *The Journal of infectious diseases*, *212*(12), 1970-1975. https://academic.oup.com/jid/article/212/12/1970/2911948

1327.) Hinman, A. R., & Koplan, J. P. (1984). Pertussis and pertussis vaccine: reanalysis of benefits, risks, and costs. *JAMA*, *251*(23), 3109-3113. https://jamanetwork.com/journals/jama/article-abstract/393222

1328.) Payne, D. C., Selvarangan, R., Azimi, P. H., Boom, J. A., Englund, J. A., Staat, M. A., ... & Parashar, U. D. (2015). Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US children, 2012–2013. *Clinical Infectious Diseases*, *61*(12), 1792-1799. https://academic.oup.com/cid/article/61/12/1792/338695?login=true

1329.) Takala, A. K., Eskola, J., Leinonen, M., Kayhty, H., Nissinen, A., Pekkanen, E., & Makela, P. H. (1991). Reduction of Oropharyngeal Carriage of Haemophilus influenzae Type b (Rib) in Children Immunized with an Rib Conjugate Vaccine. *Journal of Infectious Diseases*, *164*(5), 982-986. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1016.5883&rep=rep1&type=pdf

1330.) Goldie, S. J., Grima, D., Kohli, M., Wright, T. C., Weinstein, M., & Franco, E. (2003). A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine. *International Journal of cancer*, *106*(6), 896-904.
https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.11334

1331.) Pittman, P. R., Kim-Ahn, G., Pifat, D. Y., Coonan, K., Gibbs, P., Little, S., ... & Friedlander, A. M. (2002). Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. *Vaccine*, *20*(9-10), 1412-1420.
http://www.ssu.ac.ir/cms/fileadmin/user_upload/Moavenatha/MBehdashti/Pishgiri_Bimariha/00000000antrax2/37.pdf

1332.) Deiss, R. G., Arnold, J. C., Chen, W. J., Echols, S., Fairchok, M. P., Schofield, C., ... & Burgess, T. H. (2015). Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease. *Vaccine*, *33*(51), 7160-7167.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684491/

1333.) Pollock, K. G., Kavanagh, K., Potts, A., Love, J., Cuschieri, K., Cubie, H., ... & Donaghy, M. (2014). Reduction of low-and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. *British journal of cancer*, *111*(9), 1824-1830.
https://www.nature.com/articles/bjc2014479/

1334.) Sgambatti, S., Minamisava, R., Bierrenbach, A. L., Toscano, C. M., Vieira, M. A., Policena, G., & Andrade, A. L. (2016). Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance. *Vaccine*, *34*(5), 663-670.
https://www.sciencedirect.com/science/article/pii/S0264410X1501779X

1335.) Marin, M., Zhang, J. X., & Seward, J. F. (2011). Near elimination of varicella deaths in the US after implementation of the vaccination program. *Pediatrics*, *128*(2), 214-220.
https://www.researchgate.net/profile/Mona_Marin/publication/51520286_Near_Elimination_of_Varicella_Deaths_in_the_US_After_Implementation_of_the_Vaccination_Program/links/5693b45308ae425c6895f7b0.pdf

1336.) Andrews, R. M., Counahan, M. L., Hogg, G. G., & McIntyre, P. B. (2004). Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. *Vaccine*, *23*(2), 132-138.
https://sites.ualberta.ca/~dcl3/ABCDreview/papers/2004_Andrews_6255.pdf

1337.) Joyce, M. G., Wheatley, A. K., Thomas, P. V., Chuang, G. Y., Soto, C., Bailer, R. T., ... & Kong, W. P. (2016). Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. *Cell*, *166*(3), 609-623. https://www.sciencedirect.com/science/article/pii/S0092867416308510

1338.) Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., ... & Friedlander, T. (2020). A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, *183*(2), 347-362. https://www.cell.com/cell/pdf/S0092-8674(20)31141-7.pdf

1339.) Van Panhuis, W. G., Grefenstette, J., Jung, S. Y., Chok, N. S., Cross, A., Eng, H., ... & Burke, D. S. (2013). Contagious diseases in the United States from 1888 to the present. *The New England journal of medicine*, *369*(22), 2152-2158. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175560/

1340.) Bu, W., Joyce, M. G., Nguyen, H., Banh, D. V., Aguilar, F., Tariq, Z., ... & Andrews, S. F. (2019). Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. *Immunity*, *50*(5), 1305-1316. https://www.sciencedirect.com/science/article/pii/S107476131930127X

1341.) Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A., Cao, B., ... & Muruato, A. E. (2017). Vaccine mediated protection against Zika virus-induced congenital disease. *Cell*, *170*(2), 273-283. https://www.sciencedirect.com/science/article/pii/S0092867417307596#sec3

1342.) Hegde, N. R., & Gore, M. M. (2017). Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. *Human vaccines & immunotherapeutics*, *13*(6), 1320-1337. https://www.tandfonline.com/doi/full/10.1080/21645515.2017.1285472

1343.) Podda, A., & Del Giudice, G. (2003). MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. *Expert review of vaccines*, *2*(2), 197-204. https://www.tandfonline.com/doi/abs/10.1586/14760584.2.2.197

1344.) Bilyy, R., Paryzhak, S., Turcheniuk, K., Dumych, T., Barras, A., Boukherroub, R., ... & Szunerits, S. (2019). Aluminum oxide nanowires as safe and effective adjuvants for next-generation vaccines. *Materials Today*, *22*, 58-66. https://hal.archives-ouvertes.fr/hal-01944313/document

1345.) Ramsay, L. C., Buchan, S. A., Stirling, R. G., Cowling, B. J., Feng, S., Kwong, J. C., & Warshawsky, B. F. (2019). The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. *BMC medicine*, *17*(1), 1-16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327561/

1346.) Rose, A. M., Kissling, E., Gherasim, A., Casado, I., Bella, A., Launay, O., ... & Machado, A. (2020). Vaccine effectiveness against influenza A (H3N2) and B among laboratory‐confirmed, hospitalised older adults, Europe, 2017‐18: A season of B lineage mismatched to the trivalent vaccine. *Influenza and other respiratory viruses*, *14*(3), 302-310. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182608/

1347.) Valenciano, M., Kissling, E., Reuss, A., Jiménez-Jorge, S., Horváth, J. K., Donnell, J. M., ... & I-MOVE Multicentre Case Control Study Team. (2015). The European I-MOVE Multicentre 2013–2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A (H1N1) pdm09 and heterogenous results by country against A (H3N2). *Vaccine*, *33*(24), 2813-2822. https://www.sciencedirect.com/science/article/pii/S0264410X1500465X

1348.) Chen, Y. C., Zhou, J. H., Tian, J. M., Li, B. H., Liu, L. H., & Wei, K. (2020). Adjuvanted-influenza vaccination in patients infected with HIV: a systematic review and meta-analysis of immunogenicity and safety. *Human Vaccines & Immunotherapeutics*, *16*(3), 612-622. https://www.tandfonline.com/doi/abs/10.1080/21645515.2019.1672492

1349.) Sekuloski, S., Batzloff, M. R., Griffin, P., Parsonage, W., Elliott, S., Hartas, J., ... & Carapetis, J. (2018). Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. *PloS one*, *13*(7), e0198658. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028081/

1350.) Findlow, J., & Knuf, M. (2019). Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence. *Future microbiology*, *14*(7), 563-580. https://www.futuremedicine.com/doi/10.2217/fmb-2018-0343?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

1351.) Sow, S. O., Okoko, B. J., Diallo, A., Viviani, S., Borrow, R., Carlone, G., ... & Elie, C. (2011). Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. *New England Journal of Medicine*, *364*(24), 2293-2304. https://www.nejm.org/doi/full/10.1056/nejmoa1003812

1352.) Petäjä, T., Keränen, H., Karppa, T., Kawa, A., Lantela, S., Siitari-Mattila, M., ... & Dubin, G. (2009). Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. *Journal of Adolescent Health*, *44*(1), 33-40. https://www.jahonline.org/article/S1054-139X(08)00434-5/fulltext

1353.) Tristram, D. A., Welliver, R. C., Mohar, C. K., Hogerman, D. A., Hildreth, S. W., & Paradiso, P. (1993). Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. *Journal of Infectious Diseases*, *167*(1), 191-195. https://academic.oup.com/jid/article-abstract/167/1/191/845263

1354.) Van Damme, P., Olsson, S. E., Block, S., Castellsague, X., Gray, G. E., Herrera, T., ... & Christiano, S. (2015). Immunogenicity and safety of a 9-valent HPV vaccine. *Pediatrics*, *136*(1), e28-e39. https://pediatrics.aappublications.org/content/136/1/e28

1355.) Knuf, M., Habermehl, P., Zepp, F., Mannhardt, W., Kuttnig, M., Muttonen, P., ... & Descamps, D. (2006). Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. *The Pediatric infectious disease journal*, *25*(1), 12-18. https://journals.lww.com/pidj/Abstract/2006/01000/Immunogenicity_and_Safety_of_Two_Doses_of.5.aspx

1356.) Schuster, V., Otto, W., Maurer, L., Tcherepnine, P., Pfletschinger, U., Kindler, K., ... & Pierson, P. (2008). Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. *The Pediatric infectious disease journal*, *27*(8), 724-730. https://journals.lww.com/pidj/Abstract/2008/08000/Immunogenicity_and_Safety_Assessments_After_One.10.aspx

1357.) Pichichero, M. E., Bernstein, H., Blatter, M. M., Schuerman, L., Cheuvart, B., Holmes, S. J., & Study Investigators. (2007). Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. *The Journal of pediatrics*, *151*(1), 43-49. https://www.jpeds.com/article/S0022-3476(07)00132-1/fulltext

1358.) Knuf, M., Habermehl, P., Cimino, C., Petersen, G., & Schmitt, H. J. (2006). Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. *Vaccine*, *24*(22), 4727-4736.

https://d1wqtxts1xzle7.cloudfront.net/49831695/j.vaccine.2006.03.03220161024-6581-1bsap39.pdf?1477311387=&response-content-disposition=inline%3B+filename%3DImmunogenicity_reactogenicity_and_safety.pdf&Expires=1604150747&Signature=DZYq~EmuExdOcsimus1swRWqoQ2tx3T9yUtJKg5dg8SLoUzcSEJT6tTy1TEyL0g~i0pW5ymUE5W4ux~efdFW92lwf3j9GJo~lwSozPXvgY3OlvAKCDXs6i3UBRif4OYVvkATzaPAvgPpKhNQibYxew0~-JDjPZnJi-VBGAQ0iLqV0-K9JpkYvVN~m6gjcQLqJUCbuL2rSPL0af0hiYA520kT9~0YoglW6ReDKaGD3bs0My~f3sm3ZvUI130ZEOFSvB3ri6VUi0ToFwVbcng2R92G3CULMIdSjhofWfPWGuuIGgKjC5jC7zYMQxBWFfKIVPgd6UTZp0Rfl0Zda162cg__&Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA

1359.) Tichmann-Schumann, I., Soemantri, P., Behre, U., Disselhoff, J., Mahler, H., Maechler, G., ... & Schuerman, L. (2005). Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. *The Pediatric infectious disease journal*, *24*(1), 70-77. https://journals.lww.com/pidj/Abstract/2005/01000/Immunogenicity_and_Reactogenicity_of_Four_Doses_of.13.aspx

1360.) Scheifele, D. W., Halperin, S. A., Smith, B., Ochnio, J., Meloff, K., & Duarte-Monteiro, D. (2006). Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP. IPV/PRP-T Hib and hepatitis B vaccines in infants 2–7 months of age. *Vaccine*, *24*(12), 2057-2064. https://www.sciencedirect.com/science/article/pii/S0264410X05011667

1361.) Sigurdardottir, S. T., Davidsdottir, K., Arason, V. A., Jonsdottir, O., Laudat, F., Gruber, W. C., & Jonsdottir, I. (2008). Safety and immunogenicity of CRM197-conjugated pneumococcal–meningococcal C combination vaccine (9vPnC–MnCC) whether given in two or three primary doses. *Vaccine*, *26*(33), 4178-4186. https://www.sciencedirect.com/science/article/pii/S0264410X0800683X

1362.) Käyhty, H., Åhman, H., Eriksson, K., Sörberg, M., & Nilsson, L. (2005). Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. *The Pediatric infectious disease journal*, *24*(2), 108-114. https://journals.lww.com/pidj/Abstract/2005/02000/Immunogenicity_and_Tolerability_of_a_Heptavalent.4.aspx

1363.) Offit, P. A., Quarles, J., Gerber, M. A., Hackett, C. J., Marcuse, E. K., Kollman, T. R., ... & Landry, S. (2002). Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system?. *Pediatrics*, *109*(1), 124-129. https://www.aap.org/en-us/Documents/immunization_overwhelm.pdf

1364.) Schlecht, N. F., Masika, M., Diaz, A., Nucci-Sack, A., Salandy, A., Pickering, S., ... & Burk, R. D. (2019). Risk of oral human papillomavirus infection among sexually active female adolescents receiving the quadrivalent vaccine. *JAMA network open*, *2*(10), e1914031-e1914031. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2753522?resultClick=1

1365.) Sinclair, D. R., Grefenstette, J. J., Krauland, M. G., Galloway, D. D., Frankeny, R. J., Travis, C., ... & Roberts, M. S. (2019). Forecasted size of measles outbreaks associated with vaccination exemptions for schoolchildren. *JAMA network open*, *2*(8), e199768-e199768. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2748595?resultClick=1

1366.) Bastidas, A., de la Serna, J., El Idrissi, M., Oostvogels, L., Quittet, P., López-Jiménez, J., ... & Gaidano, G. (2019). Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. *Jama*, *322*(2), 123-133. https://jamanetwork.com/journals/jama/fullarticle/2737683?resultClick=1

1367.) Pillet, S., Couillard, J., Trépanier, S., Poulin, J. F., Yassine-Diab, B., Guy, B., ... & Landry, N. (2019). Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and≥ 50 years old adults. *PloS one*, *14*(6), e0216533. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0216533

1368.) de Cellès, M. D., Rohani, P., & King, A. A. (2019). Duration of Immunity and Effectiveness of Diphtheria-Tetanus–Acellular Pertussis Vaccines in Children. *JAMA pediatrics*, *173*(6), 588-594. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547082/

1369.) Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., ... & Haymaker, C. (2019). Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial. *JAMA oncology*, *5*(1), 67-73. https://jamanetwork.com/journals/jamaoncology/fullarticle/2703886?resultClick=1

1370.) Welters, M. J., van der Sluis, T. C., van Meir, H., Loof, N. M., van Ham, V. J., van Duikeren, S., ... & van Poelgeest, M. I. (2016). Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. *Science translational medicine*, *8*(334), 334ra52-334ra52. https://openaccess.leidenuniv.nl/bitstream/handle/1887/43077/05.pdf?sequence=8

1371.) Bernstein, D. I., Guptill, J., Naficy, A., Nachbagauer, R., Berlanda-Scorza, F., Feser, J., ... & Albrecht, R. A. (2020). Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. *The Lancet Infectious Diseases*, *20*(1), 80-91. https://www.sciencedirect.com/science/article/pii/S1473309919303937

1372.) Chung, V., Kos, F. J., Hardwick, N., Yuan, Y., Chao, J., Li, D., ... & Diamond, D. J. (2019). Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. *Clinical and Translational Oncology*, *21*(3), 363-372. https://link.springer.com/article/10.1007/s12094-018-1932-2

1373.) Gatti‐Mays, M. E., Redman, J. M., Donahue, R. N., Palena, C., Madan, R. A., Karzai, F., ... & McMahon, S. (2020). A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. *The Oncologist*, *25*(6), 479-e899. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288633/

1374.) Newman, J. H., Chesson, C. B., Herzog, N. L., Bommareddy, P. K., Aspromonte, S. M., Pepe, R., ... & Lee, M. (2020). Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. *Proceedings of the National Academy of Sciences*, *117*(2), 1119-1128. https://www.pnas.org/content/pnas/117/2/1119.full.pdf

1375.) Tai, L. H., Zhang, J., Scott, K. J., de Souza, C. T., Alkayyal, A. A., Ananth, A. A., ... & Bell, J. C. (2013). Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. *Clinical Cancer Research*, *19*(18), 5104-5115. https://clincancerres.aacrjournals.org/content/19/18/5104.full

1376.) Tai, L. H., Zhang, J., & Auer, R. C. (2013). Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination. *Oncoimmunology*, *2*(11), e26618. https://www.tandfonline.com/doi/pdf/10.4161/onci.26618

1377.) Nooka, A. K., Wang, M. L., Yee, A. J., Kaufman, J. L., Bae, J., Peterkin, D., ... & Raje, N. S. (2018). Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial. *JAMA oncology*, *4*(12), e183267-e183267. https://jamanetwork.com/journals/jamaoncology/fullarticle/2696714?resultClick=1

1378.) Wood, N., Nolan, T., Marshall, H., Richmond, P., Gibbs, E., Perrett, K., & McIntyre, P. (2018). Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial. *JAMA pediatrics*, *172*(11), 1045-1052. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2698966?resultClick=1

1379.) Healy, C. M., Rench, M. A., Swaim, L. S., Smith, E. B., Sangi-Haghpeykar, H., Mathis, M. H., ... & Baker, C. J. (2018). Association between third-trimester Tdap immunization and neonatal pertussis antibody concentration. *Jama*, *320*(14), 1464-1470. https://jamanetwork.com/journals/jama/fullarticle/2706137?resultClick=1

1380.) Troeger, C., Khalil, I. A., Rao, P. C., Cao, S., Blacker, B. F., Ahmed, T., ... & Kang, G. (2018). Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. *JAMA pediatrics*, *172*(10), 958-965. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2696431?resultClick=1

1381.) Macartney, K., Gidding, H. F., Trinh, L., Wang, H., Dey, A., Hull, B., ... & Crawford, N. (2017). Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. *JAMA pediatrics*, *171*(10), 992-998. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2647982?resultClick=1

1382.) Resik, S., Tejeda, A., Sutter, R. W., Diaz, M., Sarmiento, L., Alemañi, N., ... & Burton, A. (2013). Priming after a fractional dose of inactivated poliovirus vaccine. *New England Journal of Medicine*, *368*(5), 416-424. https://www.nejm.org/doi/full/10.1056/NEJMoa1202541

1383.) Cuba IPV Study Collaborative Group. (2007). Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. *New England Journal of Medicine*, *356*(15), 1536-1544. https://www.nejm.org/doi/full/10.1056/NEJMoa054960

1384.) Fathima, P., Snelling, T. L., & Gibbs, R. A. (2019). Effectiveness of rotavirus vaccines in an Australian population: A case-control study. *Vaccine*, *37*(41), 6048-6053. https://www.sciencedirect.com/science/article/pii/S0264410X19311119

1385.) Burnett, E., Lopman, B. A., & Parashar, U. D. (2017). Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortality. *Vaccine*, *35*(51), 7198-7203. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841463/

1386.) Karppinen, S., Toivonen, L., Schuez-Havupalo, L., Teros-Jaakkola, T., Waris, M., Auranen, K., ... & Peltola, V. (2019). Effectiveness of the ten-valent pneumococcal Haemophilus

influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age. *Vaccine*, *37*(22), 2935-2941. https://www.sciencedirect.com/science/article/pii/S0264410X19304773

1387.) Hviid, A., Svanström, H., Mølgaard-Nielsen, D., & Lambach, P. (2017). Association between pandemic influenza A (H1N1) vaccination in pregnancy and early childhood morbidity in offspring. *JAMA pediatrics*, *171*(3), 239-248. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2587560?resultClick=1

1388.) Payne, D. C., Sulemana, I., & Parashar, U. D. (2016). Evaluation of effectiveness of mixed rotavirus vaccine course for rotavirus gastroenteritis. *JAMA pediatrics*, *170*(7), 708-710. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2526062?resultClick=1

1389.) Andrews, N., Kent, A., Amin-Chowdhury, Z., Sheppard, C., Fry, N., Ramsay, M., & Ladhani, S. N. (2019). Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006–2018. *Vaccine*, *37*(32), 4491-4498. https://www.sciencedirect.com/science/article/pii/S0264410X19308485

1390.) Kim, J. H., Chun, B. C., Song, J. Y., Kim, H. Y., Bae, I. G., Kim, D. M., ... & Kwon, H. H. (2019). Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study. *Vaccine*, *37*(21), 2797-2804. https://www.sciencedirect.com/science/article/pii/S0264410X1930458X

1391.) Robison, S. G., & Thomas, A. R. (2018). Assessing the effectiveness of high-dose influenza vaccine in preventing hospitalization among seniors, and observations on the limitations of effectiveness study design. *Vaccine*, *36*(45), 6683-6687. https://www.sciencedirect.com/science/article/pii/S0264410X18313197

1392.) Jackson, L. A., Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., ... & Thomsen, I. P. (2015). Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. *Jama*, *314*(3), 237-246. https://jamanetwork.com/journals/jama/fullarticle/2397832?resultClick=1

1393.) Cortese, M. M., Dahl, R. M., Curns, A. T., & Parashar, U. D. (2015). Protection against gastroenteritis in US households with children who received rotavirus vaccine. *The Journal of infectious diseases*, *211*(4), 558-562. https://academic.oup.com/jid/article/211/4/558/2910569

1394.) Mailand, M. T., & Frederiksen, J. L. (2017). Vaccines and multiple sclerosis: a systematic review. *Journal of Neurology*, *264*(6), 1035-1050. https://link.springer.com/article/10.1007%2Fs00415-016-8263-4

1395.) Chao, C., Klein, N. P., Velicer, C. M., Sy, L. S., Slezak, J. M., Takhar, H., ... & Emery, M. (2012). Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. *Journal of internal medicine*, *271*(2), 193-203. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2796.2011.02467.x

1396.) Ferdinands, J. M., Thompson, M. G., Blanton, L., Spencer, S., Grant, L., & Fry, A. M. (2021). Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. *Vaccine*, *39*(28), 3678–3695. https://pubmed.ncbi.nlm.nih.gov/34090700/

1397.) Bonkoungou, I. J. O., Aliabadi, N., Leshem, E., Kam, M., Nezien, D., Drabo, M. K., ... & Ouédraogo-Traoré, R. (2018). Impact and effectiveness of pentavalent rotavirus vaccine in children< 5 years of age in Burkina Faso. *Vaccine*, *36*(47), 7170-7178. https://www.sciencedirect.com/science/article/pii/S0264410X17318170

1398.) Adar, Y., Singer, Y., Levi, R., Tzehoval, E., Perk, S., Banet-Noach, C., ... & Ben-Yedidia, T. (2009). A universal epitope-based influenza vaccine and its efficacy against H5N1. *Vaccine*, *27*(15), 2099-2107. https://www.biondvax.com/wp-content/uploads/2015/06/7-JVAC8977-adar-et-al.pdf

1399.) Segaloff, H. E., Leventer-Roberts, M., Riesel, D., Malosh, R. E., Feldman, B. S., Shemer-Avni, Y., ... & Katz, M. A. (2019). Influenza vaccine effectiveness against hospitalization in fully and partially vaccinated children in Israel: 2015–2016, 2016–2017, and 2017–2018. *Clinical Infectious Diseases*, *69*(12), 2153-2161. https://academic.oup.com/cid/article-abstract/69/12/2153/5314854

1400.) Blyth, C. C., Jacoby, P., Effler, P. V., Kelly, H., Smith, D. W., Robins, C., ... & Richmond, P. C. (2014). Effectiveness of trivalent flu vaccine in healthy young children. *Pediatrics*, *133*(5), e1218-e1225.
https://pediatrics.aappublications.org/content/133/5/e1218.short

1401.) Araki, K., Hara, M., Tsugawa, T., Shimanoe, C., Nishida, Y., Matsuo, M., & Tanaka, K. (2018). Effectiveness of monovalent and pentavalent rotavirus vaccines in Japanese children. *Vaccine*, *36*(34), 5187-5193.
https://www.sciencedirect.com/science/article/pii/S0264410X1830937X

1402.) Huang, Y. C., Wu, F. T., Huang, Y. C., Liu, C. C., Lin, H. C., Chi, H., ... & Hsiung, C. A. (2020). Long-term effectiveness of pentavalent and monovalent rotavirus vaccines against hospitalization in Taiwan children. *Vaccine*, *38*(41), 6435-6441.
https://www.sciencedirect.com/science/article/pii/S0264410X20310112

1403.) Lopez, A. L., Daag, J. V., Esparagoza, J., Bonifacio, J., Fox, K., Nyambat, B., ... & Tate, J. E. (2018). Effectiveness of monovalent rotavirus vaccine in the Philippines. *Scientific reports*, *8*(1), 1-8.
https://www.nature.com/articles/s41598-018-32595-9

1404.) Maiden, M. C., Ibarz-Pavón, A. B., Urwin, R., Gray, S. J., Andrews, N. J., Clarke, S. C., ... & Ala'Aldeen, D. A. (2008). Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. *The Journal of infectious diseases*, *197*(5), 737-743.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767871/

1405.) Ali, M., Emch, M., Von Seidlein, L., Yunus, M., Sack, D. A., Rao, M., ... & Clemens, J. D. (2005). Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. *The Lancet*, *366*(9479), 44-49.
https://www.sciencedirect.com/science/article/abs/pii/S0140673605665506

1406.) Biering-Sørensen, S., Aaby, P., Napirna, B. M., Roth, A., Ravn, H., Rodrigues, A., ... & Benn, C. S. (2012). Small randomized trial among low–birth-weight children receiving Bacillus Calmette-Guérin vaccination at first health center contact. *The Pediatric infectious disease journal*, *31*(3), 306-308.
https://journals.lww.com/pidj/Fulltext/2012/03000/Commentary___BCG_Vaccination_Halves_Neonatal.22.aspx

1407.) Kristiansen, P. A., Diomandé, F., Ba, A. K., Sanou, I., Ouédraogo, A. S., Ouédraogo, R., ... & Clark, T. A. (2013). Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. *Clinical infectious diseases*, *56*(3), 354-363. https://academic.oup.com/cid/article/56/3/354/428439

1408.) Tabrizi, S. N., Brotherton, J. M., Kaldor, J. M., Skinner, S. R., Liu, B., Bateson, D., ... & Malloy, M. (2014). Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. *The Lancet infectious diseases*, *14*(10), 958-966. https://www.sciencedirect.com/science/article/abs/pii/S1473309914708412

1409.) Haber, M., Barskey, A., Baughman, W., Barker, L., Whitney, C. G., Shaw, K. M., ... & Stephens, D. S. (2007). Herd immunity and pneumococcal conjugate vaccine: a quantitative model. *Vaccine*, *25*(29), 5390-5398. https://www.sciencedirect.com/science/article/pii/S0264410X07005336

1410.) Campbell, H., Andrews, N., Borrow, R., Trotter, C., & Miller, E. (2010). Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. *Clinical and Vaccine Immunology*, *17*(5), 840-847. https://cvi.asm.org/content/17/5/840

1411.) Paulke-Korinek, M., Kundi, M., Rendi-Wagner, P., de Martin, A., Eder, G., Schmidle-Loss, B., ... & Kollaritsch, H. (2011). Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. *Vaccine*, *29*(15), 2791-2796. https://www.sciencedirect.com/science/article/pii/S0264410X11001769

1412.) Bouma, A., De Smit, A. J., De Jong, M. C. M., De Kluijver, E. P., & Moormann, R. D. (2000). Determination of the onset of the herd-immunity induced by the E2 sub-unit vaccine against classical swine fever virus. *Vaccine*, *18*(14), 1374-1381. https://www.sciencedirect.com/science/article/pii/S0264410X99003989

1413.) Mikamo, H., Yamagishi, Y., Murata, S., Yokokawa, R., Han, S. R., Wakana, A., ... & Tanaka, Y. (2019). Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. *Vaccine*, *37*(12), 1651-1658. https://www.sciencedirect.com/science/article/pii/S0264410X19301549

1414.) Arredondo-García, J. L., Hadinegoro, S. R., Reynales, H., Chua, M. N., Medina, D. R., Chotpitayasunondh, T., ... & Frago, C. (2018). Four-year safety follow-up of the tetravalent

dengue vaccine efficacy randomized controlled trials in Asia and Latin America. *Clinical Microbiology and Infection*, *24*(7), 755-763. https://www.sciencedirect.com/science/article/pii/S1198743X18300892

1415.) Qiao, Y. L., Wu, T., Li, R. C., Hu, Y. M., Wei, L. H., Li, C. G., ... & Pan, Q. J. (2020). Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial. *JNCI: Journal of the National Cancer Institute*, *112*(2), 145-153. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019098/

1416.) Olsson, S. E., Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Malm, C., ... & Andersson-Ellstrom, A. (2007). Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. *Vaccine*, *25*(26), 4931-4939. http://www.hu.ufsc.br/projeto_hpv/Induction%20of%20immune%20memory%20following%20administration%20of%20a.pdf

1417.) Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Bock, H. L., Leyssen, M., & Jacquet, J. M. (2010). Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. *Vaccine*, *28*(3), 730-736. https://pajooheshyar.sums.ac.ir/attachment/92-01-80-6424/persistence.pdf

1418.) Keyserling, H., Papa, T., Koranyi, K., Ryall, R., Bassily, E., Bybel, M. J., ... & Reinhardt, A. (2005). Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. *Archives of pediatrics & adolescent medicine*, *159*(10), 907-913. https://jamanetwork.com/journals/jamapediatrics/article-abstract/486143

1419.) Perrett, K. P., Snape, M. D., Ford, K. J., John, T. M., Ly-Mee, M. Y., Langley, J. M., ... & Halperin, S. A. (2009). Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. *The Pediatric infectious disease journal*, *28*(3), 186-193. https://journals.lww.com/pidj/Abstract/2009/03000/Immunogenicity_and_Immune_Memory_of_a.5.aspx

1420.) Dou, Y., Fu, B., Sun, R., Li, W., Hu, W., Tian, Z., & Wei, H. (2015). Influenza vaccine induces intracellular immune memory of human NK cells. *PloS one*, *10*(3), e0121258. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0121258#sec013

1421.) Rowhani-Rahbar, A., Alvarez, F. B., Bryan, J. T., Hughes, J. P., Hawes, S. E., Weiss, N. S., & Koutsky, L. A. (2012). Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. *Journal of clinical virology*, *53*(3), 239-243. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279625/

1422.) Guevara, A., Cabello, R., Woelber, L., Moreira Jr, E. D., Joura, E., Reich, O., ... & Luxembourg, A. (2017). Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine. *Vaccine*, *35*(37), 5050-5057. https://www.arca.fiocruz.br/bitstream/icict/26034/2/Guevara%20A%20Antibody%20persistence...pdf

1423.) Nolan, T., Lambert, S., Roberton, D., Marshall, H., Richmond, P., Streeton, C., ... & Boutriau, D. (2007). A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. *Vaccine*, *25*(51), 8487-8499. https://www.sciencedirect.com/science/article/pii/S0264410X07011553

1424.) Van Herck, K., Jacquet, J. M., & Van Damme, P. (2011). Antibody persistence and immune memory in healthy adults following vaccination with a two‐dose inactivated hepatitis A vaccine: Long‐term follow‐up at 15 years. *Journal of medical virology*, *83*(11), 1885-1891. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.22200

1425.) Eko, F. O., Ekong, E., He, Q., Black, C. M., & Igietseme, J. U. (2011). Induction of immune memory by a multisubunit chlamydial vaccine. *Vaccine*, *29*(7), 1472-1480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032637/

1426.) Pereira, S. M., Barreto, M. L., Pilger, D., Cruz, A. A., Sant'Anna, C., Hijjar, M. A., ... & Rodrigues, L. C. (2012). Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial. *The Lancet infectious diseases*, *12*(4), 300-306. https://tinyurl.com/659rrzr8

1427.) Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Leroux-Roels, G., Crasta, P. D., & Hardt, K. (2012). Persistence and immune memory to hepatitis B vaccine 20 years after

primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers. *Human vaccines & immunotherapeutics*, *8*(7), 896-904. https://www.tandfonline.com/doi/full/10.4161/hv.19989

1428.) Galli, G., Hancock, K., Hoschler, K., DeVos, J., Praus, M., Bardelli, M., ... & Del Giudice, G. (2009). Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. *Proceedings of the National Academy of Sciences*, *106*(19), 7962-7967. https://www.pnas.org/content/106/19/7962

1429.) Van Damme, P., Leroux‐Roels, G., Crasta, P., Messier, M., Jacquet, J. M., & Van Herck, K. (2012). Antibody persistence and immune memory in adults, 15 years after a three‐dose schedule of a combined hepatitis A and B vaccine. *Journal of medical virology*, *84*(1), 11-17. https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.22264

1430.) Chen, Y., Zhou, C. L., Zhang, X. J., Hao, Z. Y., Zhang, Y. H., Wang, S. M., ... & Wang, B. (2018). Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis A vaccine. *Vaccine*, *36*(1), 114-121. https://www.researchgate.net/profile/Zhou_Chenliang/publication/321313912_Immune_memory_at_17-years_of_follow-up_of_a_single_dose_of_live_attenuated_hepatitis_A_vaccine/links/5b126e400f7e9b4981038b7d/Immune-memory-at-17-years-of-follow-up-of-a-single-dose-of-live-attenuated-hepatitis-A-vaccine.pdf

1431.) Wu, Q., Zhuang, G. H., Wang, X. L., Wang, L. R., Li, N., & Zhang, M. (2011). Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. *Vaccine*, *29*(12), 2302-2307. https://www.sciencedirect.com/science/article/pii/S0264410X11000533

1432.) Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L., & Ahmed, R. (2003). Cutting edge: long-term B cell memory in humans after smallpox vaccination. *The Journal of Immunology*, *171*(10), 4969-4973. https://www.jimmunol.org/content/171/10/4969.full

1433.) Galli, G., Medini, D., Borgogni, E., Zedda, L., Bardelli, M., Malzone, C., ... & Brauer, V. (2009). Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. *Proceedings of the National Academy of Sciences*, *106*(10), 3877-3882. https://www.pnas.org/content/106/10/3877.full#abstract-1

1434.) Borrow, R., Goldblatt, D., Finn, A., Southern, J., Ashton, L., Andrews, N., ... & Allan, G. (2003). Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. *Infection and immunity*, *71*(10), 5549-5555. https://iai.asm.org/content/71/10/5549

1435.) Valéa, I., Adjei, S., Usuf, E., Traore, O., Ansong, D., Tinto, H., ... & Kotey, A. (2020). Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS, S/AS01E malaria vaccine in African children: a randomized trial. *Human Vaccines & Immunotherapeutics*, *16(*6), 1464-1470. https://www.tandfonline.com/doi/full/10.1080/21645515.2019.1695457

1436.) FitzSimons, D., François, G., Hall, A., McMahon, B., Meheus, A., Zanetti, A., ... & Akarca, U. (2005). Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. *Vaccine*, *23*(32), 4158-4166. https://pubmed.ncbi.nlm.nih.gov/15964484/

1437.) Fraser, C., Tomassini, J. E., Xi, L., Golm, G., Watson, M., Giuliano, A. R., ... & Ault, K. A. (2007). Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. *Vaccine*, *25*(21), 4324-4333. http://www.hu.ufsc.br/projeto_hpv/Modeling%20the%20long-term%20antibody%20response%20of%20a%20human%20papillomavirus.pdf

1438.) Wang, H., Hu, Y., Zhang, G., Zheng, J., Li, L., & An, Z. (2014). Meta-analysis of vaccine effectiveness of mumps-containing vaccine under different immunization srategies in China. *Vaccine*, *32*(37), 4806-4812. https://www.sciencedirect.com/science/article/pii/S0264410X14007373

1439.) Mast, T. C., Wang, F. T., Su, S., & Seeger, J. D. (2015). Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States. *The Pediatric infectious disease journal*, *34*(6), 615-620. https://journals.lww.com/pidj/FullText/2015/06000/Evidence_of_Herd_Immunity_and_Sustained_Impact_of.17.aspx

1440.) Walsh, L. K., Donelle, J., Dodds, L., Hawken, S., Wilson, K., Benchimol, E. I., ... & Fell, D. B. (2019). Health Outcomes of Young Children Born to Mothers Who Received 2009 Pandemic H1N1 Influenza Vaccination During Pregnancy: Retrospective Cohort Study. BMJ, 366, l4151. https://www.bmj.com/content/366/bmj.l4151.full

1441.) Turner, N., Pierse, N., Bissielo, A., Huang, Q. S., Radke, S., Baker, M. G., ... & Kelly, H. (2014). Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. *Eurosurveillance*, *19*(34), 20884. https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/19/34/art20884-en.pdf?expires=1604236954&id=id&accname=guest&checksum=411391EC58E5641473A5903591399DB1

1442.) Liu, E. Y., Smith, L. M., Ellis, A. K., Whitaker, H., Law, B., Kwong, J. C., ... & Lévesque, L. E. (2018). Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study. *Cmaj*, *190*(21), E648-E655. https://www.cmaj.ca/content/cmaj/190/21/E648.full.pdf

1443.) Basta, N. E., Halloran, M. E., Matrajt, L., & Longini Jr, I. M. (2008). Estimating influenza vaccine efficacy from challenge and community-based study data. *American Journal of Epidemiology*, *168*(12), 1343-1352. https://academic.oup.com/aje/article/168/12/1343/154948

1444.) Belshe, R. B., Coelingh, K., Ambrose, C. S., Woo, J. C., & Wu, X. (2010). Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. *Vaccine*, *28*(9), 2149-2156. https://www.sciencedirect.com/science/article/pii/S0264410X09018714

1445.) Dunkle, L. M., Izikson, R., Patriarca, P., Goldenthal, K. L., Muse, D., Callahan, J., & Cox, M. M. (2017). Efficacy of recombinant influenza vaccine in adults 50 years of age or older. *New England Journal of Medicine*, *376*(25), 2427-2436. https://www.nejm.org/doi/full/10.1056/nejmoa1608862

1446.) Belshe, R. B., Gruber, W. C., Mendelman, P. M., Mehta, H. B., Mahmood, K., Reisinger, K., ... & Kotloff, K. (2000). Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. *The Journal of infectious diseases*, *181*(3), 1133-1137. https://pubmed.ncbi.nlm.nih.gov/10720541/

1447.) Kurath, G., Garver, K. A., Corbeil, S., Elliott, D. G., Anderson, E. D., & LaPatra, S. E. (2006). Protective immunity and lack of histopathological damage two years after DNA vaccination against infectious hematopoietic necrosis virus in trout. *Vaccine*, *24*(3), 345-354. https://www.sciencedirect.com/science/article/pii/S0264410X05007462

1448.) Shan, C., Muruato, A. E., Jagger, B. W., Richner, J., Nunes, B. T., Medeiros, D. B., ... & Pierson, T. C. (2017). A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. *Nature communications*, *8*(1), 676. https://www.nature.com/articles/s41467-017-00737-8.pdf?origin=ppub

1449.) Balmer, P., Borrow, R., & Miller, E. (2002). Impact of meningococcal C conjugate vaccine in the UK. *Journal of medical microbiology*, *51*(9), 717-722. https://www.microbiologyresearch.org/docserver/fulltext/jmm/51/9/mjm5109.717.pdf?expires=1604244429&id=id&accname=guest&checksum=DD58F00A2208123FD1D0D848C5FF5548

1450.) Hviid, A., & Melbye, M. (2004). Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. *Vaccine*, *22*(3-4), 378-382. https://www.sciencedirect.com/science/article/pii/S0264410X03005772

1451.) Adamkiewicz, T. V., Silk, B. J., Howgate, J., Baughman, W., Strayhorn, G., Sullivan, K., & Farley, M. M. (2008). Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. *Pediatrics*, *121*(3), 562-569. https://pediatrics.aappublications.org/content/121/3/562.short

1452.) Trotter, C. L., Gay, N. J., & Edmunds, W. J. (2005). Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. *American journal of epidemiology*, *162*(1), 89-100. https://academic.oup.com/aje/article/162/1/89/166230#1453322

1453.) Quian, J., Rüttimann, R., Romero, C., Dall'Orso, P., Cerisola, A., Breuer, T., ... & Verstraeten, T. (2008). Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997–2005. *Archives of disease in childhood*, *93*(10), 845-850. https://adc.bmj.com/content/archdischild/93/10/845.full.pdf

1454.) Bogaards, J. A., Coupé, V. M., Xiridou, M., Meijer, C. J., Wallinga, J., & Berkhof, J. (2011). Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer Incidence. *Epidemiology*, *22*(4), 505-515. https://journals.lww.com/epidem/Fulltext/2011/07000/Long_term_Impact_of_Human_Papillomavirus.13.aspx

1455.) Cohen, S. A., Chui, K. K., & Naumova, E. N. (2011). Influenza vaccination in young children reduces influenza‐associated hospitalizations in older adults, 2002–2006. *Journal of the American Geriatrics Society*, *59*(2), 327-332. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111961/

1456.) Rha, B., Tate, J. E., Payne, D. C., Cortese, M. M., Lopman, B. A., Curns, A. T., & Parashar, U. D. (2014). Effectiveness and impact of rotavirus vaccines in the United States–2006–2012. *Expert review of vaccines*, *13*(3), 365-376. https://www.researchgate.net/profile/Daniel_Payne2/publication/259605260_Effectiveness_and_impact_of_rotavirus_vaccines_in_the_United_States_-_2006-2012/links/0046353b4215460031000000/Effectiveness-and-impact-of-rotavirus-vaccines-in-the-United-States-2006-2012.pdf

1457.) Zickafoose, J. S., Benneyworth, B. D., Riebschleger, M. P., Espinosa, C. M., & Davis, M. M. (2012). Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States. *Archives of pediatrics & adolescent medicine*, *166*(4), 350-355. https://jamanetwork.com/journals/jamapediatrics/fullarticle/1148402

1458.) Iwata, S., Nakata, S., Ukae, S., Koizumi, Y., Morita, Y., Kuroki, H., ... & Lawrence, J. (2013). Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. *Human vaccines & immunotherapeutics*, *9*(8), 1626-1633. https://www.tandfonline.com/doi/full/10.4161/hv.24846

1459.) Martinón-Torres, F., Martinón-Torres, N., Alejandro, M. B., Collazo, L. R., Pértega-Díaz, S., Seoane-Pillado, M. T., ... & San-Martín, M. (2012). Acute gastroenteritis hospitalizations among children aged< 5 years before and after introduction of rotavirus vaccines: a hospital-based surveillance study in Galicia, Spain. *Human vaccines & immunotherapeutics*, *8*(7), 946-952. https://www.tandfonline.com/doi/full/10.4161/hv.20178

1460.) Dagan, R., Melamed, R., Muallem, M., Piglansky, L., Greenberg, D., Abramson, O., ... & Yagupsky, P. (1996). Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. *Journal of Infectious Diseases*, *174*(6), 1271-1278. https://academic.oup.com/jid/article/174/6/1271/817335

1461.) Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O. E., ... & Barr, E. (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. *British journal of cancer*, *95*(11), 1459-1466. https://www.nature.com/articles/6603469?report=reader#Abs1

1462.) Ault, K. A., & Future II Study Group. (2007). Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. *The Lancet*, *369*(9576), 1861-1868. https://www.sciencedirect.com/science/article/abs/pii/S0140673607608526

1463.) Joura, E. A., Giuliano, A. R., Iversen, O. E., Bouchard, C., Mao, C., Mehlsen, J., ... & Pitisuttithum, P. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *New England Journal of Medicine*, *372*(8), 711-723. https://www.nejm.org/doi/full/10.1056/NEJMoa1405044

1464.) Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H. A., ... & Jimenez, S. (2013). Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. *PloS one*, *8*(7), e68329. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0068329

1465.) Kreimer, A. R., González, P., Katki, H. A., Porras, C., Schiffman, M., Rodriguez, A. C., ... & van Doorn, L. J. (2011). Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. *The lancet oncology*, *12*(9), 862-870. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172992/

1466.) Jeong, S., Jang, E. J., Jo, J., & Jang, S. (2019). Effects of maternal influenza vaccination on adverse birth outcomes: A systematic review and Bayesian meta-analysis. *PloS one*, *14*(8), e0220910. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0220910

1467.) Mehrabadi, A., Dodds, L., MacDonald, N. E., Top, K. A., Benchimol, E. I., Kwong, J. C., ... & Fell, D. B. (2021). Association of Maternal Influenza Vaccination During Pregnancy With Early Childhood Health Outcomes. *JAMA*, *325*(22), 2285-2293. https://jamanetwork.com/journals/jama/article-abstract/2780619

1468.) Swedish, K. A., Factor, S. H., & Goldstone, S. E. (2012). Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. *Clinical infectious diseases*, *54*(7), 891-898. https://academic.oup.com/cid/article/54/7/891/297522

1469.) Johnson, C. E., Whitwell, J., Kumar, M. L., Nalin, D. R., Chui, L. W., & Marusyk, R. G. (1994). Measles vaccine immunogenicity in 6-versus 15-month-old infants born to mothers in the measles vaccine era. *Pediatrics*, *93*(6), 939-943. https://pediatrics.aappublications.org/content/93/6/939

1470.) Treanor, J. J., Wilkinson, B. E., Masseoud, F., Hu-Primmer, J., Battaglia, R., O'Brien, D., ... & Katz, J. M. (2001). Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. *Vaccine*, *19*(13-14), 1732-1737. https://www.sciencedirect.com/science/article/pii/S0264410X00003959

1471.) Hu, M. C., Walls, M. A., Stroop, S. D., Reddish, M. A., Beall, B., & Dale, J. B. (2002). Immunogenicity of a 26-valent group A streptococcal vaccine. *Infection and immunity*, *70*(4), 2171-2177. https://iai.asm.org/content/70/4/2171.full

1472.) Thanavala, Y., Mahoney, M., Pal, S., Scott, A., Richter, L., Natarajan, N., ... & Mason, H. S. (2005). Immunogenicity in humans of an edible vaccine for hepatitis B. *Proceedings of the National Academy of Sciences*, *102*(9), 3378-3382. https://www.pnas.org/content/pnas/102/9/3378.full.pdf

1473.) Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Krieg, A. M., Li, Y., ... & Cameron, D. W. (2004). Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. *Vaccine*, *22*(23-24), 3136-3143. https://www.sciencedirect.com/science/article/pii/S0264410X04001483

1474.) Brokstad, K. A., Cox, R. J., Olofsson, J., Jonsson, R., & Haaheim, L. R. (1995). Parenteral influenza vaccination induces a rapid systemic and local immune response. *Journal of Infectious Diseases*, *171*(1), 198-203. https://www.researchgate.net/profile/Karl_Brokstad/publication/15399871_Parenteral_Influenza_Vaccination_Induces_A_Rapid_Systemic_And_Local_Immune_Response/links/02e7e5178089a62453000000.pdf

1475.) Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Klein, N. P., Cheetham, T. C., Naleway, A., ... & McCarthy, N. L. (2014). Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. *Jama*, *312*(18), 1897-1904. https://jamanetwork.com/journals/jama/fullarticle/1930817

1476.) Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Klein, N. P., Cheetham, T. C., Naleway, A. L., ... & McCarthy, N. (2016). Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007–2013. *Vaccine*, *34*(7), 968-973. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506839/

1477.) Morgan, J. L., Baggari, S. R., McIntire, D. D., & Sheffield, J. S. (2015). Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. *Obstetrics & Gynecology*, *125*(6), 1433-1438. https://journals.lww.com/greenjournal/FullText/2015/06000/Pregnancy_Outcomes_After_Antepartum_Tetanus,.23.aspx

1478.) Munoz, F. M., Patel, S. M., Jackson, L. A., Swamy, G. K., Edwards, K. M., Frey, S. E., ... & Keitel, W. A. (2020). Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. *Vaccine*, *38*(33), 5355-5363. https://www.sciencedirect.com/science/article/pii/S0264410X20307040

1479.) Govaert, T. M., Thijs, C. T. M. C. N., Masurel, N., Sprenger, M. J. W., Dinant, G. J., & Knottnerus, J. A. (1994). The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. *Jama*, *272*(21), 1661-1665. https://jamanetwork.com/journals/jama/article-abstract/383571

1480.) Horowitz, M. M., Ershler, W. B., McKinney, W. P., & Battiola, R. J. (1988). Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. *Annals of internal medicine*, *108*(2), 185-189. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.949.8809&rep=rep1&type=pdf

1481.) Herron, A., Dettleff, G., Hixon, B., Brandwin, L., Ortbals, D., Hornick, R., & Hahn, B. (1979). Influenza vaccination in patients with rheumatic diseases: safety and efficacy. *Jama*, *242*(1), 53-56. https://jamanetwork.com/journals/jama/article-abstract/365609

1482.) Jäger, E., Karbach, J., Gnjatic, S., Neumann, A., Bender, A., Valmori, D., ... & Panicali, D. (2006). Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. *Proceedings of the National Academy of Sciences*, *103*(39), 14453-14458. https://www.pnas.org/content/103/39/14453.full

1483.) Dodds, L., MacDonald, N., Scott, J., Spencer, A., Allen, V. M., & McNeil, S. (2012). The association between influenza vaccine in pregnancy and adverse neonatal outcomes. *Journal of Obstetrics and Gynaecology Canada*, *34*(8), 714-720. https://www.sciencedirect.com/science/article/abs/pii/S1701216316353361

1484.) Li, X., Mukandavire, C., Cucunubá, Z. M., Londono, S. E., Abbas, K., Clapham, H. E., ... & Vaccine Impact Modelling Consortium. (2021). Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. *The Lancet*, *397*(10272), 398-408. https://www.sciencedirect.com/science/article/pii/S014067362032657X

1485.) Riley, I. D., Alpers, M. P., Gratten, H., Lehmann, D., Marshall, T. D., & Smith, D. (1986). Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. *The Lancet*, *328*(8512), 877-881. https://www.sciencedirect.com/science/article/abs/pii/S0140673686904095

1486.) Perrett, K. P., Halperin, S. A., Nolan, T., Pancorbo, C. M., Tapiero, B., Martinón-Torres, F., ... & Mesaros, N. (2020). Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. *Vaccine*, *38*(8), 2095-2104. https://www.sciencedirect.com/science/article/pii/S0264410X19315075

1487.) Wood, N., McIntyre, P., Marshall, H., & Roberton, D. (2010). Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. *The Pediatric infectious disease journal*, *29*(3), 209-215. https://evidenciasenpediatria.es/files/41-40-RUTA/24%20EeP5_Wood_PertusisVac_2010.pdf/files/41-10828-RUTA/29AVC.pdf

1488.) Ji, J., Sundquist, J., & Sundquist, K. (2018). Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients. *Nature communications*, *9*(1), 1-7. https://www.nature.com/articles/s41467-018-04814-4.pdf?origin=ppub

1489.) Ji, J., Sundquist, J., & Sundquist, K. (2018). Cholera vaccine use is associated with a reduced risk of death in patients with colorectal cancer: a population-based study. *Gastroenterology*, *154*(1), 86-92. https://www.sciencedirect.com/science/article/abs/pii/S0016508517361498

1490.) Paternina-Caicedo, A., Parashar, U. D., Alvis-Guzmán, N., De Oliveira, L. H., Castaño-Zuluaga, A., Cotes-Cantillo, K., ... & De la Hoz-Restrepo, F. (2015). Effect of rotavirus vaccine on childhood diarrhea mortality in five Latin American countries. *Vaccine*, *33*(32), 3923-3928. https://www.sciencedirect.com/science/article/pii/S0264410X15008592

1491.) Cross, R. W., Xu, R., Matassov, D., Hamm, S., Latham, T. E., Gerardi, C. S., ... & Luckay, A. (2019). Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. *The Journal of Clinical Investigation*, *130*(1), 539-551. https://www.jci.org/articles/view/131958

1492.) Miller, E. R., Alter, M. J., & Tokars, J. I. (1999). Protective effect of hepatitis B vaccine in chronic hemodialysis patients. *American journal of kidney diseases*, *33*(2), 356-360. https://www.sciencedirect.com/science/article/abs/pii/S0272638699703124

1493.) Schuring, R. P., Richardus, J. H., Pahan, D., & Oskam, L. (2009). Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. *Vaccine*, *27*(50), 7125-7128. https://www.researchgate.net/profile/Jan_Richardus/publication/257309573_The_combined_effect_of_chemoprophylaxis_with_single_dose_rifampicin_and_immunoprophylaxis_with_BCG_to_prevent_leprosy_in_contacts_of_newly_diagnosed_leprosy_cases_A_cluster_randomized_controlled_trial/links/549aab0c0cf2d6581ab29636.pdf

1494.) Zou, H., Chen, Y., Duan, Z., & Zhang, H. (2011). Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers. *PloS one*, *6*(10), e26748. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026748

1495.) Tamura, S. I., Samegai, Y., Kurata, H., Nagamine, T., Aizawa, C., & Kurata, T. (1988). Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. *Vaccine*, *6*(5), 409-413. https://www.sciencedirect.com/science/article/pii/0264410X88901405

1496.) Slepushkin, V. A., Katz, J. M., Black, R. A., Gamble, W. C., Rota, P. A., & Cox, N. J. (1995). Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. *Vaccine*, *13*(15), 1399-1402. https://www.sciencedirect.com/science/article/pii/0264410X9592777Y

1497.) Zhu, F. C., Wang, H., Fang, H. H., Yang, J. G., Lin, X. J., Liang, X. F., ... & Liu, W. D. (2009). A novel influenza A (H1N1) vaccine in various age groups. *New England Journal of Medicine*, *361*(25), 2414-2423. https://www.nejm.org/doi/10.1056/NEJMoa0908535?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

1498.) Clark, T. W., Pareek, M., Hoschler, K., Dillon, H., Nicholson, K. G., Groth, N., & Stephenson, I. (2009). Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. *New England Journal of Medicine*, *361*(25), 2424-2435. https://www.nejm.org/doi/full/10.1056/nejmoa0907650

1499.) Greenberg, M. E., Lai, M. H., Hartel, G. F., Wichems, C. H., Gittleson, C., Bennet, J., ... & Basser, R. L. (2009). Response to a monovalent 2009 influenza A (H1N1) vaccine. *New England Journal of Medicine*, *361*(25), 2405-2413. https://www.nejm.org/doi/full/10.1056/NEJMoa0907413

1500.) Ehrlich, H. J., Müller, M., Oh, H. M., Tambyah, P. A., Joukhadar, C., Montomoli, E., ... & Vartian, N. (2008). A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. *New England Journal of Medicine*, *358*(24), 2573-2584. https://www.nejm.org/doi/full/10.1056/NEJMoa073121

1501.) Kahn, J. A., Widdice, L. E., Ding, L., Huang, B., Brown, D. R., Franco, E. L., & Bernstein, D. I. (2016). Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. *Clinical Infectious Diseases*, *63*(10), 1281-1287. https://academic.oup.com/cid/article/63/10/1281/2457209

1502.) Baxter, R., Bakshi, N., Fireman, B., Lewis, E., Ray, P., Vellozzi, C., & Klein, N. P. (2013). Lack of association of Guillain-Barré syndrome with vaccinations. *Clinical infectious diseases*, *57*(2), 197-204. https://academic.oup.com/cid/article/57/2/197/313432

1503.) Nation, M. L., Moss, R., Spittal, M. J., Kotsimbos, T., Kelly, P. M., & Cheng, A. C. (2021). Influenza vaccine effectiveness against influenza-related mortality in Australian hospitalized patients: a propensity score analysis. *Clinical Infectious Diseases*, *72*(1), 99-107. https://academic.oup.com/cid/article-abstract/72/1/99/5696795

1504.) Thangarajah, D., Malo, J. A., Field, E., Andrews, R., Ware, R. S., & Lambert, S. B. (2021). Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018. *Vaccine*, *39*(4), 729-737. https://www.sciencedirect.com/science/article/pii/S0264410X20315796

1505.) Ikeda, S., Ueda, Y., Hara, M., Yagi, A., Kitamura, T., Kitamura, Y., ... & Sobue, T. (2021). Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case‐control study. *Cancer Science*, *112*(2), 839-846. https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.14682

1506.) Romanowski, B., de Borba, P. C., Naud, P. S., Roteli-Martins, C. M., De Carvalho, N. S., Teixeira, J. C., ... & GlaxoSmithKline Vaccine HPV-007 Study Group. (2009). Sustained Efficacy and Immunogenicity of the Human Papillomavirus (HPV)-16/18 AS04-adjuvanted Vaccine: Analysis of a Randomised Placebo-Controlled Trial Up to 6.4 Years. *Lancet*, *374*(9706), 1975-1985. https://pubmed.ncbi.nlm.nih.gov/19962185/

1507.) Lee, C., Gong, Y., Brok, J., Boxall, E. H., & Gluud, C. (2006). Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. *Bmj*, *332*(7537), 328-336. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1363909/

1508.) Goullé, J. P., & Grangeot-Keros, L. (2020). Aluminum and vaccines: Current state of knowledge. *Medecine et maladies infectieuses*, *50*(1), 16-21. https://www.sciencedirect.com/science/article/pii/S0399077X18308448

1509.) Grazina, I., Mannocci, A., Meggiolaro, A., & La Torre, G. (2020). Is there an association between Stevens-Johnson Syndrome and vaccination? A systematic review. *Annali di igiene: medicina preventiva e di comunita*, *32*(1), 81-96. http://www.seu-roma.it/riviste/annali_igiene/open_access/articoli/32-01-09-Grazina.pdf

1510.) Lanckriet, C., Lévy-Bruhl, D., Bingono, E., Siopathis, R. M., & Guérin, N. (1995). Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui. *International journal of epidemiology*, *24*(5), 1042–1049. https://academic.oup.com/ije/article-abstract/24/5/1042/704687?redirectedFrom=fulltext

1511.) Garolla, A., De Toni, L., Bottacin, A., Valente, U., Ponce, M. D. R., Di Nisio, A., & Foresta, C. (2018). Human Papillomavirus Prophylactic Vaccination improves reproductive outcome in infertile patients with HPV semen infection: a retrospective study. *Scientific reports*, *8*(1), 1-9. https://www.nature.com/articles/s41598-018-19369-z

1512.) Kharbanda, E. O., Vazquez-Benitez, G., DeSilva, M. B., Naleway, A. L., Klein, N. P., Hechter, R. C., ... & Lipkind, H. S. (2021). Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. *JAMA Network Open*, *4*(4), e214340. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022219/

1513.) Sun, Z. W., Fu, Y., Lu, H. L., Yang, R. X., Goyal, H., Jiang, Y., & Xu, H. G. (2021). Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 Years: A Systematic Review and Meta-analysis of Randomized Clinical Trials and Observational Studies. *JAMA pediatrics*, *175*(7), e210347. https://jamanetwork.com/journals/jamapediatrics/article-abstract/2779857?resultClick=1

1514.) MacIntyre, C. R., Heywood, A. E., Kovoor, P., Ridda, I., Seale, H., Tan, T., ... & Dwyer, D. E. (2013). Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study. *Heart*, *99*(24), 1843-1848. https://heart.bmj.com/content/heartjnl/99/24/1843.full.pdf

1515.) Awadalla, M., Golden, D., Mahmood, S. S., Alvi, R. M., Mercaldo, N. D., Hassan, M., Banerji, D., Rokicki, A., Mulligan, C., Murphy, S., Jones-O'Connor, M., Cohen, J. V., Heinzerling, L. M., Armanious, M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., Kirchberger, M. C., Moslehi, J. J., … Neilan, T. G. (2019). Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. *Journal for immunotherapy of cancer*, *7*(1), 53. https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-019-0535-y.pdf

1516.) La Torre, G., Saulle, R., Unim, B., Meggiolaro, A., Barbato, A., Mannocci, A., & Spadea, A. (2017). The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. *Human vaccines & immunotherapeutics*, *13*(8), 1879-1883. https://www.tandfonline.com/doi/pdf/10.1080/21645515.2017.1330733

1517.) Inns, T., Fleming, K., Iturriza-Gomara, M., & Hungerford, D. (2021). Paediatric rotavirus vaccination, coeliac disease and type 1 diabetes in children: A population-based cohort study. *BMC Medicine*. https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-021-02017-1.pdf

1518.) Reddy, S. N., Nair, N. P., Tate, J. E., Thiyagarajan, V., Giri, S., Praharaj, I., Mohan, V. R., Babji, S., Gupte, M. D., Arora, R., Bidari, S., Senthamizh, S., Mekala, S., Goru, K. B., Reddy, B., Pamu, P., Gorthi, R. P., Badur, M., Mohan, V., Sathpathy, S., … Kang, G. (2020). Intussusception after Rotavirus Vaccine Introduction in India. *The New England journal of medicine*, *383*(20), 1932–1940. https://www.nejm.org/doi/10.1056/NEJMoa2002276?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

1519.) Aronson, N. E., Santosham, M., Comstock, G. W., Howard, R. S., Moulton, L. H., Rhoades, E. R., & Harrison, L. H. (2004). Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. *JAMA*, *291*(17), 2086–2091. https://jamanetwork.com/journals/jama/fullarticle/198681

1520.) Sugaya, N., & Takeuchi, Y. (2005). Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan. *Clinical infectious diseases*, *41*(7), 939–947.https://academic.oup.com/cid/article/41/7/939/309053

1521.) Hviid, A., Thorsen, N. M., Valentiner-Branth, P., Frisch, M., & Mølbak, K. (2020). Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: population based, self-controlled, case series analysis. *BMJ , 370*, m2930. https://www.bmj.com/content/370/bmj.m2930.long

1522.) de Castro, M. J., Pardo-Seco, J., & Martinón-Torres, F. (2015). Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. *Clinical Infectious Diseases*, *60*(11), 1611-1619. https://academic.oup.com/cid/article/60/11/1611/356084

1523.) Siedler, A., & Dettmann, M. (2014). Hospitalization with varicella and shingles before and after introduction of childhood varicella vaccination in Germany. *Human vaccines & immunotherapeutics*, *10*(12), 3594-3600. https://www.tandfonline.com/doi/pdf/10.4161/hv.34426

1524.) Mohseni, H., Kiran, A., Khorshidi, R., & Rahimi, K. (2017). Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study. *European heart journal*, *38*(5), 326-333. https://academic.oup.com/eurheartj/article/38/5/326/2661779

1525.) Gilbertson, D. T., Guo, H., Arneson, T. J., & Collins, A. J. (2011). The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. *Nephrology Dialysis Transplantation*, *26*(9), 2934-2939. https://academic.oup.com/ndt/article/26/9/2934/1818670

1526.) Lindstrand, A., Bennet, R., Galanis, I., Blennow, M., Ask, L. S., Dennison, S. H., ... & Alfvén, T. (2014). Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine. *Pediatrics*, *134*(6), e1528-e1536. https://sci-hub.se/10.1542/peds.2013-4177

1527.) Sung, L. C., Chen, C. I., Fang, Y. A., Lai, C. H., Hsu, Y. P., Cheng, T. H., ... & Liu, J. C. (2014). Influenza vaccination reduces hospitalization for acute coronary syndrome in elderly

patients with chronic obstructive pulmonary disease: a population-based cohort study. *Vaccine*, *32*(30), 3843-3849. https://www.sciencedirect.com/science/article/pii/S0264410X14006021

1528.) Liu, I. F., Huang, C. C., Chan, W. L., Huang, P. H., Chung, C. M., Lin, S. J., ... & Leu, H. B. (2012). Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease: a nationwide population-based study. *Preventive medicine*, *54*(6), 431-433. https://www.sciencedirect.com/science/article/abs/pii/S0091743512001065

1529.) Uhlig, U., Kostev, K., Schuster, V., Koletzko, S., & Uhlig, H. H. (2014). Impact of rotavirus vaccination in Germany: rotavirus surveillance, hospitalization, side effects and comparison of vaccines. *The Pediatric infectious disease journal*, *33*(11), e299-e304. https://journals.lww.com/pidj/FullText/2014/11000/Impact_of_Rotavirus_Vaccination_in_Germany_.18.aspx

1530.) Chiu, S. S., Chua, H., Kwan, M. Y., Chan, E. L., Wong, J. S., Peiris, J. M., & Cowling, B. J. (2020). Influenza vaccination effectiveness in preventing influenza hospitalization in children, Hong Kong, winter 2019/20. *Vaccine*, *38*(51), 8078-8081. https://www.sciencedirect.com/science/article/pii/S0264410X20314018

1531.) Mearns, H., Geldenhuys, H. D., Kagina, B. M., Musvosvi, M., Little, F., Ratangee, F., Mahomed, H., Hanekom, W. A., Hoff, S. T., Ruhwald, M., Kromann, I., Bang, P., Hatherill, M., Andersen, P., Scriba, T. J., & THYB04 study group (2017). H1:IC31 vaccination is safe and induces long-lived TNF-α^{+}IL-2^{+}CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial. *Vaccine*, *35*(1), 132–141. https://web.archive.org/web/20210816004122/https://sci-hub.do/https://doi.org/10.1016/j.vaccine.2016.11.023

1532.) Michelsen, S. W., Soborg, B., Koch, A., Carstensen, L., Hoff, S. T., Agger, E. M., ... & Melbye, M. (2014). The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland. *Thorax*, *69*(9), 851-856. https://thorax.bmj.com/content/69/9/851.long

1533.) Colditz, G. A., Brewer, T. F., Berkey, C. S., Wilson, M. E., Burdick, E., Fineberg, H. V., & Mosteller, F. (1994). Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA*, *271*(9), 698–702. https://jamanetwork.com/journals/jama/article-abstract/366365

1534.) Abarca, K., Rey-Jurado, E., Muñoz-Durango, N., Vázquez, Y., Soto, J. A., Gálvez, N., Valdés-Ferrada, J., Iturriaga, C., Urzúa, M., Borzutzky, A., Cerda, J., Villarroel, L., Madrid, V., González, P. A., González-Aramundiz, J. V., Bueno, S. M., & Kalergis, A. M. (2020). Safety and

immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. *EClinicalMedicine*, *27*, 100517. https://www.sciencedirect.com/science/article/pii/S2589537020302613

1535.) Navaratna, S., Estcourt, M. J., Burgess, J., Waidyatillake, N., Enoh, E., Lowe, A. J., Peters, R., Koplin, J., Dhamage, S. C., & Lodge, C. J. (2021). Childhood vaccination and allergy: A systematic review and meta-analysis. *Allergy*, *76*(7), 2135–2152. https://onlinelibrary.wiley.com/doi/10.1111/all.14771

1536.) Mangtani, P., Abubakar, I., Ariti, C., Beynon, R., Pimpin, L., Fine, P. E., Rodrigues, L. C., Smith, P. G., Lipman, M., Whiting, P. F., & Sterne, J. A. (2014). Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. *Clinical infectious diseases*, *58*(4), 470–480. https://academic.oup.com/cid/article/58/4/470/347668

1537.) Roy, A., Eisenhut, M., Harris, R. J., Rodrigues, L. C., Sridhar, S., Habermann, S., Snell, L., Mangtani, P., Adetifa, I., Lalvani, A., & Abubakar, I. (2014). Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. *BMJ*, *349*, g4643. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122754/

1538.) Katelaris, A. L., Jackson, C., Southern, J., Gupta, R. K., Drobniewski, F., Lalvani, A., Lipman, M., Mangtani, P., & Abubakar, I. (2020). Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A Cross-sectional Analysis of a UK-Based Cohort. *The Journal of infectious diseases*, *221*(1), 146–155. https://web.archive.org/web/20210816020736/https://sci-hub.do/https://doi.org/10.1093/infdis/jiz430

1539.) Nunes, M. C., & Madhi, S. A. (2018). Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: a systematic review and meta-analysis. *Human vaccines & immunotherapeutics*, *14*(3), 758-766. https://www.tandfonline.com/doi/abs/10.1080/21645515.2017.1345385?journalCode=khvi20

1540.) Zhang, C., Wang, X., Liu, D., Zhang, L., & Sun, X. (2018). A systematic review and meta-analysis of fetal outcomes following the administration of influenza A/H1N1 vaccination during pregnancy. *International journal of gynaecology and obstetrics*, *141*(2), 141–150. https://pubmed.ncbi.nlm.nih.gov/29149524/

1541.) Andrews, N., Stowe, J., Al-Shahi Salman, R., & Miller, E. (2011). Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. *Vaccine*, *29*(45), 7878–7882. https://pubmed.ncbi.nlm.nih.gov/21875631/

1542.) Liu, J. C., Hsu, Y. P., Kao, P. F., Hao, W. R., Liu, S. H., Lin, C. F., Sung, L. C., & Wu, S. Y. (2016). Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study. *Medicine*, *95*(9), e2868. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782855/

1543.) Liu, J. C., Wang, T. J., Sung, L. C., Kao, P. F., Yang, T. Y., Hao, W. R., Chen, C. C., Hsu, Y. P., & Wu, S. Y. (2017). Influenza vaccination reduces hemorrhagic stroke risk in patients with atrial fibrillation: A population-based cohort study. *International journal of cardiology*, *232*, 315–323. https://www.internationaljournalofcardiology.com/article/S0167-5273(16)34563-6/fulltext

1544.) Lee, K. R., Bae, J. H., Hwang, I. C., Kim, K. K., Suh, H. S., & Ko, K. D. (2017). Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. *Neuroepidemiology*, *48*(3-4), 103–110. https://pubmed.ncbi.nlm.nih.gov/28628919/

1545.) Romio, S., Weibel, D., Dieleman, J. P., Olberg, H. K., de Vries, C. S., Sammon, C., Andrews, N., Svanström, H., Mølgaard-Nielsen, D., Hviid, A., Lapeyre-Mestre, M., Sommet, A., Saussier, C., Castot, A., Heijbel, H., Arnheim-Dahlström, L., Sparen, P., Mosseveld, M., Schuemie, M., van der Maas, N., … Sturkenboom, M. C. (2014). Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. *PloS one*, *9*(1), e82222. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880265/

1546.) Pebody, R. G., Whitaker, H., Ellis, J., Andrews, N., Marques, D. F., Cottrell, S., ... & Zambon, M. (2020). End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. *Vaccine*, *38*(3), 489-497. https://strathprints.strath.ac.uk/70743/1/Pebody_etal_Vaccine_2019_End_of_season_influenza_vaccine_effectiveness_in_primary_care.pdf

1547.) Tenforde, M. W., Chung, J., Smith, E. R., Talbot, H. K., Trabue, C. H., Zimmerman, R. K., ... & Patel, M. M. (2021). Influenza vaccine effectiveness in inpatient and outpatient settings in the United States, 2015–2018. *Clinical Infectious Diseases*, *73*(3), 386-392. https://academic.oup.com/cid/article/73/3/386/5818114

1548.) Grave, C., Boucheron, P., Rudant, J., Mikaeloff, Y., Tubert-Bitter, P., Escolano, S., ... & Weill, A. (2020). Seasonal influenza vaccine and Guillain-Barré syndrome: A self-controlled case series study. *Neurology*, *94*(20), e2168-e2179. https://n.neurology.org/content/94/20/e2168.abstract

1549.) Magnus, P., Gunnes, N., Tveito, K., Bakken, I. J., Ghaderi, S., Stoltenberg, C., ... & Håberg, S. E. (2015). Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. *Vaccine*, *33*(46), 6173-6177. https://www.publichealth.columbia.edu/sites/default/files/pdf/cii_2015_cfsme_associated_with_influenza_not_with_vaccine.pdf

1550.) Chen, Y., Zhang, J., Chu, X., Xu, Y., & Ma, F. (2020). Vaccines and the risk of Guillain-Barré syndrome. *European journal of epidemiology*, *35*(4), 363-370. https://encephalitis.by/wp-content/uploads/2020/02/vaccines-and-the-risk-of-guillain-barr-syndrome-2019.pdf

1551.) Hviid, A., & Myrup Thiesson, E. (2021). Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort. *JAMA network open*, *4*(8), e2120391. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783512?utm_source=twitter&utm_medium=social_jamajno&utm_term=5372129226&utm_campaign=article_alert&linkId=129161327

1552.) Ghaderi, S., Gunnes, N., Bakken, I. J., Magnus, P., Trogstad, L., & Håberg, S. E. (2016). Risk of Guillain-Barré syndrome after exposure to pandemic influenza A (H1N1) pdm09 vaccination or infection: a Norwegian population-based cohort study. *European journal of epidemiology*, *31*(1), 67-72. https://link.springer.com/content/pdf/10.1007/s10654-015-0047-0.pdf

1553.) Zhang, L., van der Hoek, W., Krafft, T., Pilot, E., Asten, L. V., Lin, G., ... & Wang, Q. (2020). Influenza vaccine effectiveness estimates against influenza A (H3N2) and A (H1N1) pdm09 among children during school-based outbreaks in the 2016–2017 season in Beijing, China. *Human vaccines & immunotherapeutics*, *16*(4), 816-822. https://www.tandfonline.com/doi/pdf/10.1080/21645515.2019.1677438

1554.) Chung, J. R., Rolfes, M. A., Flannery, B., Prasad, P., O'Halloran, A., Garg, S., ... & Reed, C. (2020). Effects of influenza vaccination in the United States during the 2018–2019 influenza season. *Clinical Infectious Diseases*, *71*(8), e368-e376. https://academic.oup.com/cid/article/71/8/e368/5697292

1555.) McCarthy, N. L., Gee, J., Sukumaran, L., Weintraub, E., Duffy, J., Kharbanda, E. O., Baxter, R., Irving, S., King, J., Daley, M. F., Hechter, R., & McNeil, M. M. (2016). Vaccination

and 30-Day Mortality Risk in Children, Adolescents, and Young Adults. *Pediatrics*, *137*(3), e20152970. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511986/

1556.) Kalligeros, M., Shehadeh, F., Mylona, E. K., Dapaah-Afriyie, C., van Aalst, R., Chit, A., & Mylonakis, E. (2020). Influenza vaccine effectiveness against influenza-associated hospitalization in children: a systematic review and meta-analysis. *Vaccine*, *38*(14), 2893-2903. https://www.sciencedirect.com/science/article/pii/S0264410X20302619

1557.) Hviid, A., Svanström, H., Scheller, N. M., Grönlund, O., Pasternak, B., & Arnheim‐Dahlström, L. (2018). Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. *Journal of internal medicine*, *283*(2), 154-165. https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.12694

1558.) Sheffield, J. S., Greer, L. G., Rogers, V. L., Roberts, S. W., Lytle, H., McIntire, D. D., & Wendel, G. D., Jr (2012). Effect of influenza vaccination in the first trimester of pregnancy. *Obstetrics and gynecology*, *120*(3), 532–537. https://journals.lww.com/greenjournal/Fulltext/2012/09000/Effect_of_Influenza_Vaccination_in_the_First.6.aspx

1559.) Lu, Q. C., Zhang, T. Y., Bundhun, P. K., & Chen, C. (2021). One "misunderstood" health issue: demonstrating and communicating the safety of influenza a vaccination in pregnancy: a systematic review and meta-analysis. *BMC public health*, *21*(1), 703. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034177/

1560.) Macias Saint-Gerons, D., Solà Arnau, I., De Mucio, B., Arévalo-Rodríguez, I., Alemán, A., Castro, J. L., & Ropero Álvarez, A. M. (2021). Adverse events associated with the use of recommended vaccines during pregnancy: An overview of systematic reviews. *Vaccine*, *39 Suppl 2*, B12–B26. https://www.sciencedirect.com/science/article/pii/S0264410X20309798?via%3Dihub#s0025

1561.) Ludvigsson, J. F., Ström, P., Lundholm, C., Cnattingius, S., Ekbom, A., Örtqvist, Å., Feltelius, N., Granath, F., & Stephansson, O. (2015). Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. *BMJ*, *351*, h5585. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644812/

1562.) Tavares, F., Nazareth, I., Monegal, J. S., Kolte, I., Verstraeten, T., & Bauchau, V. (2011). Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. *Vaccine*, *29*(37), 6358–6365. https://pubmed.ncbi.nlm.nih.gov/21596080/

1563.) Yin, J. K., Khandaker, G., Rashid, H., Heron, L., Ridda, I., & Booy, R. (2011). Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. *Influenza and other respiratory viruses*, *5*(5), 299–305. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986623/

1564.) Knuf, M., Leroux-Roels, G., Rümke, H. C., Abarca, K., Rivera, L., Lattanzi, M., Pedotti, P., Arora, A., Kieninger-Baum, D., & Della Cioppa, G. (2015). Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. *Vaccine*, *33*(1), 174–181. https://www.sciencedirect.com/science/article/pii/S0264410X14015047?via%3Dihub

1565.) Askling, H. H., Rombo, L., van Vollenhoven, R., Hallén, I., Thörner, Å., Nordin, M., Herzog, C., & Kantele, A. (2014). Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. *Travel medicine and infectious disease*, *12*(2), 134–142. https://www.sciencedirect.com/science/article/pii/S1477893914000350?via%3Dihub

1566.) Heinz, F. X., Holzmann, H., Essl, A., & Kundi, M. (2007). Field effectiveness of vaccination against tick-borne encephalitis. *Vaccine*, *25*(43), 7559–7567. https://pubmed.ncbi.nlm.nih.gov/17869389/

1567.) Lehtinen, M., Lagheden, C., Luostarinen, T., Eriksson, T., Apter, D., Harjula, K., Kuortti, M., Natunen, K., Palmroth, J., Petäjä, T., Pukkala, E., Siitari-Mattila, M., Struyf, F., Nieminen, P., Paavonen, J., Dubin, G., & Dillner, J. (2017). Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of *three cohorts from randomized trials*. *BMJ open*, *7*(8), e015867. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629648/

1568.) Dhar, J. P., Essenmacher, L., Dhar, R., Magee, A., Ager, J., & Sokol, R. J. (2017). The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. *Vaccine*, *35*(20), 2642–2646. https://pubmed.ncbi.nlm.nih.gov/28404357/

1569.) Rondaan, C., Furer, V., Heijstek, M. W., Agmon-Levin, N., Bijl, M., Breedveld, F. C., D'Amelio, R., Dougados, M., Kapetanovic, M. C., van Laar, J. M., Ladefoged de Thurah, A., Landewé, R., Molto, A., Müller-Ladner, U., Schreiber, K., Smolar, L., Walker, J., Warnatz, K., Wulffraat, N. M., van Assen, S., … Elkayam, O. (2019). Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. *RMD open*, *5*(2), e001035. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744079/#R185

1570.) Panagiotakopoulos, L., McCarthy, N. L., Tepper, N. K., Kharbanda, E. O., Lipkind, H. S., Vazquez-Benitez, G., ... & Weintraub, E. S. (2020). Evaluating the association of stillbirths after maternal vaccination in the Vaccine Safety Datalink. *Obstetrics & Gynecology*, *136*(6), 1086-1094. https://pubmed.ncbi.nlm.nih.gov/33156197/

1571.) Pringle, K. D., Burke, R. M., Steiner, C. A., Parashar, U. D., & Tate, J. E. (2018). Trends in rate of seizure-associated hospitalizations among children< 5 years old before and after rotavirus vaccine introduction in the United Sates, 2000–2013. *The Journal of infectious diseases*, *217*(4), 581-588. https://academic.oup.com/jid/article/217/4/581/4796788

1572.) Matheson, M. C., Haydn Walters, E., Burgess, J. A., Jenkins, M. A., Giles, G. G., Hopper, J. L., Abramson, M. J., & Dharmage, S. C. (2010). Childhood immunization and atopic disease into middle-age--a prospective cohort study. *Pediatric allergy and immunology*, *21*(2 Pt 1), 301–306. https://onlinelibrary.wiley.com/doi/10.1111/j.1399-3038.2009.00950.x

1573.) Ott, J. J., Irving, G., & Wiersma, S. T. (2012). Long-term protective effects of hepatitis A vaccines. A systematic review. *Vaccine*, *31*(1), 3–11. https://www.sciencedirect.com/science/article/pii/S0264410X12006731?via%3Dihub

1574.) Moro, P. L., Tepper, N. K., Grohskopf, L. A., Vellozzi, C., & Broder, K. (2012). Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy. *Expert review of vaccines*, *11*(8), 911–921. https://pubmed.ncbi.nlm.nih.gov/23002972/

1575.) Tsatsaris, V., Capitant, C., Schmitz, T., Chazallon, C., Bulifon, S., Riethmuller, D., Picone, O., Poulain, P., Lewin, F., Lainé, F., Jacqz-Aigrain, E., Aboulker, J. P., Launay, O., & Inserm C09-33 PREFLUVAC (Immunogenicity and Safety of an Inactivated Nonadjuvanted A[H1N1v] Influenza Vaccine in Pregnant Women) Study Group (2011). Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial. *Annals of internal medicine*, *155*(11), 733–741. https://www.acpjournals.org/doi/10.7326/0003-4819-155-11-201112060-00005?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&

1576.) Velázquez, R. F., Linhares, A. C., Muñoz, S., Seron, P., Lorca, P., DeAntonio, R., & Ortega-Barria, E. (2017). Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. *BMC pediatrics*, *17*(1), 14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237165/

1577.) Sankaranarayanan, R., Joshi, S., Muwonge, R., Esmy, P. O., Basu, P., Prabhu, P., Bhatla, N., Nene, B. M., Shaw, J., Poli, U., Verma, Y., Zomawia, E., Pimple, S., Tommasino, M.,

Pawlita, M., Gheit, T., Waterboer, T., Sehr, P., Pillai, M. R., & Indian HPV vaccine study group (2018). Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. *Vaccine*, *36*(32 Pt A), 4783–4791. https://www.sciencedirect.com/science/article/pii/S0264410X1830286X?via%3Dihub

1578.) Vickers, E. R., McClure, D. L., Naleway, A. L., Jacobsen, S. J., Klein, N. P., Glanz, J. M., Weintraub, E. S., & Belongia, E. A. (2017). Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink. *Vaccine*, *35*(43), 5872–5877. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508529/

1579.) Frisch, M., Besson, A., Clemmensen, K., Valentiner-Branth, P., Mølbak, K., & Hviid, A. (2018). Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism. *International journal of epidemiology*, *47*(2), 634–641. https://academic.oup.com/ije/article/47/2/634/4840712

1580.) Herweijer, E., Leval, A., Ploner, A., Eloranta, S., Simard, J. F., Dillner, J., Netterlid, E., Sparén, P., & Arnheim-Dahlström, L. (2014). Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. *JAMA*, *311*(6), 597–603. https://jamanetwork.com/journals/jama/fullarticle/1829685

1581.) Tosun, S., Olut, A. I., & Tansug, N. (2017). Adverse effects of single-component measles vaccine in school children. *Vaccine*, *35*(52), 7309–7311. https://pubmed.ncbi.nlm.nih.gov/29128384/

1582.) Rosillon, D., Willame, C., Tavares Da Silva, F., Guignard, A., Caterina, S., Welby, S., & Struyf, F. (2020). Meta-analysis of the risk of autoimmune thyroiditis, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine. *Pharmacoepidemiology and drug safety*, *29*(9), 1159–1167. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539912/

1583.) Dieleman, J., Romio, S., Johansen, K., Weibel, D., Bonhoeffer, J., Sturkenboom, M., & VAESCO-GBS Case-Control Study Group (2011). Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. *BMJ*, *343*, d3908. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134565/

1584.) Baxter, R., Lewis, E., Goddard, K., Fireman, B., Bakshi, N., DeStefano, F., Gee, J., Tseng, H. F., Naleway, A. L., & Klein, N. P. (2016). Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. *Clinical infectious diseases*, *63*(11), 1456–1462. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708556/

1585.) Tenforde, M. W., Talbot, H. K., Trabue, C. H., Gaglani, M., McNeal, T. M., Monto, A. S., ... & Patel, M. M. (2021). Influenza vaccine effectiveness against hospitalization in the United States, 2019–2020. *The Journal of Infectious Diseases*, *224*(5), 813-820. https://academic.oup.com/jid/article/224/5/813/6055595

1586.) Bar-Zeev, N., Swarthout, T. D., Everett, D. B., Alaerts, M., Msefula, J., Brown, C., ... & VacSurv Consortium. (2021). Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies. *The Lancet Global Health*, *9*(7), e989-e998. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00165-0/fulltext

1587.) Lochlainn, L. M. N., de Gier, B., van der Maas, N., Strebel, P. M., Goodman, T., van Binnendijk, R. S., ... & Hahné, S. J. (2019). Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis. *The Lancet Infectious Diseases*, *19*(11), 1235-1245. https://www.sciencedirect.com/science/article/pii/S1473309919303950

1588.) Bonneton, M., Antona, D., Danis, K., Ait-Belghiti, F., & Levy-Bruhl, D. (2020). Are vaccinated measles cases protected against severe disease?. *Vaccine*, *38*(29), 4516-4519. https://www.sciencedirect.com/science/article/pii/S0264410X20306113

1589.) Blomberg, M., Dehlendorff, C., Munk, C., & Kjaer, S. K. (2013). Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. *Clinical infectious diseases*, *57*(7), 929-934. https://academic.oup.com/cid/article/57/7/929/338361?view=extract

1590.) Kumar, R., Dwivedi, A., Kumar, P., & Kohli, N. (2005). Tuberculous meningitis in BCG vaccinated and unvaccinated children. *Journal of Neurology, Neurosurgery & Psychiatry*, *76*(11), 1550-1554. https://jnnp.bmj.com/content/76/11/1550

1591.) van Wijhe, M., Tulen, A. D., Altes, H. K., McDonald, S. A., de Melker, H. E., Postma, M. J., & Wallinga, J. (2018). Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands. *Epidemiology & Infection*, *146*(6), 716-722. https://www.cambridge.org/core/services/aop-cambridge-core/content/view/DAC3C982B1F8CD1C78727B069A100DB1/S0950268818000481a.pdf/div-class-title-quantifying-the-impact-of-mass-vaccination-programmes-on-notified-cases-in-the-netherlands-div.pdf

1592.) Kandeil, W., van den Ende, C., Bunge, E. M., Jenkins, V. A., Ceregido, M. A., & Guignard, A. (2020). A systematic review of the burden of pertussis disease in infants and the

effectiveness of maternal immunization against pertussis. *Expert Review of Vaccines*, *19*(7), 621-638. https://www.tandfonline.com/doi/pdf/10.1080/14760584.2020.1791092

1593.) Polachek, A., Korobko, U., Mader-Balakirski, N., Arad, U., Levartovsky, D., Kaufman, I., Anouk, M., Litinsky, I., Wigler, I., Mendelson, E., Paran, D., Matz, H., Caspi, D., Mandelboim, M., & Elkayam, O. (2015). Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis. *Clinical and experimental rheumatology*, *33*(2), 181–186. https://www.clinexprheumatol.org/abstract.asp?a=8341

1594.) Abdelahad, M., Ta, E., Kesselman, M. M., & Demory Beckler, M. (2021). A Review of the Efficacy of Influenza Vaccination in Autoimmune Disease Patients. *Cureus*, *13*(5), e15016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197698/

1595.) Mefford, M. T., Liu, R., Bruxvoort, K., Qian, L., Doris, J. M., Koyama, S. Y., ... & Reynolds, K. (2021) Influenza vaccination and mortality among adults with heart failure in an integrated healthcare delivery system, 2009-2018. *Journal of general internal medicine*. https://link.springer.com/article/10.1007%2Fs11606-021-07068-x#Abs1

1596.) Luo, C. S., Chi, C. C., Fang, Y. A., Liu, J. C., & Lee, K. Y. (2020). Influenza vaccination reduces dementia in patients with chronic obstructive pulmonary disease: a nationwide cohort study. *Journal of investigative medicine*, *68*(4), 838–845. https://jim.bmj.com/content/68/4/838.long

1597.) Scherrer, J. F., Salas, J., Wiemken, T. L., Jacobs, C., Morley, J. E., & Hoft, D. F. (2021). Lower Risk for Dementia Following Adult Tetanus, Diphtheria, and Pertussis (Tdap) Vaccination. *The journals of gerontology. Series A, Biological sciences and medical sciences*, *76*(8), 1436–1443. https://academic.oup.com/biomedgerontology/article/76/8/1436/6226396?login=true

1598.) Biering-Sørensen, S., Aaby, P., Lund, N., Monteiro, I., Jensen, K. J., Eriksen, H. B., ... & Benn, C. S. (2017). Early BCG-Denmark and neonatal mortality among infants weighing< 2500 g: a randomized controlled trial. *Clinical Infectious Diseases*, *65*(7), 1183-1190. https://academic.oup.com/cid/article/65/7/1183/4079383

1599.) DeSilva, M., Vazquez-Benitez, G., Nordin, J. D., Lipkind, H. S., Romitti, P. A., DeStefano, F., & Kharbanda, E. O. (2016). Tdap vaccination during pregnancy and microcephaly and other structural birth defects in offspring. *Jama*, *316*(17), 1823-1825. https://jamanetwork.com/journals/jama/article-abstract/2576582

1600.) Dbaibo, G., Amanullah, A., Claeys, C., Izu, A., Jain, V. K., Kosalaraksa, P., Rivera, L., Soni, J., Yanni, E., Zaman, K., Acosta, B., Ariza, M., Arroba Basanta, M. L., Bavdekar, A., Carmona, A., Cousin, L., Danier, J., Diaz, A., Diez-Domingo, J., Dinleyici, E. C., … Flu4VEC Study Group (2020). Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial. *The Pediatric infectious disease journal*, *39*(1), e1–e10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004464/

1601.) Arnheim-Dahlström, L., Hällgren, J., Weibull, C. E., & Sparén, P. (2012). Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. *BMJ*, *345*, e7594. https://www.bmj.com/content/345/bmj.e7594

1602.) Stowe, J., Andrews, N., Bryan, P., Seabroke, S., & Miller, E. (2011). Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study. *Vaccine*, *29*(51), 9467-9472. https://www.sciencedirect.com/science/article/pii/S0264410X11016367

1602.) Nordin, J. D., Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H., Lee, G. M., & Naleway, A. L. (2014). Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events. *Vaccine*, *32*(39), 4985–4992. https://pubmed.ncbi.nlm.nih.gov/25045808/

1603.) Hadinegoro, S. R., Arredondo-García, J. L., Capeding, M. R., Deseda, C., Chotpitayasunondh, T., Dietze, R., ... & Saville, M. (2015). Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. *New England Journal of Medicine*, *373*(13), 1195-1206. https://www.nejm.org/doi/full/10.1056/NEJMoa1506223

1604.) Chong, C. R., Park, V. J., Cohen, B., Postow, M. A., Wolchok, J. D., & Kamboj, M. (2020). Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. *Clinical Infectious Diseases*, *70*(2), 193-199. https://academic.oup.com/cid/article/70/2/193/5381697?login=true

1605.) Miranda, S., Chaignot, C., Collin, C., Dray-Spira, R., Weill, A., & Zureik, M. (2017). Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. *Vaccine*, *35*(36), 4761-4768. https://www.sciencedirect.com/science/article/pii/S0264410X17308071

1606.) Grimaldi-Bensouda, L., Michel, M., Aubrun, E., Leighton, P., Viallard, J. F., Adoue, D., Magy-Bertrand, N., Tisserand, G., Khellaf, M., Durand, J. M., Quittet, P., Fain, O., Bonnotte, B.,

Morin, A. S., Limal, N., Costedoat-Chalumeau, N., Morel, N., Pan-Petesch, B., Decaux, O., Mahevas, M., … PGRx Immune Thrombocytopenia Study Group (2012). A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. *Blood*, *120*(25), 4938–4944. https://ashpublications.org/blood/article/120/25/4938/31134/A-case-control-study-to-assess-the-risk-of-immune

1607.) Klein, N. P., Hansen, J., Chao, C., Velicer, C., Emery, M., Slezak, J., Lewis, N., Deosaransingh, K., Sy, L., Ackerson, B., Cheetham, T. C., Liaw, K. L., Takhar, H., & Jacobsen, S. J. (2012). Safety of quadrivalent human papillomavirus vaccine administered routinely to females. *Archives of pediatrics & adolescent medicine*, *166*(12), 1140–1148. https://jamanetwork.com/journals/jamapediatrics/fullarticle/1363509

1608.) Smith, L. M., Kaufman, J. S., Strumpf, E. C., & Lévesque, L. E. (2015). Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. *Canadian Medical Association journal*, *187*(2), E74–E81. https://www.cmaj.ca/content/187/2/E74

1609.) Donahue, J. G., Kieke, B. A., Lewis, E. M., Weintraub, E. S., Hanson, K. E., McClure, D. L., Vickers, E. R., Gee, J., Daley, M. F., DeStefano, F., Hechter, R. C., Jackson, L. A., Klein, N. P., Naleway, A. L., Nelson, J. C., & Belongia, E. A. (2019). Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. *Pediatrics*, *144*(6), e20191808. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780202/

1610.) Ryan, M. A., Gumbs, G. R., Conlin, A. M., Sevick, C. J., Jacobson, I. G., Snell, K. J., Spooner, C. N., Smith, T. C., & Department of Defense Birth and Infant Health Registry Team (2008). Evaluation of preterm births and birth defects in liveborn infants of US military women who received smallpox vaccine. *Birth defects research. Part A, Clinical and molecular teratology*, *82*(7), 533–539. https://pubmed.ncbi.nlm.nih.gov/18496830/

1611.) Badell, M. L., Meaney-Delman, D., Tuuli, M. G., Rasmussen, S. A., Petersen, B. W., Sheffield, J. S., Beigi, R. H., Damon, I. K., & Jamieson, D. J. (2015). Risks Associated With Smallpox Vaccination in Pregnancy: A Systematic Review and Meta-analysis. *Obstetrics and gynecology*, *125*(6), 1439–1451. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710134/

1612.) Zhang, Y., Zhang, H., Wang, B., Song, G., Hayden, J. C., Amirthalingam, P., Rahmani, J., Bhagavathula, A. S., & Li, Z. (2020). Pregnancy outcomes after a mass vaccination campaign with an oral cholera vaccine: a systematic review and meta-analysis. *BJOG*, *127*(9), 1066–1073. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.16260

1613.) Khan, A. I., Ali, M., Lynch, J., Kabir, A., Excler, J. L., Khan, M. A., Islam, M. T., Akter, A., Chowdhury, F., Saha, A., Khan, I. A., Desai, S. N., Kim, D. R., Saha, N. C., Singh, A. P., Clemens, J. D., & Qadri, F. (2019). Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial. *BMC infectious diseases*, *19*(1), 422. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518748/

1614.) Khan, A. I., Ali, M., Chowdhury, F., Saha, A., Khan, I. A., Khan, A., Akter, A., Asaduzzaman, M., Islam, M. T., Kabir, A., You, Y. A., Saha, N. C., Cravioto, A., Clemens, J. D., & Qadri, F. (2017). Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh. *Vaccine*, *35*(11), 1538–1543. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341737/

1615.) Payne, D. C., Rose, C. E., Jr, Kerrison, J., Aranas, A., Duderstadt, S., & McNeil, M. M. (2006). Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. *Archives of neurology*, *63*(6), 871–875. https://jamanetwork.com/journals/jamaneurology/fullarticle/791637

1616.) Ma, X., Does, M. B., Metayer, C., Russo, C., Wong, A., & Buffler, P. A. (2005). Vaccination history and risk of childhood leukaemia. *International journal of epidemiology*, *34*(5), 1100–1109. https://academic.oup.com/ije/article/34/5/1100/645894

1617.) Conklin, L., Hviid, A., Orenstein, W. A., Pollard, A. J., Wharton, M., & Zuber, P. (2021). Vaccine safety issues at the turn of the 21st century. *BMJ global health*, *6*(Suppl 2), e004898. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137241/

1618.) Miller, E., Andrews, N., Waight, P., & Taylor, B. (2003). Bacterial infections, immune overload, and MMR vaccine. Measles, mumps, and rubella. *Archives of disease in childhood*, *88*(3), 222–223. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1719482/pdf/v088p00222.pdf

1619.) Mrozek-Budzyn, D., Kiełtyka, A., Majewska, R., & Augustyniak, M. (2013). Measles, mumps and rubella (MMR) vaccination has no effect on cognitive development in children - the results of the Polish prospective cohort study. *Vaccine*, *31*(22), 2551–2557. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684783/

1620.) Marlow, R., Kuriyakose, S., Mesaros, N., Han, H. H., Tomlinson, R., Faust, S. N., Snape, M. D., Pollard, A. J., & Finn, A. (2018). A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. *Vaccine*, *36*(17),

2300–2306.
https://www.sciencedirect.com/science/article/pii/S0264410X18303669?via%3Dihub

1621.) Myléus, A., Stenlund, H., Hernell, O., Gothefors, L., Hammarström, M. L., Persson, L. Å., & Ivarsson, A. (2012). Early vaccinations are not risk factors for celiac disease. *Pediatrics*, *130*(1), e63–e70. https://pediatrics.aappublications.org/content/130/1/e63.long

1622.) Gidengil, C., Goetz, M. B., Newberry, S., Maglione, M., Hall, O., Larkin, J., Motala, A., & Hempel, S. (2021). Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. *Vaccine*, *39*(28), 3696–3716. https://www.sciencedirect.com/science/article/pii/S0264410X21003856

1623.) Cocchio, S., Baldovin, T., Bertoncello, C., Buja, A., Furlan, P., Saia, M., & Baldo, V. (2017). Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. *BMC infectious diseases*, *17*(1), 249. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2361-5

1624.) Kawai, A. T., Li, L., Kulldorff, M., Vellozzi, C., Weintraub, E., Baxter, R., ... & Lee, G. M. (2014). Absence of associations between influenza vaccines and increased risks of seizures, Guillain–Barre syndrome, encephalitis, or anaphylaxis in the 2012–2013 season. *Pharmacoepidemiology and drug safety*, *23*(5), 548-553. https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.3575

1625.) Gazibara, T., Thygesen, L. C., Algren, M. H., & Tolstrup, J. S. (2020). Human Papillomavirus Vaccination and Physical and Mental Health Complaints Among Female Students in Secondary Education Institutions in Denmark. *Journal of general internal medicine*, *35*(9), 2647–2654. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458962/

1626.) Longini Jr, I. M., Halloran, M. E., Nizam, A., Wolff, M., Mendelman, P. M., Fast, P. E., & Belshe, R. B. (2000). Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. *Vaccine*, *18*(18), 1902-1909. https://www.sciencedirect.com/science/article/pii/S0264410X99004193

1627.) Miller, C., Andrews, N., Rush, M., Munro, H., Jin, L., & Miller, E. (2004). The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990-2002. *Archives of disease in childhood*, *89*(12), 1145–1148. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1719740/pdf/v089p01145.pdf

1628.) Bellini, W. J., Rota, J. S., Lowe, L. E., Katz, R. S., Dyken, P. R., Zaki, S. R., Shieh, W. J., & Rota, P. A. (2005). Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. *The Journal of infectious diseases*, *192*(10), 1686–1693. https://academic.oup.com/jid/article/192/10/1686/875860#15137827

1629.) Rothstein, E. P., Bernstein, H. H., Glode, M. P., Laussucq, S., Nonenmacher, J., Long, S. S., & Hackell, J. G. (1993). Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. *American journal of diseases of children (1960)*, *147*(8), 854–857. https://pubmed.ncbi.nlm.nih.gov/8394646/

1630.) Nichol K. L. (1999). The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. *Vaccine*, *17 Suppl 1*, S91–S93. https://www.sciencedirect.com/science/article/pii/S0264410X99001140?via%3Dihub

1631.) Velentgas, P., Amato, A. A., Bohn, R. L., Chan, K. A., Cochrane, T., Funch, D. P., Dashevsky, I., Duddy, A. L., Gladowski, P., Greenberg, S. A., Kramer, J. M., McMahill-Walraven, C., Nakasato, C., Spettell, C. M., Syat, B. L., Wahl, P. M., Walker, A. M., Zhang, F., Brown, J. S., & Platt, R. (2012). Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. *Pharmacoepidemiology and drug safety*, *21*(12), 1350–1358. https://onlinelibrary.wiley.com/doi/10.1002/pds.3321

1632.) Grimaldi‐Bensouda, L., Le Guern, V., Kone‐Paut, I., Aubrun, E., Fain, O., Ruel, M., ... & PGRx Lupus Study Group. (2014). The Risk of Systemic Lupus Erythematosus Associated With Vaccines: An International Case‐Control Study. *Arthritis & Rheumatology*, *66*(6), 1559-1567. https://onlinelibrary.wiley.com/doi/full/10.1002/art.38429

1633.) Greene, S. K., Rett, M. D., Vellozzi, C., Li, L., Kulldorff, M., Marcy, S. M., ... & Lee, G. M. (2013). Guillain-Barré syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009–2011. *PLoS One*, *8*(6), e67185. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0067185

1634.) Sestili, C., Grazina, I., & La Torre, G. (2021). HBV vaccine and risk of developing multiple sclerosis: A systematic review and meta-analysis. *Human vaccines & immunotherapeutics*, *17*(7), 2273-2278. https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1528835

1635.) Perez-Vilar, S., Hu, M., Weintraub, E., Arya, D., Lufkin, B., Myers, T., ... & Forshee, R. A. (2021). Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018–2019 Season. *The Journal of infectious diseases*, *223*(3), 416-425. https://academic.oup.com/jid/article/223/3/416/5952165#227899430

1636.) Chen, Y., Ma, F., Xu, Y., Chu, X., & Zhang, J. (2018). Vaccines and the risk of acute disseminated encephalomyelitis. *Vaccine*, *36*(26), 3733-3739. https://www.sciencedirect.com/science/article/pii/S0264410X18307035

1637.) de Oliveira, L. H., Camacho, L. A., Coutinho, E. S., Ruiz-Matus, C., & Leite, J. P. (2015). Rotavirus vaccine effectiveness in Latin American and Caribbean countries: A systematic review and meta-analysis. *Vaccine*, *33 Suppl 1*, A248–A254. https://www.sciencedirect.com/science/article/pii/S0264410X14016399?via%3Dihub

1638.) Williamson, G., Ahmed, B., Kumar, P. S., Ostrov, B. E., & Ericson, J. E. (2017). Vaccine-Preventable Diseases Requiring Hospitalization. *Pediatrics*, *140*(3), e20170298. https://pediatrics.aappublications.org/content/140/3/e20170298.full

1639.) Kazantzi, M., Prapa, M., Christakou, E., Paraschou, D., Kalabalikis, P., Barbaressou, C., & Papaevangelou, V. (2021). Admissions due to vaccine preventable diseases in a large paediatric intensive care unit in Greece over a 10-year period. *Journal of paediatrics and child health.* https://onlinelibrary.wiley.com/doi/10.1111/jpc.15711

1640.) Baxter, R., Ray, P., Tran, T. N., Black, S., Shinefield, H. R., Coplan, P. M., ... & Saddier, P. (2013). Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study. *Pediatrics*, *131*(5), e1389-e1396. https://www.researchgate.net/profile/Trung-Tran-21/publication/236096595_Long-term_Effectiveness_of_Varicella_Vaccine_A_14-Year_Prospective_Cohort_Study/links/53e017d20cf2aede4b4cbb8a/Long-term-Effectiveness-of-Varicella-Vaccine-A-14-Year-Prospective-Cohort-Study.pdf

1641.) Baxter, R., Bartlett, J., Fireman, B., Marks, M., Hansen, J., Lewis, E., ... & Saddier, P. (2018). Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. *American journal of epidemiology*, *187*(1), 161-169. https://academic.oup.com/aje/article/187/1/161/3883627

1642.) Artemchuk, H., Eriksson, T., Poljak, M., Surcel, H. M., Dillner, J., Lehtinen, M., & Faust, H. (2019). Long-term antibody response to human papillomavirus vaccines: up to 12 years of follow-up in the Finnish maternity cohort. *The Journal of infectious diseases*, *219*(4), 582-589. https://academic.oup.com/jid/article/219/4/582/5099444

1643.) Roukens, A. H., van Halem, K., de Visser, A. W., & Visser, L. G. (2018). Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. *Annals of internal medicine*, *169*(11), 761-765. https://www.acpjournals.org/doi/abs/10.7326/m18-1529

1644.) Hess, L., Riesenberg, K., Rolston, K. V., & Nesher, L. (2020). Administering an additional hepatitis B vaccination dose after 18 years maintains adequate long-term protection levels in healthcare workers. *Infectious Diseases*, *52*(5), 330-335. https://www.tandfonline.com/doi/abs/10.1080/23744235.2020.1718201

1645.) Rosenstein, M. D., de Visser, A. W., Visser, L. G., & Roukens, A. H. (2021). Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study. *Journal of Travel Medicine*. https://academic.oup.com/jtm/advance-article/doi/10.1093/jtm/taab126/6353012?login=true

1646.) Giamarellos-Bourboulis, E. J., Tsilika, M., Moorlag, S., Antonakos, N., Kotsaki, A., Domínguez-Andrés, J., ... & Netea, M. G. (2020). Activate: randomized clinical trial of BCG vaccination against infection in the elderly. *Cell*, *183*(2), 315-323. https://www.cell.com/cell/pdf/S0092-8674(20)31139-9.pdf

1647.) Leentjens, J., Kox, M., Stokman, R., Gerretsen, J., Diavatopoulos, D. A., van Crevel, R., ... & Netea, M. G. (2015). BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. *The Journal of infectious diseases*, *212*(12), 1930-1938. https://academic.oup.com/jid/article/212/12/1930/2911938

1648.) Heijstek, M. W., de Bruin, L. O., Borrow, R., van der Klis, F., Koné-Paut, I., Fasth, A., ... & Wulffraat, N. M. (2011). Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. *Autoimmunity reviews*, *11*(2), 112-122. https://www.sciencedirect.com/science/article/abs/pii/S1568997211001911

1649.) Rousseau, M. C., El‐Zein, M., Conus, F., Legault, L., & Parent, M. E. (2016). Bacillus Calmette‐Guérin (BCG) Vaccination in Infancy and Risk of Childhood Diabetes. *Paediatric and perinatal epidemiology*, *30*(2), 141-148. https://onlinelibrary.wiley.com/doi/abs/10.1111/ppe.12263

1650.) El-Zein, M., Parent, M. E., Benedetti, A., & Rousseau, M. C. (2010). Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies. *International journal of epidemiology*, *39*(2), 469-486.

https://academic.oup.com/ije/article/39/2/469/678314

1651.) Choi, I. S., & Koh, Y. I. (2002). Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. *Annals of Allergy, Asthma & Immunology*, *88*(6), 584-591. https://www.sciencedirect.com/science/article/abs/pii/S108112061061890X

1652.) Walker, J. L., Andrews, N. J., Amirthalingam, G., Forbes, H., Langan, S. M., & Thomas, S. L. (2018). Effectiveness of herpes zoster vaccination in an older United Kingdom population. *Vaccine*, *36*(17), 2371-2377.
https://www.sciencedirect.com/science/article/pii/S0264410X18301956
1653.) Amirthalingam, G., Andrews, N., Keel, P., Mullett, D., Correa, A., de Lusignan, S., & Ramsay, M. (2018). Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. *The Lancet Public Health*, *3*(2), e82-e90.
https://www.sciencedirect.com/science/article/pii/S2468266717302347

1654.) Elkayam, O., Yaron, M., & Caspi, D. (2002). Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. *Annals of the rheumatic diseases*, *61*(7), 623-625.
https://ard.bmj.com/content/61/7/623

1655.) McMahon, B. J., Dentinger, C. M., Bruden, D., Zanis, C., Peters, H., Hurlburt, D., ... & Hennessy, T. W. (2009). Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. *The Journal of infectious diseases*, *200*(9), 1390-1396.
https://academic.oup.com/jid/article/200/9/1390/851238?login=true

1656.)Bruce, M. G., Bruden, D., Hurlburt, D., Zanis, C., Thompson, G., Rea, L., ... & McMahon, B. J. (2016). Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. *The Journal of infectious diseases*, *214*(1), 16-22. https://academic.oup.com/jid/article/214/1/16/2469742

1657.) Lang, A. B., Rüdeberg, A., Schöni, M. H., Que, J. U., Fürer, E., & Schaad, U. B. (2004). Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. *The Pediatric infectious disease journal*, *23*(6), 504-510.
https://journals.lww.com/pidj/fulltext/2004/06000/Vaccination_of_Cystic_Fibrosis_Patients_Against.5.aspx

1658.) Döring, G., Meisner, C., Stern, M., & Flagella Vaccine Trial Study Group. (2007). A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. *Proceedings of the National Academy of Sciences*, *104*(26), 11020-11025. https://www.pnas.org/content/pnas/104/26/11020.full.pdf

1659.) Ahmed, F., Lindley, M. C., Allred, N., Weinbaum, C. M., & Grohskopf, L. (2014). Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence. *Clinical infectious diseases*, *58*(1), 50-57. https://academic.oup.com/cid/article/58/1/50/372080

1660.) Nunes, M. C., Cutland, C. L., Jones, S., Downs, S., Weinberg, A., Ortiz, J. R., ... & Madhi, S. A. (2017). Efficacy of maternal influenza vaccination against all-cause lower respiratory tract infection hospitalizations in young infants: results from a randomized controlled trial. *Clinical Infectious Diseases*, *65*(7), 1066-1071. https://academic.oup.com/cid/article/65/7/1066/3858145

1661.) Cheng, Y., Cao, X., Cao, Z., Xu, C., Sun, L., Gao, Y., Wang, Y., Li, S., Wu, C., Li, X., Wang, Y., & Leng, S. X. (2020). Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality. *Ageing research reviews*, *62*, 101124. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365105/

1662.) Martínez-Baz, I., Navascués, A., Portillo, M. E., Casado, I., Fresán, U., Ezpeleta, C., & Castilla, J. (2021). Effect of influenza vaccination in preventing laboratory-confirmed influenza hospitalization in patients with diabetes mellitus. *Clinical Infectious Diseases*, *73*(1), 107-114. https://academic.oup.com/cid/article-abstract/73/1/107/5837528

1663.) Martínez-Baz, I., Navascués, A., Casado, I., Portillo, M. E., Guevara, M., Gómez-Ibáñez, C., ... & Castilla, J. (2021). Effect of influenza vaccination in patients with asthma. *CMAJ*, *193*(29), E1120-E1128. https://www.cmaj.ca/content/cmaj/193/29/E1120.full.pdf

1664.) Fisman, D. N., Abrutyn, E., Spaude, K. A., Kim, A., Kirchner, C., & Daley, J. (2006). Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. *Clinical infectious diseases*, *42*(8), 1093-1101. https://academic.oup.com/cid/article/42/8/1093/282324

1665.) Feeney, M., Clegg, A., Winwood, P., & Snook, J. (1997). A case-control study of measles vaccination and inflammatory bowel disease. *The Lancet*, *350*(9080), 764-766. https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1008.5592&rep=rep1&type=pdf

1666.) de Chambrun, G. P., Dauchet, L., Gower-Rousseau, C., Cortot, A., Colombel, J. F., & Peyrin-Biroulet, L. (2015). Vaccination and risk for developing inflammatory bowel disease: a meta-analysis of case–control and cohort studies. *Clinical Gastroenterology and Hepatology*, *13*(8), 1405-1415. https://hal.archives-ouvertes.fr/hal-01997123/document

1667.) Yu, O., Bohlke, K., Hanson, C. A., Delaney, K., Rees, T. G., Zavitkovsky, A., ... & Jackson, L. A. (2007). Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study. *Pharmacoepidemiology and drug safety*, *16*(7), 736-745. https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.1354

1668.) Tasker, S. A., Treanor, J. J., Paxton, W. B., & Wallace, M. R. (1999). Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. *Annals of internal medicine*, *131*(6), 430-433. https://www.acpjournals.org/doi/full/10.7326/0003-4819-131-6-199909210-00006?journalCode=aim

1669.) Lepow, M. L., Barkin, R. M., Berkowitz, C. D., Brunell, P. A., James, D., Meier, K., Ward, J., Zahradnik, J. M., Samuelson, J., & McVerry, P. H. (1987). Safety and immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in infants. *The Journal of infectious diseases*, *156*(4), 591–596. https://academic.oup.com/jid/article-abstract/156/4/591/2190239?redirectedFrom=fulltext

1670.) Elwood, J. M., & Ameratunga, R. (2018). Autoimmune diseases after hepatitis B immunization in adults: Literature review and meta-analysis, with reference to 'autoimmune/autoinflammatory syndrome induced by adjuvants' (ASIA). *Vaccine*, *36*(38), 5796–5802. https://www.sciencedirect.com/science/article/pii/S0264410X18310946?via%3Dihub

1671.) Genovese, C., LA Fauci, V., Squeri, A., Trimarchi, G., & Squeri, R. (2018). HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature. *Journal of preventive medicine and hygiene*, *59*(3), E194–E199. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196376/

1672.) Meggiolaro, A., Migliara, G., & La Torre, G. (2018). Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review. *Human vaccines & immunotherapeutics*, *14*(5), 1266-1274. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989905/

1673.) Hernán, M. A., Alonso, A., & Hernández-Díaz, S. (2006). Tetanus vaccination and risk of multiple sclerosis: a systematic review. *Neurology*, *67*(2), 212-215. https://n.neurology.org/content/67/2/212.short

1674.) Vielot, N. A., & Becker-Dreps, S. (2020). Hazard of complex regional pain syndrome following human papillomavirus vaccination among adolescent girls in the United States: a case-cohort analysis of insurance claims data. *Expert opinion on drug safety*, *19*(1), 107-112. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938534/

1675.) Grönlund, O., Herweijer, E., Sundström, K., & Arnheim‐Dahlström, L. (2016). Incidence of new‐onset autoimmune disease in girls and women with pre‐existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. *Journal of internal medicine*, *280*(6), 618-626. https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.12535

1676.) Klein, N. P., Goddard, K., Lewis, E., Ross, P., Gee, J., DeStefano, F., & Baxter, R. (2019). Long term risk of developing type 1 diabetes after HPV vaccination in males and females. *Vaccine*, *37*(14), 1938-1944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719305/

1677.) Schmuhl, N. B., Mooney, K. E., Zhang, X., Cooney, L. G., Conway, J. H., & LoConte, N. K. (2020). No association between HPV vaccination and infertility in US females 18–33 years old. *Vaccine*, *38*(24), 4038-4043. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255493/

1678.) Stowe, J., Andrews, N. J., Turner, P. J., & Miller, E. (2020). The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: a self-controlled case-series analysis. *Vaccine*, *38*(32), 4935-4939. https://www.sciencedirect.com/science/article/pii/S0264410X20307568

1679.) Andrews, N., Stowe, J., & Miller, E. (2020). Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: An ecological study. *Vaccine*, *38*(31), 4816-4819. https://researchonline.lshtm.ac.uk/id/eprint/4659432/1/Andrews_Stowe_2020_Nephrotic-syndrome-in-infants-and-toddlers-1.pdf

1680.) Dehlendorff, C., Baandrup, L., & Kjaer, S. K. (2021). Real-world effectiveness of Human Papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers. *JNCI: Journal of the National Cancer Institute*, *113*(7), 869-874. https://www.sgo.or.kr/html/user/core/view/reaction/main/201/inc/data/djaa209.pdf

1681.) Shibata, N., Kimura, S., Hoshino, T., Takeuchi, M., & Urushihara, H. (2018). Effectiveness of influenza vaccination for children in Japan: four-year observational study using a large-scale claims database. *Vaccine*, *36*(20), 2809-2815. https://www.sciencedirect.com/science/article/pii/S0264410X18304602

1682.) Wang, F. T., Mast, T. C., Glass, R. J., Loughlin, J., & Seeger, J. D. (2013). Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. *The Pediatric infectious disease journal*, *32*(3), 278-283. https://journals.lww.com/pidj/Fulltext/2013/03000/Effectiveness_of_an_Incomplete_RotaTeq__RV5_.20.aspx

1683.) Baandrup, L., Dehlendorff, C., & Kjaer, S. K. (2020). One-dose human papillomavirus vaccination and the risk of genital warts: a Danish nationwide population-based study. *Clinical Infectious Diseases*. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1067/5922377?login=true

1684.) Drolet, M., Bénard, É., Pérez, N., Brisson, M., Ali, H., Boily, M. C., ... & Yu, B. N. (2019). Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. *The Lancet*, *394*(10197), 497-509. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316527/

1685.) Gagneur, A., Nowak, E., Lemaitre, T., Segura, J. F., Delaperrière, N., Abalea, L., ... & Oger, E. (2011). Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study. *Vaccine*, *29*(21), 3753-3759. https://www.sciencedirect.com/science/article/pii/S0264410X11004038

1686.) Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H., Naleway, A., Lee, G., Nordin, J. D., & Vaccine Safety Datalink Team. (2013). Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. *Obstetrics & Gynecology*, *122*(3), 659-667. https://journals.lww.com/greenjournal/Fulltext/2013/09000/Inactivated_Influenza_Vaccine_During_Pregnancy_and.23.aspx(4)22

1687.) Elding Larsson, H., Lynch, K. F., Lönnrot, M., Haller, M. J., Lernmark, Å., Hagopian, W. A., ... & Hyöty, H. (2017). Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children. *Diabetologia*, *61*(1), 193-202. https://mediatum.ub.tum.de/doc/1536491/file.pdf

1688.) Wang, Y., Li, J., Dai, P., Liu, P., & Zhu, F. (2021). Effectiveness of the oral human attenuated pentavalent rotavirus vaccine (RotaTeq™) postlicensure: a meta-analysis-2006-2020. *Expert review of vaccines*, *20*(4), 437–448. https://pubmed.ncbi.nlm.nih.gov/33709863/

1689.) Mo, Z., Mo, Y., Li, M., Tao, J., Yang, X., Kong, J., Wei, D., Fu, B., Liao, X., Chu, J., Qiu, Y., Hille, D. A., Nelson, M., & Kaplan, S. S. (2017). Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial. *Vaccine*, *35*(43), 5897–5904. https://www.sciencedirect.com/science/article/pii/S0264410X17311817?via%3Dihub

1690.) Villumsen, M., Jess, T., Sørup, S., Ravn, H., Sturegård, E., Benn, C. S., Aaby, P., & Roth, A. (2013). Risk of inflammatory bowel disease following Bacille Calmette-Guérin and smallpox vaccination: a population-based Danish case-cohort study. *Inflammatory bowel diseases*, *19*(8), 1717–1724. https://academic.oup.com/ibdjournal/article/19/8/1717/4603123?login=true#108349497

1691.) Eriksen, E. M., Perlman, J. A., Miller, A., Marcy, S. M., Lee, H., Vadheim, C., ... & Ward, J. I. (2004). Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project. *The Pediatric infectious disease journal*, *23*(7), 656-662. https://journals.lww.com/pidj/fulltext/2004/07000/lack_of_association_between_hepatitis_b_birth.12.aspx

1692.) Joe, W., & Kumar Verma, A. (2021). Association of basic vaccination with cognitive and learning ability among children: insights from the India Human Development Survey, 2004-05 and 2011-12. *Journal of biosocial science*, 1–14. https://pubmed.ncbi.nlm.nih.gov/33436127/

1693.) Bekkat-Berkani, R., Wilkinson, T., Buchy, P., Dos Santos, G., Stefanidis, D., Devaster, J. M., & Meyer, N. (2017). Seasonal influenza vaccination in patients with COPD: a systematic literature review. *BMC pulmonary medicine*, *17*(1), 79. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415833/

1694.) Frøbert, O., Götberg, M., Erlinge, D., Akhtar, Z., Christiansen, E. H., MacIntyre, C. R., ... & Pernow, J. (2021). Influenza vaccination after myocardial infarction: A randomized, double-blind, placebo-controlled, multicenter trial. *Circulation*. https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.057042

1695.) Langan, S. M., Smeeth, L., Margolis, D. J., & Thomas, S. L. (2013). Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. *PLoS medicine*, *10*(4), e1001420.

https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001420#abstract1

1696.) Wang, I. K., Lin, C. L., Lin, P. C., Liang, C. C., Liu, Y. L., Chang, C. T., ... & Sung, F. C. (2013). Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. *PloS one*, *8*(3), e58317. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0058317

1697.) Rodrigues, L. C., Diwan, V. K., & Wheeler, J. G. (1993). Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. *International journal of epidemiology*, *22*(6), 1154-1158. https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.883.1418&rep=rep1&type=pdf

1698.) Biswal, S., Borja-Tabora, C., Vargas, L. M., Velásquez, H., Alera, M. T., Sierra, V., ... & Tricou, V. (2020). Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial. *The Lancet*, *395*(10234), 1423-1433. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30414-1/fulltext

1699.) DiazGranados, C. A., Denis, M., & Plotkin, S. (2012). Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. *Vaccine*, *31*(1), 49-57. https://www.sciencedirect.com/science/article/pii/S0264410X12015575

1700.) Naito, T., Suzuki, M., Kanazawa, A., Takahashi, H., Fujibayashi, K., Yokokawa, H., ... & Watanabe, A. (2020). Pneumococcal vaccination reduces in-hospital mortality, length of stay and medical expenditure in hospitalized elderly patients. *Journal of Infection and Chemotherapy*, *26*(7), 715-721. https://www.sciencedirect.com/science/article/pii/S1341321X20301100

1701.) Hviid, A., Thorsen, N. M., Thomsen, L. N., Møller, F. T., Wiwe, A., Frisch, M., Valentiner-Branth, P., Rytter, D., & Mølbak, K. (2021). Human papillomavirus vaccination and all-cause morbidity in adolescent girls: a cohort study of absence from school due to illness. *International journal of epidemiology*, *50*(2), 518–526. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128452/

1702.) Skufca, J., Ollgren, J., Artama, M., Ruokokoski, E., Nohynek, H., & Palmu, A. A. (2018). The association of adverse events with bivalent human papilloma virus vaccination: a nationwide register-based cohort study in Finland. Vaccine, 36(39), 5926-5933. https://www.sciencedirect.com/science/article/pii/S0264410X18309253

1703.) Burnett, E., Parashar, U. D., & Tate, J. E. (2020). Real-world effectiveness of rotavirus vaccines, 2006–19: a literature review and meta-analysis. *The Lancet Global Health*, *8*(9), e1195-e1202.
https://www.sciencedirect.com/science/article/pii/S2214109X2030262X

1704.) Talbird, S. E., Carrico, J., La, E. M., Carias, C., Marshall, G. S., Roberts, C. S., Chen, Y. T., & Nyaku, M. K. (2022). Impact of Routine Childhood Immunization in Reducing Vaccine-Preventable Diseases in the United States. *Pediatrics*, *150*(3), e2021056013.
https://doi.org/10.1542/peds.2021-056013

Covid 19 Vaccines

1.) Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine*, *383*(27), 2603-2615.
https://www.nejm.org/doi/full/10.1056/NEJMoa2034577

2.) Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., ... & Bijker, E. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet*, *397*(10269), 99-111.
https://www.sciencedirect.com/science/article/pii/S0140673620326611

3.) Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... & Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England Journal of Medicine*, *384*(5), 403-416.
https://www.nejm.org/doi/full/10.1056/nejmoa2035389

4.) Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., ... & Beigel, J. H. (2020). Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *New England Journal of Medicine*, *383*(25), 2427-2438.
https://www.nejm.org/doi/full/10.1056/NEJMoa2027906

5.) Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., ... & Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses. *Nature*, *586*(7830), 594-599. https://www.nature.com/articles/s41586-020-2814-7

6.) Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., ... & Demissie, T. (2020). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *The Lancet*, *396*(10267), 1979-1993. https://www.sciencedirect.com/science/article/pii/S0140673620324661

7.) Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Jansen, K. U. (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature*, *586*(7830), 589-593. https://www.nature.com/articles/s41586-020-2639-4

8.) Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., ... & Barouch, D. H. (2020). Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature*, *586*(7830), 583-588. https://www.nature.com/articles/s41586-020-2607-z?elqTrackId=4a779cff52a6429c991dcd18014ea740

9.) Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatullin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., ... & Gintsburg, A. L. (2020). Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. *The Lancet*, *396*(10255), 887-897. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext?utm_source=yxnews&utm_medium=mobile&utm_referrer=https%3A%2F%2Fyandex.uz%2Fnews%2Fstory%2FV_Rossii_obyavili_o_mezhdunarodnom_priznanii_vakciny_Sputnik_V--d8a5a126f6e3164510f9189e43f9bf42

10.) Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., ... & Glenn, G. M. (2020). Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *New England Journal of Medicine*, *383*(24), 2320-2332. https://www.nejm.org/doi/full/10.1056/NEJMoa2026920

11.) Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., ... & Graham, B. S. (2020). Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *New England Journal of Medicine*, *383*(16), 1544-1555. https://www.nejm.org/doi/full/10.1056/NEJMoa2024671

12.) Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., ... & Hamlyn, J. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*, *396*(10249), 467-478. https://www.sciencedirect.com/science/article/pii/S0140673620316044

13.) Zhu, F. C., Guan, X. H., Li, Y. H., Huang, J. Y., Jiang, T., Hou, L. H., ... & Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet*, *396*(10249), 479-488. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext?hss_channel=tw-27013292

14.) Vasileiou, E., Simpson, C. R., Shi, T., Kerr, S., Agrawal, U., Akbari, A., ... & Sheikh, A. (2021). Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *The Lancet*, *397*(10285), 1646-1657. https://www.sciencedirect.com/science/article/pii/S0140673621006772

15.) Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., ... & Alroy-Preis, S. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *The Lancet*, *397*(10287), 1819-1829. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099315/

16.) Renoud, L., Khouri, C., Revol, B., Lepelley, M., Perez, J., Roustit, M., & Cracowski, J. L. (2021). Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. *JAMA Internal Medicine*. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2779389

17.) Munitz, A., Yechezkel, M., Dickstein, Y., Yamin, D., & Gerlic, M. (2021). BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B. 1.1. 7 in high-risk populations in Israel. *Cell Reports Medicine*, *2*(5), 100264. https://www.sciencedirect.com/science/article/pii/S266637912100080X

18.) Angel, Y., Spitzer, A., Henig, O., Saiag, E., Sprecher, E., Padova, H., & Ben-Ami, R. (2021). Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. *JAMA*. https://jamanetwork.com/journals/jama/fullarticle/2779853

19.) Stamatatos, L., Czartoski, J., Wan, Y. H., Homad, L. J., Rubin, V., Glantz, H., ... & McGuire, A. T. (2021). mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science.*
https://science.sciencemag.org/content/early/2021/03/24/science.abg9175

20.) Ebinger, J. E., Fert-Bober, J., Printsev, I., Wu, M., Sun, N., Prostko, J. C., ... & Sobhani, K. (2021). Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nature Medicine*, 1-4.
https://www.nature.com/articles/s41591-021-01325-6#Abs1

21.) Reynolds, C. J., Pade, C., Gibbons, J. M., Butler, D. K., Otter, A. D., Menacho, K., ... & Boyton, R. (2021). Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. *Science*.
https://science.sciencemag.org/content/sci/early/2021/04/29/science.abh1282.full.pdf

22.) Liu, J., Liu, Y., Xia, H., … & Shi, P. Y. (2021). BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. *Nature*.
https://www.nature.com/articles/s41586-021-03693-y#Abs1
Preprint:
https://assets.researchsquare.com/files/rs-540721/v1/572d5c1c-5e9a-45f9-b586-2a0d95da1981.pdf

23.) Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., ... & Meaney-Delman, D. M. (2021). Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. *New England Journal of Medicine*.
https://www.nejm.org/doi/full/10.1056/NEJMoa2104983

24.) Bowman, C. J., Bouressam, M., Campion, S. N., Cappon, G. D., Catlin, N. R., Cutler, M. W., ... & Lindemann, C. (2021). Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. *Reproductive Toxicology*, *103*, 28-35.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163337/

25.) Orvieto, R., Noach-Hirsh, M., Segev-Zahav, A., Haas, J., Nahum, R., & Aizer, A. (2021). Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?. *Reproductive Biology and Endocrinology*, *19*(1), 1-4.
https://link.springer.com/content/pdf/10.1186/s12958-021-00757-6.pdf

26.) Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., ... & Virk, A. (2021). Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. *Clinical Infectious Diseases*. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab361/6253721?login=true

27.) Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K., ... & Pouwels, K. (2021). Impact of vaccination on new SARS-CoV-2 infections in the UK. *Nature Medicine*. https://www.nature.com/articles/s41591-021-01410-w.pdf

28.) Gonzalez, D. C., Nassau, D. E., Khodamoradi, K., Ibrahim, E., Blachman-Braun, R., Ory, J., & Ramasamy, R. (2021). Sperm Parameters Before and After COVID-19 mRNA Vaccination. *JAMA*. https://jamanetwork.com/journals/jama/fullarticle/2781360?resultClick=1

29.) Formeister, E. J., Chien, W., Agrawal, Y., Carey, J. P., Stewart, C. M., & Sun, D. Q. (2021). Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data. *JAMA otolaryngology-- head & neck surgery*, e210869. https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2780288?resultClick=1

30.) Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., ... & Cowley, A. (2021). COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *The Lancet*, *397*(10286), 1725-1735. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064668/

31.) Emary, K. R., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., ... & Oxford COVID-19 Vaccine Trial Group. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial. *The Lancet*, *397*(10282), 1351-1362. https://www.sciencedirect.com/science/article/pii/S0140673621006280

32.) Collier, A. Y., McMahan, K., Yu, J., Tostanoski, L. H., Aguayo, R., Ansel, J., Chandrashekar, A., Patel, S., Apraku Bondzie, E., Sellers, D., Barrett, J., Sanborn, O., Wan, H., Chang, A., Anioke, T., Nkolola, J., Bradshaw, C., Jacob-Dolan, C., Feldman, J., Gebre, M., … Barouch, D. H. (2021). Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. *JAMA*, *325*(23), 2370–2380. https://jamanetwork.com/journals/jama/fullarticle/2780202?resultClick=1

33.) Al Kaabi, N., Zhang, Y., Xia, S., Yang, Y., Al Qahtani, M. M., Abdulrazzaq, N., Al Nusair, M., Hassany, M., Jawad, J. S., Abdalla, J., Hussein, S. E., Al Mazrouei, S. K., Al Karam, M., Li, X., Yang, X., Wang, W., Lai, B., Chen, W., Huang, S., Wang, Q., … Yang, X. (2021). Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA*, e218565. https://jamanetwork.com/journals/jama/fullarticle/2780562?resultClick=1

34.) Levine-Tiefenbrun, M., Yelin, I., Katz, R., Herzel, E., Golan, Z., Schreiber, L., ... & Kishony, R. (2021). Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nature medicine*, *27*(5), 790-792. https://www.nature.com/articles/s41591-021-01316-7?fbclid=IwAR0kkdYBQuXgR2KU-QeiQhGVBObIQgXYddLzINgSqg7SL1-LTq1SzfQDqjM

35.) Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O'Doherty, M., Brown, K., Cameron, C., Stockton, D., McMenamin, J., & Ramsay, M. (2021). Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ*, *373*, n1088. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116636/

36.) Frenck, R. W., Jr, Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B., Senders, S., Bailey, R., Swanson, K. A., Ma, H., Xu, X., Koury, K., Kalina, W. V., Cooper, D., Jennings, T., Brandon, D. M., Thomas, S. J., Türeci, Ö., … fC4591001 Clinical Trial Group (2021). Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *The New England journal of medicine*, NEJMoa2107456. https://www.nejm.org/doi/10.1056/NEJMoa2107456?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

37.) Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K. L., Robb, M. L., Treanor, J., Barouch, D. H., Stoddard, J., Ryser, M. F., Marovich, M. A., Neuzil, K. M., … ENSEMBLE Study Group (2021). Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *The New England journal of medicine*, *384*(23), 2187–2201. https://www.nejm.org/doi/10.1056/NEJMoa2101544?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

38.) Yu, J., Tostanoski, L. H., Mercado, N. B., McMahan, K., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Atyeo, C., Martinez, D. R., Anioke, T., Bondzie, E. A., Chang, A., Gardner, S., Giffin, V. M., Hope, D. L., Nampanya, F., Nkolola, J., Patel, S., Sanborn, O., Sellers, D., … Barouch, D. H. (2021). Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. *Nature.* https://www.nature.com/articles/s41586-021-03732-8_reference.pdf

39.) Martinez, D. R., Schaefer, A., Leist, S. R., De la Cruz, G., West, A., Atochina-Vasserman, E. N., ... & Baric, R. S. (2021). Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice. *Science*. https://science.sciencemag.org/content/early/2021/06/22/science.abi4506

40.) Shemer, A., Pras, E., Einan-Lifshitz, A., Dubinsky-Pertzov, B., & Hecht, I. (2021). Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. *JAMA otolaryngology-- head & neck surgery.* https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2781367

41.) Tande, A. J., Pollock, B. D., Shah, N. D., Farrugia, G., Virk, A., Swift, M., ... & Berbari, E. F. (2021). Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening. *Clinical Infectious Diseases*. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab229/6167855?login=true

42.) Golan, Y., Prahl, M., Cassidy, A., Lin, C. Y., Ahituv, N., Flaherman, V. J., & Gaw, S. L. (2021). Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk. *JAMA pediatrics*. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2781679

43.) Milman, O., Yelin, I., Aharony, N., Katz, R., Herzel, E., Ben-Tov, A., ... & Kishony, R. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. *Nature medicine*. https://www.nature.com/articles/s41591-021-01407-5.pdf

44.) Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M. G., Al Romaihi, H. E., Al-Thani, M. H., … Abu-Raddad, L. J. (2021). mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nature medicine.* https://www.nature.com/articles/s41591-021-01446-y.pdf

45.) Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K. D., Jones, J., House, T., VanSteenHouse, H., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I.,

Rourke, E., Studley, R., Crook, D., Peto, T., Walker, A. S., & Pouwels, K. B. (2021). Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nature medicine*. https://www.nature.com/articles/s41591-021-01410-w.pdf

46.) Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., Mangino, M., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *The Lancet. Infectious diseases*, *21*(7), 939–949. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078878/

47.) Kow, C. S., & Hasan, S. S. (2021). Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. *Inflammopharmacology*, 1–16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266992/

48.) Goldshtein, I., Nevo, D., Steinberg, D. M., Rotem, R. S., Gorfine, M., Chodick, G., & Segal, Y. (2021). Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. *JAMA*. https://jamanetwork.com/journals/jama/fullarticle/2782047

49.) Bueno, S. M., Abarca, K., González, P. A., Gálvez, N., Soto, J. A., Duarte, L. F., Schultz, B. M., Pacheco, G. A., González, L. A., Vázquez, Y., Ríos, M., Melo-González, F., Rivera-Pérez, D., Iturriaga, C., Urzúa, M., Domínguez, A., Andrade, C. A., Berrios, R. V., Canedo-Marroquín, G., Covián, C., … CoronaVac03CL Study Group (2021). Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. *Clinical infectious diseases*, ciab823. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab823/6372423?searchresult=1

50.) Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., ... & Balicer, R. D. (2021). Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. *New England Journal of Medicine*. https://www.nejm.org/doi/full/10.1056/nejmoa2110475

51.) Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., ... & Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. *JAMA*. https://jamanetwork.com/journals/jama/fullarticle/2784015

52.) Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., ... & Finn, A. (2021). Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. *The Lancet Infectious Diseases*. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221734/

53.) Medeiros-Ribeiro, A. C., Aikawa, N. E., Saad, C., Yuki, E., Pedrosa, T., Fusco, S., Rojo, P. T., Pereira, R., Shinjo, S. K., Andrade, D., Sampaio-Barros, P. D., Ribeiro, C. T., Deveza, G., Martins, V., Silva, C. A., Lopes, M. H., Duarte, A., Antonangelo, L., Sabino, E. C., Kallas, E. G., … Bonfa, E. (2021). Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. *Nature medicine.* https://www.nature.com/articles/s41591-021-01469-5.pdf

54.) John, B. V., Deng, Y., Scheinberg, A., Mahmud, N., Taddei, T. H., Kaplan, D., ... & Dahman, B. (2021). Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. *JAMA internal medicine*. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782121

55.) Bookstein Peretz, S., Regev, N., Novick, L., Nachshol, M., Goffer, E., Ben-David, A., Asraf, K., Doolman, R., Gal Levin, E., Regev Yochay, G., & Yinon, Y. (2021). Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. *Ultrasound in obstetrics & gynecology, 58*(3), 450–456. https://obgyn.onlinelibrary.wiley.com/doi/10.1002/uog.23729

56.) Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., Olsho, L., Caban-Martinez, A. J., Fowlkes, A. L., Lutrick, K., Groom, H. C., Dunnigan, K., Odean, M. J., Hegmann, K., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., Kuntz, J. L., … Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. *The New England journal of medicine*, *385*(4), 320–329. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262622/

57.) Mateus, J., Dan, J. M., Zhang, Z., Moderbacher, C. R., Lammers, M., Goodwin, B., ... & Weiskopf, D. (2021). Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory. *Science*. https://www.science.org/doi/10.1126/science.abj9853

58.) Dagan, N., Barda, N., Biron-Shental, T., Makov-Assif, M., Key, C., Kohane, I. S., ... & Balicer, R. D. (2021). Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. *Nature Medicine.* https://www.nature.com/articles/s41591-021-01490-8

59.) Carazo, S., Talbot, D., Boulianne, N., Brisson, M., Gilca, R., Deceuninck, G., Brousseau, N., Drolet, M., Ouakki, M., Sauvageau, C., Barkati, S., Fortin, É., Carignan, A., De Wals, P., Skowronski, D. M., & De Serres, G. (2021). Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design

from Quebec, Canada. *Clinical infectious diseases*, ciab739. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab739/6359881?searchresult=1

60.) Kharbanda, E. O., Haapala, J., DeSilva, M., Vazquez-Benitez, G., Vesco, K. K., Naleway, A. L., & Lipkind, H. S. (2021). Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy. *JAMA*. https://jamanetwork.com/journals/jama/fullarticle/2784193?resultClick=1

61.) Skowronski, D. M., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Galanis, E., ... & Krajden, M. (2021). Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada. *Clinical Infectious Diseases*. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab616/6318435?searchresult=1

62.) Yassi, A., Grant, J. M., Lockhart, K., Barker, S., Sprague, S., Okpani, A. I., Wong, T., Daly, P., Henderson, W., Lubin, S., & Kim Sing, C. (2021). Infection control, occupational and public health measures including mRNA-based vaccination against SARS-CoV-2 infections to protect healthcare workers from variants of concern: A 14-month observational study using surveillance data. *PloS one*, *16*(7), e0254920. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284646/

63.) Achiron, A., Dolev, M., Menascu, S., Zohar, D. N., Dreyer-Alster, S., Miron, S., Shirbint, E., Magalashvili, D., Flechter, S., Givon, U., Guber, D., Stern, Y., Polliack, M., Falb, R., & Gurevich, M. (2021). COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. *Multiple sclerosis*, *27*(6), 864–870. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114441/

64.) Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Clutterbuck, E. A., Collins, A. M., Cutland, C. L., Darton, T. C., Dheda, K., Dold, C., Duncan, C., … Oxford COVID Vaccine Trial Group (2021). Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet*, *397*(10277), 881–891. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894131/

65.) Bahl, A., Johnson, S., Maine, G., Garcia, M. H., Nimmagadda, S., Qu, L., & Chen, N. W. (2021). Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. *Lancet Regional Health. Americas*, 100065. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428472/

66.) García-Grimshaw, M., Michel-Chávez, A., Vera-Zertuche, J. M., Galnares-Olalde, J. A., Hernández-Vanegas, L. E., Figueroa-Cucurachi, M., ... & Valdés-Ferrer, S. I. (2021). Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. *Clinical Immunology*, *230*, 108818. https://www.sciencedirect.com/science/article/pii/S1521661621001558

67.) Bleicher, I., Kadour, E., Sagi-Dain, L., & Sagi, S. (2021). COVID-19 vaccination safety and efficiency during pregnancy: a prospective observational study. *Vaccine*. https://www.sciencedirect.com/science/article/pii/S0264410X21012342

68.) El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., ... & Miller, J. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *New England Journal of Medicine*. https://www.nejm.org/doi/full/10.1056/NEJMoa2113017

69.) Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., ... & Gam-COVID-Vac Vaccine Trial Group. (2021). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *The Lancet*, *397*(10275), 671-681. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext?fbclid=IwAR2K-Ji22HaASGeMwKl02huGvrb6sgTX1ZWtu85SuXfEjIuIccy1s8rDBDY&utm_source=mandiner&utm_medium=link&utm_campaign=mandiner_202105

70.) Thomas, S. J., Moreira Jr, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months. *New England Journal of Medicine*. https://www.nejm.org/doi/10.1056/NEJMoa2110345?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

71.) Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., ... & Toback, S. (2021). Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. *New England Journal of Medicine*. https://www.nejm.org/doi/full/10.1056/NEJMoa2107659

72.) Skowronski, D. M., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Galanis, E., Naus, M., Patrick, D. M., Sbihi, H., El Adam, S., Henry, B., Hoang, L., Sadarangani, M., Jassem, A. N., & Krajden, M. (2021). Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada. *Clinical infectious diseases*, ciab616. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406884/

73.) Tande, A. J., Pollock, B. D., Shah, N. D., Binnicker, M., & Berbari, E. F. (2021). mRNA Vaccine Effectiveness Against Asymptomatic SARS-CoV-2 Infection Over a Seven-Month Period. *Infection control and hospital epidemiology*, 1–7. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/mrna-vaccine-effectiveness-against-asymptomatic-sarscov2-infection-over-a-sevenmonth-period/0B67BE1950C88E93B73C15F75E2FC497

74.) Jones, N. K., Rivett, L., Seaman, S., Samworth, R. J., Warne, B., Workman, C., Ferris, M., Wright, J., Quinnell, N., Shaw, A., Cambridge COVID-19 Collaboration, Goodfellow, I. G., Lehner, P. J., Howes, R., Wright, G., Matheson, N. J., & Weekes, M. P. (2021). Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. *eLife*, *10*, e68808. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064747/

75.) Glatman-Freedman, A., Bromberg, M., Dichtiar, R., Hershkovitz, Y., & Keinan-Boker, L. (2021). The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data. *EBioMedicine*, *72*, 103574. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445746/

76.) Pilishvili, T., Gierke, R., Fleming-Dutra, K. E., Farrar, J. L., Mohr, N. M., Talan, D. A., ... & Schrag, S. J. (2021). Effectiveness of mRNA Covid-19 Vaccine among US Health Care Personnel. *New England Journal of Medicine*. https://www.nejm.org/doi/full/10.1056/NEJMoa2106599

77.) Paris, C., Perrin, S., Hamonic, S., Bourget, B., Roué, C., Brassard, O., ... & Tattevin, P. (2021). Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data. *Clinical Microbiology and Infection*. https://www.sciencedirect.com/science/article/pii/S1198743X21003797

78.) Thompson, M. G., Stenehjem, E., Grannis, S., Ball, S. W., Naleway, A. L., Ong, T. C., ... & Klein, N. P. (2021). Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. *New England Journal of Medicine*. https://www.nejm.org/doi/full/10.1056/NEJMoa2110362

79.) Gupta, K., O'Brien, W. J., Bellino, P., Linsenmeyer, K., Doshi, S. J., Sprague, R. S., & Charness, M. E. (2021). Incidence of SARS-CoV-2 Infection in Health Care Workers After a Single Dose of mRNA-1273 Vaccine. *JAMA network open*, *4*(6), e2116416. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209555/

80.) Wainstock, T., Yoles, I., Sergienko, R., & Sheiner, E. (2021). Prenatal maternal COVID-19 vaccination and pregnancy outcomes. *Vaccine*, *39*(41), 6037–6040. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421099/

81.) Fadlyana, E., Rusmil, K., Tarigan, R., Rahmadi, A. R., Prodjosoewojo, S., Sofiatin, Y., ... & Kartasasmita, C. B. (2021). A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18–59 Years: An Interim Analysis in Indonesia. *Vaccine*. https://www.sciencedirect.com/science/article/pii/S0264410X2101255X

82.) Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., ... & McLaughlin, J. M. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet.* https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02183-8/fulltext

83.) Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., ... & Virk, A. (2021). Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. *Clinical Infectious Diseases*, *73*(6), e1376-e1379. https://academic.oup.com/cid/article/73/6/e1376/6253721

84.) Khan, N., & Mahmud, N. (2021). Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs Cohort of Inflammatory Bowel Disease Patients with Diverse Exposure to Immunosuppressive Medications. *Gastroenterology*. https://www.sciencedirect.com/science/article/abs/pii/S0016508521030663

85.) Charmet, T., Schaeffer, L., Grant, R., Galmiche, S., Chény, O., Von Platen, C., Maurizot, A., Rogoff, A., Omar, F., David, C., Septfons, A., Cauchemez, S., Gaymard, A., Lina, B., Lefrancois, L. H., Enouf, V., van der Werf, S., Mailles, A., Levy-Bruhl, D., Carrat, F., … Fontanet, A. (2021). Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. *The Lancet regional health. Europe*, *8*, 100171. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277121/

86.) Antonelli, M., Penfold, R. S., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L. S., Graham, M. S., Klaser, K., Modat, M., Murray, B., Kerfoot, E., Chen, L., Deng, J., Österdahl, M. F., Cheetham, N. J., Drew, D. A., Nguyen, L. H., Pujol, J. C., Hu, C., … Steves, C. J. (2021). Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *The*

Lancet. Infectious diseases, S1473-3099(21)00460-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409907/

87.) Cabezas, C., Coma, E., Mora-Fernandez, N., Li, X., Martinez-Marcos, M., Fina, F., Fabregas, M., Hermosilla, E., Jover, A., Contel, J. C., Lejardi, Y., Enfedaque, B., Argimon, J. M., Medina-Peralta, M., & Prieto-Alhambra, D. (2021). Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study. *BMJ*, *374*, n1868. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371258/

88.) Domi, M., Leitson, M., Gifford, D., Nicolaou, A., Sreenivas, K., & Bishnoi, C. (2021). The BNT162b2 vaccine is associated with lower new COVID-19 cases in nursing home residents and staff. *Journal of the American Geriatrics Society*, *69*(8), 2079–2089. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242377/

89.) Hillus, D., Schwarz, T., Tober-Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., Schmidt, M. L., Riege, J., Solarek, A., von Kalle, C., Dang-Heine, C., Gruell, H., Kopankiewicz, P., Suttorp, N., Drosten, C., Bias, H., … Sander, L. E. (2021). Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. *The Lancet. Respiratory medicine*, S2213-2600(21)00357-X. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360702/

90.) Emary, K., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E. A., Collins, A. M., Cox, T., Darton, T. C., Dold, C., Douglas, A. D., Duncan, C., Ewer, K. J., Flaxman, A. L., Faust, S. N., … Oxford COVID-19 Vaccine Trial Group (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *Lancet (London, England)*, *397*(10282), 1351–1362. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009612/

91.) Wang, J., Hou, Z., Liu, J., Gu, Y., Wu, Y., Chen, Z., Ji, J., Diao, S., Qiu, Y., Zou, S., Zhang, A., Zhang, N., Wang, F., Li, X., Wang, Y., Liu, X., Lv, C., Chen, S., Liu, D., Ji, X., … Qi, X. (2021). Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. *Journal of hepatology*, *75*(2), 439–441. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185617/

92.) Massarweh, A., Eliakim-Raz, N., Stemmer, A., Levy-Barda, A., Yust-Katz, S., Zer, A., Benouaich-Amiel, A., Ben-Zvi, H., Moskovits, N., Brenner, B., Bishara, J., Yahav, D., Tadmor, B., Zaks, T., & Stemmer, S. M. (2021). Evaluation of Seropositivity Following BNT162b2

Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. *JAMA oncology*, *7*(8), 1133–1140. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164144/

93.) Xing, K., Tu, X. Y., Liu, M., Liang, Z. W., Chen, J. N., Li, J. J., Jiang, L. G., Xing, F. Q., & Jiang, Y. (2021). Efficacy and safety of COVID-19 vaccines: a systematic review. *Zhongguo dang dai er ke za zhi*, *23*(3), 221–228. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969187/

94.) Broseta, J. J., Rodríguez-Espinosa, D., Rodríguez, N., Mosquera, M., Marcos, M. Á., Egri, N., Pascal, M., Soruco, E., Bedini, J. L., Bayés, B., & Maduell, F. (2021). Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. *American journal of kidney diseases*, *78*(4), 571–581. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223037/

95.) Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., de Lamballerie, X., & André, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. *European journal of cancer (Oxford, England : 1990)*, *154*, 30–34. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220943/

96.) Tan, C. W., Chia, W. N., Young, B. E., Zhu, F., Lim, B. L., Sia, W. R., Thein, T. L., Chen, M. I., Leo, Y. S., Lye, D. C., & Wang, L. F. (2021). Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. *The New England journal of medicine*, NEJMoa2108453. https://www.nejm.org/doi/full/10.1056/NEJMoa2108453

97.) Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021). Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. *mBio*, *12*(3), e0069621. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262901/

98.) Mateus, J., Dan, J. M., Zhang, Z., Rydyznski Moderbacher, C., Lammers, M., Goodwin, B., Sette, A., Crotty, S., & Weiskopf, D. (2021). Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. *Science*, eabj9853. https://www.science.org/doi/10.1126/science.abj9853

99.) Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., … AstraZeneca AZD1222 Clinical Study Group (2021). Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *The New England journal of medicine.* https://www.nejm.org/doi/full/10.1056/NEJMoa2105290

100.) Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., Myers, R., Campbell, C., Amirthalingam, G., Edmunds, M., Zambon, M., Brown, K. E., Hopkins, S., Chand, M., & Ramsay, M. (2021). Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *The New England journal of medicine*, *385*(7), 585–594. https://www.nejm.org/doi/full/10.1056/nejmoa2108891

101.) Lucas, C., Vogels, C. B., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., ... & CoV-2 Genomic Surveillance Initiative. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. *Nature*. https://www.nature.com/articles/s41586-021-04085-y_reference.pdf

102.) Nordström, P., Ballin, M., & Nordström, A. (2021). Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members. *JAMA internal medicine*. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785141

Thank you